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MEDICAL CANNABIS AND RECREATIONAL MARIJUANA: PATIENT PERCEPTIONS,
STIGMA, AND GENDER DURING A TIME OF EMERGING LEGALIZATION

Matt Reid, Ph.D.
Western Michigan University, 2020
Marijuana’s status as an illegal drug has been redefined over the previous three decades.
Despite Michigan and 32 other states having comprehensive medical cannabis programs, both
academics and laypeople commonly present the medicalization of marijuana as an intermediary
phase or proxy for fully legalized recreational use. While some evidence exists to support this
position, this framework marginalizes the struggles and experiences of patients who have found
relief through their therapeutic use of cannabis. As such, the goal of this study is to re-center the
voices of cannabis patients in academic conversations of cannabis as medicine.
My study is unique in that it is the first qualitative investigation of cannabis patients in
Michigan, and since Michigan legalized adult-use (recreational) marijuana in 2018, my study is
also the first to document patient experiences in a post-prohibition state. The research questions
that guided my descriptive qualitative inquiry revolved around the areas of medicalization,
normalization, and gender. The primary method utilized in my study was five semi-structured
focus groups of medical cannabis patients (n=21) where the groups were asked to reflect upon
their histories, current struggles, and their anticipations of the future. To expand the perspectives
analyzed in my research, I also performed observations at several cannabis businesses and events
(n=6), and I conducted semi-structured interviews with key informants (n=9) in Michigan’s

medical cannabis community, including dispensary owners, caregivers, activists, industry
advocates, and a certifying physician.
This descriptive study expands our sociological understanding of medicalization,
normalization, gender as experienced by medical cannabis. Results indicate patients prefer the
current “alternative medicalization” of cannabis where their medicine is legitimized and made
accessible outside of biomedical institutions. Patients in my study recounted intolerance and
ultimatums to stop using cannabis by health care professionals, and they loathed how physicians
pushed pharmaceuticals while criticizing cannabis medicines. Furthermore, since patients in my
study continued to experience a range of social and structural stigmas, my results call into
question claims that marijuana is normalized in American society. Indeed, these sweeping
assertations of normalization may have been made from positions of race, gender, class, and/or
generational privilege. Finally, both men and women in my study reported gender-specific
stigmas over their use of medical cannabis, though men who use cannabis may more readily
break with our culture’s hegemonic construction of masculinity.
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CHAPTER I

INTRODUCTION
Marijuana’s status as an illegal drug has been largely redefined over the previous two
decades. As of the writing of this study, 33 states have approved marijuana for medical use and
11 states have moved to legalize recreational use. Though the laws regulating consumption and
sales vary by state, each exists within a broader legal climate of federal prohibition. California
was the first state to authorize medicinal use in 1996 and critics have continually raised
skepticism over whether such policies are deceptive legal loopholes. Both academics and
laypeople commonly claim the medicalization of marijuana is an intermediary phase or proxy for
fully legalized recreational use. While some evidence exists to support this position, this
framework marginalizes the struggles and experiences of patients who have found relief through
their therapeutic use of cannabis. The goal of this study is to re-center the perspectives of
cannabis patients in the academic conversation of cannabis as medicine.
Legalization is steadily happening on a state-by-state basis, with Michigan voters passing
a ballot measure in 2018 to permit the sale and use of recreational marijuana. My dissertation
examines the experiences and perceptions of medical cannabis patients during a time of
emerging legalization. We are in a unique moment where a medical cannabis system is
established in Michigan while a young recreational industry is blossoming. What will happen to
cannabis as a medicine once recreational marijuana becomes widely available? Only 11 states
and Canada have undergone this transformation, and while data is surely still emerging, the
voices of patients during this transition have not been collected or analyzed by social scientists.
Furthermore, while many studies have examined medical and recreational cannabis through a
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wide variety of standpoints, no research on these topics has been conducted where the researcher
identifies as a patient. With this research and my insider knowledge, I hope to give voice to the
community of patients during this period of state-by-state marijuana reform.
Gender has also been largely ignored by social scientists studying these issues though
much can be gained through a feminist analysis of cannabis culture. My observations lead me to
believe the commercialized cannabis culture will cater to hegemonic masculinity with sexist
tactics like those used by the alcohol industry. These inequalities may reflect our broader
patriarchal culture, but unlike most other sectors, legitimate cannabis businesses are relatively
new. Since these new businesses do not have a history of entrenched male-dominated power
structures, this could be an opportune moment for women and gender minorities to claim equal
space in the emerging industry. Some evidence indicates this is happening, but there are also
concerns that legalization will only result in consolidation under male-controlled corporations.
Cannabis may be the next billion-dollar industry, but the people who appear poised to benefit the
most are the familiar white men in suits with deep pockets.
This is historically interesting because cannabis was legalized for medical use by a social
movement that shared similar values and membership to the women’s health care movement of
the 1960s-1990s. This movement fought for access to medicine outside of disempowering
medical institutions, the right to utilize non-professional care providers, and sought to restore
trust in natural remedies. Cannabis was one of these alternative therapies and those working in
the medical cannabis movement of the 1990s prioritized patient wellbeing over economic gain.
Indeed, the original activists often provided free medicine to those who could benefit, especially
those in the late stages of AIDS or cancer. Yet social rhetoric surrounding cannabis seems to
have shifted from an emphasis on care and relief to a focus on business and profit. Very soon, we
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may see the gendering of cannabis culture and its associated stakeholders become more
masculinized, more feminized, or perhaps even less gendered altogether.
The purpose of this study is to explore the community of medical cannabis patients
during a time of emerging recreational legalization. My research began with semi-structured
interviews with key organizational actors in Michigan’s medical cannabis community and
continued with observations of several field sites. This data was used in conducting focus groups
of registered patients in southwest Michigan, and the groups were asked to reflect on their
histories, current struggles, as well as their anticipations of the future. For the purposes of this
study, medical cannabis patients were defined as those registered in Michigan’s Medical
Marihuana Program (MMMP).
This descriptive study expands our sociological understanding of medicalization,
normalization, gender as experienced by medical cannabis patients through documenting grouplevel knowledge, something other researchers have so far neglected through their exclusive use
of survey and interview methods. Results from my research may be of interest to those who
serve the medical cannabis community as well as to the policymakers who shape regulations
surrounding both medical and recreational cannabis. I hope to contribute evidence that supports
cannabis’s construction as a medicine, and my work may help the health care community better
understand the perspective of cannabis patients. This research may also be empowering to
patients who participated in my focus groups as support networks and opportunities to meet other
patients are scarce in the State of Michigan. Merely coming together to discuss medical cannabis
may prove to be an encouraging and illuminating moment in the lives of individual patients.
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Research Questions
The research questions that guide this descriptive qualitative inquiry are:
(RQ1) How does the medical cannabis community feel about the normative status of
medical cannabis in this moment of emerging recreational legalization? And, what challenges do
patients face in their social and professional lives?
(RQ2) How do medical cannabis patients view the legalization of recreational
marijuana? And, do patients think medical cannabis will survive once marijuana is fully
legalized?
(RQ3) How does gender shape the experiences of medical cannabis patients? And, how
might hegemonic gender roles be adhered to or challenged by cannabis patients?
These questions anchored my subsequent data collection, analysis, and reporting of my
research. The questions are purposely broad and are flexible enough to produce engaging focus
group prompts. I tried to craft these in a manner that covers the central themes I investigated
since I began my proposal by reviewing and summarizing the literature on this topic. After I read
through most peer-reviewed articles published on medical and recreational cannabis in the social
sciences, I honed my inquiry deeper into several issues that sparked my interest. These are
discussed and briefly connected to social theory in the next section.

Theoretical Frameworks
Many studies on cannabis approach the topic through one dimension, typically treating it
as either a recreational drug or medicinal plant. In doing so, they usually adopt the framework of
normalization for the former and medicalization for the latter. These trends are each discussed in
detail throughout my dissertation, but my overarching point is that scholars acknowledge one or
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the other, rarely both. Normalization implies stigmas related to cannabis have become
insignificant or vanished altogether. If cannabis use has become normalized, medical patients
and recreational users should not be concerned about negative evaluations from others.
Medicalization implies that a substance is accepted by, and defined through, medical authorities.
However, patient activists medicalized cannabis in spite of resistance from medical, political,
and legal institutions. Its status as a medicine appears to be uneven and much controversy still
remains. Most interestingly, some speculate if medical cannabis will survive once recreational
marijuana is fully legalized. In other words, does the normalization of cannabis threaten its
medicalization? These two trends are co-occurring and are often juxtaposed to criminalization
rather than each other.
In addition to the theoretical frameworks of normalization and medicalization, I believe
considering gender dynamics can yield valuable insight into the cannabis community. Social
scientists have yet to meaningfully interrogate gender in their investigations of either recreational
or medical cannabis. The scant existing research on the topics typically frames gender through
the obsolete perspective of sex differences rather than seeing gender as a social accomplishment.
Furthermore, since male privilege often conceals how men do gender by framing masculinity as
the cultural default, I draw from the masculinities literature when interpreting my data. Existing
evidence suggests medical cannabis permits men to eschew some hegemonic traits of
masculinity through aligning their identity with therapeutic substance use as opposed to
competitive substance use (e.g., binge drinking). Examining how femininities manifest within
the medical cannabis subculture is also interesting as women are increasingly taking part in the
community. As such, my analysis of gender pays particular attention to how gender roles
mediate the use of medical cannabis, and perhaps how hegemonic gender scripts are transformed
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when they intersect with the use of medical cannabis. Since the medicalization of cannabis
diverges much from our society’s dominant biomedical model, my attention to gender in this
study is primarily in relation to cannabis use rather than medicine in general.
In the following sections, I offer a review of academic and popular literature pertaining to
both medical and recreational cannabis. Where possible, I have indicated gaps in the knowledge
base as well as some disagreements between studies. It is most fruitful to begin with an overview
of “blurred boundaries”, a concept describing how medical and recreational use blend together in
often indistinguishable ways. This leads to an overview of stigma concerning cannabis use, and I
offer a look into how cannabis activists resist stigmatizing forces. I will then discuss how
normalization and medicalization are occurring simultaneously but not necessarily harmoniously,
followed by a synopsis of the controversy on cannabis pharmaceuticals. Afterward, I analyze
how gender has been examined in relation to cannabis use while paying attention to how
masculinities manifest in cannabis culture. Following this, I discuss the methods researchers
have used to explore these topics and then explain the methods used in this study. Finally, there
are three analysis chapters where I discuss my findings before I summarize and conclude my
study.
A final note-- Appendix A provides an overview of cannabis’ long and nuanced social
history within the United States. Appendix B concerns cannabis in the state of Michigan while
considering how other states have managed to regulate medical and recreational systems. I
provide these to contextualize my research as well as to educate those unfamiliar with cannabis’
place in our society. A dictionary with detailed descriptions of key terms can also be found in
Appendix C.
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CHAPTER II

CANNABIS IN SOCIETY
To begin my investigation of medical cannabis in a post-prohibition state, it is necessary
to address the debate surrounding whether cannabis is a normalized or stigmatized substance.
There is no consensus here aside from how cannabis has become more normalized overtime, but
are we at a point where can we say it has been completely normalized? Much of the uncertainty
on cannabis normalization appears to stem from divergent understandings of what cannabis is.
As such, this chapter explains how the cannabis plant has been imbued with contrasting
meanings stemming from medical, recreational, political, criminal, spiritual, and entrepreneurial
definitions. I begin with a discussion on the difficulties of classifying cannabis as either a
recreational drug or therapeutic medicine. I then discuss social stigma and stereotypes related to
cannabis use, whether recreational or medical. Finally, I provide an overview of the
normalization hypothesis and the controversy surrounding cannabis going mainstream. These
topics are essential for understanding how cannabis has been constructed as a medicine, a topic
discussed in detail in the next chapter.

Blurred Boundaries
Cannabis has a multiplicity of uses along medical, recreational, spiritual, and commercial
dimensions. These uses often blur together, resulting in competing and inconsistent meanings
attached to the same plant (Bostwick 2012). One prominent theme in the literature is that of
blurred boundaries, a term referring to the unclear line between medicine and recreational
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intoxicant (Ryan & Sharts-Hopko 2017; Reinarman et al. 2011; Ogborne et al. 2000). There is a
significant overlap between medical and recreational uses of cannabis, and people who use
cannabis for medical purposes also use their medicine in recreational fashions (Satterlund, Lee &
Moore 2015; Bostwick 2012). For example, Page and Verhoef (2006) found some MS patients
occasionally medicated with their friends who recreationally use marijuana. Yet this does not
necessarily mean the patients had situationally switched to a purely recreational mindset. Even
within the same social setting, medical users may use less cannabis than recreational users as the
prior tend to medicate until the desired effect is reached rather than in pursuit of becoming
“stoned” (Bostwick 2012). Either way, “much drug use does not fit into two neat boxes, medical
and nonmedical, but rather exists on a continuum where one shades into the other as patients’
purposes shift the suit situational exigencies in their health and their daily lives” (Reinarman et
al. 2011:134). This chapter will explore the issue of blurred boundaries and the variety of
meanings ascribed to plants in the genus Cannabis.
To reconstruct cannabis as a medicine rather than a recreational drug, patients often
downplay the euphoria they experience from using their medicine (Chapkis 2007). This is a
prevalent tactic as framing cannabis exclusively as a medicine counters the dominant public
perception of cannabis as a pleasurable drug. Yet some medical cannabis scholars such as Lester
Grinspoon (1999) take the position that it would be wrong to view cannabis as only a medicine.
It has therapeutic properties but also appears to enhance the overall quality of life and promote
enjoyment in one’s activities: “Cannabis use simply cannot be made to conform to the
boundaries established by present medical institutions” (Grinspoon 1999:155). It can
simultaneously be a source of relief, pleasure, prophecy, profit, and so much more.
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Wendy Chapkis (2007) reached a similar conclusion in her study of medical cannabis
patients with terminal illnesses. Changes in consciousness can increase wellbeing for those
whose attention is dominated by bodily pain and depressive states stemming from illness. The
euphoria experienced from consuming cannabis shifts one’s focus away from misery, often
towards a more present-oriented state: “Few joys are as pure or profound as relief from
suffering” (Newhart & Dolphin 2019:159). The high could also be interpreted as a convenient
sign that the medicine is working. Either way, patients claim cannabis and its associated high
allows them to engage in more activities and may even increase productivity (Chapkis 2007). In
sum, medical cannabis patients enjoy the high in the same way recreational users do, and this
inconsistent style of use poses problems for those hoping to classify the plant as either a therapy
or intoxicant. Therefore, attention to the context of use is arguably more important than cannabis
use itself or the resulting effects. For example, medical patients are more likely to use cannabis
alone and without the desire to enhance fun or sociality (Newhart & Dolphin 2019). They may
also restrict their use of medical cannabis to times when their discomfort interferes with their
ability to perform their daily routine or when pain prevents one from sleeping through the night.
Aside from the context of how cannabis is used, different chemical compounds found
within cannabis plants produce different bodily effects. The two major cannabinoids are widely
abbreviated THC and CBD, though numerous subtypes of each exist. Tetrahydrocannabinol
(THC) is psychoactive and is responsible for most of the intoxication experienced by consuming
cannabis. It would be wrong, however, to think of THC as being medically worthless. Not only
can changes in consciousness be life-preserving for those in chronic pain, but THC also acts as
an appetite stimulant, anti-emetic, and helps with muscle spasms, sleeping difficulties, and more
(Frye 2018). Cannabidiol (CBD) is non-psychoactive and is almost exclusively constructed as
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medically valuable (rather than recreationally desirable). CBD can help with bodily pain,
inflammation, seizures, and much more. All cannabinoids are processed in the body by the
endocannabinoid system of neurotransmitters and specialized cellular receptors. Indeed, many
claims makers like to point out our bodies have literally evolved to receive the unique
compounds found in cannabis. This system is further explored in Chapter 3, and a dictionary
with more information on cannabinoids has been provided as an appendix.
Medical cannabis patients are a diverse group and cannabis itself is more nuanced than
commonly thought. The lack of uniformity necessary for adequate classification has also been
noted by scholars studying recreational marijuana. Osborne and Fogel (2008) found Canadians
used recreational marijuana for two seemingly contradictory reasons: to relax by “tuning out” the
world and to concentrate by “tuning into” the world. These reasons largely depended on the
social context and the user’s motives. Those who worked in occupations with high demands for
emotional labor found their marijuana use to be relaxing, as did people with busy schedules. One
single mother who worked full time and attended school part-time said: “I find that I don’t have
time for ‘real’ recreation, so my recreation is to smoke a joint, lay in bed and read a book.
Smoking weed is my meditation, my relaxation, my therapy, and my hobby all wrapped in one
neat little white paper” (Osborne & Fogel 2008:549). Though this person is classified as a
recreational marijuana user, the way she describes her use clearly illuminates some healthpromoting qualities. Similarly, cannabis patients in Colorado interviewed by Newhart and
Dolphin (2019) reported “microdosing” during the day in order to remain focused, and they
occasionally consumed more of their medicine as a “treat” in the contexts of relaxation or social
smoking.
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Such narratives blur the boundaries between recreational intoxicant and therapeutic
medicine. While our culture seems to enjoy mutually exclusive categories, we may be better off
seeing cannabis as a “tool” that can be used for a variety of purposes (Lucas 2009). Utility helps
structure meaning, and owing to the plant’s plurality of uses, there exists a panoply of terms
describing the plant itself, its effects, and the people who consume it.

Terminology
Participants interviewed by Satterlund and colleagues (2015) say there are two kinds of
substances and two types of consumers: The plant is either framed as “cannabis” to convey its
use as a legal medicine or it is framed as “marijuana”, “pot” or “weed” to describe its use as an
illegal drug. Likewise, there are two contrasting identities of cannabis users: the legitimate
identity as a patient and the illegitimate identity as a drug user. Moreover, “[t]hese two
substances and these two identities slide over each other in uncomfortable ways” (Satterlund et
al. 2015:10). Similar findings were uncovered elsewhere, such as a study with cannabis patients
in Canada where participants were keen on descriptive terminology (Athey, Boyd & Cohen
2017). Even though their sample insisted researchers use the term “medical patient” over
“medical user”, the research team still adopts the later terminology to fit better with their
analytical framework based on Howard Becker’s work on deviant drug careers (Athey et al.
2017:229).
While there is no consensus among experts, patients, or scientists, the trend appears to be
using “cannabis” when referring to a medicine and “marijuana” when referring to a drug
(Newhart & Dolphin 2019). Potter et al. (2011) say “marijuana” is often used explicitly for
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describing herbal forms of the drug,1 while “cannabis” is much broader as it encompasses
everything from the plant, its resins, and its derivatives. However, others use “cannabis” and
“marijuana” interchangeably (Chapkis & Webb 2008). Bureaucratic identities further complicate
things. While the terminology is still evolving, “medical marijuana” is often used to denote
patients who participate in an official medical marijuana program while “therapeutic cannabis” is
commonly used to describe health-related use among those not registered in a state-sponsored
program (Fischer et al. 2015).
In this study, I have made efforts to use “cannabis” when referring to medicine or the
plant in general. More specifically, I use “marijuana” when referring to recreational drug use
unless discussing formal polices using the term. From my personal observations, patients in
Michigan’s “Medical Marihuana Program” (MMMP) have expressed resentment over the state’s
choice of terminology with many preferring “cannabis” be used instead. This is not only an issue
of semantics because perceived synonyms may have divergent political and cultural meanings. In
a recent analysis of keywords in academic articles, Seeber and Stott (2019) found 60% of
“marijuana” articles were of negative (anti-drug) sentiment compared to 49% of “cannabis”
articles. They suspect this is because “marijuana” has been the preferred term for criminologists
while “cannabis” is more commonly used by medical researchers. Interestingly, the use of the
word “cannabis” is growing, overtaking the frequency of “marijuana” in academic publications
in 2008 (Seeber & Stott 2019).
“Marijuana” is also a term more popular in the United States than abroad (Seeber & Stott
2019), and as you may have already noticed with the MMMP, its spelling has changed over time.

Specifically, “marijuana” is the flower (or bud) produced by female cannabis plants. This is the only part of the
plant which produces psychoactive THC. For more information on terminology and cannabis in general, see the
annotated dictionary as Appendix C.
1
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Unfortunately, this modern spelling with a “j” is believed to be rooted in the xenophobic
business practices of William Randolph Hearst, a newspaper tycoon in the early twentieth
century. Hearst had invested heavily in northwestern forestry companies and wanted American
newspapers to abandon their tradition of printing on hemp-based paper. Hemp is a term for
cannabis plants with minimal (practically zero) levels of THC, often grown by farmers for
industrial purposes (Wesheit 2011). Tapping into anti-Mexican sentiments was one way to
tarnish the reputation of hemp, and Hearst instructed his own newspapers to switch from the
common terminology of hemp, cannabis, or marihuana to the more Spanish-looking marijuana
(Gahlinger 2004). Anti-drug crusaders of the era quickly realized the new spelling could help
their missions as well. In December 2018, Michigan officials switched from spelling
“marihuana” as codified in the 1937 federal Marihuana Tax Act to the common spelling of
“marijuana” (Biolchini 2018). This change only affects official communications and not the titles
of state programs, bills, or laws.
The divide between “marijuana” and “cannabis” illustrates some of the tension resulting
from different constructions of the same plant. Terminology should ideally be as specific as
possible, but as I have already discussed, the constructed boundaries between the medicine and
the drug overlap significantly. One radical way to approach the issue of blurred boundaries is to
see all cannabis use as having some degree of medical or therapeutic value (Newhart & Dolphin
2019). An interesting study from Canada found teens who use cannabis recreationally often do
so in natural spaces such as woods, providing them with fresh air and exercise. The teens
frequently described their ventures outdoors as restorative, a type of “liberating rupture from the
busyness, noise and pressures of their usual routines” (Moffat, Johnson & Shoveller 2009:8990). As such, the findings from this study provide tantalizing evidence that even recreational use
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of marijuana may often border on therapeutic use. Moreover, a survey of 236 medical students in
Colorado found students who used cannabis recreationally in the past were more likely to
endorse its therapeutic properties for prospective patients (Chan et al. 2016). We know there is
something innately therapeutic within cannabis, but perhaps this is also true within the manner of
how cannabis is consumed. Researchers have documented how cannabis is interpreted as
something that needs to be shared with friends, and socialization certainly has health-promoting
qualities (Sandberg 2012; Zimmerman & Wieder 1977; Becker 1973/1963).
Nevertheless, our imperfect categorization of cannabis use has been used as evidence
against cannabis’ medical value, especially since most patients have used recreationally prior to
obtaining medical certifications. While many patients report abstaining for years before seeking
cannabis for medicinal purposes, many also report using cannabis throughout their adult lives
(Newhart & Dolphin 2019; Athey et al. 2017; Reinarman et al. 2011; Ogborne et al. 2000). As
we shall see, this is just one of the many reasons some are skeptical of cannabis’ therapeutic
value, as no other medicine appears to be intrinsically pleasurable for the patient. Some
researchers have even found that the plant itself is not stigmatized so much as the intoxicating
effects (Pedersen & Sandberg 2013; Chapkis 2007). Historian John Charles Chasteen (2016)
says: “[M]arijuana’s euphoriant qualities, the basis of its recreational appeal, worry many
religious people, because the euphoria seems unearned and, therefore, immoral. The objection
that medical marijuana users will feel better partly because they are high is essentially moralistic.
It accompanies the worry that marijuana users are disrespecting traditional models” (136-137).
This concern over intoxication is not new as clinical publications on cannabis treatments
between 1839 to 1937 often focused on methods to reduce intoxicating side effects, favoring
alcohol extracts with less THC when compared to inhaled smoke (Lochte et al. 2017; Dahl &
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Frank 2011). Those who use cannabis for therapeutic reasons in Denmark say “medical
cannabis” is defined as use primarily for relief, with any other effects being secondary or
somewhat unavoidable (Dahl & Frank 2011). There is also the problem of treating cannabis as a
singular, uniform plant. For example, Brand and Zhao (2017) argue cannabis used in ancient
Chinese medicine had less psychoactive properties than modern cannabis. Not only did the
Chinese have different breeds of cannabis plants than we do today, they primarily utilized the
plant’s fibers and seeds, both of which contain minimal amounts of psychoactive THC.
While blurred boundaries is an interesting concept to be further explored in this study, it
complicates the creation of a cohesive literature review. For the most part, scholars have studied
recreational users and medical patients separately. Furthermore, research on medical cannabis
patients tends to be restricted to areas with permissible medical use, though people still use
cannabis for medical purposes in areas without medical cannabis laws. While they are not
officially recognized as medical cannabis patients, little else separates these users from cardcarrying patients in regions with medical cannabis policies. Yet it is possible that policy may
create differences between patients in areas with and without a medical cannabis infrastructure.
For example, in places without a legitimate cannabis industry, patients may rely on an
unregulated black market largely accustomed to recreational buyers.
Blurred boundaries also manifest in the divergent frameworks used by social scientists,
with some exploring the normalization of cannabis and others exploring the medicalization of
cannabis. Proponents of normalization often advocate for decriminalization while proponents of
medicalization often advance a general framework of harm reduction. Evidence supports that
both trends are happening simultaneously but not necessarily harmoniously as one trend may
represent a threat to the other. For example, recreational marijuana is potentially problematic for
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cannabis’ status within biomedicine since the profession relies on maintaining strict boundaries
between what is and what is not a legitimate medicine (Newhart & Dolphin 2019). Yet before I
review normalization or medicalization, I must explicate the social stigmas associated with using
cannabis. Understanding the role of stigma allows one to appreciate better the ways cannabis is
being both normalized and medicalized.

Stigma and Stereotypes
In his exploration of the deep history of cannabis throughout the world, John Charles
Chasteen concludes it has been a substance associated with outsiders in every society. Until the
latter part of the twentieth century, cannabis was “used by the poor, by the marginal, by the
chronically ill, by the artistically and philosophically and spiritually inclined, by seekers after the
meaning of life, and by social and religious nonconformists of various stripes” (Chasteen
2016:137). Stated otherwise, cannabis is a substance historically used by the marginalized
whereas alcohol has held a relatively privileged place throughout global history. The universal
deviant status of cannabis likely stems from a variety of social factors, but one lesson is clear—
all across the world, social groups who used cannabis were not considered a part of respectable
society.2 Moreover, as is documented in Appendix A, these groups tended to be racial and ethnic
minorities.
In the social sciences, research on disgraced identities stems from the work of sociologist
Erving Goffman and his influential book, Stigma: Notes of the Management of Spoiled Identity

2

Even in India, cannabis was consumed primarily by religious visionaries who intentionally distanced themselves
from mainstream society. The exception to this was the seasonal drinking of bhang, a beverage made with cannabis
leaf paste and mixed with milk and spices. The drink was consumed in celebratory occasions, notably by the
members of the upper caste. However, consumption of cannabis by the lower castes was frowned upon, perhaps
because they typically smoked the flowering tops of the plant called ganja (Lawrence 2019; Chasteen 2016).
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(1963). Loosely defined, stigma is a term describing a part of the self that is socially devalued to
where it becomes morally offensive. This aspect can be a physical abnormality, faults of an
individual’s character, or membership in a distasteful group. Either way, the “undesired
differentness” (5) negatively distinguishes the individual from normal individuals in a society
(Goffman 1963). This negative evaluation goes beyond individual sentiments and is a form of
shared cultural knowledge, often making the stigmatized targets of socially-acceptable prejudice
and discrimination. This part of my dissertation will explore the different types of stigma in
relation to both medical and recreational cannabis use. I also review strategies identified by other
researchers on how the stigmatized cope with or resist social stigma.
Stigma has become a popular concept in sociology and has been investigated in the
contexts of mental illness, deviant sexualities, drug abuse, religious affiliation, and much more.
As other scholars have built on Goffman’s foundational work, five defining features of stigma
have so far been identified (Herek 2004). These include the endurance of stigmatizing features
within individuals; the socially constructed meanings of the stigmatizing feature; the negative
evaluation of the stigmatizing feature by society; the tendency of the feature to become a master
status, engulfing the entire identity of a person; and the oppression of stigmatized groups through
the restriction of power, resources, and social rights. One striking finding from Satterlund and
colleagues (2015) was that many cannabis patients used the word “stigma” unprompted by the
interviewer. The use of this word was consistent with how it is used in the social sciences,
indicating the participants had an accurate understanding of the nature of stigma. They knew
marijuana was viewed negatively by society and that their own history as a past recreational user
would result in judgment from others.
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Contemporary conceptualizations of stigma are more attentive to socio-cultural contexts
and variations in experience (Livingston & Boyd 2010). For example, the stigma of being a
cannabis user may be differentially applied and experienced between social classes, races, and
genders. Those with social privileges are often able to conceal their stigmas better or resist
stigmatizing labels becoming their master status. Furthermore, stigma may result from unequal
power relations where privileged groups devalue the identity, lifestyle, and existence of groups
with less social power (Herek 2007). The important thing here is that prejudices directed towards
a target group become shared cultural knowledge and exist outside of individual attitudes and
actions (Herek 2007; Goffman 1963). Since privileged groups wield more social power and
cultural influence, they may have a more considerable say in what becomes a widely accepted
cultural attitude. Stigmas also vary in their source. Michael Hammer (2015) says, “Medical
marijuana is a rare issue where social, medical, and political stigmas intersect” (286). In other
words, our negative attitudes towards the medical use of marijuana stem from a combination of
overlapping institutional forces. Stigma also interacts on multiple analytical levels with
researchers differentiating between structural, social, and internalized stigma.
Structural stigma operates on the macro level and results from institutional policies and
procedures that oppress non-normal people (Livingston & Boyd 2010; Herek, Gillis & Cogan
2009; Corrigan, Watson & Barr 2006). Patrick Corrigan and colleagues (2005) define structural
stigma as institutional policies that restrict rights and diminish the life opportunities of people
with stigmatized identities. Examples of this include state legislation that restricts firearm
ownership and parental rights of people with mental illness (Corrigan et al. 2005). Likewise,
many states have laws that forbid felons from participating in some parts of public life even after
they serve their time. Anti-sodomy laws are also an example of structural stigma as these were
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once used to justify the discriminatory treatment of gays and lesbians (Herek 2007).
“Criminalizing activities render them deviant, and it is generally assumed within society that
there is a good reason for this status” (Bottorff et al. 2013:8). Structural stigma can also be
ideological wherein cultural attitudes work to privilege one group at the expense of others. An
example of this is heterosexism, a cultural default that presumes everyone to be heterosexual
while problematizing visible sexual minorities as abnormal and inferior (Herek et al. 2009;
Herek 2007).
Ideology and institutional policy work together to create structural prejudices that
disadvantage stigmatized groups. Most importantly, these macro-level forces create the context
for stigmatizing actions and beliefs within groups and individuals. As applied to cannabis, some
structural sources of stigma include laws criminalizing cannabis, policies banning cannabis and
cannabis users in the workplace as well as (public) housing, school programs where cannabis is
taught to be a dangerous drug, and organizational views that problematize cannabis, such as
those found within Child Protective Services or the medical profession.
On a societal level, the degree of perceived dangers or immortality posed by the
stigmatized varies over time and between groups, as does the degree of perceived blame (Lloyd
2013). We are said to have a uniquely Puritanical culture where pleasure and intoxication are
stigmatized, and so too are the tools to achieve these states (DeAngelo 2015; Reinarman 1994).
This general drug stigma can crystallize into specific drug stigmas (Lloyd 2013), as is the case
with “stoners” and “potheads”. The stigma of drugs is also one in which the individual is blamed
for their irresponsible decisions and poor choices, framing drug-related stigmas as warranted or
deserved (Lloyd 2013). Some may perceive marijuana users to be making a poor lifestyle choice,
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much like obese people (Satterlund et al. 2015). Regardless of their exact manifestations,
structural stigmas inform how individuals and groups view the stigmatized.
Social stigma works on the meso level and describes how groups endorse cultural
stereotypes that disadvantage stigmatized people (Livingston & Boyd 2010). There is some
disagreement between scholars on the exact terminology used at this analytical level. Patrick
Corrigan and colleagues (2006) call this public stigma, whereas Herek and colleagues (2009) call
this enacted stigma. Regardless, this type of stigma is overt and manifests in both group and
individual actions, epithets, shunning, ostracism, discrimination, and violence towards the
stigmatized group (Herek 2007). Additionally, Michael Hammer (2015) provides evidence that
informal norms on the cultural level impact state and local policy decisions, as when a cannabisintolerant community votes to block (medical) marijuana reform or ban marijuana businesses
within the community.
This type of enacted stigma can also be directed towards those who associate with the
stigmatized group, resulting in what Goffman (1963) called courtesy stigma. This occurs when
an individual is stigmatized for who they associate with rather than their own group affiliations
or behaviors. For example, health care workers who treat AIDS patients may be socially
distanced by their peers in much of the same way as someone suffering from AIDS. Courtesy
stigma is also present in a study of straight teenagers with LGB (lesbian, gay, bisexual) siblings
where Amy Brainer (2015) found the teens were frequently accused of being homosexual by
their peers. Even though the teens interviewed were straight, their heterosexuality was called into
question by their peers for having an openly LGB sibling. Using similar reasoning, a courtesy
stigma may also be applied by non-cannabis users who have friends or family whose cannabis
use is publicly known. The group association is what is targeted rather than something about the
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individual or their behaviors. In fact, recent organizational research revealed cannabis stigmas
are often transferred to businesses associated with the cannabis industry, such as law offices,
accounting firms, and public relations agencies (Lashley & Pollock 2019).
At the individual level, stigma can be felt, internalized, or both. Felt stigma results from
the awareness that an identity is culturally devalued and can result in anticipatory behavior to
avoid negative interactions (Herek et al. 2009; Herek 2007). Felt stigma causes behavioral
adjustments in both the stigmatized and normative groups. In the context of heterosexism, both
heterosexual and non-heterosexuals may avoid gender nonconforming behavior and deviant
sexual expressions in order to avoid the label of a stigmatized sexual identity (Herek et al. 2009;
Pascoe 2007). David Karp (2006) documented the stresses of felt stigma on the romantic lives of
patients taking antidepressants. He found patients worried about adverse reactions when first
disclosing their medication regiments to new love interests, often obsessing over when and how
to disclose such information. A couple of Karp’s participants even described concealing their
medicine cabinets once new relationships blossomed into spending nights together. However,
felt stigma does not necessarily have to be internalized as it results from the mere knowledge that
an identity carries negative social consequences.
Felt stigma may lead to enacted stigma when an individual is motivated to publicly prove
they are not part of a stigmatized group. For example, C.J. Pascoe (2007) found that teenage
boys routinely rebuke homosexuality in order to reaffirm their heterosexuality to others. Using
“fag” as an insult (an example of enacted stigma) signals to others that one is not a fag, even if
the target of the abuse has nothing to do with homosexuality (Pascoe 2007). Anticipating
rejection from others, both cannabis users and non-users may avoid cannabis culture, individuals
known to consume cannabis, and anything else that may raise suspicions of cannabis use.
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Research by Corrigan et al. (2006) proposes a similar model using the language of
stereotypes instead of stigma. They call public stigma stereotype awareness in that people know
negative attitudes towards some identities exist within society. After becoming aware of these
negative evaluations, an individual may start to endorse such beliefs through stereotype
agreement. If this occurs and the individual applies devalued cultural stereotypes onto
themselves, it may result in decreases in self-esteem and self-efficacy (Corrigan et al. 2006).
This is also known as internalized stigma and results when individuals come to believe in the
cultural stereotypes surrounding a stigmatized identity (Livingston & Boyd 2010). Both the
stigmatized and normative groups may internalize cultural stigmas, resulting in self-stigma in the
former and prejudice in the later (Herek et al. 2009; Herek 2007). Anti-homosexual prejudices
can be accepted by heterosexuals and manifest as personal biases towards non-heterosexual
people. The same negative attitudes can also be accepted by non-heterosexuals and manifest as
internalized homophobia, internalized heterosexism, and internalized homonegativity (Herek
2007). All of these result in self-directed prejudice by stigmatized individuals as they internalize
society’s negative evaluation of their identity (Herek et al. 2009). However, Corrigan et al.
(2006) note that not all people who are aware of or endorse cultural stigmas will internalize such
stigmas, and this resistance protects their self-esteem and self-efficacy.
This internalization of stigma is distinct from an isolated individual attitude, as stigma
constitutes shared cultural knowledge that benefits some groups at the expense of others.
Furthermore, how an individual acquires a stigmatizing label is not uniform and depends on the
specifics of the situation. For example, Gregory Herek (2004) accurately points out that
homosexual behavior may be dismissed if it only occurs in adolescence, under the influence of
alcohol or drugs, or within the confines of a sex-segregated institution like prisons. Anecdotally,
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the same is true with marijuana. Bill Clinton avoided the stoner label by claiming he tried
marijuana only once and did not inhale. Intermittent marijuana use during one’s teenage years
may be forgiven if the individual ceases use at some point before adulthood. The stoner label can
also be avoided by saying one only smoked when they were drunk, by claiming they mistook a
joint for a cigarette, or that they unknowingly once ate food infused with cannabis. You may also
not think someone is a stoner if they admitted to using marijuana while on vacation in Jamaica,
Amsterdam, or another location with a well-known cannabis culture. In all these cases, marijuana
use is seen as incidental and not characteristic of the individual.3
Making matters more complicated, stigmas vary in their degree of public visibility.
Goffman (1963) termed visible stigmas discrediting and non-visible stigmas as discredible.
Since the latter is concealable, an individual is only devalued once their stigma becomes known
to others. People with non-visible stigmas routinely manage the extent to which others are aware
of their stigma (Herek 2004; Goffman 1963). This is a strategy that protects the self on the one
hand but may also diminish self-esteem and self-efficacy on the other. For example, Herek and
colleagues (2009) found negative self-perceptions were significantly lower among LGB
individuals who were out to family and friends compared to LGB individuals who merely
believed their family and friends knew their closeted sexual identity. This reduction of selfstigma is highest for those who had explicit conversations about their sexual identity (Herek et
al. 2009). As such, while keeping a stigmatized identity a secret may protect against negative
reactions from others, it may also damage one’s sense of self and mental health. After all, our
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The endurance of stigmas also varies on the organizational level, with researchers differentiating between event
stigmas and category stigmas. Event stigmas result from occurrences like bankruptcies or lawsuits which often fade
from the public’s memory over time. Category stigmas, also referred to as core stigmas, result from an
organization’s identity or central operational attributes where the very nature of the business is stigmatized. For
example, core stigma is problematic for enterprises such as sex toy retailers, weapons manufacturers, and cannabis
businesses (Lashley & Pollock 2019).
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sense of self is partly formed by those who we find emotionally important. We internalize the
expectations and opinions of others, creating “a chorus of voices that shape our internal
conversations about who we are, what we ought to feel, and how we should act” (Karp
2006:126).

Resistance and Empowerment
Since stigma results in lasting social disgrace, the term is increasingly used in a manner
of advocacy to describe the prejudice and discrimination experienced by stigmatized peoples
(Lloyd 2013; Bayer 2008). Empowerment is particularly important here as the stigmatized face a
vicious cycle of compounding disadvantages. Stigmas are associated with lower levels of hope,
self-efficacy, self-esteem, social support, and quality of life (Livingston & Boyd 2010). The
stigma of being a medical cannabis patient can lead to chronic stress and social isolation
(Satterlund et al. 2015). For example, their health may also suffer as a result of underutilizing
health care services out of the fear of disapproving health care providers. There is a tendency for
medical professionals to spend time analyzing the patient’s moral fiber and addictive potential
rather than the patient’s underlying illness. This takes time away from meaningful care and
discourages patients from being honest with their care providers (Bottorff et al. 2013). Dubin and
colleagues (2017) suspect there may be a mismatch between physicians’ formal curriculum,
which emphasizes stigma reduction, and the hidden curriculum, which implicitly reproduces
anti-marijuana attitudes. Furthermore, when patients forgo medical cannabis over concerns of
stigma, they may experience unnecessary pain, suffering, and unwarranted stress (Ryan &
Sharts-Hopko 2017). “Medicine can only be effective if it is taken, and stigma and lack of
acceptability can interfere with compliance and safe access” (Rudski 2014:318).
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A 2013 qualitative study by Bottorff and colleagues identified three sources of stigma
directed towards medical cannabis patients. The first of these was negative views of cannabis as
a recreational drug where larger society constructed patients as “potheads” or “stoners”
(Bottorff et al. 2013). Patients reported that friends and family members questioned the
legitimacy of their illness and choice of medication, often not believing cannabis had any
medicinal benefits. This lack of trust manifested in enacted stigma wherein others explicitly
doubted the severity of a patient’s illness and motives for cannabis use. Perceived stigma also
forced patients to conceal their cannabis use from their social networks, withdraw from
disapproving family and friends, and sometimes even relocate to another area (Bottorff et al.
2013).
The second source of stigma found by Bottorff et al. (2013) was illegal activity
surrounding cannabis use whereby patients are viewed as engaging in illicit drug activity. Some
patients found comfort in having a state-issued medical card since such cards distinguish patients
from illegal recreational users. Other users, however, feared a centralized database of patient
information could be abused by authorities with one participant saying, “[B]efore I was
anonymous and I think I was in a better position” (Bottorff et al. 2013:5). Patients who cultivated
their own medicine were suspected of being drug dealers and reported repeated harassment by
police, landlords, and housing authorities for those in state-subsidized housing. Women also
have the added stigma of being labeled negligent mothers if it was known they consume
marijuana, a well-founded fear in light of child protective services intervening in the homes of
families who use medical cannabis (Reinarman et al. 2011).
The third and final source of stigma identified by Bottorff et al. (2013) was using
cannabis in the context of layered vulnerabilities or how medical cannabis use can be entangled
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in a web of other marginalized identities. Patients often suffer from a marginalized or
controversial disorder, such as fibromyalgia, HIV/AIDS, or mental illness. Those in poverty, as
well as gender and sexual minorities, may already be framed as “problem patients” by the larger
medical establishment with the addition of cannabis use further adding to their social devaluation
(Bottorff et al. 2013). Perhaps another term this source of stigma could be intersectional stigma.
Intersectionality acknowledges our lives are not experienced one identity at a time, but instead
we experience a simultaneous plurality of social privileges and oppressions (Collins & Bilge
2016). Layered vulnerabilities are particularly sensitive in the United States with its history of
socially constructed drug scares. Recurring moral panics related to drugs are often accompanied
by ideologically constructed enemies, such as immigrants or countercultural youth. Sociologist
Craig Reinarman calls drugs “richly functional scapegoats” (1994:165) for social fears rooted in
racism, xenophobia, classism, ageism, and more.
How can we resist or combat stigmatizing forces? From a psychological standpoint, selfstigma can be reduced through one of two general strategies (Mittal et al. 2012). The first
strategy is to alter stigmatizing beliefs and attitudes in an individual through practices such as
cognitive restructuring and psychoeducation. The second strategy, which is gaining popularity
among stigma experts, is one of mindful acceptance. This latter approach does not challenge
stigmatizing forces or stereotypical thinking, but instead aims to make the individual more
comfortable with their current self. Mindful acceptance can enhance a patient’s overall selfesteem, empowerment, and help-seeking behavior (Mittal et al. 2012). Outside of clinical
practice, contact with stigmatized people has also been shown to reduce internalized stigma
within both stigmatized and non-stigmatized populations (Herek 2007). Positive interactions
with the stigmatized can be beneficial for everyone involved.
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Yet the most effective stigma reduction strategy may be in changing societal beliefs and
attitudes (Herek et al. 2009). If stigma is conceptualized as being a top-down model wherein
individuals internalize negative cultural stereotypes, it makes sense to enact destigmatizing
changes on the structural, cultural, and organizational levels. Part of the stigma towards medical
cannabis patients comes from the ambiguous state of the medicine, something that is both illegal
and therapeutic. Changes in drug policy may help shift our cultural framework surrounding
cannabis by stopping institutional messages aimed at presenting users as morally deficient,
criminal, or psychologically ill (Hathaway et al. 2011). Structural changes can be accomplished
through legal reform, but also through educating medical practitioners and publicly addressing
the consequences of cannabis’ criminalization (Bottorff et al. 2013). Legalization will not
eliminate the stigma surrounding cannabis, but it will re-classify medical users as normal, lawabiding citizens. However, the legacy of stigma will still differentially impact those with less
social privileges. A good example of this can be found in a statement by Anqunette Sarfoh, a
former news anchor who quit her job to open a medical cannabis dispensary in Detroit. Sarfoh
reflects on the challenges in recruiting diverse staff in a story reported by Kathleen Gray (2019):
In our community, cannabis use has been stigmatized, because of how the
legal impacts have affected our community… In [white] communities, kids can go
in a cornfield and smoke a joint and go on about their lives. But in our
communities, what happens when you're caught, your future is gone. And so for
the longest time, you just don't even touch it and you grow up knowing that it
could ruin your life (Anqunette Sarfoh quoted in Gray 2019).
Even after cannabis is legalized, the trauma resulting from prohibition will continue to
exist as will entrenched anti-cannabis ideologies. Participants in several studies thought much of
the stigma surrounding cannabis use is a result of societal ignorance or deliberate misinformation
(Satterlund et al. 2015; Hathaway, Comeau, & Erickson 2011). Changing institutional messages
about cannabis would be a good place to start, but the general public’s perception of drug use is
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also shaped by the media, their personal experiences, and their surrounding environments.
Environments that facilitate contact between the public and the stigmatized can change negative
attitudes, relying on the principle that with familiarity comes empathy (Lloyd 2013; Herek
2007). As such, while some patients may prefer nondescript cannabis facilities (Satterlund et al.
2015), reducing the visibility of such locations may adversely impact public perceptions of
medical cannabis users.
Conspicuous medical cannabis services could reduce some social stigma, but the quasilegal industry faces strict regulations on permissible public outreach and advertising4. Even
Facebook has a corporate policy prohibiting paid advertisements about cannabis and actively
suppresses cannabis-related information. In fact, a company trying to promote a cannabis
educational seminar is currently suing Facebook for this very reason. Cannaramic Media, Inc.
charges that “the Facebook algorithm systematically removes, bans and limits not only the
promotion, but also the sharing of information related to legal cannabis, the industry,
legalization, social equity and medical uses of marijuana, even though the plant is now legal in
33 states, the District of Columbia, several U.S. territories, and dozens of countries around the
world” (Hasse 2019). Until this type of blanket censorship ends, the current public relations
strategy will remain one where cannabis entrepreneurs are active in politics and encourage
(positive) news reporting on the industry (Kilmer & MacCoun 2017).
The operational structure of medical cannabis facilities access may also impact social
stigma. Amanda Reiman (2008) details two different models of medical cannabis facilities, the
pharmacy model and the social club model. The pharmacy model is how facilities in most states,

4

A company called MedMen based in California has been advertising on the Howard Stern Show for several years.
They may be allowed to do this because SiriusXM Satellite Radio is a paid subscription service and exempt from
some of the regulations on content over public airwaves. Interestingly, the commercial emphasizes how the
company is professional and medically-focused, so customers shouldn’t worry about stigma and stereotypes.
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as well as Michigan, operate, characterized by the narrow mission of offering medicine for
purchase. This model is often administered in a top-down manner where laws dictate permissible
conduct and sales (Reiman 2008). The social club model, on the other hand, is built from a
bottom-up approach where patient needs are the starting point. This was the model pioneered by
Dennis Person, who in 1992 started the first medical cannabis buyers club in California, largely
serving patients with AIDS (Reiman 2008; Grinspoon 1999; Feldman & Mandel 1998). The
defining characteristics of the social club model are the ability to consume medicine on-site and
service integration. These dispensaries not only sell medicine, but they also function as
community centers where patients develop social bonds and exchange information (Nicholls-Lee
2019; Feldman & Mandel 1998). There may be support groups for specific populations (e.g.,
veterans and gender-specific groups) as well as programs such as art classes, bingo, movie
nights, excursions, and even doggy daycare. The idea is to facilitate social support among
patients while allowing the use of medication at the same time, “to infuse a feeling of support
and comfort into the client population served” (Reiman 2008:40).5
With medical cannabis carrying a social stigma, these social clubs may help protect
against some of the ostracization and mental health consequences that come with being a patient.
They provide a compassionate community designed to address the physical, mental, and social
needs of patients. Interestingly, similar forms of social support have been documented among
other groups including graduate students who smoke marijuana within the social context of
marijuana prohibition. While the graduate students in Emily Garner’s (2016) phenomenological
study spoke about how society oppresses their non-medical use of marijuana, they also spoke
about a mutual sense of community that comes with knowing other users. One student described

Alaska became the first state to permit “social marijuana use” in April 2019. Dispensaries can apply for a license to
run a cannabis lounge section in their facilities for adults ages 21 and up. This is in a recreational context, though.
5
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their smoking friends as their support system while another discussed the bonding that results
from smoking with professors, an act that helps break down institutional status differences. In
other words, the mutual sense of secrecy associated with smoking marijuana may help users
develop meaningful social bonds. Knowing other academic marijuana users validated the
graduate students’ sense of self, as knowing other high achievers who smoked allowed them to
know their lofty goals were possible (Garner 2016). These underground smoking circles may
serve as protective and beneficial networks for graduate students in the often-alienating academic
community.
In lieu of radical social or structural change, individuals must learn to cope with or resist
stigmatizing forces. Bottorff et al. (2013) identify four coping strategies used by medical
cannabis patients, including: concealing their cannabis use, convincing others of cannabis’
benefits, using cannabis responsibly, and engaging in political action to defend their right to use
cannabis as a medicine. The first of these, concealing cannabis use, connects back to the
discredible nature of marijuana consumption. Being a medical cannabis patient comes with a
concealable stigma which causes patients to take precautionary measures about others knowing
their patient status. While most people taking prescribed medications keep it a secret from others,
there is something unique about prescribed cannabis and its illicit nature (Satterlund et al. 2015).
The strategy of keeping cannabis use undercover is best exemplified by a 55-year-old woman
who said: “Keep your mouth shut, grow it, use it, don’t tell anybody, don’t even tell your family,
don’t tell our friends, keep it to yourself and save your own life” (Bottorff et al. 2013:6). Other
strategies for secrecy included using incense, changing clothes after smoking, and keeping
vigilant about who else could be watching. Relatedly, research on medical cannabis cultivators
discovered many workers use “cover stories” when conversing with strangers or community
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outsiders. These individuals often say they work in a related occupation or generically express
they are small business owners (Adelman 2013). Satterlund and colleagues (2015) also found
patients would also refrain from commenting on marijuana-related issues when they arose in
everyday conversations. However, an irony exists when this tactic is used within the current
bureaucratic system of medical cannabis. In order to become a medical cannabis patient,
individuals are made identifiable through state registries and medical evaluations by physicians
(Newhart & Dolphin 2019).
The second coping strategy patients use is to confront the stigma by convincing others of
cannabis’ benefits through education and candid discussion. One patent took pride in
transforming her once-disapproving mother into a “full on cannabis granny” (Bottorff et al.
2013:7). These conversations are necessary in a social context where marijuana use is associated
with addiction, laziness, crime, and other social ills. In other words, popular thinking says
marijuana use is incompatible with conventional roles and responsibilities (Hathaway et al.
2011). The task of changing these sentiments falls largely on patients though recreational
marijuana enterprises may also help in this regard. A study of cannabis tourism in Colorado
found the industry consciously tries to challenge perceptions of deviance through maintaining a
professional appearance and conveying the latest scientific research on cannabis to their guests
(Keul & Eisenhauer 2019). However, these public-facing and polished cannabis experts are using
proven tactics borrowed from early medical cannabis activists.
Thirdly, medical cannabis users also stress the importance of using cannabis responsibly
and in an appropriate, respectful manner. Some expressed resentment towards recreational users,
who they perceived as irresponsible and detrimental to cannabis’ public image (Bottorff et al.
2013). It is common for cannabis users to use disidentifiers (Goffman 1963) wherein individuals
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explicitly reduce their involvement in the drug trade and/or avoid other drugs or drug users.
These disidentifiers help defend the user from deviant labels associated with the drug. When
cannabis users take defensive positions regarding their use, it’s often a good sign they are
attempting to avoid stigma (Sandberg 2012). Patients can prevent some stigma by making it
known to others that their cannabis use is for medical purposes as opposed to recreational
purposes (Ryan & Sharts-Hopko 2017; Satterlund et al. 2015; Bottorff et al. 2013). Michael
Hammer (2015) notes that the word “medical” as a qualifier has had some success in shifting
cultural attitudes towards marijuana from a dangerous drug to a legitimate medicine. More
fascinating, though, is that recreational marijuana users also look down on people who misuse or
abuse cannabis, effectively stigmatizing heavy users much like non-users would (Hathaway et al.
2011). Many of the recreational users emphasize the need to retain control over their marijuana
use, moderate their consumption, and express a lack of interest in stronger forms of the drug.
These findings build on Hathaway’s (2004) suggestion that much of self-regulation and selfcensorship is done to avoid the risky label, as risk-avoidance is now deeply connected to
morality.
The fourth and final strategy to manage cannabis-related stigma is engaging in political
action by becoming a cannabis activist and advocating for the right to use cannabis as a
medication (Bottorff et al. 2013). Many medical cannabis patients exhibit tertiary deviance,
defined as deviants who fight to change social stigma related to their identity. Primary deviance
is characterized by denial, secondary deviance is categorized as acceptance, but tertiary deviance
is characterized by advocacy and mobilization (Adler & Adler 2016/1994; Becker 1973/1963).
Goffman (1963) described how empowered individuals may become public representatives for
their stigma, a situation we now see with celebrities sharing their stories of addiction, mental
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illness, and other discredible traits (Lloyd 2013). Sandberg (2012) described how Norwegian
cannabis users employed “bravado” to boast about the benefits of cannabis, such as how it
enhances creativity and is therefore used by prestigious people. This bravado allows users to
frame cannabis as normalized while downplaying undesirable side effects (Sandberg 2012). It
should also be noted here that individuals have the agentic ability to resist stigmatizing messages
from society. Research has shown people who have experienced stigma may be less willing to
stigmatize others (Herek 2004). Finally, stigma does not necessarily lower self-esteem because
people have a capacity for cognitive resistance and may fight against the moral judgments of
others (Bayer 2008).
The classic literature on stigma emerged from clinical studies but now social scientists
who study stigma often do so from a perspective of advocacy. This is because stigmas are often
imposed by the powerful onto those with less social power, constituting a classic form of
oppression (Lloyd 2013; Bayer 2008). However, non-elites may also be complicit as they police
and enforce social stigmas as if they were following orders from those with social power. People
like labels, and being labeled as normal (i.e., non-stigmatized) may be partly accomplished by
directing stigmas away from the self and on to others. However, while many would argue we
have a moral responsibility to defend those with less social power, a contrasting perspective
acknowledges that stigma can bring about positive changes for the whole of society. Stigma has
long been used as a means of social control wherein the public is discouraged from partaking in
damaging behaviors such as illicit drug use (Ahern, Stuber & Galea 2006). This principle of
deterrence through stigma has been successfully deployed against tobacco.
Anti-tobacco campaigns of the 1970s successfully denormalized public smoking by
directing stigma towards smokers. This was facilitated by framing smoking as an environmental
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health hazard as opposed to merely a personal health problem. However, while strong evidence
existed for the latter, there was little scientific evidence at the time connecting smoking to public
health risks like second-hand smoke (Bayer 2008). Philippe Lucas (2009) also notes how
bureaucracies rely on moral justifications when the available scientific evidence does not support
their position, and this was the case with both marijuana prohibition and public tobacco smoking.
The push to frame smoking as an undesirable anti-social behavior continues to this day, and
Bayer (2008) suggests it may be more effective in curbing smoking than other anti-tobacco
policies like consumption taxes. Increasing the price of tobacco products disproportionately
burdens those at the bottom of the socioeconomic ladder while stigmatizing tobacco use cuts
across class lines. The only problem with applying these ideas to marijuana consumption is that
smoking marijuana in public has rarely been a problem. As other scholars have noted, most
smoke marijuana in private spaces and practice an etiquette of seclusion (Johnson et al. 2008).
Nonetheless, there are reasons we should be cautious of imposing stigmas as a means of
deterrence. While stigmas impact all social groups (Bayer 2008), those with social privileges
often have more power to resist being labeled as deviant or a greater ability to conceal their
devalued identity. For example, our culture stereotypically associates marijuana use within
minority groups (e.g., immigrants and communities of color) when facts point to higher use of
marijuana among white people (Garner 2016). Likewise, stigmas obscure facts by emphasizing
immorality over logical reasoning. I would also add to this that when we link marijuana use to
deviants, reckless youth, and addicts, we increase the stigma and consequences for normative
professionals who use the same substance. Furthermore, while stigma may help to deter drug
use, it also results in dire physical and mental health complications among the stigmatized
population (Ahern et al. 2006). Stigmatized people may respond with anger, self-imposed
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isolation, or attempts to conceal their identity, all of which are associated with negative mental
health outcomes. Institutional discrimination also results in lower physical health as drug users
are treated as problematic by the medical establishment (Ahern et al. 2006). A final concern with
socially-beneficial stigmatizing is that once a stigma is established, it is very difficult to change
or remove. Normalizing a stigma requires a significant cultural shift often occurring over many
years.

Normalization
The reasons people use substances are varied, complex, and change over time, yet we still
tend to develop and apply one-dimensional theories of drug use. In doing so, we form inaccurate
conclusions that commonly lead to inappropriate policies (Osborne and Fogel 2008). For
example, those who argue marijuana is a normalized drug may frame the substance through a
recreational perspective that neutralizes medical or spiritual uses as crafty recreational use.
Similarly, those who argue cannabis is a medicine may also neglect the pleasurable qualities of
the substance and how healthy people use the substance for fun. In either case, differential
constructions of the substance are ignored in favor of a cohesive theory which may be
appealingly simple but conceals contrasting explanations.
The normalization hypothesis is prominent in both criminological and sociological
literature (Duff et al 2012; Sandberg 2012) and suggests that the moral boundaries surrounding
marijuana have been redrawn to accommodate non-abusive use. Critics have argued this is an
oversimplification wherein social contexts are ignored, as social tolerance towards marijuana is
based on a variety of factors (Hathaway 2004). Nevertheless, more people are enjoying
marijuana today than ever before. In 2017, nearly 15% of American adults reported using
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marijuana in the past year (Keyhani et al. 2018). Despite the growing popularity of marijuana
use, increased consumption is only one part of the normalization process.
Another key dimension of normalization is the reduction or elimination of social stigma.
Normalization theory came from studies on disability and has since been used as an interpretive
tool for how marijuana is becoming an ordinary intoxicant in society, largely starting in the
1990s (Sandberg 2012). This is distinct from neutralization theory which sees deviant drug users
as attempting to manage a stigma because they are invested in mainstream society. Likewise,
Erving Goffman (1963) distinguished between normification, which describes how deviants
assimilate into society by attempting to pass as normal, and normalization, which describes the
societal transformation wherein a once-deviant identity becomes accepted by others. While
normification essentially attempts to conceal deviance, some scholars have argued normification
has facilitated cannabis normalization. Lau et al. (2015) say cannabis users help normalize
cannabis through normifying harm reduction techniques like self-regulation and not using at
work. Such strategies help users pass as normally functioning in their everyday lives, but this
claim fails to consider medical patients who may need to medicate in order to optimally function
through their daily routines. It is also reminiscent of the closet in the LGBTQ community,
something that oppresses the individual and diminishes the group’s visible presence in society.
Nonetheless, normalization theory applied to marijuana would assume there is no longer
a stigma associated with being a marijuana user (Sandberg 2012; Parker, Williams & Aldridge
2002; Goffman 1963). While the stigma of marijuana use appears to have diminished, there is
little evidence that such stigma has entirely disappeared. Some scholars argue the social stigma
surrounding marijuana use now only applies to irresponsible use (Duff et al. 2012; Hathaway et
al. 2011; Jarvinen & Demant 2011). Moderate recreational use has become normalized while
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excessive and/or dependent use is still problematized as drug abuse. A “normal marijuana user”
is one who practices self-control, discretion, and moderation (Duff et al. 2012). Similar
sentiments have been found among medical cannabis patients who routinely emphasize the need
for responsible use, often balancing symptom management with self-imposed limits on
consumption during the workday (Newhart & Dolphin 2019). Hathaway and colleagues (2011)
say, “A sense of normalcy is preserved by avoiding attributions and behaviors seen as risky, and
thereby the associated stigma” (456). Therefore, the residual stigma of marijuana may function
to discourage risky use of marijuana, as “participants routinely insisted that this stigma had more
to do with the circumstances of [marijuana] consumption than with the act itself” (Duff et al.
2012:281).
Even though marijuana use may be becoming more normalized, the fact that most users
remain guarded about their use suggests we still have a social structure or culture (or both) in
which cannabis is stigmatized. This is particularly true for women who use cannabis because
they are judged more negatively by others and therefore take extra steps to remain discreet:
“Because marijuana is often seen as a masculine activity, a normalised marijuana using image is
unavailable to many women” (Mostaghim 2019:64). The gendered dynamics of cannabis will be
discussed thoroughly in Chapter 4, but the point is raised here because normalization is an
uneven process along the lines of gender, race, social class, and generation. Indeed, marijuana
may be more normalized for those with elite statuses including musicians, athletes, and other
celebrities. These individuals were relatively immune from the “othering” endemic in Canadian
newspaper articles on marijuana use where Haines-Saah et al. (2014) uncovered a “tendency to
use a person’s race, class, or other irrelevant characteristics to position him or her as different,
problematic, or ‘other’” (55). Nonetheless, it appears being a marijuana user no longer denotes a
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master status and has instead become just another aspect of a person’s life (Jarvinen & Ravn
2014; Sandberg 2012; Hathaway et al. 2011). Yet since the stigma of reefer madness still
endures, recreational users practice self-regulation and self-censorship when it comes to their
own consumption (Johnson et al. 2008).
While many researchers have pointed to lingering stigma to argue against normalization,
a pair of Norwegian researchers claim normalization is problematic because a distinct marijuana
subculture still exists despite marijuana use becoming more widespread (Pedersen 2014;
Pedersen & Sandberg 2013; Sandberg 2012). Subcultures may be conceptualized as specific
groups of people, but Sandberg (2012) argues subcultures should be defined by rituals, stories,
and symbols. Cannabis or marijuana subcultures, for example, are characterized by a shared
symbolic universe where users are acculturated to smoking rituals and construct meanings
related to the plant that oppose conventional meanings. This subculture has also been
characterized by a mutual emphasis on embodied pleasures and sensual experiences (Keul &
Eisenhauer 2019). Furthermore, participants in the subculture share values that emphasize
naturalness and authenticity (Sandberg 2012; Shukla 2006; Zimmerman & Wieder 1977), a
feature also found by Canadian researchers studying teens who smoke marijuana (Moffat,
Johnson, & Shoveller 2009).
Though increased use of a substance among the population is often cited to be part of
normalization, Sandberg (2012) finds that marijuana users in Norway still view the drug as
oppositional and a symbolic marker of difference. This does not mean to suggest that this
subculture has been static over the past several decades, but rather that users still classify
themselves as existing apart from the mainstream (Sandberg 2012). Not all scholars agree with
this conclusion, though. A study of adult marijuana users in Canada found most perceived

38

cannabis to be mainstream rather than confined to a subculture or alternative lifestyle (Duff et al.
2012). Yet this cannabis subculture has been described in the United States with ethnographic
research documenting regional differences between west coast and east coast marijuana users
(Johnson et al. 2008). More importantly, these subcultures have historically been a powerful
counter to the interests of U.S. drug policy and enforcement.
Subcultures can also be commodified as the rise of cannabis tourism in Colorado, as
described by Keul and Eisenhauer (2019), exemplifies the continued existence of a distinct
cannabis culture. Cannabis tourism not only promotes cannabis consumption, but it also
immerses visitors in the cannabis universe through a bus tour of the industry. With expert guides
acting as cultural interpreters, visitors are transported to locations like dispensaries, growing
operations, glass blowers and paraphernalia makers, and even restaurants that offer selected food
pairings to accompany specific strains. Along this journey, visitors are encouraged to observe the
facilities, indulge in the smell of growing plants, taste the variety of cannabis strains, experiment
with different methods of consumption, learn about classic and innovative smoking rituals, and
experience the unique effects of each cannabis strain they consume. Furthermore, visitors often
share stories of cannabis and prohibition in their home states (Keul & Eisenhauer 2019),
something perhaps akin to folktales or myth-making. As one may have noticed, the cannabis
tourism industry resembles the model adopted by Napa Valley vineyards, though regulations
limit the conglomeration of different cannabis facilities on one site (hence the need to drive to
multiple destinations).
This brings us to another part of the normalization debate where cannabis normalization
is seen as contextual since users navigate social settings of both normalized and stigmatized
cannabis use (Lau et al. 2015:11). While no one denies that perceptions of cannabis vary
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between social settings, we should question the utility of applying the concept of normalization
on a situational basis. Afterall, isn’t every deviant activity more or less normal depending on the
setting? Cannabis consumption is normal during the dispensary bus tour described above, just
like nudity is normal at a nude beach or in the private confines of one’s home. This is why
normalization should be understood as occurring on the societal and/or cultural levels. We have
seen some degree of cultural accommodation concerning cannabis, but we have yet to move
beyond the stigmas and structural penalties that have been elements in our society for so long.
The debate surrounding marijuana normalization is ongoing and much work still needs to
be done in the area. For example, most of the literature on marijuana normalization focuses on
the macro, rather than micro, levels of analysis (Duff et al. 2012). We have little understanding
of how social groups or individuals come to change their views on marijuana, though we have
some evidence that institutional change requires activism and patience. Normalization arguments
also need to account for how different social groups perceive marijuana, as Erickson and
Hathaway (2010) believe normalized marijuana use is largely a youth phenomenon. Indeed, the
argument that cannabis is normalized came from longitudinal research on UK teenagers in the
1990s (Pennay & Measham 2016; Parker, Williams & Aldridge 2002). This assertion continues
to live on perhaps because most empirical studies on marijuana use trends focus on youth
populations (Duff et al. 2012). Nonetheless, 43% of full-time college students reported using
cannabis in 2018 (Schulenberg et al. 2019), a figure that far eclipses the percentage of adults who
have done so. Since these young adults will be our future leaders, it is common to assume we
have achieved normalization already.
In fact, this is how many narratives on marijuana normalization proceed. They typically
begin with the rediscovery of marijuana on the part of the counter culture of the 1960s. These
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young people desired liberation from the conservative status quo of the era and approached
psychedelics as tools to free the mind from traditional ways of thinking. As this hip generation
grew older, they claimed positions of social power in government, law enforcement, business,
medicine, and more. This model of social change is known as cohort replacement, where
younger generations replace the older generation as leaders in society. Opinion polls are an
insightful way to appreciate this process of change as those ages 65 and up are the only age
demographic where the majority oppose legalization (DeAngelo 2015). Other scholars have also
found that age is one of the most powerful predictors of support for marijuana legalization (Elder
& Greene 2019). As we work our way down the age groups, support for legalization increases
making it only a matter of time until legalization and normalization are realized.
The above model of social change works well in civil democracies, but it is
fundamentally limited. For one, social power is never so easily surrendered, and those in power
may fix the system so it cannot be coopted by newcomers. Anti-cannabis ideology has been
ingrained into how law enforcement operates, how drug research is funded, and how educational
systems treat cannabis. Moreover, cohort replacement is disempowering as it conceives social
change as something that will happen in the future, but not something that can happen right now.
Nowhere was this more atrocious than in the PR campaign of “it gets better”, a message that was
supposed to reassure LGBT youth that their harassment would one day come to an end. When
would this better time come? No one knows, but the message had the tacit implication to
begrudgingly accept heterosexist oppression until it does. The same issue is present with
narratives saying social and legal cannabis reform is eminent because of generational change.
Activism and civic engagement are also effective forces of social change, and they do not
require waiting until positions of influence are vacated. Largely beginning in the 1990s, a social
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movement formed in California which politically medicalized cannabis, and this framework of
cannabis as medicine has since spread elsewhere. This is discussed more in the next chapter, but
the point is raised here because we need to account for medicalization’s role in the normalization
process. Scholars have yet to integrate these two trends which is understandable given that
studies on marijuana normalization and cannabis medicalization target different populations and
thus come away with different conclusions. Harm reduction studies with medical cannabis users
often focus on those who are most exposed to institutional oppression, such as seriously-ill
patients who medicate with cannabis frequently. While such research is valuable, the emphasis
on a small segment of the population neglects a significantly more substantial part of the
population, like recreational marijuana users, who also experience some level of risk (Erickson
& Hathaway 2010). Studies that provide evidence for the normalization of marijuana use may
also become counterproductive to the mission of medical cannabis. As researchers find more and
more evidence for marijuana becoming a normalized substance in modern society, conservative
anti-drug forces may renew their efforts to prevent the legalization of marijuana by targeting the
emergence of medical cannabis. This backlash to normalization’s (scientific) publicity may
perpetuate the institutional oppression of high-risk patients (Erickson & Hathaway 2010).

Conclusion
The debate continues whether cannabis is becoming normalized or has already become
normalized. Those who claim cannabis has reached a normative status in society point to
growing use among the population as well as changes in the law. Those who claim cannabis has
yet to be normalized point to a subculture where cannabis is seen as an oppositional to
mainstream values, how recreational users and medical patients still feel the need for secrecy,
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and how the medicalization of cannabis is an ongoing process. Some of their arguments suggest
that if cannabis loses its social stigma, there would no longer be a need for medicalization. This
debate is explored more in the next chapter.
CHAPTER III

THE INCOMPLETE MEDICALIZATION OF CANNABIS
This chapter explicates research on how cannabis came to be constructed as a medicine in
a social environment where it is classified as a prohibited substance. Since this is an area with a
rich history, this chapter primarily examines academic studies related to medicalization, health
movements, pharmaceuticalization, and debates on cannabis’ place within or outside of
mainstream medicine. For an overview of the social history of medical cannabis, please
reference Appendix A.
I begin by defining what medicalization means and then move into a discussion of how
medical cannabis is received by our dominant model of medicine, otherwise referred to as
allopathic or mainstream medicine. As I will show, health care professionals have had mixed
reactions to the medicalization of cannabis. I then move into a discussion of pharmaceutical
developments and the intense disdain cannabis patients have towards the pharmaceutical
industry. Following this is a summary of the skepticism and debates surrounding cannabis’ use
as a medicine, and why some believe medical cannabis will disappear in the near future.

Medicalization
Loosely defined, the term medicalization implies the extension of medical authority onto
a deviant behavior (Newhart & Dolphin 2019; Pedersen 2015; Pedersen & Sandberg 2013;
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Chapkis & Webb 2008; Conrad 2007). This change does not remove stigma or normalize a
behavior but shifts the default reaction from condemnation to situational sympathy (Fischer,
Kuganesan & Room 2015). It is important to note that cannabis is more therapeutic than it is
curative. Patients use it to relieve the symptoms of their illness rather than in hopes of curing
themselves of illness (Dahl & Frank 2011; Chapkis 2007). Indeed, our perceptions about whether
cannabis is an acceptable medicine are influenced by how the cannabis is consumed as well as
the underlying condition being treated. For example, Jeffrey Rudski (2014) found that people
find cannabis to be more acceptable for people with terminal illness rather than as a tool to
ameliorate negative side effects of therapeutic treatments (e.g., cancer drugs, antibiotics, allergy
medicines). The same study also found that cigarettes and water pipes (i.e. bongs) were more
stigmatized than consumption through pills or oral suspensions (Rudski 2014).
Cannabis was used as food, fiber, sacrament, and medicine long before it was used as a
recreational drug. The earliest reference in Greek literature occurs in the fifth century BCE when
it was observed the Scythians heated cannabis seeds as part of their death ritual (Butrica 2002).
Cannabis seeds were also widely consumed by Greeks though it was not until 65 CE where
records show the seeds could be used as a treatment for nocturnal emissions6. Evidence of
cannabis in Chinese medicine stretches back roughly 1,800 years (Brand & Zhao 2017), and this
is surprising because cannabis in Western medicine was not popularized until the 1840s before
declining in the early Twentieth century (Dahl & Frank 2011). Cannabis entrepreneur Steven
DeAngelo (2015) believes the decline of cannabis patent medicines is mostly attributable to the
Butrica (2002) extensively documents how the ancient Greeks prescribed large quantities of cannabis seeds to “dry
the semen” in men and boys who “suffered” from nocturnal emissions (wet dreams). Less common preparations of
cannabis included using the leaves to dress wounds, a preparation of dried leaves for nosebleeds, and liquid
infusions of cannabis seeds for ear infections. It is doubtful these preparations made an individual intoxicated since
THC is found only in the plant’s flower and needs to be heated to be absorbed into the body. Nonetheless, several
accounts of cannabis concoctions “seizing the head” are found in ancient Greek texts. though Butrica concludes the
Greeks clearly did not consider it an intoxicating substance on par with alcohol.
6
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production of the hypodermic syringe in 1858 and the availability of more potent, water-soluble
painkillers like cocaine, heroin, and morphine. Since cannabinoids are fat-soluble and not watersoluble, cannabis was unsuitable for the new hypodermic syringes favored by doctors of the era.
Similarly, Patricia Frye, M.D. (2018) believes the popularization of pills (aka tablets) in the
nineteenth century made cannabis medicines, mostly available in tinctures, less attractive to
physicians desiring consistent dosages.
In the United States, the (re)medicalization of cannabis largely began in the 1990s with
patient activism in California as well as the discovery of the endocannabinoid system, even
though cannabis as a folk medicine has roots extending to ancient times (Newhart & Dolphin
2019; Ryan & Sharts-Hopko 2017; Rendon 2012; Chapkis & Webb 2008; Gahlinger 2004).
California was the first state to permit medical cannabis in 1996, and since then, 33 states have
followed their lead. Wendy Chapkis and Richard Webb (2008) believe the surge of patient
activism in the 1990s is partly related to a “social movement spillover” from the women’s health
and AIDS-rights movements. The subsequent medical cannabis was based mainly in California
and spearheaded by a man named Dennis Perone, who helped craft the medical cannabis ballot
initiative and opened the country’s first buyers club. His Oakland-based Cannabis Buyers Club
model was adopted by many others, including the Berkeley Patients Group, the Cannabis Action
Network, the Oakland Cannabis Buyers Cooperative, and Californian Helping Alleviate Medical
Problems (DeAngelo 2015). These buyers clubs required membership, provided physician
certifications, and collectivized cannabis distribution as opposed to offering it for
commercialized sales. There was also the Woman’s Alliance for Medical Marijuana (WAMM), a
buyers club and community organization profiled by Chapkis and Webb (2008). WAMM never
asked for payment for the medicine they dispensed, only asking (but not requiring) members
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volunteer to help with cultivation and preparation. Moreover, cannabis clubs were also hot spots
for activism focused on political cannabis reform.
Yet cannabis is still a Schedule I controlled substance on the federal level resulting in its
absolute prohibition throughout the United States. Unlike other countries such as the
Netherlands, the United States does not officially distinguish “hard” and “soft” drugs, and
instead uses a five-level categorization scheme where all Schedule I substances are deemed
equally problematic. Since federal law trumps state law, this medicalization process has been a
hard-fought battle with patients and care providers frequently subjected to federal raids and
prison sentences (Chapkis & Webb 2008). Nearly every buyers club was raided and shut down
by the DEA, some on multiple occasions. In the eyes of the federal government, these patients
are no different than the narcotics traffickers and drug abusers who fill federal prisons. Despite
strong support from biomedical research, patients must still navigate hostile layers of
bureaucracy when it comes to their medicine. They faced resistance at every turn from political,
legal, medical, and financial institutions. This is why the medicalization of cannabis is best
understood as a grassroots, patient-led movement (Chapkis & Webb 2008).

Incomplete Medicalization
The concept of medicalization has largely been advanced through the work of medical
sociologist Peter Conrad. His original use of the term focuses on the process transforming social
problems into medical issues, usually in terms of disorders, diseases, and syndromes (Conrad
2007, 2005, 1992, 1979; Conrad & Barker 2010; Conrad & Leiter 2004; Conrad & Schneider
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1992/1980)7. This has been done with deviant identities like homosexuality and drug addiction,
as well as with unavoidable life processes like aging and social anxiety. In all cases, the formerly
non-medical problem becomes defined and described using a medical framework that invites
medical intervention. “Medicalization narrows the definition of health and widens the definition
of sickness” (Conrad & Leiter 2005:171) by treating life’s imperfections or poor social situations
as treatable conditions.
Medicalization is best understood as occurring to varying degrees as “remnants of a
previous definition may cloud the picture” (Conrad 2007:6), like when criminal definitions
coexist with medical definitions of cannabis. It is for this reason that Newhart and Dolphin
(2019) argue cannabis is incompletely medicalized. Cannabis is defined medically, but it is also
defined criminally, recreationally, capitalistically, spiritually, and beyond. As the hegemony of
the criminal definition breaks down, these other definitions may find themselves more and more
at odds with one another. Medicalization is not only concerned with the expansion of medical
jurisdiction, but it is also realized through “the cultural acceptance of medical categorization”
(Newhart & Dolphin 2019:12). It should also be noted that the medical profession does not have
sole ownership of medical rhetoric and vocabulary (Conrad 1979). Interests outside of medicine
may appropriate medical language and medical evidence as they strive to establish social
legitimacy (Conrad & Schneider 1992/1980). These non-medical interests may be successful in
medicalizing something within the popular imagination, but collaboration with medical
authorities is needed to medicalize something in practice (Conrad 1992). This is another reason

Writing in 1980, Peter Conrad and Joseph Schneider make a curious prediction: “It is interesting to speculate
whether the decriminalization of marijuana, gambling, and prostitution would lead to medicalization. It is likely that
with marijuana and gambling, ‘compulsive’ and excessive indulgence would be defined as ‘sick’; with prostitution,
medical certification might be required, as is presently the case in several European countries” (Conrad & Schneider
1992/1980:254). It seems marijuana was medicalized before it was decriminalized, and that this medicalization may
have played a significant role in lessening the grip of its criminalization.
7
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why Newhart and Dolphin (2019) say the medicalization of cannabis has been partial for it has
yet to be institutionalized within mainstream medical practice.
When something becomes fully medicalized, social discourse shifts in a manner where
previous constructions are largely forgotten. Since this has not yet happened with cannabis, it
another piece of evidence that cannabis is incompletely rather than fully medicalized (Newhart &
Dolphin 2019). Parts of our collective conscience still frame marijuana as a party drug or
criminalized substance, and these constructions compete with medical frameworks for
dominance when defining the plant. Additionally, access to cannabis is not entirely controlled by
medical instructions, and individuals may consider non-medical reasons for becoming a patient,
namely enhanced legal protections (Newhart & Dolphin 2019). The researchers ultimately
purpose cannabis is best understood to be a part of complementary and alternative medicines
(CAM). This federally unregulated category includes therapies treated with skepticism by
mainstream biomedicine even though they may have widespread popular support as well as some
scientific evidence supporting their efficacy. Other forms of CAM include chiropractic care,
herbal supplements, meditation, and acupuncture. It is common for individuals to turn to CAM
when standard biomedical therapies have not produced any meaningful benefits (Newhart &
Dolphin 2019; Brenton & Elliott 2014).
When medicalization is successful, it extends the sick role onto deviant identities thereby
reducing individual blame and social stigma (Conrad 2007; Conrad & Schneider 1992/1980).
Drug addiction is an excellent example of this, with many now advocating for an approach of
harm reduction as opposed to heightened enforcement and harsher penalties. However, this
sympathy is unevenly applied to addicts as Rebecca Tiger (2017) demonstrates in her analysis of
the current opioid epidemic. Addiction in wealthier, whiter communities is commonly met with
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calls for mercy and rehabilitation. Addiction in poorer communities, on the other hand, is
commonly met with a type of punitive social Darwinism; to let addicts die or, at the very least, to
lock addicts up (Tiger 2017). This could be because many drug scares and drug laws are
constructed to control populations deemed problematic by those with social power. For example,
the infamous 100:1 rule concerning sentencing for crack compared to powdered cocaine
disproportionately penalized people of color for using a cheaper version of the same drug as their
wealthier, whiter counterparts. As such, it would not be surprising if medical cannabis is
tolerated less when it is used among the working class or among people of color.
Part of this double standard is due to the competing forces of medical and legal social
control, and how medicalization disproportionately serves the interests of those with social
power (Conrad & Barker 2010). This pattern is also evident in Peter Conrad and Joseph
Schneider’s (1992/1980) history of heroin addiction. Heroin went from being a nonproblematized remedy when it was first introduced by the pharmaceutical company Bayer in
1898, to medicalized through physician supervision when its addictive qualities became
apparent. Heroin was subsequently de-medicalized through the hegemony of a criminal
designation established by the Harrison Narcotics Act of 1914. Eventually, heroin would be remedicalized with the advent of methadone maintenance and its renewed popularity among the
middle class. “This is not to say that criminal designations of addiction disappeared. Rather,
claimsmakers were promoting a medical designation of addiction that would challenge, and
ultimately coexist with, law-enforcement agencies' criminal approach” (Conrad & Schneider
1992/1980:132).
This is all to say that medicalization is a multidimensional process that extends beyond
the domain of biomedicine. In the case of cannabis, it “involves cultural, institutional, and
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interactional changes in response to these altered definitions. To accomplish this requires
collective actions and risks taken by patients, doctors, researchers, and stakeholders in
government” (Newhart & Dolphin 2019:30). Furthermore, while medicalization is a powerful
force in modern technological societies, it is rarely total in scope and can be reversed. For
example, masturbation has been de-medicalized and is now infrequently defined in medical
terms. Similar transformations have occurred with disability and homosexuality, both of which
are now primarily framed through the discourses of civil rights and social acceptance (Conrad
2007).
International research also provides interesting lessons in the medicalization of cannabis.
There is no medical cannabis program in Norway, but some of the recreational users interviewed
by Pedersen and Sandberg (2013) were analytically classified as “medical activists” because they
distinguished their use as medical and many actively worked to reform Norway’s drug laws. The
researchers note how this group had an impressive research-based knowledge of the therapeutic
effects of cannabis, some of whom created networks to share the latest cannabis research.
Furthermore, these medical activists often utilized the language of the medical system in
attempts to legitimize their use to medical professionals while simultaneously distancing
themselves from recreational drug users (Pedersen & Sandberg 2013). These findings are similar
to those of other researchers who find medical cardholders get most of their knowledge outside
of mainstream medical authorities (Athey et al. 2017; O’Brien 2013). In fact, medical cannabis is
commonly positioned in opposition to mainstream allopathic medicine, and patients are very
suspicious of the pill-pushing physicians who critique their use of natural medicine (Newhart &
Dolphin 2019; Lau et al. 2015b). Medical cannabis patients in Michigan surveyed by Kruger and
Kruger (2019) report considerably more trust in medical cannabis than in mainstream healthcare.
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Many also do not discuss their use of medical cannabis with their regular healthcare providers.
Overall, there appears to be widespread distrust of mainstream medicine among medical
cannabis patients.

Cannabis as Controversial in Mainstream Medicine
Medicalization often results from collective action as opposed to a top-down medical
colonization of new problems. Patients may mobilize with sympathetic professionals, lay
advocates, and pharmaceutical companies to politicize their illnesses by demanding recognition
as sufferers of a medical condition. Conrad (2005) even argues the engines of medicalization are
shifting from the medical profession to expert patients, insurance companies, and biotechnology.
Moreover, individuals are decreasingly thought of as patients overseen by a medical authority
and increasingly thought of as consumers who can be targeted with marketing campaigns. A
buyer-driven system is emerging that challenges the traditional role of physicians as the sole
authoritative gatekeepers of medical services (Conrad & Leiter 2004). Though medical cannabis
is often positioned as oppositional to pharmaceutical corporate interests, the two forces appear to
empower lay individuals as opposed to mainstream medical authorities.
Rebecca A. Penn (2014) argues the medicalization of cannabis is best understood through
the lens of an embodied health movement (EHM). EHMs have three characteristics: (1) activists
frame their organizing efforts and critique of the biomedical system through the experiences of
their biological bodies, (2) they seek biomedical support for their illness claims by challenging
what counts as scientific evidence, and (3) activist-experts collaborate with biomedical
authorities for research, funding, and expanded access (Penn 2014; Brown et al. 2004). Each of
these characteristics are elaborated on below.
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Rather than being constructed around a disease category like other EHMs (see Brown et
al. 2004), medical cannabis patients constructed a collective identity around their therapeutic use
of cannabis and struggles for legal access, social legitimacy, and biomedical recognition. Using
medical cannabis is embodied because instead of relying on standard scientific and medical
models of treatment, medical cannabis users primarily draw upon their lived bodily experiences
where their use of cannabis brings meaningful comfort. Furthermore, the identity of being a
cannabis patient arises from a “lack of institutional support for medical cannabis from the
government, law enforcement, scientific bodies, and health professionals, and the criminalization
of medical cannabis patients” (Penn 2014:374). The patient identity helps establish a new
discursive frame where users are seen as deserving of compassion and care as opposed to
condemnation for using a stigmatized substance.
EHMs also challenge the process of biomedical knowledge which privileges randomized
controlled clinical trials. While the medical cannabis movement does not seek to discredit RCTs,
they seek to expand what is considered empirical evidence by valuing qualitative and/or
anecdotal evidence (Penn 2014). Medical cannabis patients also tend to rely on subjective
definitions of health and wellness (Newhart & Dolphin 2019) as opposed to those based on
objective, authoritative data like clinical studies. “EHM activists often judge science based on
intimate, firsthand knowledge of their bodies and illnesses” (Brown et al. 2004:56), and most of
the evidence on cannabis’ efficacy comes from self-report studies or clinical observations. These
studies are also typically performed by sympathetic professionals who personally believe
cannabis should be available for medical purposes (Penn 2014).
Since the medical cannabis movement developed its own scientific knowledge base
without much institutional support, those who have worked to advance our understanding of
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medical cannabis have become cognitive and cultural authorities on the issue. “Even if activists
do not get to participate in the research enterprise, they often realize that their movement’s
success will be defined in terms of scientific advances, or in terms of transformation of scientific
processes” (Brown et al. 2004: 57). As such, the medical cannabis movement has produced
scores of “activist-experts” who collaborate with researchers, health professionals, and
policymakers. Working as individuals or collectively as organizations (e.g., Patients of Our
Time, Americans For Safe Access, and the American Cannabis Nurses Association), they seek
policy reform, research funding, and enhanced professional education regarding cannabis.
Research has firmly established the utility and benefits of using cannabis in conjunction
with other therapies (Frye 2018; Abrams et al. 2011), but not all health professionals are
enthusiastic about the medicalization of cannabis. Overall, medical use of cannabis tends to be an
individualized routine as opposed to the institutionalized regiments of care found within
mainstream biomedicine (Newhart & Dolphin 2019). Unlike a prescription with directions for
use, dosages, and possible side effects, cannabis patients receive little to no guidance from a
physician after obtaining their medical cannabis certification. The patient is ultimately
responsible for deciding upon the type, quantity, and potency of their cannabis medicines, as
well as establishing their own medication regiment. Indeed, finding the optimal strain type and
medication routine is often achieved through self-experimentation with multiple products or
strain types. Since certifying physicians typically only see the patient every year or so for
program renewals, this could be an area where mainstream health care providers can offer
valuable support. Victorson et al. (2019) found cannabis patients trust their regular physicians
but that patients were also dissatisfied with the limited knowledge their physicians had on
medical cannabis. Improving physician education on cannabis medicines is important because
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patients were uncomfortable with “having to get information about [medical cannabis] from
untrustworthy and unreliable sources, such as the internet, dispensaries and their peers” (7).
Likewise, some are critical of cannabis’ status as a state-endorsed therapy rather than a
scientifically-supported or physician-endorsed therapy. While substantial evidence exists
supporting cannabis’ efficacy for some conditions like chronic pain and muscle spasticity, statequalifying conditions for medical cannabis include many wherein efficacy has yet to be
empirically established (Choo, Feldstein & Lovejoy 2016). Physicians also find it unsettling that
state medical cannabis laws were passed without much physician input (Kondrad & Reid 2013).
It should be noted, though, that physician input may be more valuable when it comes to specific
regulatory decisions. If doctors do not embrace cannabis reform, they may miss an opportunity to
provide feedback on regulatory policies. For example, there is much concern about appealing to
children through the packaging and marketing of cannabis products. As cannabis may impede
cognitive development when used by youth, physicians should have an interest in advising
lawmakers on safer cannabis sales (Nathan, Clark & Elders 2017).
Some doctors have even cautioned against medicalizing cannabis because many users
smoke the plant rather than use oral or inhaled cannabinoid pharmaceuticals (Jones & Hathaway
2008; Kahan & Srivastava 2007). However, patients with severe illness may not worry about the
harm of smoking because their illness has a more significant impact on their overall health (Page
& Verhoef 2006). There also appears to be more satisfaction with smoking medicine among the
community of patients. A survey of 1429 cannabis patients in Washington found nearly 85%
prefer inhalation over other methods of ingestion (Sexton et al. 2016). Indeed, the therapeutic
effects of cannabis vary depending on the type of cannabis being consumed as well as the route
of administration
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Smoking cannabis results in a more rapid, intense absorption of cannabinoids than does
ingestion (Elikottil, Gupta & Gupta 2009). Cannabis users have also reported that the effects of
smoking and eating cannabis feel different (Ogborne et al. 2000), which may explain why some
patients continue to smoke the plant despite the risks associated with smoking. Other studies
have found patients describing edibles as being too difficult to accurately dose, increasing the
risk of undesirable side effects (O’Connell & Bou-Matar 2007). Their concerns are wellgrounded. Of 75 edible medical cannabis products from California and Washington tested by
Vandrey et al. (2015), only 17% were accurately labeled. Over half of the products tested had
significantly less THC than the product advertised8. Fortunately, in the event too much cannabis
is consumed, the person simply has to wait until their body metabolizes the cannabinoids (Frye
2018), though products now exist which claim to mitigate the effects. Edibles also cost
substantially more money when compared to smoking raw plant material. A participant in an
exploratory study by Ogborne et al. (2000) noted that eating cannabis-infused foods is more
expensive than smoking, and my anecdotal observations confirm this.
The medicalization of cannabis has also affected the role of health care providers.
Medical cannabis inverts the typical model of prescribed medicine wherein control is largely
held by the physician (Newhart & Dolphin 2019; Zolotov et al. 2016; Bostwick 2012;
Nussbaum, Boyer & Kondrad 2011). Jones and Hathaway (2008) go as far as saying “marijuana
represents a challenge to allopathic medicine inasmuch as it enables patients to wrest control of
their symptom relief from established medical practitioners” (170). In the United States,
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Aside from fraud or error, another possible reason for the discrepancy in edibles is expressed by Laurie Wolf in the
Netflix series Rotten (Season 2, Episode 6): “When you’re deciding to try making edibles, [consistency] is the most
critical thing to consider. What you’re making has to be the same. You know, 5,000 of them have to have the exact
same potency or pretty close. We did a spiced nut mix, but there were five different kinds of nuts that all have
different sizes and all have different textures. The pecans absorbed and held in between their little lines more THC
than the peanuts did. So, we just kind of gave up because I have no idea how we could infuse that in order to have
every batch be homogenous” (2019, 24:20-25:10).
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prescriptions for cannabis are technically illegal, so doctors may only recommend cannabis to
their patients (Cohen 2010). Physicians “certify” that patients have a qualifying medical
condition for a state’s medical cannabis program and may only “recommend” cannabis as
opposed to “prescribe” cannabis (Sideris et al. 2018). One consequence of this is the actual dose
and regiment of cannabis is determined by the patient themselves rather than mandated by a
physician (Bostwick 2012). Some have criticized this arrangement as it narrows the doctorpatient relationship to a mere recommendation, whereas nearly every other medical intervention
requires frequent physician monitoring and assessment of treatment (Kondrad & Reid 2013;
Nussbaum, Boyer & Kondrad 2011). However, patients interviewed by Michelle Newhart had an
interesting view of this required doctor-patient relationship. While none objected to the
requirements, many expressed “the doctor’s recommendation was less about medical advice and
more about meeting system obligations” (Newhart & Dolphin 2019:107). Patients are aware of
the efficacy and safety of cannabis, and many use their medicine in self-directed manners to suit
their immediate needs.
Scant physician oversight does not totally leave patients without expert guidance and
support. Staff members at cannabis dispensaries, commonly known as “budtenders”, are the
public face of the industry and, in many ways, mediate experiences patients have with their
medicine. Fortunately, most dispensary staff make product recommendations that are consistent
with empirical evidence on therapeutic effects (Haug et al. 2016). Budtenders often receive
training, many are patients themselves, and interactions with returning patients allow them to
gauge the efficacy of previously purchased products. However, there is almost no research on
patient trust in budtenders aside from a brief conference presentation by Jennifer Rineer and
Nicholas Peiper (2017). By surveying the perceived degree of trust budtenders had with their
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patients, the researchers found training did not increase patient trust and that years of experience
as a budtender actually decreased patient trust. The only factor that raised patient trust was the
budtender’s personality, particularly their openness in discussing medical cannabis with the
patient (Rineer & Peiper 2017). This finding is similar to a study on clinics of alternative
medicine where trust was partly established by a practitioner’s verbal and nonverbal
communication skills (Pedersen, Hansen, and Grunenberg 2016).
The lack of expert guidance at medical cannabis dispensaries is concern enough to where
states such as Minnesota and Pennsylvania require dispensaries to have an onsite pharmacist or
licensed medical professional. Other states may simply require these medical professionals to be
on call, but Michigan has no such requirements. “More than half the states with medical cannabis
allow budtenders to help patients choose products to address anything from back pain to
chemotherapy side effects” (Roubein 2019, paragraph 6). Yet it appears that having suboptimal
medically-focused dispensaries is better than a cannabis marketplace monopolized by
dispensaries catering to recreational users. Medical users in the Netherlands express
disappointment in the country’s preferred model of retail coffee shops because the staff is not
trained in medicinal uses of cannabis (Nicholls-Lee 2019). This may be due to how the coffee
shops cater their business to tourists rather than locals, as they can make more money with the
former. Moreover, cannabis patients in Canada report a preference for dispensaries specifically
focused on providing cannabis for therapeutic purposes. These medically-focused dispensaries
commonly feature a variety of strain and product options along with staff knowledgeable of
cannabis’ efficacy for various ailments (Capler et al. 2017). In Michigan, some medical cannabis
dispensaries offer private consultations with a budtender where a patient can discuss their needs
without being overheard by others. I have even seen a dispensary which has a physician stop in
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once a month where they are available to answer questions rather than to certify patients for the
MMMP (which is illegal to do in a dispensary).
Perhaps the largest source of unease among physicians in the U.S. and Canada is in their
legal role as gatekeepers to cannabis since it is their recommendations that authorize patient use
(Fischer et al. 2015). Doctors are dissatisfied with deceptive patients who utilize scarce clinician
services as a ticket to accessing the medical cannabis market. While legal scholars (Cohen 2010)
and some medical researchers (Choo et al. 2016; Zolotov et al. 2016) have called for greater
regulations and physician oversight of medical cannabis, this does not appear to be a popular
argument among the health care community nor the community of patients. Patricia Frye, M.D.
(2018) says the quick, in-and-out visits with a certifying physician are optimal for patients who
have prior experience with cannabis and uncomplicated medical histories. They will still have
the opportunity to ask questions and may learn more about cannabis’ medical efficacy, but
extensive testing or consultations are not needed for this group. On the other hand, Frye (2018)
advises patients with complex medical histories to consider seeing a cannabis specialist9 who can
provide them with individualized information. These appointments may be more protracted and
more expensive, but it is crucial to evaluate how one’s existing medication regiment,
cardiovascular status, and/or mental health will be affected by cannabis.
A final source of unease pertains to physician financial interest in medical cannabis
facilities (Nussbaum et al. 2011). Though most state laws forbid recommending physicians from
having stakes in cannabis enterprises, many dispensaries advertise their ability to secure quick
physician approvals for new patients. A survey of 520 family physicians in Colorado found just

9

Frye (2018) offers little to designate between the two types of certifying physicians. She says clinics with multiple
locations often provide the quick in-and-out visits whereas independently-owned clinics typically have a physician
who will spend more time with the patient. Her major piece of advice is to call and ask how much time a typical
visit takes.
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10% supported the state’s existing dispensary business model despite most having favorable
views regarding cannabis’ therapeutic properties (Kondrad & Reid 2013). They took issue with
the system’s lax gatekeeping for individuals pursuing medical cannabis certifications as well as
the lack of an ongoing relationship between certifying physicians and their patients.
Other medical professionals are against medical cannabis policies because the
consumption of cannabis is highly skewed among registered patients. Miller and
Oberbarnschiedt (2017) claim current medical cannabis initiatives allow heavy users to continue
their addiction. They say most of the cannabis in both medical and legal states is consumed by
daily (or near-daily) users, not “responsible adults” looking for occasional recreation or relief.
The fear here is that big marijuana businesses will thrive by exploiting heavy users, much like
the tobacco and alcohol industries (Miller & Oberbarnschiedt 2017). Their argument has merit as
other researchers have found there are small but significant differences between studying
cannabis users and studying cannabis consumption (Burns et al. 2013). When we examine the
specific measure of past-month use days (as opposed to the number of individuals using
cannabis), we find heavy users account for a large share of the total use. Yet one group accounts
for most heavy use: those ages 50 and up. Their use days nearly tripled between 2002 and 2012,
while the use days for every other age group remained relatively stable (Burns et al. 2013).
Perhaps this is due to more age-related illness within this group, especially conditions associated
with chronic pain.
Concern has also been raised over “doctor mills”, or physicians who certify large
numbers of patients without extensive evaluations or adequate medical proof. According to
Nussbaum and colleagues (2011), 49% of the 128,698 registered patients in Colorado were
certified by just 15 physicians in the decade following the enactment of the state’s medical
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cannabis law. It has also been found that physicians with a high-volume of recommendations are
more likely to qualify patients based on the catch-all category of chronic, severe pain compared
to family physicians with a low-volume of recommendations (Kondrad & Reid 2013).
There are several problems with the concept of doctor mills. To begin, physicians report
having little familiarity with the medical benefits of cannabis, which may explain why many do
not directly suggest cannabis to their patients (Sideris et al. 2018). Most medical schools do not
teach about the endocannabinoid system or anything to do with cannabinoids in general
(DeAngelo 2015). A majority (71%) of New York State physicians support cannabis use for
medical purposes, and many are willing to refer patients to doctors who specialize in medical
cannabis. A similar finding was uncovered in patient interviews by Newhart and Dolphin (2019)
where over half of their sample reported discussing medical cannabis with their regular
physician, but over 80% ended up getting certified through a specialty physician. Regular
physicians opt to not recommend cannabis themselves due to their limited area of medical
specialty and the illicit federal status of the drug (Sideris et al. 2018). Furthermore, physicians
who recommend cannabis to their patients become subject to intrusive state oversight and risk
significant repercussions should any discrepancies in paperwork emerge. Medical licenses may
be revoked, the certifying physician may face jail time or career-ending fines, and their
reputation becomes tarnished in an industry dominated by powerful pharmaceutical companies
(Newhart & Dolphin 2019). It is for these reasons that many certifying physicians perceive
intangible rewards from their work as opposed to the money or professional prestige associated
with a career in biomedicine.
As for the catch-all category of chronic pain, it is perhaps more fruitful to consider the
narrow list of approved conditions for medical cannabis in each state. A recent survey by Kruger
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and Kruger (2019) found four of the most common ailments reported among Michigan medical
cannabis patients are not specifically included in the list of qualifying conditions. These include
general pain, back problems, depression or bipolar disorder, and headaches or migraines. Since
their conditions are not recognized as qualifying for medical cannabis by the state, their certified
condition must be listed as severe, chronic pain. Despite this practice receiving some criticism,
“off-label” uses of prescriptions have long been utilized by medical practitioners. Our current
system requires that all prescribed drugs be approved for specific medical conditions, though
doctors have the ability to prescribe drugs for non-approved conditions (Newhart & Dolphin
2019). As such, the concern over off-label uses of cannabis can appear as double standard when
compared with the off-label uses of pharmaceutical drugs. These inconsistent standards of
efficacy are explored in the next section of this chapter.

(Anti)Pharmaceuticalization
Surveys of patients find many use cannabis as an alternative to or means of reducing
pharmaceutical prescriptions, most commonly those for opioid painkillers (Kruger & Kruger
2019; Boehnke, Litinas & Clauw 2016; Sexton et al. 2016; Zaller et al. 2015). Moreover, 30% of
patients surveyed by Kruger and Kruger (2019) claimed their primary health provider was
unaware of their use of medical cannabis. The same survey found patients prefer cannabis over
pharmaceuticals in terms of effectiveness, side effects, safety, addictiveness, availability, and
cost. In this section, I detail why patients chose cannabis over traditional options as well as
controversies surrounding pharmaceutical cannabis products.
Travis Satterlund and colleagues (2015) identified three interesting reasons why patients
prefer herbal medicine over pharmaceutical cannabis products. First, there is the fact that plant-
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based marijuana is “natural” and perceived to be safer than synthetic chemicals. Interviews done
by Joan Bottorff and colleagues (2011) reveal patients frame cannabis as a means to break free of
the toxic “trial and error” cycle of pharmaceutical therapies. Cannabis not only offers physical
relief but also relief from the frustrating sequence of failed prescriptions with unpleasant side
effects. Many patients blame such side effects on the toxicity of pharmaceutical medications, and
many fear becoming “overtoxified” (Bottorff et al. 2011:773). Even if cannabis brings them little
relief, it lacks the side effects, risk of dependency, and synthetic ingredients of pharmaceuticals.
It also allows one to retain more personal control over their medicine since one could stop using
at any moment without going into withdrawal (Newhart & Dolphion 2019).
Secondly, many patients viewed pharmaceutical companies with contempt and cynicism
(Satterlund et al. 2015). Colorado patients interviewed by Newhart and Dolphin (2019) were
deeply offended by the ability of big pharma to peddle dangerous drugs for profit while
suppressing medical research and development concerning cannabis. Overall, patients seem to
harbor resentment towards the pharmaceutical industry. The medical activists in Norway
interviewed by Pedersen and Sandberg described the side effects of prescription drugs in “rich
and living language” (2013:22), and this is something I have anecdotally observed among
medical cannabis patients in the United States. Cannabis patients tend to have horror stories of
impairment, disability, addiction, and debt stemming from their previously prescribed
medications. Patients are well aware of the industry’s unscrupulous business practices, and many
loathe the industry’s abilities to profit from “toxic” substances or drugs with concerning side
effects (Newhart & Dolphin 2019; Victorson et al. 2019; Lau et al. 2015; Satterlund et al. 2015;
Pedersen & Sandberg 2013).
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Finally, framing pharmaceutical products as “somewhat evil” allowed patients to
rationalize their cannabis use as relatively benign, safe, and relatively normal (Satterlund et al.
2015:8). This perspective also allows the patients to minimize self-stigma and negative
perceptions about their personal use (Pedersen 2015). A survey of physicians in New York State
found the majority of (84%) believed opioids were more dangerous than cannabis (Sideris et al.
2018). As I will discuss later in this section, cannabis may be the safest medicine known to
humankind. Therapeutic use stretches back millennia with no deaths, overdoses, or permanent
side effects. Yet we have only recently begun to understand cannabis through pharmacological
science.

Synthesizing Cannabis
When the endocannabinoid system was discovered by science in 1996, it clarified the
biological processes of consuming cannabis-based compounds. This discovery allowed
researchers to understand how cannabinoids like THC and CBD are processed by the human
body. In fact, the body has specialized cell receptors specifically built to receive cannabinoids.10
In this way, cannabis as a folk remedy is similar to opium or ephedra, as each was used for
therapeutic purposes long before their distinct mechanisms were detailed by scientists (Bostwick
2012).
Medical researchers have so far distinguished three types of cannabis compounds or
cannabinoids, though there may be more (Bostwick 2012; Elikottil et al. 2009). The first are
endocannabinoids, the natural chemicals produced by the human body and function as

10

Cannabinoid receptors have not been found in the brain stem, the region of the nervous system responsible for
regulating involuntary functions like respiration and circulation. Perhaps this is why it is impossible to overdose on
cannabis as excessive amounts will perhaps be psychologically, but not physically, worrisome (Frye 2019).
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neurotransmitters. Our bodies even produce minimal levels of certain cannabinoids independent
of one’s consumption of cannabis. These endogenously-produced cannabinoids help achieve a
stable internal environment, or homeostasis, as we move through fluctuating external
environments (Frye 2019; DeAngelo 2015). The second are phytocannabinoids which
encompass the hundreds of compounds found in the cannabis plant, such as THC, CBD, and
many others. The third and final form are the synthetic cannabinoids which include
pharmaceuticals and other laboratory-made substances resembling naturally-derived botanical
cannabinoids (Bostwick 2012). Scientists have even genetically engineered yeast to produce
cannabinoid precursors, the basic building materials needed to create more-complex compounds
like THC and CBD (Brodwin 2019).
Pharmaceutical advancements have made some worry that modern chemistry may be able
to isolate and manufacture the more-potent compounds present in cannabis, much like that of
cocaine from the coca leaf (Grinspoon 1999). Yet while several synthetic forms of cannabis
exist, nothing comes close to the therapeutic power of whole-plant medicine. The oldest
synthetic cannabinoid is known by the brand name Marinol (dronabinol) and has been legally
prescribed for nearly 30 years. Since Marinol is essentially synthetic THC, some scholars have
noted the irony of prescribing the plant’s most psychoactive substance in place of the natural
plant itself (Chapkis & Webb 2008; Chapkis 2007). Cesamet (nabilone) is also a synthetic
cannabinoid that mimics THC but may be even more potent (Lochte et al. 2017). Another
pharmaceutical product is known as Sativex (nabiximols) which is derived directly from
botanical cannabis and is currently undergoing FDA trials in the United States (Rendon 2012;
Chapkis & Webb 2008). Sativex comes in the form of a sublingual spray and contains a 1:1 ratio
of THC to CBD which reportedly does not make the patient high. A final pharmaceutical known
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as Epidiolex was recently approved by the FDA for children with seizures, but this is nothing
more than pharmaceutical-grade CBD (cannabidiol). Since they are each botanical extracts,
“generic” versions of Sativex and Epidiolex can be made at home or purchased from most
dispensaries.
Attempts to purify cannabinoids have been less than impressive so far, with most patients
who use synthetic cannabis preferring to smoke the natural plant instead (Webb & Webb 2014;
Grinspoon 1999). Part of the problem with synthetic cannabinoids is that while many active
compounds are present in raw cannabis plant material, pharmaceutical drugs approved in the
United States must isolate only one of these compounds (Elikottil et al. 2009; Grinspoon 1999).
Furthermore, pharmaceutical products are significantly more expensive and less effective than
the botanical cannabis available to medical cannabis patients (Chapkis & Webb 2008; Ogborne,
et al. 2000). The hundreds of unique compounds in the natural cannabis plant work in synergy to
produce effects greater than the sum of isolated compounds, a phenomenon some have dubbed
“the entourage effect” (Frye 2018; Rendon 2012).
Natural marijuana with its many chemical compounds cannot be evaluated by the
standard FDA approval process (Grinspoon 1999)11. Patients seem to enjoy this aspect of
cannabis; that “whole plant medicine” it cannot be claimed and exploited by pharmaceutical
companies. Some claim the pharmaceutical industry is well aware of cannabis’ efficacy but
widely supports continued criminalization over the fear of losing control over current treatment
options (Chapkis & Webb 2008). Incidentally, the federal prohibition of cannabis may be one of
the few things keeping pharmaceutical giants at bay. The current system of state-approved
medical cannabis is ultimately federally prohibited, and as such, beyond the reach of globalized
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Commenting on the inability of the FDA to evaluate cannabis, one medical scientist interviewed on 60 Minutes
(October 2019) called cannabis a “messy” drug.
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corporate profits. This is a large part of why cannabis was medicalized through patient activism
without much help from medical institutions or pharmaceutical companies (Pedersen &
Sandberg 2013; Chapkis & Webb 2008). Outside of patient activism, there were also
developments in cannabis cultivation that helped cannabis’ medical potential.

Improving Cannabis
Jim Rendon (2012) is a freelance business writer and though he does not explicitly
connect the dots, he identifies several developments that facilitated the medicalization of
cannabis, and these have not yet been mentioned in the academic literature. Before the twentyfirst century, the marijuana available to consumers was often of suspect quality. There was
virtually no supply of potent, pure, optimally-grown medicine available for patients. Individual
consumers would have to take their chances and trust whatever source they could find, but most
did not mind if what they purchased was less than immaculate. That began to change with the
publication of High Times, a drug culture magazine launched in 1974. Not only did the magazine
have literature on cannabis, it included Playboy-like centerfolds of magnified marijuana. As
consumer desire shifted towards more exquisite buds, the indoor growing revolution of the 1980s
and 1990s made top-tier product accessible (Rendon 2012).
Growing cannabis outdoors is risky since the crop can be damaged by rain, wind, insects,
and more. So, when the federal government began cracking down on outdoor grows in the 1980s,
it’s arguable the quality of cannabis improved as growers moved their cultivation inside (Rendon
2012, Pollan 2001). Cannabis grown indoors produces denser, more-potent buds that are often
visually-perfect. Every variable can be controlled indoors from the light, humidity, ventilation,
and plant nutrients. Growers even compete to grow the best cannabis by experimenting with
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different combinations of these elements. They also share their results and strategies over the
Internet, disseminating knowledge on message boards and websites (Rendon 2012). This all
fueled rapid improvements to quality around the same time the patient-led medical cannabis
movement was occurring. Put simply, High Times, indoor growing, and the Internet helped raise
the quality of marijuana to something more on par with what we would expect from a
medicine—something potent, pure, and produced in conjunction with other experts12 Despite
progress made in the quality of cannabis medicine over the past several decades, some still
believe the pharmaceutical industry will bring benefits to medical cannabis patients.

Pharmaceuticalization
One facet of medicalization is pharmaceuticalization, or the “translation or
transformation of human conditions, capabilities and capacities into opportunities for
pharmaceutical intervention” (Williams, Martin & Gabe 2011:711). This often manifests in
pharmaceutical drugs being promoted for small nuisances or to improve human performance
(e.g., nootropics). Examples of pharmaceutically-constructed diseases include chronic dry eyes,
restless leg syndrome, female sexual dysfunction, low testosterone, ADHD, and high cholesterol
in anyone over 30 years old. While people may experience these conditions situationally, or
while these conditions may be largely attributable to natural aging, the pharmaceutical industry
markets them as treatable ailments. This effectively allows individuals to form an identity as
someone who suffers from X. While this process is dynamic and reversible, it has created

While “lamp-grown” (indoor) cannabis may achieve museum-quality levels, it takes a significant toll on the
environment through high electrical demands. This is why Steve DeAngelo (2015) has consciously decided to
rename cannabis grown outdoors as “SunGrown”. After his California dispensary shifted to this terminology in
conjunction with an environmentally-focused ad campaign, sales of SunGrown cannabis jumped from 4% to around
30% of his total business.
12
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consumer groups of patients who mobilize around and defend their diagnoses and prescribed
medications (Williams et al. 2011). Simply stated, pharmaceuticalization provides patients with
an identity based on their consumption of specific pharmaceutical drugs. It also legitimizes their
suffering while providing them with a tool to address their health problems. More often than not,
these drugs are designed to manage biomedical risk factors in overall healthy patients.
Though Joseph Dumit (2012) does not explicitly use the term pharmaceuticalization, his
critical analysis of the pharmaceutical industry illuminates how it came to dominate biomedicine.
The most important element is that the industry began to shift our cultural definition of health
towards one of risk management and risk reduction. In other words, health is not simply being
free from illness, it is a quest to minimize biomedical risk factors like high cholesterol and high
blood pressure. The industry even established mass risk levels used to identify when someone
may “benefit” from pharmaceutical intervention. In conjunction with the new emphasis on health
risks, there was also the rise of clinical drug trials and the privileging of this type of research on
the part of the FDA. This coalesces with direct to consumer drug advertisements which the FDA
began to liberally permit in 1999 following an overhaul of the agency’s guidelines. Before the
1999 broadcasting rules, prescription advertisements had to state all possible side effects. After
the new rules, drugmakers could simply direct consumers to a published magazine advertisement
if they wanted to learn more about the drug’s side effects. All of this was explicitly planned with
the aim of growing the number of prescription medicines in our lives (Dumit 2012). The more
people who use prescriptions and the longer each person relies on them, the more money the
industry will make.
The pharmaceutical industry has also flooded the biomedical knowledge base with
research based on clinical trials and other corporate-sponsored drug studies. Clinical drug trials
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have become the gold standard in how regulators approve drugs, but they are only good at
answering very specific questions (e.g., was there a difference between the control group and the
experimental group). Much of the available scientific facts about health now come from the
pharmaceutical industry, and these facts almost always support industry products and practices
(Dumit 2012). More disturbing is how the FDA began to rely exclusively on clinical trials to
evaluate the safety and efficacy of new drugs. The FDA has the most respected regulatory
standards in the world, but it also oversees the largest market in the world. With profits being so
high, there is a significant incentive to deceive regulators or cheat the regulatory system. One of
the ways pharmaceutical companies accomplish this is by withholding unsuccessful clinic trials
from the public. Even though the FDA requests to see unsuccessful trials, these are never made
public knowledge, and the drug will be approved so long as two clinical trials were successful
(Dumit 2012). This means a drug could have had two clinical trials where it was shown to be
safe and effective, but it could also have numerous clinical trials where the same drug was shown
to dangerous or ineffective.
Another dimension to pharmaceuticalization is the creation of patient identities based on
risk factors and drug therapies. This often results in expert patient agendas aimed at the right of
choice regarding their medications (Williams et al. 2011; Conrad 2005). Expert patients are the
“idealized product of the past fifty years of pharmaceutical marketing” (Dumit 2012:184). They
embrace a definition of health as a reduction of risk factors, they keep up to date on their own
biomedical risk numbers, and they actively seek information on new risks and treatments. Expert
patients also demand access to the latest clinically-proven therapies even if such therapies have
not yet undergone regulatory evaluation. This often manifests in the form of patient activism
aimed at securing the right to try experimental or non-FDA-approved therapies (Williams et al.
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2011). Research critical of pharmaceutical lobbying practices has also documented the industry’s
work in weakening regulatory requirements designed to protect patients from ineffective and
harmful drugs (Light, Lexchin & Darrow 2013; Dumit 2012). It is no wonder, then, that most
new drugs approved since the 1970s have little advantage over the existing pharmacopeia, and
that true pharmaceutical innovation has been static or declining. The industry likes to take the
easy route of re-marketing old drugs for new uses, or re-introducing old drugs that are different
but not more effective (Light et al. 2013; Dumit 2012; Williams et al. 2011; Chapkis & Webb
2008).
Despite the conceptual inappropriateness of considering cannabis pharmaceuticalized, it
appears the medicalization of cannabis was also facilitated by the pharmaceutical industry. GW
Pharmaceuticals is the company that invented Sativex, the prescription medication made from
cannabis plant extracts. To get the medication approved in the United States and abroad, the
company conducted numerous scientific studies on the medication’s efficacy. These studies have
since been used by medical cannabis activists as evidence to support medicalizing cannabis, but
GW Pharmaceuticals does not like this. GW claims there is a significant difference between
smoked cannabis and Sativex, and even though the two substances have the same basic active
compounds (THC and CBD). Many patients think of GW Pharmaceuticals as “the Monsanto of
cannabis” (Rendon 2012:180). They worry the company will monopolize cannabis for corporate
profit through attacking the decentralized networks of growers who supply most of the medical
cannabis used by patients today. However, the company undoubtedly helps the medical cannabis
movement by providing standardization and research (Rendon 2012). It should be noted, though,
that the company was formed in 1998, two years after a medical cannabis movement had already
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succeeded in California. Perhaps it may be better to view this as the pharmaceutical industry
appropriating cannabis activism in their quest for more prescription drugs and higher profits.
Fortunately, cannabis may be one of the least toxic substances known to the modern
pharmacopeia. It is safer than any over the counter pain remedy and has a longer history of
pharmacological use than any modern medicine (Frye 2018; Webb & Webb 2014; Grinspoon
1999). Administrative judge Francis Young of the Drug Enforcement Administration even
concluded a person would have to smoke 1500 pounds of pure marijuana in 15 minutes for it to
be lethal (DEA 1988). The safe track record of cannabis poses serious problems for medical
researchers like Choo and colleagues (2016) who caution against renewed interest in medical
cannabis by comparing it to physician enthusiasm over opioid painkillers around the turn of the
twenty-first century. While opioid addiction and overdose has become a major social problem, a
lethal overdose of THC has never been reported in humans (Bostwick 2012). There are also no
consequential symptoms of withdrawl from suddenly ceasing cannabis use, and many patients
are regularly forced to do so when traveling (Webb & Webb 2014).13 Likewise, “[cannabis] has
no known long-term health consequences other than possible effects on memory and cognition in
heavy users who start at a young age” (Fyre 2018:15). Other researchers have found both
medical and recreational cannabis users practice harm reduction techniques to mitigate potential
health effects. Lau et al. (2015a) found users may switch to vaporizers to avoid the consequences
of inhaling smoke and they may self-regulate their consumption in order to avoid building
cannabinoid tolerance. Similarly, patients may restrict their cannabis use to times when their
discomfort becomes unbearable, and some report taking breaks from cannabis medicine when/if

13

Some states like Michigan accept out-of-state medical cards so patients can purchase medicine while traveling.
Carrying cannabis through an airport is a federal crime even in states which have legalized medical and recreational
use. Illinois has even placed “last chance” marijuana disposal bins at airports throughout the state.
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their circumstances improve (Newhart & Dolphin 2019). As such, many patients see no reason
for cannabis-based prescription drugs or synthetic cannabinoids. The overwhelming desire of
patients appears to be the right to use whole plant medicines grown outside of pharmaceutical or
medical control.

Connoisseurship
Researchers have documented how cannabis was medicalized primarily through the work
of patients as opposed to medical, state, or corporate institutions (Pedersen & Sandberg 2013;
Chapkis & Webb 2008). Pharmaceuticalization is not inevitable, and patient activism may both
assist and threaten the industry’s grasp on professionalized medicine. Patients emphatically do
not want big pharma encroaching upon the medicine they love so dearly. One interesting form of
resistance to the pharmaceuticalization of cannabis has been through connoisseurship (Newhart
& Dolphin 2019; Lawrence 2019). Biomedical logic demands standardization and uniformity,
but strain diversity and freedom of choice are deeply valued in the cannabis subculture (Capler et
al. 2017). The number of developed strains is somewhere in the hundreds (if not thousands)
while dispensaries routinely carry 10 to 20 varieties, and sometimes more. Each has its distinct
properties and effects attributable to its unique profile of cannabinoids and terpenes. Perhaps the
best description of this comes from journalist Michael Pollan who says each strain of cannabis
and each method of consumption has a “specific psychological texture of its high” (2001:150,
emphasis mine).
Traditionally, varietals of cannabis were placed in a binary spectrum of C. sativa which
produces an uplifting, mentally-stimulating effect, and C. indica which produces a sedating,
bodily effect. The current focus seems to be increased attention to a strain’s terpene profile,
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something largely ascertainable by smell. Terpenes are aromatic essential oils found in all plants
though cannabis has one of the most diverse terpene profiles in the plant kingdom with over 260
different terpenes identified thus far (Lawrence 2019; Frye 2018). Indeed, the scent of cannabis
is a powerful hallmark of the plant. Michael Pollan acutely describes the smell of indoor
cannabis cultivation rooms as “[s]weaty, vegetal, and sulfurous” like “a locker room in the
Amazon” (2001:136). Taking this metaphor a step further, terpenes are like the various perfumes
and body sprays used in today’s locker rooms. They add another layer to the scent of the room,
but in the case of cannabis, they also mediate the plant’s effects. A connoisseur can sensually
distinguish between strains conducive to stimulation and those which promote relaxation. There
are also a plethora of colors, tastes, and methods of consumption that further diversify the
modern cannabis marketplace. There are even organic options for consumers wary of pesticides,
though the organic label is not policed by an organization like the USDA. Likewise, pesticides
appear to be of little concern in the medical cannabis community because of cultivation standards
and mandated product testing14. All of this stands in opposition to the flattening goals of
pharmaceuticalization.
Connoisseurship is also evident in how cannabis is sold and consumed. Jim Rendon
describes California dispensaries as displaying cannabis and cannabis products with “the kind of
fetishized care reserved for expensive jewelry or custom-made suits” (2012:31). He notes the
trend towards brightly lit atmospheres with high ceilings and wood-framed, glass display cases.
There are even specialized magnifying jars with slide-off-tops that allow customers to smell buds
before purchase. I have even witnessed budtenders slowly and gently place purchased buds in a

14

Some states like Michigan require testing for pesticides, fungicides, and heavy metals before cannabis can be sold
in retail dispensaries.

73

take-home container using chopsticks (as opposed to just dumping it in). This level of care is
appreciated but appears wholly unnecessary and is often time-consuming.
Another example of connoisseurship can be found in a new book on cannabis etiquette
written by Lizzie Post, the granddaughter of the famed etiquette writer Emily Post. Among other
things, the book describes the proper way to curate a home cannabis bar with a wide selection of
strains, equipment, edibles, and other products. In order to please one’s “ganja guests”, Post
(2019) recommends strains be labeled with names, cannabinoid levels, terpene profiles, and
strain effects, such as whether it’s uplifting or sedating. If one wanted to learn more about this
diversity, an awe-inspiring overview of cannabis strains can be found in the “Explore Strains”
section of Leafly.com. Or one could consult an “interpener” trained by the Trichome Institute.
They created the term interpening by combining the words “interpreting” and “terpenes”, and
define it as “the art and science of the cannabis sommelier; evaluating flower for total quality
control, psychotropic effects, and variety type designation” (Trichome Institute 2019). The
worlds of wine, craft beer, cheese, and coffee all have their discerning experts, and now cannabis
does too.
While pharmaceuticals are known for their standardization and purity, the cannabis
community has its own quality control facilitates known as testing labs. The first testing lab
opened in California in 2008 and this type of service has flourished ever since (Michigan
currently has four licensed “safety compliance” facilities). These businesses screen cannabis for
contaminants like mold, pests, and chemicals as well as provide accurate levels of cannabinoids
like THC and CBD. This information enabled cannabis growers to practice a type of selfregulation in regards to the purity and potency of their products (Rendon 2012). Michigan even
requires that all medical cannabis sold in dispensaries be tested and verified by an independent
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lab. These labs also provide essential services to growers, such as genetic testing and crossfertilization. Testing for genetics has proved to be immensely valuable since growers no longer
have to wait until a plant matures to analyze its qualities (Rendon 2012). Efficient DNA testing
has greatly increased the speed at which new strains are developed, and this, in turn, has likely
facilitated connoisseurship among consumers. Such developments and enthusiasm over this
natural medicine are not unique to cannabis, though.

Medical Skepticism and Conflict
It has been noted that medicalization may be used as more of a strategy for criticizing the
dominant punitive approach to drugs rather than out of a deep belief in the efficacy of the hyped
medical benefits (Conrad & Schneider 1992/1980). Indeed, many media figures, politicians, and
academics have portrayed medical cannabis as a means of deceiving a prohibitionist government
into allowing some marijuana use. However, these claims are often unsubstantiated beyond
anecdotal evidence (Kilmer & MacCoun 2017; DeAngelo 2015).
People who advocate against permissible use of medical cannabis sometimes point to the
problems of medicalizing by popular vote (Choo et al. 2016; Cohen 2010). Their argument is
that all other prescribed medicines must pass rigorous regulatory standards and that marijuana
has not yet met these standards. Therefore, states that pass medical cannabis programs sidestep
important regulatory agencies such as the FDA. Furthermore, cannabis has a better safety record
than nearly every other medicine including widely-used over the counter pain remedies, with
zero fatal overdoses in known history (Frye 2018; Webb & Webb 2014; Bostwick 2012;
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Grinspoon 1999). This also means that the plant is safer than alcohol and caffeine, both of which
are drugs celebrated in American society.
Alas, the metaphors of a stalking horse or trojan horse are commonly used when
describing medical cannabis. Fischer and colleagues (2015) call it a “sneaky sidedoor” (p.185), a
means of legalization through medicalization. Open-ended comments on a survey of 520 family
physicians in Colorado also reveal many believe medical cannabis is largely used as a form of
legal protection for healthy people with recreational intentions (Kondrad & Reid 2013). Other
scholars have said legalizing recreational cannabis will “reduce the strategic use of medical
cannabis laws as a stepping-stone to the legalization of recreational use” (Hall & Lanskey
2016:1770). Media pundits frequently amplify these narratives by pointing out they have seen
young, fit, and healthy-looking people use the medical cannabis system. Steve DeAngelo even
calls this the “Able-Bodied Young Man (ABYM) theory” since he has heard it so frequently
when debating medical cannabis (2015:55). This tactic is used to question the legitimacy of
medical cannabis even though not all illnesses are visible. Not only do many individuals attempt
to conceal their sickness, but the ABYM theory also obscures the millions of veterans who suffer
from post-traumatic stress disorder. Most of these ABYM accusations come from law
enforcement, politicians, and conservative media figures who have little direct experience with
medical cannabis or patients (DeAngelo 2015).
What about the people who deceptively become patients to continue buying and
consuming marijuana legally? Perhaps we should avoid treating marijuana as a value-laden
dichotomy between medical and recreational use (Athey et al. 2017). In other words, the
recreational use of medical cannabis does not nullify the possibility that the person is receiving
some health benefits. This duality appears to be understood by medical experts. Recreational
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legalization in Colorado made medical students in the state more likely to recommend cannabis
than previous laws permitting medical use only (Chan et al. 2016). If medical cannabis is merely
a ruse, then wouldn’t recreational legalization nullify physician recommendations for cannabis?
This finding may be a result of diminished legal repercussions faced by both doctors and
patients, but it is certainly not the abandonment of medical cannabis as many anticipated.
While many have raised skepticism over medical cannabis policies, the body of social
scientific research is filled with data from patients who overwhelmingly speak of life-supporting
results. Study after study imparts patient enthusiasm for their medicine and a deep conviction in
the therapeutic value of cannabis. It seems odd to me that this sizable group of people and their
place in the debate have been largely ignored by skeptics of medical cannabis. Pundits,
bureaucrats, and scholars sometimes speak of medical cannabis as a system exclusively used by
perfectly healthy people looking to get stoned. Even stranger is the presumption that the end goal
of medical cannabis programs is full-scale legalization. It ultimately stereotypes patients as a
homogenous group of pleasure-seeking marijuana enthusiasts. However, no one has analyzed
how cannabis patients view recreational legalization. If medicalization was merely an
intermediary phase on the road to full legalization, then cannabis patients should welcome
policies that increase access for all. Yet sentiments seem to be more complicated.
The patient experience is different in areas without accessible medical cannabis
infrastructure. There is no tradition of medical cannabis in Norway and researchers have found
some users feel pressure to constantly reaffirm the medical value of their cannabis use (Pedersen
& Sandberg 2013). Since they do not want to be perceived as pleasure-seeking, recreational
users, they made intentional efforts to reduce their association with cannabis subculture: “Any
identity that endorses recreational cannabis use and traditional cannabis culture jeopardises the
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identity frame of the medical cannabis movement and risks the medical cannabis cause being
seen as ‘just another way’ to legalise cannabis” (Pedersen & Sandberg 2013:26). On the other
hand, in the United States, the symbols of the cannabis subculture have been adopted by the
medical cannabis industry: tie-dye, Rasta, marijuana-leaf iconography, and much more.
Yet even when medical cannabis use is legitimated by state and medical authorities,
patients still feel the need to socially distinguish themselves from illicit recreational users (Athey
et al. 2017). Michelle Newhart and William Dolphin (2019) found patients in Colorado prefer a
clear system boundary between medical and recreational cannabis. They were overall supportive
of recreational uses, but they were also invested in their identity as a patient along with the
medical system of cannabis access. Among other things, being a “patient” grants one access to
the medically-focused system as opposed to recreational dispensaries, it may protect against
sanctions from employers or authorities, and it helps reframe the individual’s cannabis use as
therapeutic rather than pleasure-oriented. Yet the researchers’ data collection ended before
Colorado legalized recreational cannabis in 2012. Does this identity work still exist in areas
where both recreational and medical cannabis are available? To my knowledge, no one has
studied cannabis patient sentiments in a post-prohibition state. My research attempts to answer
that question because Michigan is one of the few areas where medical and recreational sales will
exist side by side.
In States that have legalized recreational marijuana, the existing medical marijuana
industry has played a major role in crafting regulatory guidelines (Room 2013). For example,
Patrick K. O’Brien (2013) describes medical marijuana as a form of neoliberal state control. The
state has realized that enforcing cannabis prohibition through law enforcement has been an uphill
battle and has chosen instead to set strict regulations that are largely enforced by medical
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dispensaries. Much of this decision may be based on the premise of capital gain through taxation
and less public expenditures of policing marijuana use (Kilmer & MacCoun 2017). This shift to a
legal market has also made the marijuana community visible and thus identifiable by state
authorities. Since operating in the shadows is arguably less efficient than operating a site of legal
commerce, those who buy and sell marijuana can now be monitored by the state (O’Brien 2013).
Even if the intent of medical marijuana policies was not focused on recreational
legalization, such programs have played a significant role in facilitating the legalization of
recreation use through defining deviance down (Adler & Adler 1994/2016). As marijuana users
crept out of the shadows, the general public was able to see that normal, and even prestigious
people use marijuana: “The dispensary system… placed marijuana into the normative system of
community life, distancing it from previous associations with an underground market of
criminals” (O’Brien 2013:438). Furthermore, cultivators experienced in growing medical
cannabis enjoy a head start in the recreational industry as both utilize the same plants and
cultivation practices (Weisheit 2011). It seems logical growers will welcome a recreational
system since it substantially expands their customer base.

The End of Medical Cannabis?
Currently, states with both medical and recreational cannabis typically impose fewer
taxes on the production and sale of medical cannabis (Hall & Lynskey 2016). Medical cannabis
businesses may also be permitted to grow more plants and offer products with higher levels of
active cannabinoids. Nonetheless, the tax difference is relatively small for consumers and does
not consider fees involved with registering as a patient. Depending on the degree of difference,
lower taxes on medical cannabis may provide a strong economic incentive for individuals to
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remain patients as opposed to recreational buyers (Fairman 2016). Interestingly, when California
voters legalized recreational marijuana in 2016, the measure also imposed a 15% excise tax on
both medical and recreational markets. Experts reasoned lower taxes on medical cannabis would
incentivize those without legitimate medical reasons to become or remain medical patients. Since
the new tax would inevitably make medicine more expensive, a sizeable minority of patients
came out against the measure to legalize recreational marijuana in California. Among them was
Dennis Peron, the father of the modern medical cannabis movement (McGreevy 2016).
Dissatisfaction with proposed legalization has happened before among the cannabis
community. In 2010, an initiative to legalize recreational marijuana in California failed at the
polls with 46.5 percent of the vote. While many factors surely contributed to the demise of
Proposition 19, Jim Rendon (2012) argues one of these factors was a lack of support from the
state’s medical cannabis growers. Rural farmers in Northern California have been at the forefront
of advancing cannabis for decades, though often illegally. When medical cannabis took off in the
state, many small-scale farmers acquired permits to grow a medical crop, but so did urban indoor
growers. Growing indoors can produce larger yields and more-potent buds, and it’s arguably
more profitable if done on a large scale. Rural farmers feared legalization would invite corporate
interests with intents on establishing industrial indoor grows near urban areas. This would have
wrecked the cannabis economy for small outdoor growers and as such, many voted against the
legalization initiative (Rendon 2012). Despite this resistance, California legalized recreational
marijuana six years later.
Many have hypothesized legalized recreational marijuana will cause declines in the
number of cannabis patients on state medical registries. If true, Newhart and Dolphin (2019)
believe this will be due to the bureaucratic barriers involved with becoming a state-certified
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patient, a non-anonymous process riddled with paperwork and fees. While being a medical
cannabis patient may carry some social privileges, existing and potential patients may forgo the
hassle and simply buy their medicine in the more-accessible recreational marketplace. On the
other hand, this state-sponsored identity may help to preserve a medical cannabis system in states
with recreational marijuana. Cannabis patients have stronger ties to their identity partly because
of their membership in a formalized state program. Being a card-carrying member of a
community makes it more difficult to transition out of a community since it involves more than a
simple shift in perspective. Cannabis patients may be too invested in their identities to simply
abandon their membership status in a community (Newhart & Dolphin 2019).
While Kilmer & MacCoun (2017) argue that medicalization and legalization are
intertwined, they also speculate if medical marijuana programs will survive once prohibition
ends. A larger recreational industry may see medical marijuana as a source of competition for
clients. Also, as research will be easier to conduct once prohibition ends, results may no longer
support marijuana’s therapeutic benefits or may support the use of non-psychoactive, synthetic
products over the natural medicine (Kilmer & MacCoun 2017). Part of cannabis prohibition is
“federally mandated ignorance” (DeAngelo 2015:46) surrounding cannabis research, so it is
likely the golden age of cannabis research is still ahead of us.
These possibilities have significant implications for medical cannabis patients. As more
states move to legalize recreational marijuana use, they may also undermine the hard-fought
recognition of marijuana as a legitimate medicine (Satterlund et al. 2015). Legalized use of
recreational marijuana may devalue the medical distinction in the collective conscience, turning
patients back into drug users. According to Wayne Hall and Michael Lynskey (2016), the
legalization of recreational marijuana will result in lower prices, increased availability, enhanced
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safety and quality, and more social acceptance surrounding marijuana use. If being a medical
cannabis patient shielded against some of the social stigma, a more tolerant society may make
that reason obsolete.
Perhaps the biggest sign of medical marijuana’s twilight is the shift in rhetoric from
patient needs to economic generation via jobs and taxes (Kilmer & MacCoun 2017). Some have
argued this economic imperative threatens both recreational and medical cannabis with dangers
inherent in for-profit, commercialized models (Choo et al. 2016; Pardo 2014; Room 2013;
Nadelmann 2007). Craig Reinarman (1994) has identified this tension between our modern
culture of mass consumption and our historical roots as a temperance culture. We value selfcontrol and abstinence, all while living in a capitalistic environment of mass-marketed
temptation, indulgence, and instant gratification. The pressure to always grow sales may lead to
unscrupulous advertising, dangerously potent products, widespread applications of toxic
chemicals to boost yields, and other public health concerns. A recent article on “pot addicts” in
The Atlantic says: “Thousands of Americans are finding their own use problematic in a climate
where pot products are getting more potent, more socially acceptable to use, and yet easier to
come by, not that it was particularly hard before” (Lowrey 2018). The author blames
advertisements aimed at incorporating cannabis into all of life’s activities, untrained budtenders
professing the safety of their products, and lax regulatory standards regarding the potency of
consumer THC products. While much concern has been expressed over increased marijuana
consumption among youth, these fears have yet to materialize in states with recreational
marijuana (Peters & Foust 2019; Hall & Lanskey 2016).
Fears over potency are not unique to the United States. A study on small-scale cannabis
growers in Belgium uncovers some negative perceptions regarding the commercial cultivation of
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cannabis for sale in the world-renowned Dutch coffee shops (Decorte 2011). Interestingly, the
small-scale growers take pride in producing a milder, gentler product often of superior quality.
They perceive the cannabis sold in coffee shops to be stronger but also dirtier because of the
chemicals used to increase yields and potency (Decorte 2011). Large-scale cultivators push their
crops to unnatural levels where qualities like flavor and enjoyability are lost. A similar trend may
emerge in the United States where levels of THC in cannabis have skyrocketed over the past
several decades. Though scholars have critiqued the reliability of the method, seized cannabis
samples in 2009 had an average THC content of 8.49%, up from 0.9% THC in 1976 (Weisheit
2011). Based on my own experiences, it is common to see THC levels exceed 20% in the
medical cannabis sold in Michigan dispensaries. This is roughly five times more potent than the
marijuana available in the 1960s (Rendon 2012).

Conclusion
Whether or not cannabis is or becomes medicalized depends on a complex interplay
between patient demands and biomedical acceptance. For the most part, scholars have focused
on either patient desires or the perspective of mainstream medicine, but rarely have these two
standpoints been integrated to illuminate the medicalization of cannabis. My findings on this
topic are discussed in Chapter 7 where I propose cannabis is best theorized as alternatively,
rather than incompletely, medicalized.
The current backlash against cannabis appears to be aimed at potency, publicity, and
profits. Market forces have taken cannabis and transformed it into a commodity where
businesses compete to capture market share with extreme products. At the same time, some have
argued that cannabis should be placed under biomedical control if it is to be considered medicine
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in our society. This is why it is important to keep in mind that cannabis was initially medicalized
through what some have termed an embodied health movement because subjective notions of
patient wellness were discredited by biomedicine. “Biomedicine operates through the stability of
its state-supported and institutionalized structure. Because of its dominance, the biomedical
discourse has come to hold power of telling the ‘truth’ of conditions and concerns subjected to it
in a social context that values rationality, objectivity and science (Sointu 2006:340). The same
values are also emphasized in the economic discourse that has come to dominate debates on
cannabis legalization. Could there be a common cord connecting the two?
As a feminist and a gay man, I see a strong connection to masculinity in those who
support medicalizing cannabis under biomedical control as well as those who support
legalization through economic imperatives. As the plant gains legitimacy in the eyes of the law,
the male-dominated culture of venture capital is extending its grasp over the emerging industry.
Profit may not be inherently evil, but concerns within the cannabis community appear to be over
who is profiting. While cannabis is often described as the next billion-dollar industry, wealthy
white men in suits seem to have positioned themselves as the primary benefactors of legalization.
Likewise, should cannabis ever be completely medicalized, it would mean the plant is controlled
under biomedical institutions. These institutions have long been criticized as privileging male
bodies while attempting to control female bodies and neglecting women’s health in general.
But little is known about gender and cannabis use within the social sciences.
Unsurprisingly, the best research on gender and cannabis comes from outside of the United
States, most notably Canada and Norway. It is time to document how Americans craft gendered
selves within cannabis culture, and this is explored in the next chapter of my dissertation.
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CHAPTER IV

GENDER AND CANNABIS
As has been demonstrated earlier, the normalization and medicalization of cannabis tend
be masculinized— Using cannabis is more normative for men and many have called for cannabis
to be controlled under paternalistic biomedical structures. With that said, this chapter will
explore another other novel aspect of my dissertation, that of gender within Michigan’s medical
cannabis community. Since my study will be among the first to contribute to the knowledge base
of gender in relation to medical cannabis, here I provide examples from the literature on
recreational marijuana, alcohol, tobacco in relation to gender. Unfortunately, much of what we
know about gender and cannabis comes from anti-drug studies on youth populations. This is why
I have also profiled how gender has been discussed in popular media on cannabis, particularly
when it comes to women in the cannabis sector. I conclude with an overview of how scholars
theorize masculinities and propose how my intended study will contribute to the dialogue.

Gender in the Academic Literature
Aside from a Norwegian study of recreational cannabis users (Dahl & Sandberg 2015)
and a small Canadian study of medical cannabis patients (Bottorff et al. 2011), there has not been
much meaningful research on gender and cannabis. Researchers have described variations among
men and women who use cannabis, but little has been done to deeply interrogate gendered
practices. This is even truer in regard to racial and ethnic dimensions of medical cannabis as
nearly all studies approach the topic through a colorblind frame, perhaps because they have
majority white samples and/or a white research team. More gender and race-conscious research
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needs to be conducted in this area, ideally research that takes an intersectional perspective on
these two forces of privilege and oppression.
We have a good understanding that methods and quantity of consumption vary between
the sexes. Surveys find men use more cannabis and do so more frequently than women (Burns et
al. 2013), and that women are more likely to use cannabis for specific medical purposes and
often report doing so later in life (Cuttler et al. 2016). Recent statistics indicate men age 26 and
older are twice as likely as women in that age group to use marijuana at least once per month
(10% to 5%). This difference increases with age, as men between the ages 18 and 25 are only
about a third more likely than similarly-aged women to use marijuana (24% to 18%) (SAMSA
2016).

Sex Differences
The most prominent framework used to analyze men and women within the world of
cannabis is that of sex differences. This dated perspective sees gender and sex-assignment as
essentially the same, and ignores processes of socialization which instill masculinity or
femininity in the individual (Ferree & Hall 1996; West & Fenstermaker 1995). We know men
are slightly more likely to support marijuana legalization than women (Schnabel & Sevell 2017),
but without explanation these differences come across as inherent within the sexes rather than a
social product attributable to gender. An analysis of state registries found two-thirds of cannabis
patients are male but this ratio has been decreasing over time (Fairman 2016). The author
speculates males may be early adopters of medical cannabis because of their tendency to have
prior involvement with illicit recreational marijuana.
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Ratios aside, sex differences in use are reportedly small but significant among
recreational marijuana users, but sex differences in use are believed to be trivial among cannabis
patients (Cuttler et al. 2016). Biomedical research on sex differences suggests hormonal
differences between sexed bodies may explain why women are more likely to be affected by
cannabis than men. Women report better subjective effects of cannabis than men, but they are
also more prone to adverse reactions (Cooper & Haney 2014; Craft et al. 2013). Another
interesting difference reported by Cuttler et al. (2016) is men are more likely to report a sense of
enthusiasm after smoking while women are more likely to report a desire to clean. The
researchers say little more about this odd desire than attributing it to women’s larger share of
domestic labor. Without digging deeper into the role gender plays in cannabis culture, we may
risk presenting cannabis as a tool to make the oppressive second shift marginally more
enjoyable.15
Other research on sex differences finds men and women smoke medical cannabis at nearequal rates in the Netherlands, but women are slightly more likely to medicate with recentlyintroduced cannabis oils (De Hoop, Heerdink & Hazekamp 2018). This may also be true in the
United States as men report using more joints/blunts, concentrates, and vaporizers, whereas
women report using more pipes and oral methods of ingestion such as edibles, oils, and capsules
(Cuttler et al. 2016). Among people who use CBD, men are more likely to report using for
general health purposes whereas women are more likely to report using to treat specific medical
conditions (Corroon & Philips 2018). There are many more of these sex differences in the patient
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One of the Norwegian participants in the study by Dahl and Sandberg (2015:705) describes the opposite of this
sentiment. Elisabeth (age 32) stated smoking marijuana stopped her from fussing over cleaning and tidying up. It
made her laid-back to where she broke from those culturally feminine characteristics, much to the enjoyment of her
partner.
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community, but to reiterate my point, none are meaningfully analyzed within the sociology of
gender.
Part of the mission of feminist sociology has been to disenchant biological assumptions
concerning sex, gender, and nature (Flax 1987), as well as to establish gender as a significant
organizational element in all areas of social life (Fonow & Cook 1991). It’s time this powerful
perspective be applied to social research on cannabis in a way to could help break down
stereotypes and promote egalitarian change (Sprague 2016). Only two studies come close to this
type of gendered analysis: The Norwegian study mentioned earlier (Dahl & Sandberg 2015) and
a study using interviews with 23 Canadian patients by Joan L. Bottorff and colleagues (2011).
Findings from both studies are integrated throughout this chapter.

Gendering Cannabis
The lack of attention to gender may result from gender’s status as a variable rather than a
focus in most studies, but I also suspect it may be an artifact of male-dominated samples. Most
social research on both medical and recreational cannabis users is conducted on predominantly
male subjects (e.g., Newhart & Dolphin 2019; Satterlund et al. 2015; Zaller et al. 2015;
Belackova & Vaccaro. 2013; Reiman 2007). Even the paper with the most gendered analysis
uses two male-dominated samples, one with 88 men and 12 women and the other with 18 men
and seven women (Dahl & Sandberg 2015). While some studies on medical cannabis patients
have good levels of gender representation (Corroon & Phillips 2018; Sexton et al. 2016; Bottorff
et al. 2013), and while two studies have a majority female sample (Victorson et al. 2019; Haug
et al. 2016), these studies have not analyzed how gender is performed or how gender may
structure use.
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Some of this gender imbalance may be justified. The recently-published study by
Newhart and Dolphin (2019) had a roughly 70/30 male-female sample, but this ratio resembles
the demographic composition of medical cannabis patients in Colorado. Nonetheless, women are
slightly more likely than men to indicate a willingness to participate in biomedical research
regarding the efficacy of cannabis for chronic pain (Bachhuber et al. 2018). Presumably, they
should also be willing to discuss how femininity or being a woman shapes their use of medical
cannabis, but researchers have not yet explored this. On the other hand, there is some indication
there is a heightened stigma faced by women with children (Newhart & Dolphin 2019;
Reinarman et al. 2011), and this stigma may inhibit mothers from participating in studies related
to cannabis.
What we do know about gender and adult cannabis use largely comes from studies on
recreational users in criminalized contexts. Bruce Johnson and colleagues (2008) found some
modest but significant gender differences in their ethnographic study of recreational users in
New York City. Male marijuana users are more likely to smoke blunts and female users are more
likely to smoke joints. Men are also more likely to smoke in the morning, at work, and in public
places. Women were more likely to follow civic norms regarding not smoking in public, not in
the presence of children, and always in moderation. The researchers note, however, that their
sample was more alike than different, though significant gendered patterns are present (Johnson
et al. 2008). Furthermore, while drug use is mediated by gender, it may be more important to see
drug (sub)cultures as gendered (Measham 2002). In other words, gender may be a significant
organizational component within the subculture itself in addition to how gender shapes
individual use.
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Most of the literature on gender and marijuana comes from anti-drug studies on
adolescent use. A frequently cited study partly-titled “Girls Are Retarded When They’re Stoned”
(Warner, Weber & Albanes 1999) uses the separate spheres framework to analyze youth
smoking as reported through sex-segregated focus groups. Slightly better is a qualitative study of
adolescent marijuana use in Canada where gender is also discussed (Haines et al. 2009).
Interestingly, both studies observed students were less comfortable talking about gendered
practices than they were with discussing their use of illegal marijuana. The Canadian researchers
realized it was difficult for students to be reflexive about gender as a social category, so they
reformed their questions in a manner that asked students to reflect on the gender composition of
their own smoking groups. Their overall finding was that masculinity facilitates authentic use of
marijuana while femininity impedes authentic use (Haines et al. 2009). This means teenagers
doing masculinity could easily accommodate marijuana into a gendered routine while teenagers
performing femininity resorted to tactful marijuana smoking in order to maintain a feminine
presentation of self. Interestingly, femininity was also a means of accessing marijuana since girls
are largely beholden to male dealers or to their boyfriends when it comes to obtaining marijuana.
While none of the girls interviewed in the study admitted to using boys for marijuana, some of
the boys interviewed expressed that girls have an easier time getting marijuana owing to their
sexual assets (Haines et al. 2009).
Historically, research focusing on adult women’s use of drugs often approached the issue
through sex issues concerning women as prostitutes or drug-using mothers. The “mad, sad, or
bad” framework was popular through the 1980s and problematized all female drug use in a
manner that ignored agency or pleasure, factors only reconsidered by scholars beginning in the
1990s (Arnull & Ryder 2019; Dreher 2002, Measham 2002). This shift reflects changes in
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women’s structural position within society rather than women using more drugs as a social
group. For example, women who use stimulant drugs to ward off sleep may do so to extend their
leisure time in a society where they are expected to work outside of the home for pay as well as
at home for free (Measham 2002). Cannabis’ ability to alter time perceptions may also help
overworked women find greater enjoyment in the scare leisure time they spend with children.
Nonetheless, society still tends to stigmatize female intoxicant use much more than male
intoxicant use: “Too much ‘fun’ is portrayed as dangerous to a young woman’s physical safety,
appearance and national decorum… and by engaging in cultures of intoxication they are seen to
fail to perform acceptable feminine roles” (Arnull & Ryder 2019:2).
Yet cannabis is not like other intoxicants, and there are some discrepancies related to
gender and marijuana smoking in the academic literature. Young British women in their 20s
interviewed by Measham (2002) perceive marijuana as more controllable than alcohol, a drug
with a long legacy of inebriation and male aggression. On the other hand, focus groups of girls
(ages 15-16) in Denmark find the exact opposite sentiment: Marijuana is difficult to control and
unlike underage alcohol use, young people risk becoming daily users (Jarvinen & Demant 2011).
These differences may be cultural and age-related, especially since the youth interviewed by the
Danish researchers had the misconception that marijuana was a dangerous drug while alcohol
was relatively harmless. Interestingly, when these same youth were again studied at ages 18-19,
one of the girls expressed a fondness for marijuana and described it (as the boys did) as being
controllable and pleasurable (Jarvinen & Demant 2011). Such findings should raise caution
about generalizing research on adolescent drug use to adults.
The illegal marijuana marketplace has been described by others as more masculine than
the budding legitimate cannabis industry. Purchasing marijuana from a dealer is typically done
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between two men whereas legal enterprises like dispensaries are more welcoming to women
(O’Brien 2013; Bottorff et al. 2011; Warner et al. 1999). For example, Canadian cannabis
patients who are women are more likely to acquire cannabis through legitimate channels when
compared to Canadian men who are patients (Bottorff et al. 2011). Yet just as legal
establishments such as bars are highly gendered spaces (Mullen et al. 2007; Measham 2002), so
too may be cannabis dispensaries.
Masculinity’s connection to the world of marijuana may facilitate access but this
association comes at a cost. Psychological research on stereotypes has found males are more
likely to be judged as cannabis users than females (Hirst, et al. 2018). This confirms findings by
Looby and Earleywine (2010) who found reactions to cannabis stereotype threats varied by
gender. The men in this study feared their status as a cannabis user would invoke prejudice by
the evaluator measuring the participant’s performance on an exam. Stereotype threats occur
when individuals believe they may be stereotyped by others, creating a pressure that causes the
individual to adjust their appearance and/or behavior (Newhart & Dolphin 2019; Hirst, et al.
2018; Looby & Earleywine 2010). This pressure has the potential to boost one’s performance but
can also result in decreased performance owing to the added psychic stress. Most of our cultural
images of stoners are males, making men more vulnerable to cognitive distress over their
cannabis use. Women who were exposed to stoner stereotype threats actually had slightly better
cognitive performance scores than women in the control group (Looby & Earleywine 2010). This
may be due to the relative lack of female stoner stereotypes, how women identify with other
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social groups more closely than cannabis culture, or intrinsic motivation to disprove cultural
stereotypes that have disadvantaged women for so long (Looby and Earleywine 2010).16
“Stoner” was also conceptualized as masculine by high school students interviewed by
Haines et al. (2009) and by college students interviewed by Mostaghim (2019). These students
stated that habitual marijuana use by girls would be inauthentic and out of the norm. This
resembles findings by Measham (2002) who found young adults interpret excessive intoxication
as failing at femininity but succeeding at masculinity. Some of the high school girls who used
marijuana frequently took pride in how it made them “just one of the guys” (Haines et al.
2009:2033). This could be due to our patriarchal culture valuing masculinity over femininity, but
the researchers speculate this sentiment is due to the drug’s association with masculine leisure
activities and male bonding. A more potent explanation could be that there is a gendered double
standard when it comes to teenage substance use. While substance use by young men is
commonly dismissed as a risky rite of passage into adulthood, substance use by young women is
frequently denounced as unfeminine and dangerous (Arnull & Ryder 2019). The gendering of
teenage substance use is further impacted by cultural assumptions related to race, ethnicity,
social class, and more. Nonetheless, resistance to this gendered double standard was expressed
by some of the Norwegian high school girls in the study by Dahl and Sandberg (2015). These
girls interpreted smoking joints as a way to construct a more progressive femininity, with some
likening it to a “small scale gendered rebellion” (705).

16

Stoner stereotypes are also largely associated with youth and young adults (Newhart & Dolphin 2019). The
stereotype exaggerates qualities like irresponsibility, laziness, and lack of experience. This is good to keep in mind
because many academic studies on marijuana use are based on youth samples. Resulting data may help reinforce our
cultural assumptions related to age and marijuana use, essentially confirming rather than challenging the stereotype.
Furthermore, the stereotype also links adult use of marijuana to immaturity and other age-inappropriate behaviors.
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Since marijuana is coded as masculine, abstaining from marijuana in high school was a
sign of failed masculinity, and boys who refused to smoke were disparaged as “bitches” (Haines
et al. 2009; Warner, et al. 1999). This feminizing epithet is highly reminiscent of CJ Pascoe’s
book Dude You’re A Fag (2007), where the word fag was directed at (presumably) straight boys
who did anything remotely feminine. Both “bitch” and “fag” are used to establish and reinforce a
masculine hierarchy among male youth by degrading boys who act like girls. Similarly, “twobeer queer” is an epithet for young men who break with masculine tradition by consuming little
or no alcohol. This label has nothing to do with one’s sexuality but rather their failure to meet
hegemonic masculine norms (Peralta 2007). Yet other research on drinking patterns among
young adult men finds both social context and personal history are more influential than
hegemonic notions of masculinity (Mullen et al. 2007). Maturing into adult roles characterized
by responsibility and independence played a significant part in this change. As such, feminizing
epithets directed at boys who abstain from smoking marijuana may be largely attributable to a
high school setting where peer pressure is a powerful force. Again, this fact raises issues of
validity when using youth-based studies to infer gendered patterns among adults.
This masculinization of youth marijuana use may be evidence of gender hegemony in the
subculture, yet it is not without resistance on the part of guys. A survey of young urban men
found recreational marijuana use was negatively related to one’s endorsement of traditional
masculine norms (Taggart, Brown & Kershaw 2018). In other words, men who endorse
masculine status, toughness, and anti-femininity norms are less likely to use marijuana than men
who fashion alternative masculinities. The researchers speculate this is due to men valuing selfcontrol, responsibility, and accountability within disadvantaged neighborhoods.
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Similar findings are evident in studies on youth marijuana use. Young girls in the focus
group study by Jessica Warner and colleagues (1999) claimed marijuana reduced the inhibitions
of their male peers, making the boys more sociable and kinder. Likewise, some boys interviewed
by Haines et al. (2009) described marijuana use as a tool to refashion masculinity into a less
aggressive, more emotionally expressive identity. One boy stated: “Weed is just a happy drug. I
mean, it’s my drug of choice because it makes me happy and nothing bad happens when you
smoke weed” (2033). Interestingly, while this boy connected marijuana with an alternative form
of masculinity, others discussed how being “chill” while high was largely a masculine demeanor.
They chastised peers who became too excited or “heaty” while smoking. In other words, the
dominant expectation for those who smoke marijuana was to enact a form of masculine coolness
(Haines et al. 2009).
Findings such as these tell us we should resist the tendency to polarize masculine and
feminine behaviors, and instead treat drug cultures as multifaceted sites where masculinity and
femininity can be constructed and challenged. Gender should be seen as an accomplishment
within drug cultures rather than a biological imposition (Measham 2002; West & Fenstermaker
1995). This permits the possibility of social change within the drug subculture as well as within
general ways of doing masculinity and femininity.

Alcohol, Tobacco, and Gender
Gender differences have been a popular framework in research on licit substance use.
Robert Peralta (2007) found college men use stories and trophies of alcohol use as a marker of
embodied masculinity. Stories of heavy drinking are told in a manner in which the individual
enjoyed the experience, proving one’s ability to remain in control of their body and
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consciousness. Physical proof of this masculine accomplishment can be found in the scores of
empty liquor bottles proudly displayed in residences, and more recently, with social media
photographs documenting heavy drinking. College women attributed this tolerance to natural
biological differences and felt excess drinking on their part would be stigmatized and even
dangerous (Peralta 2007). In other words, excessive drinking would detract from one’s
performance of femininity. College men celebrated those who put their bodies at risk by
consuming excessive amounts of alcohol and interpreted such rituals as a sign of toughness. This
allows some men to relationally distance themselves from drinking styles characterized as
feminine (Peralta 2007). In other words, risky drinking was one way for these men to accomplish
masculinity.
Perceptions of risk may also help explain the gender gap in support for marijuana
legalization. Researchers have consistently found women are somewhat less supportive of
legalizing marijuana compared to men (Elder & Greene 2019). While women are generally more
liberal on policy issues than men (e.g., gun control, environmental regulation, government
spending on social welfare, equal rights, etc.), they also tend to be more conservative on issues
with a moral dimension (e.g., pornography, school prayer, divorce, etc.). Yet Laurel Elder and
Steven Greene (2019) found there is a more significant variable when explaining the gender gap
over support for marijuana legalization: “the white male effect”.17 This effect occurs from
(white) men’s willingness to embrace risk and manifests through less concern over issues like
climate change and as such, perhaps more support for legalizing marijuana. In other words, when
gender and race privilege coalesce, the potential risks associated with specific policies become

It should also be noted that in Elder and Greene’s (2019) statistical model, gender was a far more potent predictor
than race in explaining one’s support legal marijuana. When analyzed individually, both gender and race had a
significant effect on attitudes towards marijuana. However, masculinity was the most powerful predictor as support
did not vary significantly between white men and men of color.
17
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less of a concern. White men are more comfortable with the current status quo of weak but risky
environmental regulations, and this may also explain why white men are also more likely to
support legalizing marijuana despite the uncertain risks involved in doing so (Elder & Greene
2019).
Not all men conform to traditional notions of masculinized behavior. Young British men
interviewed by Mullen and colleagues (2007) reported a preference for drinking in mixed-sexed
groups as opposed to the exclusively-male drinking groups of their fathers. The brewing industry
itself recognizes this shift in gendered drinking patterns and has been creating products and
advertisements aimed at a more diverse consumer base (Mullen et al. 2007). Yet advertisements
and marketing also provide cultural discourses through which individuals can enact gendered
selves. Cigarette companies exploited pre-existing gender norms in order to provide women with
tobacco products in line with their performances of femininity, even though some women
enjoyed how cigarette smoking challenged conventional notions of femininity (Gilbert 2007;
Amos & Bostock 2006; Nichter et al. 2006). While the studies on youth tobacco smoking and
marijuana smoking find much in common, it is only the later studies which show us young men
breaking with hegemonic masculine codes. Alternatively, Bottorff et al. (2011) say gender
differences in smoking cannabis are muted when compared to gender differences in smoking
tobacco. They reason this is because the effects of smoking cannabis are more important than the
smoking ritual itself. In other words, smoking cigarettes may be more socially performative than
smoking cannabis since the latter is typically about getting high rather than looking cool.18
18

Steve DeAngelo (2015) hints at a possible explanation for this though he does not connect it to gender. When it
comes to substances like alcohol and tobacco, marketing never focuses on the actual effects of the substance. For
example, alcohol commercials never boast about the product’s ability to get you drunk or decrease your judgement.
Instead, they appeal to lifestyle, coolness, sexuality, glamor, luxury, and adventure. A naive viewer may not realize
the commercial is pushing a psychoactive product. My thinking here is that within these idealized images are
gendered ways of consuming the substance. Since cannabis has never been mass marketed aside from
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The methods used by researchers also have significant roles in shaping conclusions
related to gender. One of the interesting findings from Mullen et al. (2007) is that male drinking
patterns are more diverse and flexible than quantitative studies suggest. Their focus groups of
young men in the UK found masculinities are being refashioned along with the changing social
context of male drinking norms. Similarly, while quantitative methods uncover few gender
differences among tobacco smokers, ethnographic research reveals nuances in how men and
women craft gendered selves through smoking tobacco. For example, young men smoke in
solitary ways while young women, who are held more accountable for their behavior, prefer
smoking in groups in order to avoid some of the stigmas of engaging a masculine-coded activity
(Amos & Bostock 2006; Nichter et al. 2006). Arnull and Ryder (2019) also found teenage girls
were careful to balance risk and pleasure against one another in their decision to use recreational
intoxicants. The most common way to hedge risk related to substance use was to pursue such
pleasures in the context of a social group. None of the girls interviewed spoke of using drugs
alone: “Although friends may be conduits into [alcohol and other drug] use, they are also the
people who watch your back and look after you. Girls described how they look out for
themselves and others, highlighting social networks that mitigate substance-related risks,
strengthen social bonds, and demonstrate care” (Arnull & Ryder 2019:10). Doing deviant things
in a group diminishes some of the blame each individual receives, and findings like this reveal
how a gendered self is both influenced by and constructive to drug subcultures.

characterizations in popular media, it may lack culturally idealized styles of consumption. In other words, since
cannabis has never been commercially connected to an attractive lifestyle, users may focus more on the effects than
the messages their use sends to others.
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Adults, Gender, and (Medical) Cannabis
What about gendered analyses in the context of adult medical cannabis use? Only one
study focuses on the subject in an exclusive manner. Joan L. Bottorff and colleagues (2011)
found medical cannabis patients described the effects of cannabis in glowing terms such as “life
preserving” or a “life force” (772). Women were more likely to explicitly use this terminology
than men, and women were also more likely to frame cannabis as a mood-booster or a “medicine
for the mind” (773). The authors connect this culturally prescribed feminine ideals of emotional
awareness and emotion work. One Canadian man in the study told the interviewer that cannabis
allowed him to retain control over his body despite his sickness. Overall, men were more likely
to frame cannabis as enabling self-reliance when managing their illness, often avoiding
professional health care services. Women, however, were more likely to work with health care
services in regard to their cannabis use and desire to reduce prescription medications. Men also
disclosed how cannabis helped their mental health, but they tended to frame use as controlling
one’s anger or rage. These are also both characteristic of depression related to chronic illness in
men, perhaps since our culture discourages men from discussing emotions (Bottorff et al. 2011).
Either way, medical cannabis helped these men manage and perhaps refashion their enactments
of masculinity.
In their qualitative study of the gendering of illicit marijuana use, Scandinavian
sociologists Silje Dahl and Sveinung Sandberg (2015) found that men who use marijuana
typically lack celebrated cultural characteristics of masculinity (Dahl & Sandberg 2015). The
effects of marijuana are often described as mellowing and therefore have been associated with a
softer version of masculinity (Haines et al. 2009). Marijuana is not considered to be among the
hard drugs (like opioids), and it is common to see marijuana referred to in feminine ways (e.g.,
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Mary-Jane). Yet marijuana use still appears to be coded masculine as female users of the drug
feel they sacrificing feminine ideals of purity (Mostaghim 2019; Dahl & Sandberg 2015).
As part of several gender differences found in Scandinavia’s underground cannabis
subculture, the authors note how female users avoid extreme forms of ingesting cannabis and
prefer “… a softer, milder, and more gradual form of intoxication” (2015, p.704). These women
were not only concerned with being physically able to handle such intense highs, but they also
worried about breaching cultural ideals of feminine moderation and control. Smoking is an
embodied practice, and if we cannot maintain control over our bodies when smoking (e.g.,
coughing), we risk losing face in our enactments of masculinity or femininity. While female
cannabis patients in Colorado reported taking small hits until the desired medical effect was
reached, their common use of “small-capacity pipes or vaporizers” (Newhart & Dolphin
2019:141) may also be interpreted as an enactment of femininity.
Interestingly, innovative or “serious” smoking methods are also a part of the enactment of
masculinity (Mostaghim 2019; Dahl & Sandberg 2015). Extreme new ways to get high are more
favored among men than women. Just like with chugging alcohol and other quick ways to get
drunk, the Scandinavian study found that “maximizing intoxication was a practice mainly
reserved for men” (Dahl & Sveinung 2015, p.704). Unfortunately, the authors do not add much
explanation beyond this finding though clues are found elsewhere.
Detailed analyses of gender within either the medical or recreational cannabis community
has been conspicuously absent from the scientific literature. Scholars such as Sexton et al. (2016)
have pointed out the preponderance of male-dominated samples in cannabis research, and Haines
et al. (2009) remark there is little qualitative research on gendered cannabis use. They also call
for the use of participant-driven methodologies that would allow for more personal disclosure on
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sensitive topics such as gender. My dissertation answers this call by using focus groups as a
research method with medical cannabis patients in southwest Michigan. Before getting into the
specifics of my methodological approach, it is worthwhile to examine gender and cannabis as
portrayed in non-academic literature.

Women in the Cannabis Industry
Much of the discussion surrounding gender and medical cannabis comes from media
outlets as opposed to academic researchers. Additionally, as “gender” is something commonly
constructed to pertain to women as opposed to men (Ferree & Hall 1996), masculinities are
largely absent from popular discussions. A hallmark of social privilege is the ability to
comfortably live one’s life without awareness of such privilege and with little consideration of
the privileged identity. As such, it is not surprising that men and masculinities are “invisible”
within the world of cannabis because their way of doing gender is the cultural default.
Femininities, on the other hand, demand explanation within spaces defined as masculine or nongendered.
Yet because the legitimate cannabis industry is still in its infancy, it lacks a history of
male domination endemic in most other enterprises, especially those surrounding drugs. This
could provide women with an opportunity to claim and define their own spaces within the legal
cannabis world at a level on par with men. The evidence suggests this is happening to some
degree though it seems unlikely the medical or recreational industry will be egalitarian or better
yet, non-gendered.
A lengthy Newsweek article from 2015 lauds the increasing number of women entering
the multi-billion-dollar cannabis industry with the appealing title of Women in Weed: How legal

101

marijuana could be the first billion-dollar industry not dominated by men (Lidz 2015). Yet the
article steers clear of hard statistics on gender proportions in the industry and instead relies on
case studies, the profiles of select female leaders, and the uncontextualized raw growth of
women-led organizations (i.e., saying a networking group grew to over 500 members in 2 years
does not tell us much about how that fact compares with broader industry trends). We also see a
tendency to preserve traditional gendered occupational roles. Pink-collar professions within the
industry, such as the American Cannabis Nurses Association, retain a disproportionate number of
women (86% in this case), and the stereotypical female-as-caregiver role still holds true. As
Genifer Murray, a scientist and owner of a cannabis testing facility in Colorado, told Newsweek:
“This is a compassionate industry, for the most part, especially if you're dealing with the medical
side. The medical patients need time and consideration, and women are usually the better gender
for that. The industry is flat-out geared for women” (Lidz 2015, paragraph 18).
Unlike most corporate businesses, the young legal cannabis sector does not have a history
of sexist barriers. Marijuana Business Daily found in a survey of 632 cannabis industry
executives and professionals that women hold 36% of leadership positions within the industry
(Olson 2015, paragraph 8), compared to an overall average of 22% nationwide (Pew 2015,
paragraph 13). As stated by a male CEO of a cannabis company, it has “become very
unfashionable very quickly to have scantily clad women repping products at [business to
business] trade shows” (Lidz 2015, paragraph 28).
Specifically impressive is that high-level positions in testing labs are occupied by women
62% of the time, compared to 38% in dispensaries or retail. Yet overall, senior leadership roles
are still dominated by men in nearly two-thirds of cannabis businesses (Olson 2015, paragraph
14). This 2-to-1 gender disparity is a far cry from what the overly-ambitious Newsweek article
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would lead one to believe. It is also worthy to note that testing labs operate behind the scenes of
the cannabis industry. Testing labs cater their services to dispensaries, growers, and
manufacturers of products containing cannabis rather than patients or the public. These labs
serve to verify the potency of products as well as to check for mold, pests, and other potentially
toxic foreign debris. While individual consumers can certainly pay for testing services
themselves, most trust their dispensary to screen products or remain unconcerned with this
backstage sector of the legally-operating cannabis world.
More troubling are findings from an unpublished master’s thesis by Michele Cadigan
(2018). Interviewing 30 employees at recreational dispensaries in Washington state, Cadigan
found women were typically met with suspicion by customers while men were better able to
position themselves as experts. Furthermore, men working in the dispensary were often
promoted faster and enjoyed more privileges like first access to free merchant samples. This may
explain why some of the men called the dispensary their dream job while many of the women
likened the dispensary to any other retail business (aside from the unique products being sold).
Cadigan (2018) also found women quit at higher rates due to the overt and covert sexism from
their customers, coworkers, and bosses.
Unfortunately, the cannabis industry appears to be less of a utopia than many business
reports impart. Some of the women “canna-preneurs” interviewed by Borchardt (2017)
acknowledge that as the industry matures, it may be drawn towards a more male-dominated
corporate structure. Yet there is active resistance to hegemonic business culture as well.
Progressive, feminist, and queer voices are present in the young world of legal and medicinal
cannabis. Jessica Assaf, a graduate of Harvard Business School, has a website called Cannabis
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Feminist though the site content is scant and geared toward product sales. More substantial is
critical feminist blogger Angela Bacca, who writes:
The stereotypical stoner has always been one of two things; the 18-24 year
old privileged white male or the demonized drug addict, most often a person of
color or other marginalized group. Perceptions dictate personal outcomes, and
historically when white men are outed for using marijuana they still retain the
capacity in the public eye to serve as President of the United States. For
marginalized groups — women, people of color, different genders, religions, the
poor or disabled — being outed for using marijuana is more likely than for a
white male to come with devastating consequences such as abusive run-ins with
law enforcement, a justice system stacked against them, incarceration, child
removal, and job or home instability. This, of course, devastates whole
communities everywhere around the world (Bacca 2015).
Indeed, racial disparities in the legal cannabis industry are appalling. For decades, black
and brown people have been the primary victims of cannabis-related arrests and prison
sentences. A Politco article states that less than 5% of legal cannabis businesses in the United
States are owned by black people, while police officers in Oakland, California continue to arrest
black residents nearly 20 times more often than white residents for cannabis-related violations
(Blau 2018).19 This has effectively resulted in the gentrification of cannabis, a claim further
supported by a content analysis of cannabis advertisements where experts were predominantly
depicted as white males (Mabee 2019). In Michigan, licenses to operate medical cannabis

19

Massachusetts created a Social Equity Program to give underrepresented entrepreneurs an advantage in their
emerging recreational cannabis marketplace (CCC 2019). The program is supposed to aid in the licensing process
for those most impacted by marijuana prohibition. In order to be eligible for the program, an individual must meet
one of the following:
- Residence in an area of disproportionate impact for at least 5 of the past 10 years and an income that does not
exceed 400% of the Federal Poverty Level.
- A past drug conviction and residence in Massachusetts for at least the preceding 12 months.
- Married to or the child of a person with a drug conviction and residence in Massachusetts for at least the preceding
12 months.
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businesses can be denied if the applicant has a criminal record or prior bankruptcies, two factors
which disproportionately exclude non-white applicants.20
Bacca’s claim about child removal has also been noted by others. The threat of Child
Protective Services (CPS) appears to be a major reason for women, particularly those with young
children, remaining closeted about their cannabis use. In many states, CPS openly threatens to
take children away from parents who are cannabis users, even if it is medically legal (Reinhart
2014, Lidz 2015). Because of changing laws, social workers have recently called on CPS to
refocus on the context of cannabis use rather than the use of cannabis itself (Stott & Gustavsson
2016). Unfortunately, changes in policy may only partially lift barriers for cannabis use among
mothers. In addition to state intervention, the stigma of being considered an irresponsible parent
(particularly an irresponsible mother) inhibits women from openly partaking in cannabis culture
(Dahl & Sveinung 2015). Fears of negative judgment from one’s peers, coworkers, and relatives
are often enough to make women with children think twice about disclosing their status as a
medical patient or recreational user. This stigma effectively forces patients who are mothers of
young children into a closet. There are signs of change occurring in this area, though. Analysis of
2013 Pew data found parenthood status does not affect how women or men view marijuana
legalization. Furthermore, both mothers and fathers are as likely as non-parents to have used
marijuana in the past year (Elder & Greene 2019).
Despite the potential of the “bad mother” stereotype, Whoopi Goldberg has become
somewhat of a luminary in the industry. In 2011 she spoke with People Magazine about smoking

Part of Michigan’s new recreational marijuana initiative includes a social equity plan “to promote and encourage
participation in the marijuana industry by people from communities that have been disproportionately impacted by
marijuana prohibition and enforcement and to positively impact those communities” (Gray 2019). However, this
type of equity statement was not present in the ballot language for Michigan’s medical cannabis initiative. In fact, no
demographic information is available on the 230+ medical cannabis license holders in the state though such
information will be collected under the recreational licensing process.
20
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cannabis before her 1991 Oscar win (Byrne 2011) and wrote a column for The Cannabist in 2014
where she divulges the wonders of her vape pen (Goldberg 2014). She has since launched a line
of medicinal cannabis products designed to ease menstrual cramps under the business name
Whoopi & Maya. In an interview with Vanity Fair in 2016, Goldberg said she was disheartened
at industry leaders believing medicine for menstrual cramps was niche market:
Hey, this niche is half the population on the earth… This seems to be
people flippantly blowing you off, which is what you get whenever you start
talking about cramps. [Industry leaders] weren’t thinking, how do you target this?
I have grown granddaughters who have severe cramps, so I said this is what I
want to work on (Whoopi Goldberg as interviewed by Ciaramella 2016).
I have seen this view of women as a “niche market” elsewhere while I have never seen
men presented in such a way. In one special episode of CNBC’s The Profit (2017), a pair of
women are twice rebuked for making a female-focused pastry infused with a small amount of
cannabis oil. As written on the product’s label, one of the recommended uses was for menstrual
cramps (in addition to relaxation and inflammation). The Profit (Marcus Lemonis) scolds the
women by insisting their product will alienate male consumers. Later in the episode, as the
women try to explain to a potential retailer their goal of appealing to other women in a market
dominated by masculine products, The Profit literally interrupts and mansplains to everyone how
men won’t buy the product. Ironically, the hour-long episode continually emphasizes the need to
differentiate one’s business in California’s saturated cannabis marketplace.

Masculinities
Raewyn Connell’s theory of the social organization of masculinity is currently the
dominant theory in the field, so much so that nearly every masculinities theorist uses or at least
addresses this framework (Pascoe & Bridges 2016; Schwalbe 2014; Schrock & Schwalbe 2009).
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The theory is based on a dynamic structural view of gender as a social practice. For example,
Connell (1995) defines masculinity as: “simultaneously a place in gender relations, the practice
through which men and women engage that place in gender, and the effects of these types of
practices in bodily experience, personality, and culture” (138). The emphasis of this work is on
the process, practices, and projects of gender, or as Connell eventually calls these, configurations
of gender. Per this perspective, individuals commit themselves to gendered projects configured
around the reproductive arena. Accordingly, the reproductive arena refers to the wider processes
of the social reproduction of gender rather than the biological act of reproduction itself. The
arena encompasses everything from our sexual norms, popular fashions between the sexes,
gendered roles, and parenthood responsibilities (Messerschmidt 2015; Connell & Messerschmidt
2005; Connell 1995). The strength of this perspective is that gender is not isolated to a
performance like the doing gender framework, but rather that gender is evident throughout social
reality—from our bodies and our understanding of self to our culture and material goods.
Perhaps the most valuable thing about Connell’s theory is that it doesn’t stop at
explaining the differences between men and women. It goes on to explain relations among men
which becomes the crux of the theory as it is known by another name—hegemonic masculinity
theory (HMT). As a gay male, I’ve always had a degree of healthy skepticism towards any
theory of gender that assumed all men were essentially the same in terms of power and prestige.
Many perspectives on gender assume a sense of harmony among the privileged category of men,
yet relations among men are often a vicious source of inequality and conflict. Most men realize a
staunch hierarchy among men whether they would openly admit to it or not. Connell’s HMT is
valuable because it sees masculinity as being embedded in our culture in addition to something
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enacted by individuals. It has also allowed us to study differently practiced masculinities while
grounding such analyses within a common structural frame (Schwalbe 2014).
Hegemonic masculinity is the most culturally exalted form of masculinity in any given
society at any given time (Connell & Messerschmidt 2005; Connell 1995). Hegemonic
masculinity is constructed to legitimize patriarchy, wherein masculinity has power over
femininity in society. “This is the mechanism through which every male enacting an identity as a
man, whether he strives to enact hegemonic masculinity or not, is granted male privilege—
cultural benefits and unearned advantages conferred by virtue of membership in the social
category of men” (Ezzell 2016:188). Another way to express this is to think of what Connell
(1995) terms the patriarchal dividend, which refers to the rewards all men receive from their
patriarchal privilege, including power, prestige, respect, and material advantage. Some styles of
masculinity benefit more from this dividend than others, but the gender hegemony enables the
continuation of a patriarchal order by rewarding specific traits with authority, dominance, and
power. It is not just individual men who strive to meet hegemonic ideals, but women and other
men must place value in the hegemonic form as well, even if they personally reject it
It is important to note that no single individual perfectly personifies hegemonic
masculinity; rather, it is the overall framework in which we can see specific examples of
dominant and subordinate forms of masculinity (Messerschmidt 2015; Connell & Messerschmidt
2005; Connell 1995). Hegemonic masculinity provides a cultural framework through which male
bodies produce gendered selves. It does not describe individuals but rather ways of being.
Hegemonic masculinity, in other words, is an ideal type, a value-laden category used to compare
subcategories and individual enactments of masculinity (Heckman 1997). Ideal types are useful
in avoiding universalism because ideal types are the products of cultures, making it necessary to
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consider the culture itself in our analysis (Heckman 1997). The Western hegemonic ideal of
masculinity typically incorporates the following traits: anti-femininity, control over others,
control over the self, strength, rationality, toughness, competitiveness, generativity, and
heterosexual prowess (Schwalbe 2014; Peralta 2007). Though these are all qualities of human
beings rather than intrinsic qualities of men, our culture typically associates these qualities with
what a “real man” should be. Furthermore, Connell and Messerschmidt (2005) say hegemonic
masculinity may be a goal towards which many men structure their lives, but it does not
necessarily result in satisfying life experiences. In fact, hegemonic masculinity may be damaging
to one’s body and mental health (Ezzell 2016; Peralta 2007).21
While men may structure their gendered expressions towards the hegemonic ideal, many
also discover other ways to enact masculinity. There are also complicit, subordinated, and
marginalized masculine configurations (Connell & Messerschmidt 2005; Connell 1995), and
these are often lumped together under a framework termed “multiple masculinities” (Pascoe &
Bridges 2016; Schwalbe 2014). I think the best way to make sense of this is to understand the
concept of cultural creativity, a practice where individuals claim some flexibility in how their
specific roles are performed: “As social actors, men and women are presented with stages and
scripts not of their own choosing. What they do creatively within these roles and cultural
constraints, and how originally they perform their roles, however, is not preordained” (Gutmann
2007:245). Cultural creativity emphasizes that people desire a transformation of their life
situations and acknowledges their agency to do so. Many men intentionally refashion their
masculinity into non-hegemonic forms. In fact, multiplying masculinities is occasionally framed

See also the American Psychological Association’s recently-published Guidelines for Psychological Practice
With Boys and Men (August 2018): https://www.apa.org/about/policy/boys-men-practice-guidelines.pdf
21
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as the antidote to social problems stemming from hegemonic masculinity (Ezzell 2016; Pascoe &
Bridges 2016).
Yet rigid connotations of masculinity persist in American society, and this is particularly
true for enacting masculinity on the part of people of color. Nikolas Dickerson (2018)
demonstrates how the use of marijuana by black athletes creates a space for the reinforcement of
legible black masculinities, the most legible of which is the “black criminal”. Since using
marijuana is often seen as a challenge to the status quo, the other legible script of black
masculinity—that of the “good black”—is no longer viable for interpreting actions taken by the
athlete. Our larger society has yet to embrace black masculinities that fall outside of the tropes
between “good black” and “bad black,” and as such, both “legible scripts of black masculinity
objectify black men and strip them of their agency and humanity” (Dickerson 2018:390). In sum,
multiplying masculinities may be easier for white people as racial stereotypes add a layer of
categorical oppression to alternative masculinities performed by people of color.
Nonetheless, scholars have been busy documenting the multitude of non-hegemonic
masculinities for several decades, and much diversity has been added to the scientific literature
on masculine expression. But this has become somewhat of a problem as multiple masculinities
collapsed into an endless array of individualized masculinities to the point where we risk
deconstructing down to each individual man (Bridges & Pascoe 2016; Schwalbe 2014; Schrock
& Schwalbe 2009). What is perhaps most surprising here is the pace at which marginalized
masculinities have exploded in popularity among social scientists. For example, Matthew
Gutmann (2007), originally writing in 1996, stressed the need to locate and focus on diverse
expressions of gender within overgeneralized categories. Around a decade later, many
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masculinities scholars of today think the field faces the opposite problem: an overabundance of
masculine subtypes. Michael Schwalbe (2014) aptly terms this the “masculinities industry”.
My study does not seek to document a specific typology of “cannabis masculinity” or
anything similar. Rather, I am interested in how men in the medical cannabis community practice
their cultural creativity in defiance of hegemonic pressures. As discussed elsewhere in this
chapter, some of the studies on both youth and adult marijuana use indicate men craft alternative
forms of masculinity. They do not abandon social pressures to enact masculinity, but they do not
strive for the ideal hegemonic form either. It seems they may buy into some hegemonic notions
of masculinity while deferring others. Part of my dissertation research has been to describe
multiple masculinities within the medical cannabis community, and in Chapter 8, I discuss which
hegemonic notions these men support and which they refashion.

Conclusion
How gender influences medical uses of cannabis is still largely unknown. Though we
have some evidence from popular media as well as scientific literature on recreational marijuana,
the specific context of medical cannabis may affect gendered enactments differently. Cannabis is
both a substance and a socially constructed symbol that can be a resource for the enactment of a
gendered self. However, is it a symbol of femininity, masculinity, or neither? How are
masculinities and femininities enacted in the medical cannabis community? Examining these
issues may provide further evidence that gender is not static, but that it is continually being
remade and refashioned.
This concludes my review of the scientific literature related to cannabis use in both
medical and recreational contexts. My review demonstrates both breadth and depth of cannabis
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history, how scholars have theorized cannabis, and where cannabis might be headed in the
future. The next chapter explains the methodology of my study.
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CHAPTER V

METHODS AND METHODOLOGY
This chapter explicates my methodological approach and research design. I begin by
providing an overview of the methods and perspectives employed by other researchers studying
the topic of cannabis. This allows me to contextualize why my research is unique and how it
contributes to the knowledge base. I then move onto my experiences with medical cannabis and
my research questions. Following this, I detail the methods used in my study which include key
informant interviews, observations, and focus groups. Afterward, I discuss the challenges I
experienced while recruiting patients and the difficulties I encountered when sampling for focus
groups. Finally, I explain the strengths and limitations of my research along with ethical
considerations and issues of validity. I conclude with an overview of my analytical strategy.

Contextualizing My Study
Social research on medical cannabis is limited because it exists in a liminal space, being
neither totally illegal but not entirely accepted by authorities (Satterlund et al. 2015). This makes
medical cannabis patients a “half hidden population” (130) whose medicine is legitimated on the
state level while criminalized on the federal level (Reinarman et al. 2011). As such, relatively
little is known beyond patient demographics since most studies on medical cannabis utilize
surveys and produce depersonalized statistical reports. One of these demographic studies was
completed in southwest Michigan (Ilgen et al., 2013) while others have sampled elsewhere in the
state (Kruger & Kruger 2019; Boehnke, Litinas & Clauw 2016). Other surveys of patients have
been conducted in California (Reinarman et al. 2011; O’Connell & Bou-Matar 2007; Reiman
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2007), Washington (Sexton et al. 2016; Roy-Byrne et al. 2015), Rhode Island (Zaller et al.
2015), and Hawaii (Webb & Webb 2014). Demographic studies on those who use cannabis for
medical purposes also come from Isreal (Zolotov et al. 2016) and the United Kingdom (Ware,
Adams & Guy 2005). These studies typically inquire about a respondent’s history and reasons
for use, as well as methods and quantity of consumption.
Patient demographics give the impression of a unified community, but qualitative
approaches reveal cannabis patients are not a homogenous group (Loflin & Earleywine 2014;
Osborne & Fogel 2008; Chapkis 2007). This is why Ryan and Sharts-Hopko (2017) believe
qualitative inquiry is best suited for exploring medical cannabis patients. Patient experiences are
varied and diverse, being influenced by their location and state of residence, their relationships
with family members and health care providers, their diagnosis, and the patient’s personal beliefs
about marijuana. Qualitative studies with enrolled cannabis patients have been conducted in
California (Lau et al. 2015a/2015b; Satterlund et al. 2015; Chapkis & Webb 2008), Colorado
(Newhart & Dolphin 2019; O’Brien 2013), Illinois (Victorson et al. 2019; Bruce et al. 2018), and
Canada (Athey et al. 2017; Bottorff et al. 2013; Page & Verhoef 2006). Significant here is that
no one has used qualitative methods to investigate Michigan patients and only one study has
conducted focus groups with registered cannabis patients (Victorson et al. 2019). While
interviews are good for collecting individual experiences and life histories, we do not have any
group-level data to tell us about patients as a community (Hollander 2004).
Since every method has its own strengths and limitations, the best use of methods is to
combine them in a manner that yields additional insight into the topic under investigation
(Johnson 2000). When two or more research methods are used together in a single study,
scholars call this triangulation. There is some controversy surrounding this term, however. Some
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say triangulation only works if we believe in an objective truth where “every method is a
different line of sight directed towards the same point” (Berg 2009:5). Likewise, Alan Bryman
(1992) says it is common to see a pairing of methods that do not enhance the validity of a study,
as the strengths and limitations of each method are not used in a complementary fashion. On the
other hand, Michael Bloor and colleagues (2001) argue triangulation simply requires the
researcher to contrast results from one method with that of another. In this way, “triangulation is
not so much about getting to the ‘truth’ but rather about finding the multiple perspectives for
knowing the social world” (Marshall & Rossman 2011:254). Triangulated methods each focus
on a shared point but illuminate said point through different means, often resulting in different
understandings. Triangulation pluralizes our vision and can be used to enhance the
confirmability, transferability, and credibility of our study (Marshall & Rossman 2011).
I have triangulated key informant interviews, site observations, and focus groups in an
attempt to pluralize the knowledges deployed in my research. Focus groups were the primary
method in this study, and my use of key informant interviewing was to get a better sense of
Michigan-specific issues as well as to refine my focus group discussion guides (Morgan 1997).
Some of the key informants also served as gate-keepers to the medical cannabis community,
helping with participant recruitment and offering their facilities for data collection (Krueger &
Casey 2009). Finally, site observations allowed me to witness action without the information
being filtered through an authority figure. The observations were also valuable for revealing
small details that helped me communicate the milieu of medical cannabis in Michigan.
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Perspectives and Standpoints
Most research on cannabis is conducted under a paradigm of prohibition, risk, and abuse
(Subritzky 2018; Garner 2016; Ware 2007; Hammersley & Leon 2006; Zinberg & Harding
1979). The reason for this is despite cannabis having a long history as a medicine and sacrament,
it is now largely defined by the legal system as a prohibited substance (Newhart & Dolphin
2019). For example, many researchers frame their studies through a risk-dependence model,
where all cannabis use is measured in relation to harm. However, the same researchers also
routinely fail to control for other environmental factors that may reduce wellbeing, such as
variations in the strain and purity of cannabis as well as a person’s reasons for use (Temple,
Brown & Hine 2010). Not many researchers have approached cannabis from a perspective that
implies use is normal, non-deviant, or non-problematic, even though cannabis use itself is
generally regarded as normalized (Hammersley and Leon 2006). Qualitative studies by Osborne
and Fogel (2008) and Garner (2016) come close to this, but these studies pertain to recreational
use rather than medical use by patients.
The standpoint of the researcher also varies among the existing literature on medical
cannabis patients. Most of the quantitative studies are disembodied in that the researcher is
invisible. These studies value objectivity and neutrality but make it difficult to evaluate
researcher bias or experience in the area. A powerful alternative to detached observations holds
that reality is a co-construction between researchers and their participants. Known as
interpretivism, this scientific paradigm claims data are created rather than discovered (Eide &
Kahn 2008; Charmaz 2006). Furthermore, this perspective necessitates an acknowledgment of
subjectivities; “bias” for lack of a better word. Kathy Charmaz (2006) says: “We are not passive
receptacles into which data are poured… Neither observer nor observed come to a scene
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untouched by the world” (15). Rather than claim we can uniformly understand an objective
reality, interpretivists say we should illuminate the plurality of meanings, experiences, and
realities people construct. Qualitative social research methods such as interviewing, participant
observation, and focus groups allow us to appreciate the contextual nature of the data we create.
From my own exploration of the literature, there are no studies conducted where the
researcher is or was a cannabis patient. Two books come close, though. Wendy Chapkis and
Richard J. Webb (2008) were involved as caregivers and activists in California’s medical
cannabis movement. Their book, Dying to Get High: Marijuana as Medicine, examines a
caregiver community serving seriously ill patients at a time when authorities were still raiding
medical dispensaries throughout California. Michelle Newhart and William Dolphin (2019)
worked in California’s medical cannabis industry before Newhart conducted her dissertation on
patients in Colorado. Their book, The Medicalization of Marijuana: Legitimacy, Stigma, and the
Patient Experience, examines cannabis’ construction as part of complementary and alternative
medicine (CAM) through the experiences of middle-aged patients collected from 2010-2012.
Noteworthy is how Newhart’s data collection ended right before Colorado voted to legalize
recreational use on November 6, 2012. I collected data following Michigan’s legalization on
November 6, 2018, effectively picking up right where Newhart left off.
I have been a registered patient in the state of Michigan since 2014. My experiences with
medical cannabis have been overwhelmingly positive, but sometime after becoming a patient, I
realized that I was back in the closet. I spent the first 18 years of my life hiding my sexual
orientation from others and now I had another identity that carries much stigma. Unlike my
sexual orientation, this other devalued identity opens up the possibility of legal discrimination
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from employers, landlords, and more22. My social location as a gay man also places me as an
“outsider within” the category of masculinity. Owing to their position on the periphery of
privilege, the outsider within often has a clearer view of categorical power, status, and privilege
(Collins 1986).
The link between sexual orientation and marijuana goes further than just my own social
position. American attitudes towards same-sex marriage and marijuana legalization have
changed simultaneously, as these are strongly connected to maximizing individual liberty
(Schnabel & Sevell 2017). These dual trends in public opinion have also been documented by
Cameron Duff and colleagues (2012) among Canadians. Furthermore, my impression from
reading many studies of marijuana normalization is that it closely resembles the narrative for
marriage equality. Before same-sex couples had the right to marry, many states allowed for civil
unions which granted queer couples most legal rights of marriage but without the dignity of a
social institution. Medical marijuana is conceptualized much like the civil union, a type of tepid
compromise between prohibition and tolerance. As the civil union may have been an
intermediary step on the road to marriage equality, medical marijuana is treated by some scholars
in much of the same way.
Absent from this comparison are the lived experiences and perspectives of those most
impacted by cannabis policy. Cannabis is widely accepted to have therapeutic value, patient
narratives speak of life-changing results, and there is an ongoing political struggle in which

The “seclusion etiquette” described by Johnson et al. (2008) also reminds me of the historical changes
experienced by homosexuals in our society. By largely restricting marijuana use to private settings, this norm of
seclusion is primarily practiced to avoid damaging one’s reputation among their social network. These users were
much more concerned about social stigma and practiced an etiquette of seclusion in order to avoid informal social
controls, with Johnson et al. (2008) saying there is an informal compromise between police and cannabis users.
Smoking cannabis was tolerated as long as it was out of sight, just like same-sex romance used to be.
22
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many activists have sacrificed their freedom in the name of safe access. What do these people
think of the current landscape and anticipated changes concerning cannabis in our society? Does
legalized recreational marijuana help or hinder the construction of cannabis as a medicine? My
dissertation research sought to answer these questions by deploying a mixture of qualitative
research methods. My primary method of inquiry was focus groups of MMMP patients in
southwest Michigan though I began my study conducting interviews with key informants and
performing structured observations of cannabis facilities and events. Once again, the research
questions that guided my inquiry were:
(RQ1) How does the medical cannabis community feel about the normative status of
medical cannabis in this moment of emerging recreational legalization? And, what challenges do
patients face in their social and professional lives?
(RQ2) How do medical cannabis patients view the legalization of recreational
marijuana? And, do patients think medical cannabis will survive once marijuana is fully
legalized?
(RQ3) How does gender shape the experiences of medical cannabis patients? And, how
might hegemonic gender roles be adhered to or challenged by cannabis patients?
Being an insider within the medical cannabis community is also an asset in collecting
data from patients. Several qualitative investigations discuss the role of the researcher in data
collection (Newhart & Dolphin 2019, Pedersen 2015, Chapkis & Webb 2008), noting
participants were eager to know about the researcher’s cannabis use and their political positions
regarding cannabis legalization. In general, patients appear to be tired of having their medicine
placed under the microscope in a manner that introduces doubt and where any findings can be
used as evidence against their patient status. This concern is not without reason as patients fought
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hard to legitimize cannabis as a medicine through what some have called a social movement
(Chapkis & Webb 2008). My status as a cannabis patient was perhaps surprising but also
welcomed by the patients involved in my study. Since an insider was conducting the research,
patients may have felt more at ease and may have disclosed more information.

Key Informant Interviews
The key informants I was after all held public and respectable roles in Michigan’s
medical cannabis community. They included dispensary owners, activists, caregivers, individuals
within cannabis-related business and political networking organizations, a certifying physician in
Michigan’s MMMP, and an individual working in cannabis marketing. To persuade key
informants to participate in my research, I employed several strategies outlined by Andrew
Shenton and Susan Hayter (2004). These included emphasizing the value of their contributions,
highlighting my personal links to the medical cannabis community, answering their questions
openly and honestly, and remaining receptive to any suggestions they may have. While I was not
able to offer my key informants any monetary or materials incentives, pervious research on
cannabis growers found the growers were more concerned with intangible rewards than profits or
trophies (Potter et al. 2011). I believe my key informants perceived similar nonmaterial benefits
from participating in my research owing to their status within Michigan’s cannabis community.
Overall, key informants were excited to share their thoughts and experiences in the
industry, and many understandably had a perspective grounded in the worlds of business and
politics. One of the key informants even asked I meet them for lunch at a local brewery, and we
spoke about their new business for an hour or so before agreeing to do the interview another day.
Recognizing I was a broke graduate student, they even paid for my soup. In exchange for this
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kindness and their involvement in my research, I shared with them some of the academic studies
which compiled patient demographics. I made similar offers to the other key informants though
none have yet to take my offer up.
The key informants were rather eager to be interviewed and some even suggested other
notable figures to contact. I took them up on a couple of these suggestions, increasing the
number of interviews from seven in my proposal to nine in my final report. One key informant
declined to be interviewed because they considered themselves an outsider in the cannabis
community and expressed their job was to report objective facts without personal interpretations.
This was understandable, and I replaced this person with another individual who I had recently
read about in a news article.
Table 1 - Key Informant Interviews
KEY
INFORMANT
Description
INTERVIEWS

Date

Duration

Method

Randy

Board member for MI NORML and
cannabis activist.

June 25

43 Minutes

Phone

Justin

Cannabis activist, dispensary coowner, and radio host.

June 25

65 Minutes

Phone

Ramona

Owner of a cannabis marketing firm
and public relations professional.

June 27

30 Minutes

Phone

Madison

Executive in the Michigan Cannabis
Industry Association and cannabis
lobbyist.

June 28

70 Minutes

Phone

Dispensary owner in southwest
Michigan

June 28

50 Minutes

In Person

July 2

44 Minutes

Phone

July 5

78 Minutes

In Person

Kayla
Jackie
Dr. Steven

Founder of a cannabis networking
association and a leader in
Michigan’s chapter of Women Grow.
A certifying physician in the MMMP
and the owner of a holistic health
center.

May

A long-time caregiver in the MMMP.

August 15

39 Minutes

Phone

Michael

A long-time caregiver in the MMMP
and former commercial grower.

August 23

120 Minutes

In Person
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Observations
I was given permission to observe two cannabis-related facilities, and I visited each
location two times, each at different times on different days. One of these facilities was a
provisioning center (aka dispensary) and the other was the office of a certifying physician. My
observations were structured using a field note guide included as Appendix G. However, I also
followed advice from Berg (2009) and Lofland et al. (2006) where jottings are done on-site, and
detailed descriptions are undertaken immediately after exiting the field. I observed these
facilities for a total of roughly four hours and spent approximately the same amount of time
writing detailed descriptions afterward. Care was taken to be as concrete as possible where
general adjectives were avoided in favor of specific details. While mundane and thick with
description, “the objective in writing fieldnotes is to get information down as efficiently,
correctly, and honestly as possible” (Lofland et al. 2006:116). I also included my personal
feelings and impressions since qualitative research encourages us to be sensitive to our
positionality in the field as well as our emotions and biases. My detailed notes similarly include
analytic comments and subjective reflections, both of which are bracketed as not to be confused
with my narrative of field observations.
While I tried to observe another dispensary, I was unsuccessful at getting permission
from the owner. This person did not flatly deny my request but failed to respond to my emails or
phone calls. Thankfully, one of my key informants invited me to a special event they were
holding which centered on patient networking and education about the state’s new regulations.
This ended up being more of a business-centered event, but it was still valuable for insight into
the commercial structure of Michigan’s medical cannabis program. It was also interesting
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because it provided a contrast to my status as an insider in the cannabis community. I am a
complete member of the group being observed, and my role at the dispensary and medical office
was that of a full participant as an observer (Creswell 2013). However, I felt more like an
outsider at the networking event as most of my interactions with other attendees began with them
asking, “What type of business are you in”? As a social researcher, I had no use for something
like a CPA, growing equipment, or secured transport services, so I felt more removed from the
crowd in that social setting.
Table 2 - Observations
OBSERVATIONS
Nature’s Healing

Alternative
Midwestern
Medicine
MMMP
Conference

Boutique Herb
(pop in)

Kosmic Buds
(pop in)

MI Harvest Fest

Description

Observation 1

A provisioning center only accessible
to those in the MMMP. Access limited
to the waiting room as patients are
taken into private rooms for sales.
Office of a physician who certifies
patients for the MMMP in addition to
offering a range of classes and hemp
products. Not able to observe doctorpatient consultations.
An event for patients and caregivers in
a large hotel’s conference area. There
were two main rooms with one devoted
to presentations and another for vender
booths.
An upscale dispensary chain new to the
West Michigan area. I visited as a firsttime patient.
A new dispensary in the West
Michigan area with plans of vertical
integration. I visited as a first-time
patient.
The first public cannabis event in the
area following legalization. Akin to a
smaller “cannabis cup” competition.

Observation 2

July 5

July 13

6:00pm to 7:05pm

2:00pm to 3:00pm

July 10

July 15

10:20am to 11:30am

10:00am to 11:00am

July 28
1:00pm to 4:00pm

July 6
4:00pm to 4:15pm

July 24
5:20pm to 5:35pm

October 27
3:00pm to 5:30pm

na

na

na

na

Though my formal observations were conducted in July 2019, I kept a similar record of
observations I made in everyday life. These included billboards along highways, comments I
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overheard at parties, and a major grocery store selling hydroponic nutrients. I also noticed
something interesting happened over the course of my study. Several new dispensaries opened
up in southwest Michigan and I visited two of them for a number of reasons: (1) I wanted to post
advertisements for my focus groups, (2) I wanted to take advantage of their new patient discount,
and (3) I wanted to get a sense of what each one was like. I consider my visits to these sites more
personal than research-centered, but since qualitative research uses the researcher as an
instrument, I wrote reflections on each of my visits afterward. I spent roughly 15 minutes at each
location and call this style of observation a “pop-in”.
Being a complete member in Michigan’s medical cannabis community made these two
pop-ins possible. My role at each location was a customer who happened to bring fliers for his
research project. This resulted in some interesting observations, one being particularly striking.
In a small town near Lake Michigan, there is a dispensary across the street from another
dispensary, and these dispensaries couldn’t be more different. One of these establishments is new
while the other has been operating for many years, though I had not visited before since it is out
of my way. The older dispensary is rustic and quaint, similar to a local no-thrills bar, and
reminds me of the dispensaries in pre-MMFLA Michigan23. The newer dispensary is more like a
top-tier wine cellar with modern décor, high ceilings, and a floor plan similar to an Apple store.
They are also a franchise of a company with locations in cities like Las Vegas and San Francisco.
What is this place doing in a rural town with an approximate population of 700 and a preexisting dispensary? They know their status as a licensed medical facility will get them first
grabs at a recreational license, and the town is one of the few municipalities in Southwest

23

The MMFLA was implemented in 2016 and provided a pathway for cannabis businesses to legally operate by
acquiring a state-issued license. Many small provisioning centers operating in the gray area of the law were forced to
close because the licensing fees and requirements are too high.

124

Michigan which has opted in to allow medical and recreational cannabis businesses. For more
information about the history of and regulations on cannabis in Michigan, see Appendix B.

Focus Groups
My five focus groups contained a total of 21 patients and lasted between 75 and 120
minutes. Focus groups are also social events where participants drive the discussion (Bloor et al.
2001). Richard Krueger and Mary Anne Casey say: “As participants answer questions, their
responses spark ideas from other participants. Comments provide mental cues that trigger
memories or thoughts of other participants—cues that help explore the range of perceptions”
(2009:35). In this way, my research answers Garner’s (2016) call for participant-driven research
on the topic of cannabis. Furthermore, my anecdotal experiences lead me to believe cannabis
patients enjoy sharing their experiences with their medicine. Morgan (1997) says focus groups
are ideal for topics that would make for engaging discussions among participants, and I believe
the patients in my groups mostly enjoyed the chance to share their experiences and opinions with
other participants.
In terms of the repertoire of qualitative research methods, both participant observation
and focus groups are interested in group interactions. Unlike individual interviews, each provides
direct evidence about differences between and similarities among our research participants with
regards to their opinions and experiences. While the degree of naturalness is higher in participant
observation than in focus groups, the later allows the researcher to control what topics come
under discussion (Morgan 1997). Focus groups allow us to observe a range of opinions and
feelings on specific topics selected by the researcher (Kruger & Casey 2009).
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Two studies have so far used focus groups as a method to investigate recreational
marijuana users. One of these was done by Haines et al. (2009) on a sample of Canadian
teenagers, and the other was done by Jarvinen and Demant (2011) on a sample of Danish
teenagers. The Danish focus groups were analyzed for collective images of the drug, and the
focus groups tended to negotiate and compromise until a relatively uniform symbolic
representation was reached. Compromise, however, is not always desirable, and my use of focus
groups emphasized diversity in perspective rather than uniformity. I began each focus group with
a statement welcoming the participants to disagree with one another and encouraging them to
share dissimilar experiences. My research also differs from each of these former studies by using
focus groups of adult medical cannabis patients.
My focus group question guide can be found in Appendix I. As suggested by Morgan
(1997), I decided to use a semi-structured question guide where each group would be asked the
same questions but perhaps in a different order. My reasons for doing this include a desire to
maintain consistency as well as to control for my lack of experience moderating focus group
discussions. Unstructured guides may be preferred by professionals, but I was more comfortable
moderating from a set list of questions. However, the focus group setting is less controlled than
that of individual interviewing, and too much structure may inhibit the natural flow of group
interaction or turn the focus group into a question-answer group interview (Bloor et al. 2001).
Subsequent questions posed to the group should appear as natural follow-ups to the discussion
rather than abrupt transitions into other topics, so I occasionally rearranged the order in which
some questions were asked. This was done because the group’s discussion organically journeyed
into another topic on my list, and I believe my decision to continue the topical conversation

126

ultimately produced trustworthy answers to my research questions as per the rules of thumb by
Morgan (1997).
As for the questions themselves, I tried to abide by the advice given by Krueger and
Casey (2009:36-38) who say good questions should: evoke conversation, are easy to say, are
clear, are short, are one-dimensional, are usually open-ended, use words the participants would
use when talking about the issue, and include clear, well-thought-out directions. While these
suggestions may sound counter to the complexity of scientific inquiry, simple questions tend to
stimulate the most discussion and get to the core of the topic under investigation. Furthermore,
my questions proceed in the manner of a funnel (Krueger & Casey 2009; Morgan 1997) where I
move from general to specific questions. As suggested by others, I also used probes to keep the
discussion flowing and focused on the topic at hand (Krueger & Casey 2009).
Table 3 – Focus Groups
FOCUS
Participants
(n=21)
GROUPS
Group 1

n=4

July 16

(6 confirmed)

Group 2

n=6

July 23

(7 confirmed)

Group 3

n=2

July 25

(6 confirmed)

Group 4

n=2

August 4

(6 confirmed)

Group 5

n=7

August 11

(8 confirmed)

Race

Age Range

Duration

Average
Years in
MMMP

3 White
1 Biracial

18 to 43

1 Hour, 45
Minutes

2.75
(1 to 6)

6 White

34 to 66

2 Hours

3.33
(1 to 6)

2 Men

1 White
1 Biracial

39 to 53

1 Hour, 15
Minutes

7
(4 to 10)

1 Man
1 Woman

2 White

32 to 41

1 Hour, 30
Minutes

5.5
(2 to 9)

4 Men
3 Women

6 White
1 Native
American

28 to 64

2 Hours

3.42
(1 to 8)

Gender
1 Man
1 Woman
2 Non-binary
3 Men
2 Women
1 Non-binary

Recruiting Participants
As it turned out, subject recruitment was one of the most challenging parts of my study.
My initial approach was placing fliers at numerous provision centers and posting messages on
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cannabis-related social media pages. After over a week of doing this, I had a depressing total of
five respondents complete my screening survey. My hunch was that the fliers had not been
posted after I dropped them off at the dispensaries, so I made the rounds to these locations again
with new fliers. I discovered I was right, and none of the six or so locations had my study’s
information posted. Social media was also a relative failure as messages posted to pages or
groups go unseen by the vast majority of followers. I felt somewhat angry but mostly anxious,
and I knew I would have to get more creative with participant outreach or I would have to drop
my plans for focus groups.
Provisioning centers (aka dispensaries) are tightly controlled spaces in Michigan. They
are subject to strict regulations on who is allowed in, what is allowed to be sold, and how
business can be legally conducted. Prior to the 2016 MMFLA, dispensaries were more like selfstructured enterprises with no regulatory oversight but also no legitimacy in the eyes of the town
or state. Owners knew their businesses could be raided at any moment, and they logically kept
their physical locations simple and out of the public eye. While the MMFLA created a pathway
to licensure, the first two years of the program yielded few licenses due to complications with
now-defunct Michigan Medical Marihuana Licensing Board (MMMLB).
I mention this here because one of the dispensaries I intended to post fliers—and perhaps
the dispensary serving the most patients in Southwest Michigan—was once forced to close for
several months by the MMMLB. This facility was denied a license because the owners had
previously competed in one of Michigan’s HighTimes-sponsored cannabis cups, an act that was
deemed out of line for an owner of the medical cannabis provisioning center. Fortunately, the
facility was later granted a medical license after the MMMLB was abolished by the new
governor and replaced with the Marijuana Regulatory Agency (MRA). When I visited this
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location for a second time with fliers and questions, I was told they were awaiting a response
from their legal team before they would advertise my study. Since other dispensary owners
immediately agreed to post my study’s information, this was likely a precautionary measure
owing to that facility’s history with regulators. Since my materials were never posted, I take it
that the lawyers said better safe than sorry, or that the owner simply did not want to post my
fliers.
Aside from art and business information, there are no message boards or other wall
postings in provisioning centers in southwest Michigan. However, they all have little areas where
business cards accumulate from local realtors, mechanics, and insurance agents. Realizing this, I
condensed my flier into a double-sided business card and ordered 440 of them from Walgreens
for $27.92. Several days later, I returned to each dispensary with the business cards and, with the
quick approval of the front desk employee, placed them in the designated area. My fliers were
still not posted but I had solved my dilemma, and many of the participants in my focus groups
informed me they learned about the study from picking up a business card. In fact, only two of
the eight facilities I visited would end up posting my fliers, the office of a certifying physician
and a testing lab with little patient traffic.
Around the same time I turned to business cards, I also started to get more aggressive
with social media posts. After getting many promises but no actual help, I began commenting on
statuses shared by Michigan cannabis groups as well as cannabis-related articles posted by local
news organizations. I even began advertising my study on my own Facebook profile, first using a
“hashtag soup” approach where I included any relevant hashtag I could imagine. I then boosted
these Facebook posts by paying $20 for targeted advertising, a strategy I first learned when
launching my personal website and later refined as the media editor for an academic
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organization. Since Facebook does not have an option to target users with interests in cannabis, I
targeted those with interests in alternative medicine and those who follow the pages of NORML
and Weedmaps. Setting the audience to within a 50 miles radius of the study site helped keep the
advertising applicable to southwest Michigan, and only users over 18 years old saw the
advertisements. This approach reached around 2,500 people and while it is impossible to tell, I
would guess 20 or so ended up completing the screening survey.
The final saving grace for my recruitment woes came unexpectedly when I received a call
from a local reporter. They must have seen my comments on their cannabis-related news stories
and decided to feature my study in its own special article. I honestly thought I was going to be
asked to stop commenting on their posts when I began talking to the reporter, but our fourminute conversation turned into a short piece titled, “WMU student’s research probes medical
marijuana patients post-legalization” (Miller 2019). After the article was published, my
participant pool rose to over 50 eligible respondents.

Sampling and Conducting Focus Groups
Kruger and Casey (2009) say the purpose, population, and budget drive the sampling
approach used in focus group studies. Recommendations for group size typically vary between 4
to 10 participants with a total of 3 to 5 groups per project, though it is strongly advised to set a
target number of groups rather than a bare minimum (Morgan 1997; Berg 2009; Krueger &
Casey 2009). However, these are all guidelines that are flexible to suit the unique needs of the
research goals and population, though preference is given to easily identifiable groups in distinct
locations. Since medical cannabis patients typically visit dispensaries and health centers, I
planned to use these facilities to advertise my study. This type of purposefully selected sampling
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approach lacks the representativeness of true random samples, but generalizability is not a goal
of this qualitative descriptive study.
I began scheduling and inviting participants to focus groups when I had roughly 30
eligible respondents in my sample pool. The first two groups were very successful, containing
four then six participants, but problems began with filling seats for the third focus group. While
six individuals confirmed their attendance to the third group, only two attended. As
recommended by Bloor et al. (2001), participants were sent confirmation emails upon enrolling
as well as a reminder email the day of the focus group. They were also be provided with a map to
the facility and the contact information of the researcher. I had also asked participants about their
typical availability in my screening questionnaire, and I took care in inviting participants to
groups held on days where they were available. The only way I had contact with these eligible
participants was through email, and if I had to do this study again, I would ask for their phone
numbers as well. Nonetheless, all planned groups had six or seven participants RSVP, and aside
from the last group, all had multiple members drop out at the last minute or were absent without
explanation.
David L. Morgan (1997) suggests we over-recruit by about 20% in order to make sure we
have the minimum number of required participants for each group. I had a total of 70 eligible
participants in my sampling pool and after my fourth focus group where only two individuals
attended (though six RSVP’d), I had exhausted my patience for no-shows. There was a final
group scheduled for the following week, and I began sending out batches of invitations to all 56
people in my pool who had not yet participated, including those who failed to show for prior
groups. A handful of individuals responded back that they were busy, but seven eventually
confirmed. One of them backed out the day before, but luckily, another person had taken my
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screening survey and qualified for the study, and they were fortunately available for the next
day’s focus group. All seven of these participants showed up and it was my only group with a
perfect confirmed participation rate.
Scholars generally support the use of at least three or four focus groups per study though
the specific requirements and goals of the study should determine the number of planned groups
(Krueger & Casey 2009; Bloor et al. 2001). I used a total of five groups though two of these
contained only two participants. I still classify these groups of two as focus groups because there
was still a group dynamic, with participants commenting on and responding to one another.
These groups took less time than the others since we moved through topics faster, but the
conversational nature of the discussion still resulted in a lively exchange between participants
and allowed them to raise issues not covered by my questions. This was particularly interesting
with the topic of guns and marijuana as my analysis on gender will show.
I was fortunate to receive a grant from Western Michigan University’s Graduate College
that allowed me to purchase gift cards worth $25 apiece to be used as participant incentives.
These small payments may also function to reduce bias and the power differential between the
researcher and the participants (Bloor et al. 2001). While participants in social research spend
their time and energy providing data, they often receive little to no direct benefit by doing so.
The researcher, on the other hand, benefits from their participants in the form of prestige and
publications used towards professional advancement. As such, payments to participants help
balance the benefits gained from social research, and the participants are also compensated for
their time. While such payments may also incentivize participation research, some medical
cannabis patients had non-tangible motivations for participating in my study. One participant
refused the incentive, and others verbally expressed the money was not why they decided to
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participate. As mentioned elsewhere in my dissertation, there are few spaces in southwest
Michigan where cannabis patients can meet one another and discuss issues in their community.
Finally, participants in my study were informed that their involvement would not
influence their access to medical cannabis or impact their status as a patient in Michigan’s
Medical Marihuana Program (Zaller at al. 2015). Making this known is paramount because
medical cannabis patients are not a protected class in the eyes of the law. Likewise, some
patients in southwest Michigan may have purposefully abstained from my study over fears of
discrimination or other possible repercussions should their identity as a cannabis patient become
known to others. That is just one reason why confidentiality among other participant protections
is vital to this study.

Ethics and Possible Issues
In terms of ethical standards, my research adhered to practices described in the literature
as well as those used in focus groups conducted by others (Jarvinen & Demant 2011; Berg 2009;
Bloor et al. 2001). Participants signed informed consent forms and were guaranteed the right to
withdraw from the focus group at any point. They were also given a statement on group
confidentiality that is not legally enforceable, but is designed to get participants thinking about
the private nature of the information shared in the focus group. However, Morgan (1997) says
groups of self-acknowledged deviants (deviants who are open to others or even proud of their
deviant status) may not be too concerned about confidentiality in focus groups since such groups
are the informal equivalent of their deviant subcultures. I believe this was the case with medical
cannabis patients, though confidentiality statements were nonetheless signed by all participants.
Likewise, the statement allows a participant to withdraw from the group should they fear for
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their own confidentiality or if they believe they will be unable to keep the group’s information
private (Berg 2009). I also came prepared with a list of counseling resources should any
emotional distress arise. While one may be tempted to serve as therapist or life-coach, Eide and
Kahn (2008) contend the ethics of care stipulate a researcher should seek alternative forms of
support for participants. If we act as therapists in believing we can remedy any burdens a
participant has, we may be inadvertently keeping the participant from more effective
professional help. My prepared list of mental health resources may have also helped to foster a
sense of care between my participants and myself.
As the discussion moderator, I maintained an atmosphere of trust, respect, and civility in
each focus group. I also paid special attention to the setting of the group since this can impact
disclosure and interaction. Each focus group was held in a large yoga room at a holistic health
center, a site that was available and convenient for both the researcher and the participants
(Morgan 1997). As suggested by experts, the group was arranged in a circle, so I did not become
a focal point (Bloor et al. 2001). Likewise, I provided nametags and refreshments. Aside from a
low participant turn out, no problems emerged in any of the groups. In fact, the final focus group
concluded with a discussion on the lack of patient-focused organizations, and how the region
once had its own subchapter of NORML. Since MI NORML operates on the east side of the
state, several group members exchanged contact information in hopes of reestablishing a
southwest Michigan chapter.

Establishing Validity
The paradigms of quantitative and qualitative research necessitate different evaluative
standards based on their different approaches to scientific knowledge. A paradigm integrates
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specific epistemological, ontological, and methodological premises (Denzin & Lincoln 2013),
essentially allowing a researcher to make sense of the methods they use to investigate the social
world. So how do we evaluate qualitative research? There are many different evaluative terms in
the qualitative paradigm which all speak to something akin to validity. For quantitative
researchers, the term validity is synonymous with “truth” but should always be understood as an
approximation rather than an absolute (Cook & Campbell 1979). Qualitative researchers
commonly frame validity as “soundness”, “credibility”, or “trustworthiness” (Marshall &
Rossman 2011), and these are just a few of the many evaluative standards in the paradigm. We
must resist this push for a singular gold standard that reflects the needs of the biomedical
sciences, and instead extend a standard that values humanistic science (Denzin 2013; Denzin &
Lincoln 2013; Torrance 2013). Some scholars even believe that disagreement on evaluative
standards among qualitative researchers is a good thing. Since qualitative research is practiced by
many disciplines, researchers are encouraged to be multivocal and to use less technical jargon.
This increases the appeal and applicability of qualitative work, and the tensions between
different evaluative standards should be seen as generative while researchers debate their
usefulness (Torrance 2013).
Most simply stated, validity in qualitative research is understood as research “that is
plausible, credible, trustworthy, and, therefore, defensible” (Johnson 2000:119). While there are
many validation strategies that can be applied to qualitative research, our attention to specific
issues will most likely be directed by the peculiarities of our research. Nevertheless, John
Creswell (2013) recommends at least two strategies be used in any given qualitative study. My
dissertation research emphasizes three: trustworthiness, reflexivity, and triangulated methods.
The most important thing to keep in mind when evaluating qualitative research, however, is to
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consider if the study contributes to our understanding of important questions, the venerable So
what? question (Creswell 2013).

Trustworthiness and Reliability
Validity in focus group research is made possible by carefully explicating decisions made
and procedures used in every stage of the research process (Krueger & Casey 2009). Details
related to decision making allows others to trust and potentially verify our conclusions. Denzin
and Lincoln (2013) argue that trust is established through transparency in qualitative research.
The trustworthiness of a qualitative study is a composite concept dependent on the authenticity,
believability, and applicability of our findings (Denzin & Lincoln 2013). If a reader can gauge
these three things, then a study and its findings can be said to be trustworthy. Another component
of trustworthiness is verifiability. Verifiable analyses are central to any research and are
characterized by others reaching similar conclusions based on the same data. This essentially
safeguards against the selective perception on the part of the researcher. My research has left a
trail of evidence (Krueger & Casey 2009) in the form of transcripts, observational notes, and
recordings. My project also used a structured discussion guide which enhances trustworthiness
by ensuring each focus group is asked the same questions (Morgan 1997). This discussion guide
has been included as an appendix, and this guide can also be used to gauge the reliability of my
study. Reliability is achieved when others can perform the same the data collection proceduers
on a similar group, and if reliable, come way with similar conclusions. Since my study utilized
five focus groups, a degree of reliability is present since the biases of one group cannot
completely sway the results.
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One of the touchier elements of my research is that of participant anonymity. Protection
of subjects is standard practice in qualitative research, even though some scholars have critiqued
the masking of subjects as anti-scientific and ethically dubious (Murphy & Jerolmack 2016).
However, any and all cannabis use is still federally prohibited, and medical cannabis patients are
not a protected class. Wendy Chapkis remarks how many of the terminally-ill patients in her
sample demanded to be identified, with one saying: “This is my story, my legacy. Use my name”
(Chapkis & Webb 2008:5). Some of the middle-aged patients interviewed by Newhart and
Dolphin (2019) also wanted to remain identifiable, but these researchers were adamant in their
use of pseudonyms for subjects, businesses, and location details. My research adhered to similar
precautionary measures with my IRB insisting on pseudonyms for all participants, even wellknown key informants. Since I also collected information related to occupation and health
condition, minor changes to these details have been used in the written report to further protect
the identity of my participants.
If we put everything on the table for our audience to judge, a degree of trustworthiness,
verifiability, and reliability is arguably present in the research (Denzin 2013). The need for rich
detail is arguably most important when it comes to researcher bias, an issue discussed in the next
evaluative standard presented.

Reflexivity
Qualitative data are shaped by the researcher’s relationships with their participants, but
research can still be validated through what Altheide and Johnson (2013) term validity-asreflexive-accounting. This is a type of validity established by illuminating the interaction
between the researcher’s perspective, the researcher’s logic, and the topic under study. Michael
Bloor and colleagues (2001) note the processual nature of focus group discussions often contain
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humor, irony, and are affected by the presence of the researcher. Data should be analyzed and
conveyed while keeping these conversational factors in mind. Reflexivity is essentially an
awareness of one’s own presence in the research, and the validity of a study can be evaluated by
others when we account for ourselves (Altheide & Johnson 2013).
I have tried to account for myself and my perspective throughout this project, and I hope
my biases have been transparent enough for the reader to understand my position. While I
believe cannabis should be accessible for all who seek it, I do not have a personal affinity
towards framing cannabis as a medicine over other constructions of the plant. I also do not use
that term “bias” as a negative like it is used in positivistic epistemologies. In order to obtain
consistent, truthful results, dominant models of science stress that research should be
depersonalized, unbiased, and value-free. This stems from the belief in a singular, objective, and
measurable reality that stands apart from the researcher’s social position (Altheide & Johnson
2013). This epistemology is more germane to quantitative research as “qualitative research is a
situated activity that locates the observer in the world” (Denzin & Lincoln 2013:6). Yet when the
researcher is inextricably integrated into the research, it means their biases become part of the
research as well. Since we know the researcher’s positionality can never be fully erased, research
can be graded along a continuum of “better” to “worse” by evaluating the researcher’s
transparency through reflexivity (McCorkel & Myers 2003).
Non-reflexive writing emphasizes detached objectivity, thus concealing the relationship
between the knower and known. Feminists have critiqued this as a disarming commitment to
neutrality accomplished through a decentered subject (Sprague 2016; Harding 2005). This style
of presenting research removes perspective, human feeling, and subjectivity. As stated by C.
Wright Mills (1959), “[the positivistic] way of presenting work does not use any voice of any
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man. Such writing is not a ‘voice’ at all. It is an autonomous sound. It is a prose manufactured by
a machine” (220-221). This lack of voice comes from the masculinist assumption that humans
could be liberated from the irrational forces of the human body (Sprague 2016). Our histories,
biases, and perspectives are framed as obstacles rather than forces that shape our experiences of
reality. “Qualitative research requires a mutual standpoint, researcher to participant, human being
to human being” (Eide & Kahn 2008:199).
Qualitative sociology owes much to feminist sociology, which says that knowledge is
perspectival and produced from multiple standpoints (Smith 1974). This makes knowledge
situated and communally constructed, an insight from standpoint theory, originally a “method for
naming the oppression of women grounded in the truth of women’s lives” (Heckman 1997:356).
One’s standpoint is anchored in the everyday world rather than in some abstract situation.
Furthermore, some scholars believe oppressed standpoints tend to be more objective than
privileged standpoints (Harding 1991). For example, my identity as a gay man may grant me
more insight into masculinities owing to my position on the margins of male privilege, a similar
idea of the “outsider within” (Collins 1986). Since Connell’s (1985) theory of hegemonic
masculinity includes heterosexuality as a core component of the masculine ideal type, gay men
are marginalized by default.
Moreover, situating knowledge from a standpoint makes objectivity practical, as
something that can be validated by multiple, different standpoints. Standard objectivity via
neutrality is irresponsible because it is unlocatable and thus is unable to be called into question.
By being unaccountable, hegemonic objectivity is a “conquering gaze from nowhere” (Haraway
1988:581). Since standpoint epistemology establishes that all knowledge is perspectival, it
requires researchers to explicate the social locations from which knowledge is produced,
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discovered, and/or interpreted (McCorkel & Myers 2003). Strong objectivity can thus be
achieved by exposing oneself to the same rigorous criticality as we do our subjects in research, a
process called strong reflexivity (Harding 1991).
In contrast to strong reflexivity, weaker forms of reflexivity only provide vapid
statements of the researcher’s identity, motivations (if mentioned at all), and experiences in the
field. What strong reflexivity does is make our own unknown assumptions visible to an outside
observer. Strong objectivity is achieved when a reader can weigh the researcher’s impact on any
knowledge brought to scientific attention (Harding 1991). More basically expressed, standard
objectivity eliminates the researcher from the analysis by emphasizing the elimination of bias.
Strong objectivity positions the researcher as central to the analysis by emphasizing transparency
(Harding 2005;1991). Furthermore, strong objectivity makes the researcher locatable and
therefore accountable (Haraway 1988). This partial, locatable, critical knowledge can sustain
shared conversations about the viability of its truth and usefulness. Likewise, strong objectivity
identifies how a researcher flavors their research questions, methodological approach, and
ultimate conclusions. There are no universal standards to follow, and methodological decisions
are often made on a situational basis. The key to this process is not to detail one’s biographical
history, but to analyze how positionality shapes researcher-subject relationships (McCorkel &
Myers 2003). My hope is that I have accomplished that throughout this report.

Triangulation
I have triangulated key informant interviews, site observations, and focus groups in my
research on medical cannabis patients. My decision to do this was to pluralize the perspectives
contained in my data rather than to compensate for the specific limitations of each method. That
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positivistic approach to triangulation is rooted in the belief of an objective target or logical
validation (Bryman 1992), whereas my use of triangulation is to have the three methods inform
one another. Key informants had expert knowledge of Michigan’s cannabis environment while
focus group participants had firsthand experiences in that environment. Overall, the focus groups
did not mirror the information received by key informants, and my goal was not to unify these
two perspectives. My goal has been to richly describe the current state of medical cannabis and
to communicate the contrasting experiences among and between patients, professionals, and
myself. For example, key informants largely came from the business world and spoke from an
economically centered perspective. They were also asked different questions related to their
different roles in the industry, and most of these questions would have been irrelevant to patients
in my focus groups.
The interpretivist position holds that there is no absolute, independent truth, and we
should not assume that triangulation deepens our vision (Charmaz 2006). Once again, the goal is
a diversity of visions to achieve a more nuanced understanding of the topic at hand. However, it
is necessary to consider the merits and limitations of my primary method. David L. Morgan
(1997) says the strengths and weaknesses of focus groups are somewhat of a compromise
between those of interviewing and participant observation. In particular, focus groups are a
useful means to collect data regarding participants’ attitudes towards others. Bruce Berg (2009)
says surveys or interviews are better in collecting information related to the self, but focus
groups allow us to unearth group sentiments regarding other groups. My research falls within
these recommendations, as I am interested in how medical cannabis patients perceive their social
context, gendered behavior, and recreational uses of marijuana.
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Other strengths of focus groups include the moderator’s ability to explore unanticipated
topics as they emerge in group discussion, the ability to use simple sampling strategies, and a
reduction in power between the moderator and the participants (Berg 2009). Focus groups also
demand less active involvement from the researcher to elicit information since other group
members may naturally do so. Likewise, focus groups have a high degree of external validity
(i.e., generalizability) since elicited conversations mirror natural conversations participants have
in their everyday lives (Hollander 2004). Nonetheless, a method by itself does not automatically
yield any insight (Charmaz 2006). We must analyze, interpret, and connect our findings to
theory.
Limitations of focus groups include the fact that some participants contribute more than
others, and their dominance can skew group-level representations. This concern for overdisclosure can be somewhat mitigated by assembling groups of strangers, as I have done here
(Bloor et al. 2001). Focus groups also tend to inhibit the expression of extreme or unpopular
views which are more commonly disclosed in individual interviews (Jarvinen & Demant 2011).
There is also the problem of oversharing, particularly on the part of men. This phenomenon is
commonly known as mansplaining, though within the world of market research, it is known as
the “peacock effect” (Kruger & Casey 2009). Other limitations of focus groups include the need
to be brief with participant answers, resulting in less depth to the information shared. We also
need to be cognizant that data reflect group opinions, rather than individual opinions, and that the
moderator’s skills significantly affect the quality of data obtained (Berg 2009).
Some scholars stipulate focus group data should only be used to make statements about
group-level attitudes (Berg 2009; Hollander 2004), but David Morgan (1997) says it is also
possible to use individual participants as units of analysis. In other words, focus groups allow us
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to use individuals as a unit of analysis as long as we are careful to contextualize the data within
the group. While the group certainly influences what individuals express, the group is also
composed of individuals with unique thoughts, feelings, and perspectives. Both the group and
each individual must be understood as mutually constructive. Nonetheless, I have avoided
interpreting body language unless in extreme or notable circumstances. I am not a psychologist,
and gestures or other expressions are easily misinterpreted in focus group environments (Kruger
& Casey 2009).

Analytical Procedures
Like all stages of focus group research, the purpose of the research drives the analysis
(Krueger & Casey 2009). The audio from both the key informant interviews and focus groups
was transcribed by the researcher for readability, an imperfect style that favors efficiency above
detailed preservation of unvarnished human speech (Bloor et al. 2001). In other words, I
removed most of the numerous Uhs and You Knows. These transcripts and my field notes would
later be analyzed using qualitative coding software.
My analysis of focus group data was systematic and rigorous where statements were
coded for theoretical and emergent themes. Unexpected topics emerged in this process like
concerns related to gun ownership and occupational immobility. I informally began analysis
upon transcription where I indexed themes via brief notes when something significant was
expressed (Bloor et al. 2001). Formal analysis began with segmenting data into broad themes (or
nodes) related to medicalization, normalization, and gender. My structured question guide eased
this process since some consistency was created by asking the same questions in mostly the same
order to each group (Krueger & Casey 2009). I used the program NVivo to organize my data and
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then started to refine codes within the three broad categories mentioned above. For example, the
category of “gender” was then further segmented into themes related to masculinity, femininity,
or general statements on gender. The subtheme of masculinity was then organized between
statements indicative of hegemonic, alternative, or general masculinities. I iteratively continued
this process until I felt I could no longer meaningfully divide subthemes. There were also many
codes unrelated to my research questions, primarily those related to Michigan regulations and
specific products, and while these do not inform my subsequent analysis, they may be useful for
future research projects.
My final report is written in a manner that balances direct quotations and researcher
discussion. David Morgan (1997) encourages the use of “well-chosen” quotations that link “the
importance of the topic and vividness of the example” (p.64). Both my analysis and written
report have been careful to keep the context of statements intact, and one way of assuring this is
to use longer direct quotes (Bloor et al. 2001). Using direct quotations from the focus groups also
helps to establish interpretive validity, or the degree of accuracy behind meanings communicated
and understood in the research (Johnson 2000). I have also been careful to avoid numerical
comparisons between the groups as suggested by Kruger and Casey (2009). Since my sample
size is too small, and discussions may be skewed by over or under sharing, I am unable to
adequately infer percentages from my focus groups to the larger population of medical cannabis
patients. Modifiers like “some”, “many”, “a few”, or “most” have been used to characterize
group perceptions.
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Conclusion
More qualitative research on medical cannabis patients is needed to enrich our
understanding of this diverse and understudied group. As such, my use of focus groups, key
informant interviews, and observations should contribute rich information to the literature on this
population. What did I find? Chapter 6 discusses how patients experience stigma and how such
experiences trouble claims that cannabis is normalized. Chapter 7 concerns the medicalization of
cannabis, and my results indicate that patients prefer the current model of cannabis as a noninstitutionalized medicine. Finally, Chapter 8 details some of the ways gender shapes
experiences within the medical cannabis community. Overall, the following analysis chapters
help restore nuance and complexity to our understanding of medical cannabis patients, and I
connect my results to existing studies throughout each chapter.
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CHAPTER VI

CANNABIS STIGMAS IN A POST-PROHIBITION STATE
When scholars approach the topic of cannabis normalization, they typically point to
statistics that show more people are accepting of and using cannabis more than ever before
(Mostaghim 2019; Satterlund et al. 2015; Jarvinen & Ravn 2014; Sandberg 2012; Duff et al.
2012; Hathaway et al. 2011; Jarvinen & Demant 2011; Erickson & Hathaway 2010). However,
patients in my focus groups do not think we have yet to normalize cannabis in our society. While
our society is undoubtedly becoming more tolerant, the stigma associated with cannabis still
haunts their lives. This chapter explores how patients experience stigma in a post-prohibition
state. The research questions that guide my analysis are: How does the medical cannabis
community feel about the status of medical cannabis in this moment of emerging recreational
legalization? And, what challenges do patients face in their social and professional lives?
Overall, patients feel less constrained regarding their medicine now that it is gradually
becoming legal for adult users. I begin this chapter with an overview of how macro level,
structural stigmas have diminished, though the uneven process of legalization still presents
challenges to patients, many of whom still feel their medicine carries a non-normative status.
Afterward, I examine how social stigmas, or those operating in the meso levels of society,
impose powerful limitations on the social and professional lives of cannabis patients. It is also in
this meso level that we see how the normalization of cannabis is mediated by factors like
employment status, gender, and race. In fact, since my focus groups lacked racial diversity, this
chapter of my analysis (and the others) are primarily based on the experiences of white people.
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Finally, I discuss how my findings problematize linear narratives of normalization, and how
patient activism may still be necessary for a legal state.

Structural Stigmas
Structural stigmas stem from the macro levels of society and include laws prohibiting
cannabis as well as widely shared anti-cannabis cultural attitudes (Livingston & Boyd 2010;
Herek, Gillis & Cogan 2009; Corrigan, Watson & Barr 2006). It is on this level that patients in
my focus groups feel the most progress has been made. As states began to permit medical than
recreational cannabis use, many of my participants were relieved they no longer had to worry
about criminal penalties. Some of them, like Greg from Focus Group 2, no longer feared
persecution, but the freedom of the post-prohibition world did not extend to other areas of his
life:
Moderator: By a quick show of hands, whose family members know about their medical
cannabis use?
[everybody raises hands]
Greg: That's a general statement. Because it could be 1 person or 100.
Moderator: Right, but we are open to at least some people in our family.
Greg: Yeah, I'm just open to my wife.
Moderator: No one else?
Greg: Nope. Because it's none of their business.
Wanda: Didn't you say that you got the medical card to be more out?
Greg: Not that I'm running around telling people, but the card made it legal.
Wanda: Oh, so in terms of cops and stuff...
Greg: Yep. As I said, I spent 51 years in the shadows but I'm legal now.
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Many of the patients in my focus groups cited legality as easing their fears and reducing
the level of concealment they practiced in terms of their cannabis use. Though Greg was not
opening up to anyone aside from his wife, several patients said it eased their familial concerns as
their families were more concerned about the illegality of their medicine as opposed to other
concerns associated with cannabis. However, since legality has spread on a state-by-state basis,
and as regulations impose new challenges on the patient community, freedom from persecution
was experienced contextually and situationally. For example, patients in Focus Group 1 said the
uneven status of cannabis between states restricts their ability to travel, or at least make it
impossible to travel without worry:
Moderator: What do we think the future of medical cannabis will look like?
Avery: Hopefully it will be national by then instead of state because it is a real pain. Like,
I have to travel a bit because my dad lives in Arizona and my sister lives in Ohio, so
traveling is a nightmare.
Sophia: And that is why I stay home because I'm afraid I cannot take my medicine with
me or I won't be able to get it while I am gone.
Jimmy: I have the same concern. I've gone to a conference before for research and stuff…
Sophia: How many days, do you remember?
Jimmy: I was helping organize it, so I was there for almost a week and a half, it was
really long… ya… I bought a pack of cigarettes because I was so stressed.
Sophia: Right?! It's not even like you're planning to sell it, you just want to make sure
you're good while you are gone.
Avery: Not like you're being mischievous or whatever.
Sophia: Yeah, I would just want to take my meds with me so I can have a good time. And
I'll be discreet with it, but I think it does keep me home a lot. I thought of going on
cruises or even taking a trip to Chicago, but o my gosh…
Currently, all medical and recreational cannabis sold within legal states must remain in
that state as federal prohibition makes it illegal to send cannabis across state lines, even if it is
between legal states. Likewise, since airports and postal services are regulated by the federal
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government, no cannabis can be brought through TSA or shipped to one’s destination. This
makes travel uneasy for patients as they must illegally sneak their medicine past authorities, or
restrict their travel to states with accessible dispensaries. Fortunately, some medical states allow
dispensaries to recognize out-of-state medical cannabis cards. Michigan is one of these states,
and while I was observing patients in a dispensary, a woman visiting from Hawaii came in. After
a quick bartender-esq check of her card, she was able to purchase her medicine. The staff later
informed me they have an online tool they can use to further scrutinize suspicious-looking cards,
also noting that out-of-state cards have become common at their dispensary.
The federal prohibition of cannabis creates problems for patients seeking to travel beyond
their state borders, but even within legal states like Michigan, some patients still feel
criminalized over whether they are in compliance with stringent regulations. Deborah, from
Focus Group 5, still worries about criminal penalties whenever she visits a dispensary:
Deborah: It’s like being a kid in the candy store. But driving out there, though, I'm
looking all around for narcs hiding somewhere. I'm looking like, where are they? Where
are they watching? And honestly, I did exactly like they told me. I opened up the trunk of
the car and threw it way back there so I can't reach it. I did exactly what the law said...
But it is awesome that in my lifetime, to be able to see this industry open up and to be
able to talk about it openly...
Having medical cannabis within one’s reach while driving is a criminal offense in
Michigan, and for a long time, it was advised patients transport their medicine within a locked
box inside of their trunk. This is similar to laws on how firearms are transported though cannabis
has never killed anyone, and laws are laxer regarding the transportation of alcohol, a far more
intoxicating substance. Similar to Deborah, Alexander from Focus Group 4 still feels the lack of
social cannabis spaces makes the culture surrounding cannabis use seem criminal. He used to
visit social clubs but never felt secure:
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Alexander: Michigan used to have plenty of clubs and compassion clubs, and lounges
where you could use meds. There was one in Lansing, for example, but all of these places
were illegal.
Audrey: Like it still felt like you were doing something wrong?
Alexander: That's exactly it.
Interestingly, feelings of insecurity were also evident at a legal harvest festival I visited in
the Fall of 2019. This was one of the first public cannabis events to be held in southwest
Michigan since it was legalized nearly one year ago. Open to everyone over age 21, medical
cardholders received discounted admission to the event which featured around 40 vendors selling
flower, edibles, concentrates, and more. Smoking or consuming openly was allowed since the
organizers had secured the necessary permits, and the organizers also served as security staff for
the event. To my knowledge, no problems ever arose, but I overheard several attendees express
that caution was needed when leaving the event. One said officers in the area were “not friendly”
towards cannabis culture while he encouraged an attendee to drive carefully.
Finally, caregivers in the state’s medical system cited legal compliance as a major source
of stress in their lives. I interviewed two caregivers who had each been supplying patients with
medicine for nearly 10 years, and they each had numerous run-ins with law enforcement. For
example, May and her husband began growing as caregivers in 2008 after the passage of the
MMMP, and several of her patients weaponized law enforcement when the caregiver
relationship fell apart:
May: We had several [patients] that we had to drop. Just because, to be honest, it's the
legality of it. Two of our patients in the very beginning thought that we were cheating
them, and they turned us into the police. I don't know if the state actually was involved,
but the county and the city that we live in showed up at our house with Child Protective
Services. We had to prove everything but we were good. We were fine. We were legal.
They investigated all of their wrongful claims, but there was never an instances of us
breaking the rules, you know. So they thanked me and they apologized, and we all came
to the conclusion that it was just basically like a hate thing. They were jealous basically.
They were mad and they thought we did something wrong, but we didn't. They thought
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they could get us in trouble because they weren't getting what they thought they deserved,
I guess. Because caregivers, depending on how established they are, some of them offer
free medication. They offer different things to get someone to sign up, you know. And a
caregiver puts all of their time and all of their money into growing the product, and then
the patient thinks that they're entitled to something free.
Despite cannabis being a relatively easy-to-grow weed, getting it to produce flowers that
are pure and potent is a challenge. This may be why only a handful of patients in my focus
groups have tried growing their own medicine. Caregivers can spend tens of thousands on
equipment and electricity bills for indoor grow operations often exceed a thousand per month.
May also considers tending to her crop as a full-time job and claimed she does not know any
serious growers who are able to work in addition to being a caregiver. While some caregivers
may occasionally provide their patients with free medicine, most expect a fee that is typically
lower than what a dispensary would charge. Despite “free medicine” being somewhat of a rarity
in Michigan, patients receive a variety of benefits from having a caregiver, including consistent
access to high-quality medicine, having caregivers grow specific strains, and a relationship more
personal than those forged through retail dispensaries.

Social Stigmas
While structural sources of stigma may be diminishing, patients have seen little progress
in social sources of stigma. Social stigmas operate within the meso level of society and can
include group-related sentiments, organizational policies, and cultural stereotypes (Mortensen et
al. 2019; Hammer 2015; Livingston & Boyd 2010; Herek et al. 2009; Corrigan et al. 2006). For
example, media representations of cannabis users can reproduce social stigmas, and patients in
my focus groups desired to see more non-problematic depictions of the medical cannabis
community. Overall, my participants thought the visibility of cannabis was increasing and that
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news reporting on the topic had improved. Patients in Focus Group 5, for example, valued
objective reporting, even over reporting that was intentionally pro-cannabis:
Moderator: So, we just raised the topic of the media. How do we think the media portrays
cannabis nowadays?
Jackie: The media hasn't dropped the stigma.
Austin: I think it might depend on which state you're from. You know, in Indiana it is
always a topic, constantly, because every state around them is starting to legalize other
than Kentucky. And they've even okayed cannabis growth, you know, as far as hemp type
growth. So, Indiana just finally legalized hemp growth again, in the state. So, you know,
it'll be interesting, but I think that's kind of where people see things from. It's a state that's
built on Eli Lilly, Roche, and pharmaceuticals, and they will protect their belief that
pharmaceuticals are the way...
Deborah: They talk about it. But I don't know which way Channel Three slants it yet...
Doug: Yeah, it's just they say the words. I mean, you can generally feel the slant when
they're going one way or the other. And I think they're just passing it on...
Damien: I don't either.
Briana: Which is kind of how you want your news sources to be. You don't want them to
pick one way or the other. You want them to be unbiased.
Deborah & Damien: Right.
Doug: I'm constantly reading articles every day. And every time I open up Google to
search something, usually one of the top three articles is something about marijuana
somewhere. So, I mean, it's definitely being talked about, with some good and some bad.
It just depends on where it's at and what's going on. I've seen articles where people were
mad because a dispensary was opening near a school. You know what I mean?
The political orientation of media outlets has been shown to influence how they portray
marijuana in news stories. Mortensen and colleagues (2019) found neutral media outlets
deployed the least marijuana stereotypes when compared to liberal or conservative outlets, the
latter of which utilized the most. Yet while reporting on the topic was thought to be less
stigmatizing than before, patients in my focus groups were also critical of news coverage which
used terms like “pot shop” in describing medical cannabis provisioning centers, and many
believed too much attention was granted to opponents of legalized cannabis. Like Doug above,
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Focus Group 2 was critical of news coverage on the possibility of children purchasing adult-use
cannabis from retail locations despite this never happening before in other legal states.24 Patients
were also keen on crime reporting where officers or the reporter mention that cannabis may have
been in the wrongdoer's system. This can be somewhat of a double standard since
pharmaceutical drugs with more severe side effects are never treated with the same scrutiny.
Though participants acknowledged film and television representations of cannabis users
had diversified, many also took issue with the predominance of stoner stereotypes. The Netflix
show Disjointed was brought up in three of the focus groups, and while some patients enjoyed
the show’s comedic focus on a medical cannabis dispensary, participants in Focus Group 2 were
offended by the show’s stereotyping of cannabis patients:
Moderator: What do we think in terms of the media’s portrayal of cannabis?
Wanda: It's being discussed more but they're not doing a good job portraying it.
Sean: The media will mess anything up if you give them the chance.
Moderator: How are they messing it up?
Irene: They stick to the stereotypes.
Wanda: Exactly. Even the medical shows.
Irene: Yeah like Disjointed!
Wanda: Right! Disjointed was supposed to be about medical marijuana facility and they
were all typical stoners.
Andrew: Yeah, I couldn't even make it through the first episode.
Wanda: I thought it was hilarious but it's not medical in any way.
Andrew: I was offended. I worked in and then I managed a dispensary, and I was
offended.

24

A similar problem has occurred around Halloween for the past several years. Media reports featuring police
officers warn parents about the possibility of their children receiving THC infused trick or treat candy. However,
there is no evidence this has ever happened.
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Wanda: Well, remember also that I'm only a year-and-a-half into this so to me it was
hilarious.
Some patients in my focus groups acknowledged media stereotypes of cannabis users
were also shaped by gender and race. There is even evidence for this as a content analysis of
Canadian newspaper articles revealed normalized marijuana is masculinized and racialized
(Haines-Saah et al. 2014). Relative to men and whites, the use of marijuana by women and racial
minorities is more stigmatized. Audrey from Focus Group 5 said women who use marijuana onscreen are traditionally presented as sexually permissive or involved in prostitution. Jimmy from
Focus Group 1 said that while he has seen respectable white characters use cannabis, characters
of color who use cannabis are often involved in criminal subcultures like gangs. Overall,
participants desired media representations that reflected their diverse lived experiences rather
than traditional stoner stereotypes. Patients also wanted cannabis to be more visible in the media,
preferably where it is talked about openly and honestly. In other words, they wish for social
censorship on the topic to be removed. This is why Doug from Focus Group 5 was disheartened
when he saw High Times magazine was by request-only at a local bookstore (like pornographic
magazines) despite periodicals on alcohol being placed out in the open.
Like prior research, social stigmas also caused cannabis patients to limit public
knowledge of their use of medicine (Newhart & Dolphin 2019; Satterlund et al. 2015; Bottorff et
al. 2013). Participants in my focus groups feared negative reactions from their families,
communities, and group affiliations. However, some participants, like Gavin from Focus Group
3 and Alexander from Focus Group 4, were very blatant about their use of medical cannabis.
Alexander had stopped worrying about what his clothes smell like following legalization (though
he also said he was recently asked to leave a restaurant for smelling like cannabis), and Gavin
took the bold move of informing his neighbors and church community upon receiving his card.

154

He considered himself to be an advocate for cannabis medicines, and since he had a criminal
record, he wanted to make sure everyone knew he uses legally.
While many patients would educate their friends and family members on the medical
benefits of cannabis, Gavin and Alexander are the exceptions to the overall pattern as most of my
participants remained guarded about their personal use of medical cannabis. Many participants in
my focus groups were afraid of being “outed” by their friends or family members, like Jimmy
from Focus Group 1 who hid his patient status from his younger siblings. Similarly, some
participants in Focus Group 2 feared their use of cannabis would be leaked by their children:
Greg: The social stigma is just so predominant that you don't talk about it in church, and
you don't talk about it in school, and you don't let anybody know.
Darlene: I think it depends on where you're at.
Irene: I think that if they have a problem with it, then they just don't say anything to me.
Like my kids will be at school and they'll be doing their whole “don't do drugs” lecture,
and my kids will be like, wait a minute… and they're like challenging the teacher. And
I'm a teacher myself. So they're like, where are your kids coming up with this stuff ? And
I'm like, oh, me. I can use cannabis or I can be walking around on 80 mg of oxycodone.
Greg: Or not walking around...
[group says “right”]
Irene: Yeah, or have to use a wheelchair and I don't want to do that.
Wanda: Well, she touched on the school issue and I thought that was interesting because I
just enrolled my kids in a Montessori School. I didn't think that anybody would be
against it there, but the principal had mentioned that somebody had picked up their
children after hotboxing in their car…
Andrew: That’s different…
Irene: Ya, that’s not cool.
Wanda: ...so we got on the subject of cannabis and I said that hey, well, I do use it, but no
way would I ever do something like that… but yeah [laughs]. I guess my kids’ teacher
and even the principal all know, and I think they're all on board with it, which I am glad
because I didn't want my kids outing me either.
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For several participants in my focus groups, revealing their cannabis use to family
members resulted in being distanced or shunned. Sean and Darlene, both from Focus Group 2,
felt their relations with their parents had deteriorated upon disclosing their patient status. Sean
had not spoken to his father in years because of cannabis and Darlene felt unsupported by her
parents, a feeling amplified by their embracement of her alcoholic brother. Similarly, Sophia
from Focus Group 1 had purposefully ignored one side of her family for many years since they
were adamantly against her use of medical cannabis. Most patients had a supportive family, but
for many it was a gradual process of getting family members to accept cannabis as a medicine.
Fortunately for some, liked Briana from Focus Group 5, the new adult-use laws facilitated
familial acceptance:
Briana: My mom was probably the only family member that knew from the beginning up
until, I would honestly say, probably until it went recreational. With my dad, I might
have told him before that, but it just kind of came up one day in conversation and I was
pretty much over hiding it from him. So, I just pulled out my card one day and handed it
to him and was like, you can't really say anything to me. I'm 30 years old, I'm a
successful person, I have multiple degrees, I hold a job, and everything I have is paid for.
So, I'm like, you know, that stigma is not there, at least with me. I don't think anybody on
my mom's side of the family knows, but none of them live around here so it's not like I
ever see them. And then I think my dad's side of the family kind of knows now just
because I've been a little bit more open talking about it when they've brought it up at
family functions, about the recreational side of it. So, they know I at least know enough
about marijuana that I think they probably have an idea, but I've never came out and
confirmed it.
While the majority of patients in my focus groups still limited public knowledge of their
medical cannabis use, many were also tired of practicing discretionary measures. Since cannabis
in Michigan is now legal for anyone to consume in private confines, patients like Deborah and
Doug from Focus Group 5 did not worry about pesky neighbors anymore. This is not to say,
however, that their neighbors welcomed their cannabis use:
Deborah: My neighbors know... They live next to me, so they know. But there's also a
stigma in that, you know. Even at my age, there's people that are older than me and they
don't appreciate having cannabis around. But fuck ‘em, I don't care. It's legal now.
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Doug: As a matter of fact, I have a lady that moved in downstairs from me… So, I had a
pretty lengthy talk with her and even after I explained to her all the things going on with
me and the medical reason why I need it, she still just didn't get it. She is very... and she'll
complain every time she thinks I'm smoking. I can't even make a batch of edibles without
her complaining... But I don't care. And I think she gave up at this point.
Landlords in Michigan can prohibit general smoking in apartments as well as growing,
but they cannot prohibit cannabis itself or non-smoking methods of consumption. Nonetheless,
consumption cannot be publicly visible25, and this created problems for patients like Sophia from
Focus Group 1 who simply dreamed of being able to medicate while relaxing on her patio.

Employment Concerns and Occupational Immobility
The most consequential sources of social stigma for patients in my focus groups were
from the medical profession and employers. Patients described being given an ultimatum from
medical professionals to choose between either cannabis or conventional treatments. Policies like
pain contracts prohibit patients from using cannabis while being prescribed pain killers, and
some patients described receiving anti-cannabis lectures from their physicians. These medical
sources of stigma are discussed more in the next chapter, but sometimes they intersect with
stigmas from employers. Darlene from Focus Group 2 works in the medical field, and while her
experiences with cannabis stigma come from a variety of sources, she fears for her professional
identity:
Darlene: Hi. I'm Darlene and I've been patient for a little over two years, but it took me
three years to work up to it [laughs].
Greg: Why?
Darlene: Why? Because the stigma.
25

Perhaps the weirdest manifestation of the ban on visible cannabis consumption can be found in boating laws. In
the summer of 2019, the Michigan Coast Guard informed boaters that they may only smoke cannabis inside their
boat’s cabin. This is ironic given the concerns about smoking any substance in an enclosed space, while at the same
time, the large distance between boats on the water makes second hand smoke unlikely.
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Sean: I heard that a lot.
Darlene: And I just wasn't sure, so I did a lot of research. But ya, it took a while to get
over the stigma of it.
Sean: Yeah, the stigma and the stereotypes just ruin it for people.
Darlene: Right, because I still participate in the professional world and it’s… it's
something to be concerned about to some degree.
About three-fourths of the participants in my focus groups were employed full time, part
time, or worked odd jobs or within the gig economy. Fortunately, most of them had found a
source of income that allowed them to use medical cannabis outside of work, though many
experienced challenges with drug-free workplaces. Despite cannabis being legal for those ages
21 and up in Michigan, employers can still refuse to hire or fire those who screen positive for
cannabinoids. Some of the participants in my focus groups, and a couple of the people I
interviewed as key informants, described taking a period of absence from their medicine when
attempting to get a new job. Like Irene from Focus Group 2, they all loathed that period of
abstinence, and other patients like Andrew refused to go without their medication:
Irene: I had several employers who did everything they could to not have me go in for
drug testing. One of them was finally like, okay, I've done everything I can and it's your
fourth promotion in three years, so you have to go...
Andrew: Oh yeah, I totally forgot! When I first moved to Michigan I had a very similar
thing happen…
Irene: Yeah this was a Friday afternoon and they asked if I thought I could go Monday
morning and live through the weekend without using cannabis. I was like, yeah, sure but
you're probably not going to want to be around me.
Andrew: I had told my former employer because when I first moved here, I was in an
industry that was not cannabis-friendly at all…
Greg: Were you a cop?
[group laughs]
Andrew: No, but similar. I had told my employer, this is how I function and this is how I
do it, and he was 100% okay with it. I even went to the lab and got tested, and I had even
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gotten promoted to assistant manager. Then the ATF released a statement regarding their
position on cannabis, and this was maybe 2 or 3 years ago, and so this freaked out my
employer a little bit. So he made me choose between the job or cannabis.
Irene: I choose life.
Andrew: Exactly.
Sean: Right. Don't give me the option because it's an easy choice.
Wanda: I would never choose a job over this freedom again. That is why I am selfemployed because I won't do it.
Patients may need to medicate often and some of my participants who held jobs were
comfortable talking about the regiments they do before or during work. All of them who
disclosed such practices claimed it had no effect on, or even enhanced, their work performance.
For example, the following is a continuation of the above discussion from Focus Group 2:
Andrew: I just started my current job which is selling aquariums, and it's awesome. But I
had been going to this place for years for my fish and only recently found out that they
needed some help. The manager had known me as a cannabis user and enthusiast, and
when calling me to tell me that I had gotten the job, she said, I just want you to know that
you can't come to work high. And I said, okay. [group laughs]. But I was thinking, well,
you've never seen me not high, so...
Greg: Like that would be a problem (sarcasm).
Wanda: [laughing] What else are you going to say to that though?
Irene: Yeah, like, how would they even know the difference? And when you are in pain
you don't get a high from it. You get normal.
Sean: Most of the people that I run around with, they wouldn't know any difference if I
was high or not. Because when I leave the house I'm usually smoked up, you know?
Andrew: Right. They wouldn't know. And I'm also not leaving the house unless I'm… in
a proper mindset.
Similarly, Alexander from Focus Group 4 introduced himself this way:
Alexander: My name is Alexander. I've been a patient for four years now. And my
favorite way to medicate is smoke a joint. And to me cannabis is a way of life. It's there
in the morning, it's there at night. helps me get up and want to actually go to work, to
actually do the things I need to do during the day.
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Other participants described being tactful with how they medicated in the context of
work. Some used edibles before or during their shifts since these are more discrete than smoking,
and some even self-censored their social media feeds so that their employer would not become
suspicious. Overall, patients did not problematize cannabis and work, though they knew this
sentiment was not widely shared in society. Some patients were even critical of drug testing in
high-risk professions, like the gentlemen in Focus Group 3:
Wade: I don't know if folks should be high if they're working on heavy machinery. But
then again, how can you tell? Maybe they had done it a couple nights before? Or maybe
they just did it 10 minutes before? So that's going to be another dicey thing. Every year
there's a fight like that.
Gavin: Talking about heavy equipment, I think there really needs to be a study
specifically on that type of thing. Because how do we know what has been going on all
these years without us even thinking about it? Because I know that I've been smoking
since I was a teenager and my driving record is clean. So, I have a hard time believing
that it adversely affects us to the extent that they would like us to believe. I mean, I might
stop a little earlier at a stoplight. But I'm not going to have that road rage like the
alcoholic or even a sober person might have.
Though I did not ask about patients’ sentiments regarding drug tests, no one expressed
they thought drug tests were ever necessary for cannabinoids. Others supported drug tests for
other substances, like those in Focus Group 5, which also had two people who were open about
their use of medication to their employers:
Damien: It'll be interesting to see what a lot of the companies do as far as drug testing
now, especially for new employees now that cannabis is legal...
Jackie: At least a handful have dropped the marijuana off of their screening panels.
They're just testing for all the stuff they should be testing for.
Moderator: For those of you that do work, are you open about being a patient at work?
[Only Austin and Doug say yes].
Deborah: I just don't trust them, so I keep it under my hand.
Damien: Whatever the company is politically... The company I work for is very
Republican and I keep my mouth shut.
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Austin: I supervise security at a cannabis processing company. There's the understanding
that there's no reason for you to be stoned or messed up, you know. I believe in
medicating, and if you need to do something to keep you in a functioning state, I
understand that. But to sit and smoke a blunt or whatever, or just smelling like it, I don't
think that's something that security should be doing. But I mean, there's nothing we have
to sign or pass or anything else. I don’t smoke marijuana on the job but it is beautiful
smelling it every day [group laughs].
Doug: The only reason I say I'm honest is just because of my job. Otherwise, I think it
just depends on where you work or your environment. I work for a home repair service.
My boss is located about an hour away, and as long as I do my job and I don't have any
complaints about me, then he’s okay with it. I don't go in front of customers smelling like
weed. But my boss knows because every time he sees me, I'm usually medicated.
Because a lot of times, when I have to go meet him in his region or whatever, I might
smoke one before I see him. So, when I get there, I might smell like it or... be high. And I
tell him that I just got done medicating because that was my only break. So, I just think it
depends on your work environment.
Considerations of medical cannabis use in the workplace are important because Lau et al.
(2015a) claim users help normalize cannabis through normifying harm reduction techniques like
avoiding use at work. Such measures help users pass as normally functioning in their everyday
lives, but the medical cannabis patients in my study trouble this claim. As we have seen, patients
in my focus groups secretly medicated before or during work, and several others expressed they
wished they had the ability to do so. These individuals described feeling and acting normal
following medicating, but they knew this style of using cannabis would be interpreted as drug
abuse in their workplaces. While the normifying practice of concealment may help cannabis
patients avoid employment repercussions, it ultimately places them in a closet akin to sexual
minorities. With that said, staying closeted did not facilitate social acceptance of queer people; it
may have even perpetuated their social oppression. As such, normifcation per Lau et al. (2015a)
may not facilitate normalization and is rather used as a tactic to protect the self in the face of a
hostile social structure.
My final finding on the intersection of cannabis stigmas and employment manifests when
patients feel stuck in their current occupation, a phenomenon I call occupational immobility.
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Since many employers drug test new employees or conduct random drug screenings, several
patients in my study expressed they were with their current employer only because they thought
no other line of work would accept their medical cannabis use. For example, Wanda from Focus
Group 3 relied on the gig economy because they did not think a regular job would accommodate
their use of medical cannabis. Similarly, Sophia from Focus Group 1 would do odd jobs such as
cleaning houses, though she recently found seasonal work as a part-time house cleaner:
Sophia: Normally I smoke before I go to work. I just recently got a job where I'm doing
cleaning and they were advertising for employees all over the place, so I told them that
every two hours I'm going to need a smoke break. They know me and I can keep going,
and I'm a heck of a worker but I know what I need. So, my jobs are kind of short and
sweet, and they're usually a couple hours at a time. I also take care of my mom and I'm
usually there for four hours, but before I go in I take a little smoke break. Now if I was
working at Taco Bell it would be another story. That's why I've always avoided those
kinds of jobs where I know I wouldn't be able to get away to do it.
These two patients and others were not only wary of drug screenings but also needed the
chance to medicate every so often. Medicating while on break may be a solution but drug-free
workplaces make doing so difficult, and even if they tried to do so secretly, that would once
again lead to an omnipresent fear of what might happen if the boss found out. Audrey from
Focus Group 4 lived with that fear until she discovered a company policy that gave her immunity
for prescribed medications:
Audrey: I have my work and I don't want to get hurt and for them to be like, well, you
don't have a card for it. And just because it's legal recreationally doesn't mean it's legal at
work. One of the reasons I got my card is because in the handbook it said you need a
prescription for your medication and that is the only way. And I was like, I have this card
and it is just like a prescription. It's just like, you know, Norco. I was the first person at
my job to use my medical card while I was hurt. That was really scary because I had
worked there for nine years. You know, I could have lost my job after being injured.
Alexander: It's good that they were flexible with that to where it was for marijuana too
instead of just pills…
Audrey: Right and they didn't say that. They just said it was prescriptions. I'm like, Okay,
I have a prescription. I got hurt. You guys can change the handbook afterwards, but right
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now... And that's another reason why I have stayed there for another two years is because
they recognize my card and it's hard to get a job with having cannabis in your system.
While Audrey did not loathe her current job, she thought she could do better as a licensed
veterinary technician, an occupation in much demand. Additionally, she also stated her
coworkers eventually learned she was a cannabis patient, and ever since she believed some have
treated her differently. The conversation from Focus Group 4 on employment continued for some
time, and while Alexander’s employer was accepting of his cannabis use, Alexander thought his
medicine ultimately stifled his career prospects. Perhaps this is why Alexander had appeared to
internalize the stoner stereotype to where he thought cannabis users were less motivated than
others (Livingston & Boyd 2010; Herek 2007):
Moderator: Is there a difference between guys who use cannabis and guys who don’t?
Alexander: Guys I know that smoke cannabis aren't the most motivated individuals. Guys
I know that don't smoke are very motivated and have achieved higher life goals.
Moderator: What do you mean by motivation and life goals?
Alexander: Just making more money. That's very much what it boils down to. They were
able to stay motivated to get that good job where a person like me had to settle for the
dead-end job that accepts my marijuana use.
Audrey: Yeah, well I have a boyfriend that uses cannabis and he's been very motivated.
Alexander: Well, even if he has a good job now it's still a dead-end job because he will
never be the boss or CEO...
Audrey: He will be the boss because it's his family’s business that he's working at. But
before that he was a manager elsewhere and then decided to go work for his family
because he would have a better career. Like, he'll be the owner one day, you know? So
that's nice for him. I have had boyfriends who had dead-end jobs. But then again, if
they... Like, I'm stuck in the job where I'm at. I want to get a different job but it's really
hard because I don't want to stop smoking. And I want places to recognize my card, so
until then, I'm stuck where I'm at... Like, if you could get a different job that recognized
your card, would you do something different?
Alexander: Definitely.
Audrey: You have talent that's there that they don't recognize because of your card,
because you smoke, you know?... My main issue is that nobody really recognizes it like
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they should. I can smoke and come back to work unlike the girl that went out and took a
frickin’ Valium and then came back into work. Because I'm not going to pass out in the
chair while she might.
While headlines typically portray the cannabis industry as brimming with opportunity,
the social stigma associated with cannabis is still so strong that public leaders act against the
economic interests of their communities to prohibit taxable cannabis commerce. Patients in my
study were amazed at how many municipalities have opted-out of the medical or recreational
cannabis market. As of November 2019, 80% of Michigan’s municipalities have banned
recreational cannabis businesses, including Detroit (Carmody 2019). This prohibition of cannabis
businesses may be caused by social stigma, but it also helps to reproduce such stigmas by
eliminating visible cannabis spaces. It also reduces opportunities for patients to become gainfully
employed in an industry they love, especially for those who do not drive or live far from the
nearest licensed business. Focus Group 5 thought such preemptive measures made little sense in
a deindustrializing state like Michigan:
Deborah: I think because pot has been considered bad for so long, that all the little birds
in Michigan now are blocking all these stores and these facilities. They're just shooting
themselves in the foot. I think this would be an awesome industry to welcome into your
village, community, or town.
Damien: I agree.
Austin: It's going to bring hundreds if not thousands of jobs into just this area. Maybe
even more. So how can it not be beneficial? I mean, that's about how many GM jobs were
lost at one time. And they're going to be good paying jobs too.
Doug: And not only that, but when I saw that there was a job fair, I was like that
something's serious... For real, there was a job fair the other week... It was a 420 job fair.
I've never seen one of those before so that means there's something coming.
Deborah: Yeah, I think so too.
Several cannabis job fairs have been held in southwest Michigan over the first year of the
adult-use market, and all were heavily attended. Perhaps it would be good practice if these
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businesses gave preference to medical patients, especially since their patronage of the state’s
licensed medical businesses has partially helped pave the way for the emerging recreational
industry. Since the state requires applicants for adult-use licenses to have operated for at least
one year as a medically licensed business, patients as a customer base have literally made soonto-be licensed adult-use stores possible. The same is true with the other types of licensed
businesses—growers, processors, transporters, and testing labs. While it is unknown how many
of the current employees at such businesses are patients, my informal observations of cannabis
job postings lead me to believe not all of them are patients, as many postings say “no medical
card required”.

Normalization as Colorblind
Historically, cannabis use on the part of racial and ethnic minority groups served as the
impetus for prohibition and tough penalties (see Appendix A). Moreover, despite rates of drug
use being similar across racial lines, drug enforcement in communities of color is significantly
more severe than enforcement in which communities (Alexander 2010). For a whole host of
reasons from racism to implicit biases, society generally problematizes drug use when the user
lacks white privilege. As such, the stigma associated with cannabis use is also mediated by race,
and several of my participants were keen to point this out. When I asked questions about gender,
participants in two focus groups mentioned they felt cannabis was more racialized than gendered.
For example, Jimmy from Focus Group 1, who is a white man, took issue with the gentrification
of the industry:
Jimmy: I'm worried about the continued gentrification of the industry because it is
increasingly becoming white-washed in a way, and even culturally speaking. That makes
me nervous because here we have something that was the War on Drugs and cannabis
used to be a taboo topic or sin or something like that. But now it's kind of being
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celebrated among a lot of rich white people who are like, let's revitalize this city or this
neighborhood or whatever by opening a dispensary or a growing warehouse or
something.
Indeed, many of Michigan’s licensed cannabis businesses are owned and operated by
white people with deep pockets. One of the key informants I interviewed was very critical of
Michigan’s social equity program which is supposed to reduce licensing barriers in communities
most impacted by the war on drugs. Madison, who is a woman of color, explained to me that
since the scope of the legitimate cannabis industry has never been measured, we do not have an
adequate means to judge what is equitable. She also criticized the state’s colorblind approach to
the social equity program since eligibility is based on zip code because Michigan prohibits
racial/ethnic information being used in the state bureaucracy. Madison was also very attentive to
the sentiments within communities of color, something that she worked to improve when adultuse cannabis was on Michigan ballot:
Madison: During the campaign I was advocating for Proposal 1 and the Detroit NAACP
was in opposition to Proposal 1, which is the only proposal they opposed. At one
NAACP meeting the speakers for the other two proposals would get up and do their
thing, but I was the only one who had any opposition. So during these discussions at a lot
of African-American forums, I was acutely aware that there was so much misinformation
being given about what the plant was, and because we have a history... an emotional
history of over incarceration associated with the plant, it was a very touchy topic. When I
would try to talk about how it is a plant with medical benefits people would say: No, this
is something that is going to send people to jail. They do not even perceive it as a
medical tool, and this is compounded by the fact that there was a marketing campaign
that was done by Healthy and Productive Michigan who is in conjunction with the
NAACP, that said this is crack weed and this is the return of the crack epidemic (they
even had T shirts with this).
Resistance to legalization within communities of color is understandable when
considering the relative absence of racial justice from the mainstream legalization conversation.
Steven Bender (2016) argues that campaigns to legalize medical and recreational cannabis have
so far failed to focus on racial equity despite the enforcement of prohibition being largely
racialized. With the exception of Washington D.C., racial justice was rarely mentioned as a
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reason why cannabis should be legal for medical or adult use. In fact, when race was brought
into the pro-legalization debate, it was often in the form of disdain for Latin American drug
cartels. With this racialized menace in mind, “voters may have been making the choice between
their perception of shady cartels of color controlling the illicit market, and of more trusted white
business owners and local government profiting from marijuana consumption” (Bender
2016:694).
People of color are not only underrepresented in legal cannabis commercial sectors, they
also face disproportionate challenges when consuming cannabis, even in legal states (Vitiello
2019; Bender 2016). Price is one concern as regulated retail dispensaries are more expensive
than the unregulated illicit market. Since dispensaries test their products for purity, the appeal of
affordable black-market marijuana may have health consequences for poorer consumers who are
more likely to be racial minorities. There are also legal consequences for such transactions since
the sale of marijuana is restricted to licensed entities in states with medical and recreational laws
(Bender 2016).
Likewise, racial profiling survives in a legalization regime, and since people of color are
more likely to be pulled over than their white peers, they may have disproportionate enforcement
of no-THC diving laws. The same problem is also applicable to possession of marijuana by those
under age 21 as well as the public consumption of marijuana, both of which carry financial
and/or criminal penalties in legal states (Vitiello 2019). In post-prohibition Colorado, arrests for
public consumption for blacks are about double those for whites, and arrest rates for Colorado
schoolchildren are even more racially disproportionate than before legalization (Bender 2016).
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The lingering “emotional history of over-incarceration” (to use Madison’s words) was
also identified by several of the patients in my focus groups. Austin from Focus Group 5
explains why his wife is against legalization:
Austin: My wife is not recreationally believing that, you know, that there should be
marijuana. She thinks it should be medically used only. But she's a black woman who has
watched her nephews be locked up for having it on them.
Similarly, Sophia from Focus Group 1, who is biracial, did not take kindly to her collegeaged son openly using cannabis following legalization in November 2018. She explained how
she did not want him using it in her subsidized apartment as she fears eviction, and sternly
cautioned him to be discrete since police maintain a noticeable presence in her neighborhood.
This has been observed elsewhere as people of color also face more controls on their behavior
through private contracts in states with legal cannabis (Bender 2016). Employers may still drug
test workers for cannabis, but drug testing is most prevalent in low-wage professions more likely
occupied by racial minorities. The same is true with residential leases where landlords can evict a
tenant for smoking marijuana, and sometimes even for possession of cannabis products on the
premises. Sophia was perhaps more aware of these potential consequences owing to her prior
involvement with the criminal justice system over her use of cannabis before becoming a patient:
Sophia: I said the best thing about medical cannabis is avoiding jail, prison, or fines. I
don't want to go to jail, I don't want to go to prison, and I don't want to pay any more
fines. So that's probably the best.
Even though cannabis is now legal in Michigan, the state has yet to act to expunge prior
offenses and prisoners are still incarcerated for non-violent marijuana offenses. Finally, a
comment made by an acquaintance I met speaks volumes on the racialized normalization of
cannabis. As I was explaining my research to others at an Independence Day BBQ, a woman of
color commented: “I don’t think it will ever be legal for me”. Indeed, a content analysis of
Colorado news reporting found legalization did not result in a normalized depiction of minority
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cannabis users. When criminal or stoner stereotypes were used by the media, they were more
likely to feature racial minorities than white people (Mortensen et al. 2019). As such, if we make
the sweeping claim that marijuana is normalized, we may be doing so from a colorblind position
of racial privilege.

Progress and Improvements
As I have shown throughout this chapter, my research indicates we should be cautious of
making blanket statements like “cannabis is normalized”. In terms of stigma and social
disapproval, patients and key informants agreed that while things have improved, we are not yet
in a culture where cannabis is seen as normal. More simply put, the legalization of cannabis is
not the same as the normalization of cannabis, and we are still fighting a cultural battle for
acceptance. However, the legalization of cannabis has helped to reduce associated stigmas and
may even reduce internalized stigmas within cannabis patients. Sophia from Focus Group 1
credits the new legality of cannabis with easing her concerns over being in the wrong:
Moderator: In your opinions, what separates medical marijuana from recreational
marijuana?
Sophia: In my opinion, it's the word.
Moderator: Just the word?
Sophia: Sometimes and I'll tell you why. When I was younger, I thought it was more
recreational. But now when I look back on it, I feel like it was more therapeutic, or
something to help me through tough times. I used to feel bad when I smoked, like oh my
god I'm addicted to marijuana, you know what I'm saying? Because people told me that
and I heard it. But in my mind it's not a bad thing, it's awesome. So them passing the law
really relaxed my mind on that bit of it. I don't feel like such a bad guy anymore.
The federal prohibition of cannabis was frequently cited as being a cause for continued
stigma, as were the entrenched prejudices in older generations who were taught that marijuana is
a dangerous drug. In fact, many of my key informants and focus groups participants were
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optimistic that things will get better once the older generation dies off. Those who expressed this
often did so with glee in large part because their experiences with older anti-cannabis people
were demoralizing. Patients and key informants would attempt to educate them and clarify their
misconceptions, but all too often these older people did not want to listen. Justin, who worked on
the legalization campaign in Michigan, explains this well:
Justin: Everybody knows what cannabis is but most people have an incorrect perception
of it. I shouldn't even say most people because I think that tide is turning. So mainly the
discussion when we go out and do our things as activists, advocates, and business people
is more of what cannabis is not then what cannabis is. We're trying to overcome
objections and things like that… Generations of people were told cannabis is bad, they
hardly ever looked into it, and they just internalized it. The most credible sources in the
world-- my parents, my teachers, and the police around me-- are all telling me it's bad. So
there's no point of even challenging or getting through this, or even being skeptical or
critical of it. They just accept it and internalize it without thinking twice.
While we wait for the natural cycle of cohort replacement to bring into power a more
accepting generation, other structural and social changes may also help to normalize cannabis in
society. Participants in my focus groups thought the proliferation of CBD products has helped to
destigmatize cannabis, and some described getting their skeptical family or friends to start
experimenting with CBD therapies. Hemp-based CBD medicines are widely available now
thanks to Congress’ descheduling of industrial hemp from the Controlled Substances Act in
2018. The fact that Family Video now advertises their line of CBD products was something
humorously mentioned in four of my focus groups.
Additionally, the media has been improving their representations of medical cannabis and
cannabis users. While patients think more progress can be made, they valued the occasional
objective news report as well as scientific reporting on cannabis research. Several patients in my
focus groups cited Dr. Sanjay Gupta of CNN as an example of cannabis reporting done correctly,
and a couple of patients even used his series to educate their family members on cannabis’
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medical benefits. Darlene from Focus Group 2 used the documentaries to change her son’s
negative perspective on cannabis, as did Andrew from the same focus group with his parents:
Darlene: I have a teenager and he was very against cannabis. We did Boy Scouts and
everything as he grew up, and they are very anti-drug, so it took me awhile to get him to
understand because he was almost 14 when I became a patient. I didn't tell him at first
because I couldn't figure out exactly how to approach him on that. Since he had grown up
watching his uncle struggle with alcohol and stuff, he was very against self-medication
and things. So, it took a lot to get him to understand, and in all honesty that CNN
documentary… I taped it and had him watch it with me so he could ask questions as we
went along, and that's how I changed mindset. Now he's open to more herbal supplements
and things whereas he used to not even take an Aspirin for headaches. Now he's looking
at things from a more natural standpoint and is more open-minded about it.
Finally, another piece of evidence that society is becoming more accepting of cannabis
may be found in emergency situations regarding cannabis consumption. Several focus groups
commented on the increases in hospital visits associated with cannabis, the vast majority of
which occur when an adult consumes too much THC or when a child accidentally eats an edible.
However, patients were quick to point out that the increased visibility of these incidents is likely
due to people being honest. For example, three patients in my focus groups recounted a situation
where their dog had gotten a hold of their medicine, and with the exception of Deborah from
Focus Group 5, they were immediately forthcoming to the vet:
Deborah: I come from a generation where you lied about that for so long. But now to tell
somebody the truth, it's just a gut reaction... In fact, our dog ate a little nug for the first
time and I didn't know what happened to her. She was just lying there, she wouldn’t get
up, and when I picked her up, she peed all down the front of me. So, we hop in the car
and took her to the doggie emergency room, and the little lady comes out and she says
[laughs], Is there any chance that there's cannabis in the house? And I'm like, No. No.
You know, I'm like automatically lying because that's the mode I've been in for so long.
And my husband grabbed her outside of the door and said, Yeah, there's a chance, and
I'm like, Yeah, you're right. And they just told us to take her home and let her sleep it off.
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Conclusion
Like research by Satterlund and colleagues (2015), participants in my study usually
mentioned the word stigma before I did so as the focus group moderator. Furthermore, cannabis
patients were keenly attentive to stigmatizing forces at the macro, meso, and micro levels in our
society. While patients agreed progress had been made at the macro level, primarily in that laws
criminalizing cannabis have been removed throughout the state, they saw only mild changes to
cannabis stigmas within the other dimensions in our society. Moreover, since patients still
experienced cannabis stigmas in many areas of their lives, we should be cautious of claims that
cannabis has achieved a normative status, even in a legal state like Michigan.
The normalization hypothesis suggests our moral code now accepts non-abusive, nonrisky forms of cannabis use (Jarvinen & Ravn 2014; Duff et al 2012; Sandberg 2012; Hathaway
et al. 2011; Jarvinen & Demant 2011). However, the experiences of patients in my focus groups
trouble such sweeping claims. Even though cannabis may be more normalized than even a
decade ago, the fact that patients face discrimination and remain guarded about their use suggests
we still have a social structure or culture (or both) in which cannabis carries a stigma. Duff and
colleagues (2012) use the term “residual stigma” when referring to cannabis stigmas in a more
accepting society, but my research suggests the word “residual” may be premature.
Like previous studies, my results suggest social approval of cannabis is mediated by a
variety of factors like age, gender, and race (Hammer 2015; Bottorff et al. 2013; Reinarman et al.
2011; Hathaway 2004). Anti-cannabis ideologies may have crystalized within older generations,
hampering the ability of older patients to feel at ease within cannabis culture, and perhaps
causing some of my participants to look favorably upon the inevitable process of cohort
replacement. Similar to other research, my findings suggest cannabis use by white people may be
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less stigmatized than cannabis use among other racial and ethnic groups (Dickerson 2018; Lewis
& Proffitt 2012). This inequality may be amplified as whites continue to dominate the legal
cannabis marketplace, a process made easier by their relative reprieve from the war on drugs that
has devested communities of color.
Most significantly, institutions, organizations, and groups still stigmatize cannabis, even
within legal states. Often found in the form of zero-tolerance policies, these structural stigmas
(Corrigan et al. 2005) make patients worry about being out of compliance with numerous
regulations, imparting the impression that society problematizes their medicine. This fear can
manifest when police or state agents, like CPS, are called to investigate medical cannabis
patients. Similarly, little has changed in our Puritanical culture which stigmatizes intoxication
(DeAngelo 2015; Reinarman 1994), even though cannabis patients say their medicine makes
them feel “normal” as opposed to “high”. Participants in my study often stated they spent
significant amounts of time educating others on the wide variety of cannabis medicines, but since
most Americans are unfamiliar with cannabis (Lloyd 2013), they face an uphill battle in
dislodging ingrained cultural stereotypes about cannabis and cannabis users.
At the intersection between the macro and meso levels, institutions like the media,
politics, and the economy still problematize cannabis. Cannabis patients are frustrated with the
lack of diversity as the media often sticks to classic stereotypes like stoners and potheads.
Basically, the media still amplifies anti-cannabis messages (Reinarman 1994), as do political
actions taken at the local level (Hammer 2015). When municipalities opt-out of cannabis
businesses, it sends the message that cannabis is problematic.
Employment policies operate in a similar manner, and it was rare for patients in my focus
groups to feel secure and/or happy at their places of work. As states cede control over cannabis
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to the regulated dispensary system (O’Brien 2013), they may also be passing on the source of
structural cannabis stigmas to employers. In other words, while criminal penalties are no longer a
consequence of cannabis use, employment penalties now accomplish a similar deterrence effect.
More importantly, anti-cannabis workplace policies condemn all cannabis use, not just risky or
abusive use (Duff et al. 2012; Hathaway et al. 2011; Jarvinen & Demant 2011)26. Even with
employers who do not drug test, patient accounts suggest their use of cannabis results in
suspicion among others in the workplace. Everyone in the workforce has job-related stress, but
imagine if part of that stress was related to a medicine that has enabled you to work without lifelimiting pain or deleterious side effects. Changes to organizational policy or employment laws
are necessary for cannabis patients to thrive in their careers. No one should live in fear of being
fired over using a beneficial substance, and no one should be denied a position for their medical
regiment.
In sum, the lived reality of being a cannabis patient in a post-prohibition society is not the
same as being a cannabis patient in a society where cannabis is normalized. Legalization has
certainly helped to destigmatize cannabis use, but we have yet to achieve a social environment
where cannabis use no longer carries penalties. After all, the deviant label is not wholly
controlled by the legal system as various social intuitions, groups, and actors apply the label to
individuals and behaviors (Becker 1973/1963). Whether the sanctions come from one’s family,
employer, or community, patients still feel that their medicine is problematized. As a result, they
may face legal discrimination or shunning, and many still conceal their use of medical cannabis
in a manner similar to when it was illegal. Likewise, increases in use statistics appear to be a
poor barometer of social acceptance. Even though more people are enjoying cannabis today than
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In December 2019, U-Haul announced it will be implementing a nicotine-free workplace policy. While existing
employees are not affected, the company will not hire new employees who screen positive for nicotine in any form.
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ever before, they do so under the persistent possibility of social sanctions from someone or
something.
If we want to create a social context where cannabis is normalized, we need to become
conscious of social and structural stigmas stemming from non-state entities. Deviance as a
precursor to stigma is perhaps best seen as “the product of a process which involves responses of
others to the behavior… Deviance is not a quality that lies in behavior itself, but in the
interaction between the person who commits an act and those who respond to it” (Becker
1973/1963:14). The disapproving reactions by health care providers, employers, and family
members associated with the patients in my study signal cannabis still carries a deviant identity.
Even today, the “worst consequences, social and individual, seem to arise from how nonusers
react to users” (Becker 1973/1963:200).
The media, employers, and local politics can improve how they treat cannabis and
cannabis users, even if new-found acceptance applies exclusively to cannabis patients first. If
legalizing medical cannabis has been the first step on the path to total decriminalization, maybe
the normalization of medical cannabis (in particular) will be an effective way to facilitate the
complete normalization of cannabis in our society. There is some evidence this has been
happening—the media has been doing a better job at profiling cannabis patients in a nonstigmatizing fashion, some employers make exceptions for employees who are registered in the
state’s medical cannabis program, and some municipalities may allow medical cannabis business
but not those serving an adult-use market. It will be interesting to examine how these policies
evolve in the future, but in the meanwhile, we should be careful of equating legalization and
popularization with normalization. Since cannabis patients still experience significant personal
and professional challenges related to their use of medicine, it is a stretch to claim we are in a
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post-stigmatized society. The status of cannabis as a medicine is explored in the next chapter of
my analysis.
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CHAPTER VII

THE ALTERNATIVE MEDICALIZATION OF CANNABIS
This chapter of my analysis considers patient perceptions about the future of medical
cannabis. The research questions that guide this analysis are: How do medical cannabis patients
view the legalization of recreational marijuana? And, do patients think medical cannabis will
survive once marijuana is fully legalized? Overall, patients favored the legalization of adult
marijuana use, and many welcomed the ease at which cannabis can be discussed in a postprohibition environment. To this effect, my data suggests that legalization facilitates medical
uses of cannabis as non-users become curious about the benefits of the now-legalized plant.
Likewise, while patients in my focus groups thought legalization would reduce social stigmas
and institutional consequences, they believed maintaining their state-sponsored patient status
would be an additional layer of protection in a society where cannabis has yet to be normalized.
Moreover, patients are optimistic about the future of medical cannabis, and while their
perceptions are nuanced, they enjoy the current system of medical cannabis being regulated by
the state.
In this chapter, I begin by examining how patients support legalization since they think of
it as expanding access to cannabis medicines. Afterward, I show that patients favor the current
structure of medical cannabis where it exists outside of, but not in opposition to, mainstream
medicine. The next section reveals this sentiment may stem from the fact that mainstream
medicine does not welcome an alternatively medicalized model of cannabis, and patients feel as
if they are given ultimatums from traditional health care providers. Since mainstream medicine is
rather intolerant of cannabis medicines, I then move into a discussion on how patients stick with
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cannabis as opposed to obeying mandates from their physicians, and in large part, this is because
cannabis gives them superior relief without the side effects. Finally, I explore patient sentiments
towards pharmaceutical interest in cannabis, which can be described as anything except for
positive. While it may seem as if patients are unsupportive of the medicalization of cannabis, the
discussion of my findings reveals patients think medical cannabis will thrive in the future, but it
will do so as something that is medicalized outside of dominant medical institutions.

Legalization Stimulates Medical Interest
As my previous chapter has argued, participants in my research did not think cannabis
was normalized yet, but they were optimistic about the future. Interestingly, they were also
optimistic about the future of medical cannabis specifically. While some fear their medicine
would be coopted by corrupt pharmaceutical companies or paternalistic physicians, my
participants agreed that the legalization of adult-use cannabis will result in more people seeking
cannabis for therapeutic purposes.
Perhaps the most notable effect legalization had was facilitating honest conversations
about cannabis and its medical properties. Patients in my focus groups stated that they commonly
educated curious others on the medical benefits of cannabis. When I would ask how people react
upon discovering a participant was a cannabis patient, the overwhelming majority stated
something akin to this discussion from Focus Group 2:
Moderator: In general, how do people react when they find out you’re a cannabis patient?
Irene: They are very inquisitive. They tend to have a lot of questions for me and most of
them say things like, wow, I never would have thought that do you use cannabis.
Sean: Yeah most of them don't understand that CBD and marijuana is the same thing as a
hemp plant and stuff like that. So, a lot of people don't know and you have to fill in the
blanks a little bit so they understand it a little bit more.
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Darlene: I think there was just a general lack of education out there. That's why I say that
the documentaries and stuff are helpful.
Patients pride themselves as being knowledgeable on medical cannabis, and many
claimed they convinced friends or family members to try cannabis medicines. Since legalization
has made cannabis accessible to anyone over age 21, it is reasonable to think that more people
will experiment in hopes of finding relief. This is counter to the thinking of many scholars who
believe medical cannabis will fade from discourse in a post-prohibition world (Kilmer &
MacCoun 2017; Hall & Lanskey 2016; Fischer et al. 2015; Cohen 2010). If anything, medicallyfocused users may not feel the need to enroll in a state-sponsored program, and perhaps patient
registries will become a thing of the past. However, that is not likely to happen in the foreseeable
future as all but two patients in my focus groups plan to renew their medical cards. Canada’s
medical cannabis program has grown since the country legalized cannabis last year (Health
Canada 2019), and the biggest reason for this may be that structural stigmas and structural
penalties have been removed. People may feel more comfortable seeking cannabis for medical
purposes, and this is something Dr. Steven has noticed in his practice:
Dr. Steven: [Following legalization], we have seen more and more older patients who are
on the edge philosophically or socially, or for whatever reason they are on the edge about
it. They see that it is available everywhere now and they want to see what they can do for
themselves medically. They come in and they have a lot of questions and they do not
have a lot of experience, and they benefit a lot from what we have to offer, especially in
terms of experience. So, I think that it is good for the medical side, even if just
philosophically.
Michigan’s medical cannabis system had grown steadily for 10 years before voters
legalized adult-use in 2018. Like California and Colorado, regulators in Michigan plan on
maintaining separate administrative systems and supply chains, though each may be more alike
than different. Perhaps the most meaningful distinction is that patients in Michigan will have
access to products with higher levels of THC, and they are exempt from the 10% excise tax.
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When I asked what separates medical from recreational cannabis, patients and key informants
responded in largely bureaucratic terms. For example, Randy has worked as a patient advocate in
Michigan for many years and has experience working with politicians and regulators. He
interpreted my question from the perspective of the legal system:
Interviewer: So, what is the difference between recreational marijuana and medical
cannabis?
Randy: None. The only difference between recreational marijuana and medical cannabis
is whose hand it happens to be in. If I have a medical card, then all the cannabis I possess
is assumed by the law to be for medical purposes. Now if I don't have that medical card,
then I don't have any of those presumptions. That would be considered recreational
cannabis even if I acquired it from the same source. It's all about who owns it.
Cannabis is highly regulated in Michigan and elsewhere, and bureaucratic oversight may
be the first distinction on key informants’ minds. Patients also acknowledged the difference
between medical and recreational is largely something that exists on paper, but they were more
likely to think of individual intent and social perceptions. Focus Group 2 explain it this way:
Moderator: What do we think separates medical marijuana from recreational marijuana?
Andrew: How the person is using it.
Irene: Intent...
Darlene: I like that word intent.
Irene: ...Other than that there is no difference.
Sean: Perception, the way people look at it too. How we view it as a society.
Irene: I've noticed a difference in quality. There can be differences in the chemicals that
they use and also having it tested or not tested makes a difference, especially when you're
sensitive to certain chemicals.
Andrew: But I don't think that defines medical or recreational.
Wanda: Yeah because you could do both in organic grows. It's the same thing really.
Andrew: I feel like eventually the growers should be licensed and clean. But the
difference is that it's sold through this door and it's medical here, and recreational over
there. So that's kind of how I feel the system works.
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Few participants explained the difference in terms of the overall health of the user. Like
other research (Newhart & Dolphin 2019), patients may have recognized that is the context of
use is more important because individuals with health conditions may occasionally use in more
social fashions. Only one patient in my focus groups thought that there were no differences
between medical cannabis and recreational cannabis. Alexander from Focus Group 4 did not
negate the therapeutic potential of cannabis, but he believed that since anyone could justify their
use as medical, the differences between intent were null:
Moderator: In the future, do you think there will still be medical cannabis?
Audrey: I think so because there is a lot of medical uses for it. It’s not just for fun, you
know. Like when I crushed my finger recently and instead of taking pain pills, I was
actually taking my edibles. And it helped so much. I mean, I got my finger crushed and I
was prescribed Norco, and I still can't move my finger. But you know, I do my edibles a
lot more now because I am in more pain.
Alexander: And I disagree. I think it'll just be the same. There is no added benefit from
recreational marijuana or medical marijuana. It has all got the same chemicals in it and
it's the same effect.
Audrey: But what about all the kids that are doing it, like using it for medical purposes?
They wouldn't be able to do it if it was all like that. You know, like the kids with
seizures, and they need a lot for seizures. It’s more of an extract but still...
Alexander: I mean, I hope they would keep that... In my opinion, everybody's hurting in a
certain way. You can call it medical marijuana for anything, like daily life. Everybody
wakes up and we have tooth pain, body aches, or whatever. Everybody experiences that.
Though Alexander presents medical definitions of cannabis as meaningless, the majority
of patients in my focus groups and key informants believed all cannabis use had a medical
meaning. Even if the difference between medical and recreational users or intentions was small,
they acknowledged recreational users were receiving some therapeutic benefits. The most
extreme version of this sentiment can be expressed as “all use is medical”, an infamous phrase
attributed to California activist Denis Peron. However, there is nuance here as evidenced in
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statements made by three of my key informants. Justin, who worked on Michigan’s adult-use
campaign, says cannabis is inherently medical because humans have an endocannabinoid system:
Interviewer: Is there a difference between medical and recreational cannabis?
Justin: There is but it's subtle. For example, let's say there's a legalized retail store... are
you going to go in there and buy a CBD oil suppository to have fun? Probably not. But
every time somebody goes to use cannabis for fun, they're getting some sort of medical
benefit from it, in my opinion. You have an endocannabinoid system and you’re feeding
it.
Evidence, while emerging, suggests the endocannabinoid system helps maintain
homeostasis in the body as we experience ever-shifting external and internal environments (Frye
2018; Bostwick 2012). In other words, “all use is medical” because your body will respond to
cannabis in beneficial ways. Similarly, Madison works to promote cannabis business
opportunities in communities of color. She compares cannabis to foods that have healthpromoting properties:
Madison: Honestly, I think that all cannabis use has medicinal properties whether you
intend it to or not. But intent is also a big factor because it will encourage you to seek out
different forms, variations, and ingestion methods, and these vary greatly. What I mean is
cannabis is beneficial as a topical ointment or cream even if it has a very high THC level.
Because of the way it is absorbed through the skin, it will not have a psychoactive effect.
Therefore, it is always extremely beneficial. However, if you consumed burned flower or
a concentrate, or even an edible, those ingestion methods will have greatly different
reactions on the body. Even when I go speak to a crowd of people and some people have
negative views around the plant, I use this analogy of ginger ale. It's known that if you
have an upset stomach you can ease it with ginger ale, but intrinsically nothing is
different about the ginger ale if you're consuming it as a medicine or in an ice cream
sundae. And the same is true with this plant.
Like ginger with gingerol and perhaps wine with antioxidants, Madison suggests “all use
is medical” because cannabis contains health-promoting compounds. A third reason why
cannabis is inherently medical was expressed to me by Dr. Steven, a certifying physician in the
state’s medical cannabis program for over a decade. He acknowledges the legal distinction
between medical and recreational users, as well as the balancing role of the endocannabinoid
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system, but also adds that cannabis will benefit anyone by restoring their attention to the present
moment:
Dr. Steven: I think there is a lot of overlap. There are legal definitions to medical and
recreational, so let's do that first. Clearly, a lot of people who became medical patients
started using recreationally and illegally before they came in the door. And because it
was illegal, it was defined as recreational. But the reality is, a lot of people that call their
use recreational, legal or illegal, were using medically already. The things that people
tend to use cannabis the most for are chronic conditions, whether it’s pain, anxiety, or
sleeplessness. Cannabis is really interesting physiologically and it has a balancing role in
the body, or the endocannabinoid system does, and we live in a culture that is constantly
being tagged out of balance. There is a Native American term koyaanisqatsi that means
“life out of balance”. It's essentially when life and everything around you is keeping you
so off-balance that your life becomes more problematic than happy. Ultimately, we all
want to be happy and we want our friends and family to be happy. If we're honest with
ourselves, we like to be happy. And if we're really honest, we'd like to be happy all the
time. But it really doesn't work that way. When you have a body that bugs you all the
time or psychological condition that's like sand under the skin, you're uncomfortable and
your mind goes into problem solving mode. I hurt-- Why? How do I get rid of it? This
really takes your focus off of the things that may be more enjoyable to think about, like
your family or your spiritual work, whatever it happens to be. So again, I think there is a
lot of overlap… I find that marijuana creates kind of a meditative experience, and what I
see is that a lot of people who were never into meditation or weren’t feeling all that
spiritually connected at all, it’s almost like a crack in the door. There’s another way of
feeling, there’s another way of being mentally that is not quite so problematic. And it
actually starts to get them sort of interested in meditation and a lot of people ask me how
to get started. If marijuana didn’t do anything but that, to create this kind of impulse
towards mindfulness, if it only did that, I would be thrilled about it. But it does way more
than that.
Dr. Steven’s use of Native American terminology to explain a theory of balance is not
surprising given his office is filled with symbols of Eastern philosophy—Hindu sculptures,
posters on chakra alignment, and quotes from yogi gurus. Nevertheless, I find his explanation of
cannabis’ efficacy to be impactful since I practice mindfulness meditation myself. There is
something to be said about cannabis’ ability to refocus our attention on the present moment, and
several of the other participants in my study spoke of how cannabis allows them to better focus
on their work and daily tasks.
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Consistent with previous research on cannabis patients, many of the patients in my focus
groups began using cannabis in a recreational fashion through the black market but later began to
appreciate the therapeutic qualities (Newhart & Dolphin 2019; O’Brien 2013). Though their
mindset shifted over their course of the cannabis career, the majority of them now define
cannabis through predominantly medical terms. Jackie from Focus Group 5 illustrates this
change of meaning in her introduction to the group:
Jackie: I’m Jackie and I’ve been medicating for about 25 years. When I started it was
definitely recreational. That’s how it was introduced to me. But it didn’t take very long to
realize that it had its benefits and it was a medicine. So, I’ve probably been a cardholder
for about three years now. My preferred method would definitely be my beautiful little
bong that I’ve had for like 16 years. It’s an amazing piece and it just... I don’t know, I
can’t part with it. I don’t like joints that much. I do use concentrates and I make my own
edibles. I’m actually going into business, selling edibles, and I’m making basically the
same topical that [another group member uses]. I’m still in the beginning stages of that,
but my edibles are very much loved among everybody that tried them so far. So I’m
really excited about my new venture. Cancer patients just love them, so it’s awesome.
And that’s exactly what I wrote down on the card: that cannabis is a medicine to me.
Absolutely it’s a medicine first and foremost.
While Jackie hoped to turn her passion for making cannabis edibles into a small business,
she primarily ascribed medical meanings to the plant even in a post-prohibition state. While
some in the medical cannabis community have expressed their dissatisfaction with legalization
for numerous reasons (see Appendix B), participants in my focus groups did not see legalized
recreational use as detracting from the medical status of cannabis. In fact, none of my
participants were against legalization or the concept of recreational cannabis, and the
overwhelming majority planned to continue participating in Michigan’s medical marijuana
program. Only two participants in my focus groups said they did not plan to renew their cards
once the adult-use dispensaries opened, but the rest acknowledged the card would still be
worthwhile in a state like Michigan. Participants in Focus Group 2, for example, liked the status
and access brought by the card:
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Darlene: I'd like to think that you wouldn't need a card 20 years from now. That you
would be able to go and just seek the treatment that you need.
Wanda: I'm okay with needing a card.
Andrew: I'm with you. I like the distinction.
Wanda: If they want to require a card, that's fine. But I want insurance to pay for my
medicine.
Darlene: I guess when I say that, I would like it to be more available. What I mean is that
I would like it to be available to people who need it medically…
At the very least, having a medical cannabis card distinguishes one apart from society’s
dominant view of cannabis users as hedonistic and, depending on the state, criminals. It may also
help the individual reframe their use of cannabis as justified for medical reasons in a society that
commonly applies the frameworks of drug abuse and addiction to marijuana. Perhaps this is why
while Darlene dreamed of a day when the card would no longer be needed, she planned to renew
hers for the foreseeable future. Some patients, such as Irene, had experience visiting states with
both medical and adult-use cannabis facilities. In such cases, they remember little difference
between options on the medical and adult-use sides, though medical cardholders pay less through
lower taxation rates. Briana and Jackie from Focus Group 5 likened the difference to being a
VIP:
Briana: I guess I don't really see a huge difference for medical patients versus
recreational, like once they start establishing more regulations and laws on the
recreational aspect of it. I was just in Vegas last week and they are a recreational and
medical state. And really the only difference that I could see from being out there was
that if you're a medical card holder, you just pay less. You still get all of the same access
to all of the same stuff. You still can go in at the same time with somebody who is a med
card holder versus just somebody who's buying from the recreational side. You just pay
less taxes.
Jackie: Also, they kind of treat you more like a VIP. You have your own special lines and
they're usually shorter than the recreational lines because you are a medical card holder.
Briana: Yep. But other than that, I mean, your options are still very much in the same.
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Patients in my focus groups seemed to perceive the card as granting them enhanced status
and expanded access in a post-prohibition state27. While Briana noticed little to no difference
among products in Las Vegas, Michigan allows more potent edibles and concentrates to be sold
to medical patients compared to recreational consumers. Other patients noted that having a card
will allow them to purchase more products per dispensary visit, but this is not exactly true as
both medical and recreational customers are limited to 2.5 ounces of flower per day. No one in
my study mentioned ever hitting the purchasing limit, but it is conceivable that in states as large
as Michigan, patients may decide to buy in bulk if they live far away from a dispensary.
Similarly, having a card meant guaranteed access to cannabis as the emerging recreational
market shifts the business landscape.
Even though it did not affect them, many patients were frustrated with the slow rollout of
recreational businesses, and some patients feared the emerging recreational market would attract
the ire of law enforcement. For example, Audrey from Focus Group 4 had been a patient since
the dawn of the MMMP and she remembers multitudes of raids on medical dispensaries
throughout the 10 years of the program. This resulted in her having inconsistent access to her
medicine as she frequently had to find new dispensaries upon her favorite dispensaries being shut
down. While law enforcement has been more tolerant of the licensed medical dispensaries after
the regulations established by the 2016 MMFLA, Audrey and others fear a similar pattern will
result with the new recreational dispensaries.

27

The comparison to being treated like a VIP or someone with a superior status was also mentioned in an interview
with Jackie who had moved from Colorado to Michigan several years ago. Jackie now runs a cannabis networking
association in Michigan and publishes a cannabis magazine, and she likened the divide between the markets in terms
of medical connoisseurs and recreational rookies: “It's going to be awesome to watch how Michigan’s market
evolves because we have a lot of educated consumers. We have 300,000 patients, a lot of people are educated on
what they want already, and then recreational opens the door to all these rookie consumers to start trying it out”. The
idea of connoisseurship, which stands in opposition to pharmaceuticalization, is explored more in Chapter 3.
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Product options and access aside, a more significant reason for maintaining one’s status
as a cannabis patient was a sense of increased protections. Several patients thought medical
cannabis would be cleaner than recreational cannabis, but this is a misnomer because the testing
standards are the same for each system. Other protective reasons for maintaining the card may
also be misnomers, but these are ultimately situational. For example, four patients in my focus
groups cited CPS as a reason for maintaining their cards since they each had young children at
home. The current policy of CPS appears to be treating marijuana use as grounds for child
removal only if it prevents parents from safely taking care of a child, and this is evaluated on a
case by case basis. However, having a card may sway an agent to exercise their discretion and
dismiss the parent’s cannabis use, and the same is true with the criminal justice system. Two of
my participants had criminal records, and both thought of having a card as another layer of
protection from the criminal justice system, even in a legal state. Furthermore, two other patients
mentioned that their employers had drug-free workplace policies complete with random drug
tests. While employers can still terminate employees for using cannabis in most legal states, and
while there are no legal protections in Michigan for patients should they be drugged screened,
each of these patients had employers who accepted their use of medical cannabis.
The most pressing concern among patients in my focus groups involved the medical
profession. Several patients described that their doctors would still prescribe them pain
medication since they were registered cannabis patients, but this appeared to be an exception to
the rule. Pain contracts and mainstream medicine as a whole often mandate patients to choose
between either cannabis or conventional treatments, and this controversial ultimatum is discussed
in the next section of this chapter. Finally, while none of my participants mentioned this, it is
possible that patients will maintain their cards to grow more plants. Michigan’s adult-use law
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allows a household to grow up to 12 plants, and since the medical system also permits up to 12
plants, this may mean patients can technically grow 24 if they follow the strict regulations.
However, this has yet to be clarified in court or by regulators.

Cannabis as Alternatively Medicalized
As the medical cannabis community believes medical meanings attached to cannabis will
continue in a post-prohibition state, it is worthy to consider nuances within these sentiments.
Existing research on medical cannabis suggests that it is “incompletely medicalized” in that
biomedicine has yet to establish hegemony in how cannabis is defined (Newhart & Dolphin
2019). However, patients in my focus groups do not wish for cannabis to become completely
medicalized as this would mean the plant is exclusively controlled by medical institutions.
Perhaps this is because cannabis was medicalized through a grassroots, patient-led movement
(Penn 2014; Chapkis & Webb 2008), but my research also indicates patients are dissatisfied with
the structure of mainstream medicine. Instead of “doctors orders” and profitable synthetic
compounds, many patients expressed their support for the current model of medical cannabis.
The following exchange is from Focus Group 2:
Andrew: For me, the best thing about medical cannabis is that it signifies a shift in
how we treat ourselves and our medical knowledge.
Moderator: Huh… What do you mean by that?
Andrew: So, no business can succeed without money being its main concern. So with
the business of treating ourselves or going to the doctor, like many things, it could
have been done differently and it could have been done better as far as our medical
history goes. I mean, over-drugging and things like that…
Darlene: Also under-drugging… Followed by over-drugging.
Andrew: Right. And this is a more natural way to help ourselves and to treat
ourselves than with pills and other things.
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Wanda: And it is getting people to look at their own situations instead of just relying
entirely on their doctors for everything. Now they are researching their own things
and finding out what works for them.
Sean: You have to be your own advocate.
Being in control of one’s own medicine was a significant factor in their support for the
current medical model of cannabis. Similar to Newhart & Dolphin (2019) and Lau et al. (2015b),
patients in my study appreciated the self-directed nature of their medicine as opposed to the
institutionalized regiments of care found within mainstream biomedicine. Briana from Focus
Group 5, and Gavin and Wade from Focus Group 3, all exemplify this preference for being free
from strict physician supervision:
Briana: For the best thing about medical cannabis, I wrote you have an array of options.
It's a solution that is more natural. But I'd say the biggest one for me is that I'm the one
with the control. I don't have a doctor telling me you have to take this at a certain time
every day, with or without food. Or that it's going to cause 30 worse side effects than
what you're treating. So, I'm the one that has the control of when and how much.
…
Gavin: One of the main things about cannabis, especially now that it's legal, is you
regulate and control it as opposed to a doctor. And I'm all for doctors. I mean, they went
to school and everything. But only you know what you need when you need it. And it's
hard to tell that to some doctor or other authority. You know, I believe in the old
apothecary stuff. Really, like, you can learn from people that have knowledge and you
know your body better than anybody else does.
Wade: I totally agree with that one right there.
Personal control, independence, and accessibility were all frequently cited as advantages
to the current model of medical cannabis. The versatility of cannabis was also cited as an
advantage over mainstream medicine, as were the variety of cannabis medicines. Lengthy lists of
state-approved conditions for medical cannabis programs are often criticized for being too
liberal, but patients attest that cannabis helps with numerous medical conditions. Likewise,
patients have learned that cannabis is not a singular, uniform medicine, but rather exists in
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diverse forms with often different effects. The following is from Focus Group 2 in response to
my question about advice for new medical cardholders:
Moderator: What advice would we have for somebody who has just received their
medical card?
Irene: Do your research.
Wanda: Try everything in the dispensary.
Darlene: Do your research and document or journal how you feel.
Irene: And don't just go to one place for your research. Do what they actually taught you
in the old days in school. Read everything you can get your hands on and form an opinion
for yourself.
Andrew: Yep and everybody's body is different so they handle cannabis differently. So,
see what works for you.
Irene: Right and you have to keep on trying too. Like if one thing doesn't work for you,
don't give up because you should try the other 300 kinds to see if any of those work.
The individualized effects of cannabis and the need to keep on trying different cannabis
medicines were frequently cited by focus group participants and key informants alike. Though I
did not directly ask, no one complained that a product or strain was ineffective, though everyone
had their preferred method of delivery. Darlene’s comment above—the need to document
personal effects--was echoed by the certifying physician I interviewed, and one new dispensary I
observed even provides patients with a logbook for that very purpose.
What works for one person may not work as well for another, but everyone agreed that
some form or regiment of cannabis medicine could work for anyone. Dr. Steven best explains
this:
Dr. Steven: [New patients] should experiment and try a lot of different things in small
amounts. They should also take notes and come back and see me so we can talk about it.
A lot of it has to do with changing your mindset about it. They're used to getting a
medication where the doctor says, take this number of these on this schedule and you get
a refill. That's not how cannabis works. It's far from a one-size-fits-all type thing. It
varies with your physiology, your stage of life, and how you structure your day, like
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whether you have a job or are busy. But there are so many forms and varieties that you
can almost tailor it to anybody's lifestyle.
Participant sentiments stand in opposition to the critique that medical cannabis models do
not have enough physician oversight (Nussbaum, Boyer & Kondrad 2011). In fact, some patients
in my focus groups remarked that the requirement of physician certification was too onerous.
This does not mean that they objected to having to seek a physician certification, but rather that
the proof of need requirements was too burdensome. In order to become a cannabis patient, one
must seek a recommendation from a physician participating in MMMP, but different physicians
demand different amounts of paperwork. About half of my focus group participants report
supplying their physician with an extensive file detailing their condition while the other half
reported their physician needed little, if any, medical proof. Regardless of the proof required, all
of them appreciated these medical professionals expanding access to cannabis. The points above
are contained in this conversation from Focus Group 5:
Damien: I'll tell you, it was not easy getting my medical marijuana card. They wanted
every piece of information from every doctor I had ever seen. And then it still took a
month.
Austin: Ya, until you go to a High Times event or something like that, you know, one of
the Cannabis Cup things where they've got a doctor on site giving six-minute
interviews...
Briana: I'm not going to lie, when I got my medical card, it probably was not from a legit
doctor...
Doug: Me too.
Briana: Ya, like you go in and you pay them money, and they sat down and talk to you,
but you don't have to provide doctor records.
Damien: Two years ago, they wanted everything in the world from me.
Doug: Yeah, mine was three years ago, but I provided nothing...
Briana: But once you are a patient, you don't need the extensive paperwork every time
you renew. You don't have to go through all of that again. They basically just mark down
what they marked on the previous time, and they push it on through
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Damien: Ya, they just want their $75 renewal fee.
Austin: Now with the recreational rules, that's what it should be. They shouldn't even be
asking questions at this point in time anyway. You know, it doesn't matter now that it’s
legal. I'm still paying you the fees and whatnot, and I'm exercising my right to come to
you. But you know, it's gotten to that point where some doctors like [Damien’s] stick by
the rules, and others are just trying to help people get something that they feel should be
available to everybody in the first place.
It is important to keep in mind that most licensed physicians do not participate in the
state’s cannabis program, and some medical institutions like hospitals prohibit staff from
recommending cannabis. While patients had differing experiences with certifying physicians
regarding the initial approval process, all had favorable views of physicians who participated in
the MMMP. This is significant since our society’s dominant model of medicine problematizes
cannabis, sometimes to the point of withholding care.

Allopathic Intolerance
While patients enjoy medicating on their own terms, they also wish that biomedicine
would become more accepting of their medicine and care regiments. This is significant because
medical cannabis is largely theorized to be a linear continuum where the plant is moving into the
domain of biomedicine (Newhart & Dolphin 2019, Frye 2018). But my research suggests
patients value cannabis’ status as existing outside of this construction, perhaps where the two
models of medicine coexist. Though patients in my focus groups did not see state-endorsed
models of medical cannabis standing in opposition to institutionalized medicine, patient accounts
suggest institutionalized medicine might.
Overall, patients were frustrated with how traditional health care providers viewed
cannabis. This frustration manifested in two ways, the first of which is where doctors were
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scorned for ignoring cannabis as a possible treatment. As Focus Group 1 was discussing media
portrayals of cannabis, Sophia interjected with an observation:
Sophia: Can I bring something up that's kind of been weighing on me? And I don't know
if this is one of your questions or if it might not be... But I just started recently watching
TV again and I see a lot of these commercials that make me feel bad, like the sick kids in
the Saint Jude's Children's Hospital. Like, you're a research hospital, so can you just open
your mind to cannabis? Just open your mind and open your doors. I think the parents
would have wanted you to do that. Jesus would have wanted you to do that. It scares the
crap out of me that if one of my kids or one of my grandkids gets sick, that they are going
to have to do chemotherapy, and chemo is going to kill them. You know what I'm
saying? So that still really bothers me. I want access to medication that is not going to kill
me or kill my family.
There is limited evidence that cannabinoids may be useful in treating cancer and we are
far from any definitive proof on the matter. As such, Sophia’s comment may be best interpreted
as advocating for more research on cannabis and cancer (Saint Jude’s is a research hospital) as
well as the use of cannabis medicines to reduce suffering. Since “[m]edical cannabis use could
be considered as oppositional to ‘mainstream’ healthcare, which relies heavily on
pharmaceuticals” (Lau et al. 2015b:17), I think Sophia is simply implying they should look into
this unconventional medicine. Indeed, advocates for cannabis medicines have primarily sought to
expand access to cannabis as a source of relief rather than a tool to cure disease (see Appendix
A). Nonetheless, other studies have found cannabis users deploy bravado (Sandberg 2012) to
reposition a culturally devalued substance into something positive. The “bravado of subcultural
discourse” (p.380) boastfully exaggerates positive elements of cannabis and is often used to
counter social stigmas.
Patients also resent physicians who disapprove of medical cannabis. While several
patients in my study were able to find physicians who supported their use of medical cannabis,
the majority had the opposite experience. This is an excerpt from Focus Group 1 which
illuminates patient frustrations with medical professionals:
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Moderator: Has anybody here ever experienced any negative reactions based on being a
patient?
Bailey: O yeah, I have by other doctors.
[Everyone in the group immediately signals their agreement]
Sophia: I told my doctor off!
Avery: When I was going to get my card, my doctor strongly advised against it.
Jimmy: Mine did too and I was seeing a psychiatrist at the university I was attending.
They said I shouldn't do that and that they wouldn't prescribe me my medication for ADD
if I smoke cannabis.
Bailey: Yes. Psych doctors, in particular, I have found in my experience are really against
it.
Jimmy: Yeah, and I didn’t have the courage to tell my doctors that I use marijuana so I
used hypotheticals. I was very specific and told them I was considering trying marijuana
even though I had already been using it. And they were like, well, you can't do that
because then I can't prescribe you your medicine. But the weird thing is that when I went
to see a general practitioner at the same university and I told them the same hypothetical
situation, they were like, okay that's great. If it helps you, that's great. I do think this
doctor was very progressive though.
Patients wanted mainstream medicine to respect their use of cannabis, but all too often
their interactions with and treatments from medical professionals were disappointing. This may
be due to the fact that the endocannabinoid system and cannabis are not commonly covered in
medical schools (Sideris et al. 2018; DeAngelo 2015). Indeed, Victorson et al. (2019) found
cannabis patients trust their regular physicians but were dissatisfied with the limited knowledge
their physicians had on medical cannabis.
Perhaps this is why the cannabis patients in my study tended to be knowledgeable in the
areas of health and medicine, especially when it came to drugs which helped their conditions.
Like previous research, the patients in my study gained much of their knowledge from outside of
mainstream medical authorities (Victorson et al. 2019; Athey et al. 2017; O’Brien 2013;
Pedersen & Sandberg 2013). They developed extensive medical knowledge through years of trial

194

and error with surgeries, prescription drugs, and other treatments. What they know about medical
cannabis came from personal experiences, the medical cannabis community, and self-directed
research. Unfortunately, sometimes this knowledge of “what works” made doctors question their
motives for requesting certain pain relievers. Being a cannabis patient may have also influenced
doctors’ decisions to withhold certain drugs, even when undergoing surgery, as evidenced in this
discussion from Focus Group 2:
Moderator: Has anyone ever experienced any negative reactions after someone finds out
you are a patient?
Wanda: From doctors. But usually you can tell whether or not they are going to be okay
with it based on how they talk to you from the beginning. My doctors have been pretty
good, but I have heard from a lot of people that they cannot get their prescription pain
medicines because they use cannabis. Even though the prescriptions work a little bit, the
cannabis makes all their pain go away. But not without the prescriptions, they need both.
And they have to pick one or another because their doctors won't allow both.
Sean: The only negative I've ever had with it was at the VA. I went to have my surgery
and they wouldn't give me demerol even though I was in so much pain, because they said
I was a druggie…
Irene: A drug seeker.
Sean: Yeah and I was like, seriously?! Because I smoke marijuana?! And this was the
only thing that helped my pain, other than serious pain, was demerol. You know? That
was my only other pain relief and they just brow beat me every time I went in there.
Wanda: Yeah if you tell them the name of a medicine that works, you're automatically a
drug seeker.
Moderator: That's an interesting observation. So if you know something by name, they're
not going to give it to you?
Sean: It's true. It's very true.
Wanda: They want to go through their procedures.
Irene: Especially if they say, well, what if we try this? And I go, well, why don't you look
at my file first? That's where I've gotten to now. Whatever they gave me last time, it
didn't work great.
Sean: And then when you tell them what you've been through and stuff like that, they
look at you and they're like, Okay. We're still going to do this my way.
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Wanda: Usually if they take the time to sit and listen they're good, but…
Darlene: I've been told working in the medical field that we should be actively trying to
dismiss a patient if we find out they use cannabis.
Sean: Oh wow. I believe it.
Darlene: Because they don't want the liabilities in their minds that go along with…
Wanda: What liabilities? Like paying closer attention when you're under anesthesia?
Because what really else is there, and you should be paying close attention anyway.
Andrew: Money.
Greg: It's just a complete misperception about the effects of marijuana and what it does to
your body.
Darlene: In a lot of their minds, cannabis is still a gateway drug and if you happen to
need the combination of cannabis and an opioid, or really any kind of pain med…
Andrew: Yeah. I would have to use opioids when the pain would get really bad but I
would always do so with cannabis. Especially when you want to stop using those pain
meds, the withdrawals and everything, cannabis makes it easier to work through that and
stops me from wanting to take more pills.
Darlene: But in a lot of doctors’ minds, that would make someone a drug-seeking patient
and qualify them for dismissal.
Resistance to medical cannabis on the part of doctors has been documented elsewhere.
Some of the cannabis users interviewed by Lau et al (2015b) described backlash from healthcare
providers for choosing to substitute cannabis for painkillers. These individuals were dismayed by
their doctors’ preference for riskier pharmaceuticals and this may have damaged the trust integral
in biomedical doctor-patient relationships. “Substitution highlights users’ self-determination—
the right of individuals to decide which treatments or substance is most effective and least
harmful” (Lau et al. 2015:658). Yet the paternalistic nature of biomedicine seems to frown upon
empowered patients, especially if the patient has opted to use an unconventional therapy.
The more profound frustration cannabis patients had with mainstream medicine was the
ultimatum to choose between cannabis or traditional pain medications. The subject of pain
contracts came up in three of the five focus groups, and these contracts have become increasingly
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popular in the wake of the current opioid crisis. Many physicians require patients to sign the
contract in order to receive pain killers, but the contract often contains a mandate to remain drugfree, meaning cannabis-free. Patients also expressed resentment at the way pain contracts
intruded upon their lives and set structured regiments on when pain medicine can be taken. The
following conversation is from Focus Group 2 after Irene mentions she had to switch doctors
because of the pain contract requirement:
Sean: Yeah, I never had a pain contract.
Darlene: I was the person that used to make you sign the pain contract.
Moderator: What is the pain contract?
Irene: Oh God. They are ridiculous. You have to pee in a cup at random and then they
check your levels. The one that they wanted me to sign said to show up within an hour of
getting the call with my prescription. And my doctor's office is an hour drive. So, I was
like, wait a minute… You want me to have to leave work, which the reason I take the
pills is so I can keep functioning and working, and then you want me to drive an hour?
The contract also says that I can't carry my prescription with me because if it gets stolen,
then I am responsible. So that means I would have to go home first, which is another 20
minutes out of the way, get the prescription, and then drive an hour to the office. I would
already be over that 60 minute time limit. I'm like, do I have any drug felonies? Do I
have any charges? And of course I don't, so I told them I'm not signing it.
Wanda: They made me sign one after my surgery and I laughed because I didn't even fill
the prescription. They gave me oxy which doesn't do anything for me, so why would I fill
it?
Sean: I would never sign one of those. I would have laughed at them and walked out.
Darlene: It was hard to have people sign those because you could tell that people needed
it, whatever the drug is. And they make you abide by a pill count, and if you're off by just
one freaking pill... and who doesn’t make mistakes... you're in violation of the contract.
Wanda: I always drop them on the floor and everything, and if it goes under the sink or
something, you're screwed.
Greg: Same.
Darlene: Or if there was just one day where you needed one extra tablet…
Irene: Or even if you needed to cut that one in half to take an extra half or something.
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Darlene: And we have patients that we know have filled their prescription at five
different pharmacies on the same day. That's the person you need to watch out for, not
the person who lost two pills in a couple month period. This is not the same kind of
grievance.
Wanda: And you know what? The people who want to get their pills illegally are going to
find ways to do it anyway regardless of what they make us sign.
Darlene: It just makes them so skeptical. And then when you start throwing laws on top
of it, which could happen with marijuana… They're easing laws right now but they're
also going to bring back and impose new rules on top of it…
Greg: Yep.
Irene: They always said that you have to choose between one or the other. You can use
your narcotics or you can use your marijuana, but you cannot use both since we won't
write a script. And I was like, wait a minute… if you're on a prescription for something,
are you ever giving someone just one prescription? Or are you writing somebody a
prescription for pain, and then also a muscle relaxer, or are you also prescribing
something for their stomach, or something for this, that, or the other thing? So how is it
an either-or? They have no way of knowing if they complement each other. One
medicine might even make the other one more effective. But my current doctor was like,
here is your prescription for pain meds, and don't panic, but you're going to have to go
downstairs and sign a pain contract. But this is my last day here and I have already
prepared your paperwork for transfer to my new office, so even if you don't sign the
contract downstairs, you can still get your medicine tomorrow. That's why I drive an
extra hour to go see this doctor.
Pain contracts (or pain management agreement plans [PMAP]) have become a popular
mechanism to surveil patients being prescribed narcotic medications. In Michigan, pain contracts
are recommended in the quasi-regulatory guidelines for the prescription of controlled substances,
but these guidelines are not legally binding (Davis n.d.). Daniel Cobaugh and colleagues (2014)
say: “The intent of the PMAP is to provide full disclosure of the risks and benefits of opioid
therapy and institutional policies with regard to ongoing regular pain assessment, random urine
drug screening, and the use of a single opioid prescriber group and pharmacy” (1550). There are
no standard criteria for pain contracts, but a popular sample from the American Academy of Pain
Medicine specifically mentions marijuana use as a violation of the agreement (see Sample n.d.).
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There is dissent in the biomedical community regarding the necessity and rational of pain
contracts. Buchman and Ho (2014) note these contracts rarely contain themes about the goals of
care, and that such contracts place the onus of trustworthiness on the patient rather than the
physician: “Some providers may assume irrationality and attribute to these patients a credibility
deficit regarding their knowledge of their bodies, their experiences with medications and both
licit and illicit drugs, and their reports of pain and suffering. In this way, opioid contracts may
send the clarion message that the physician does not trust the patient” (675). Despite placing
burdens on the individual patient, Rager and Schwartz (2017) argue such contracts are ethically
justified because they address a public health need to control opioid abuse. Nonetheless, there is
limited evidence on the effectiveness of pain contracts in deterring opioid abuse (Rager &
Schwartz 2017; Buchman & Ho 2014).
Jackie and Doug from Focus Group 5 had a similar experience with pain contracts:
Jackie: There are also a lot of medications that your doctor will not and cannot prescribe
you if they know that you're using cannabis. I have to sign agreements to get my pain
relievers because there are some things that even the cannabis doesn't totally relieve. But
to get my pain relievers for extreme headaches and things like that, I have to sign an
agreement, which I obviously break. It's the only way that my doctor will prescribe me
the meds that I need, so I have to lie.
Doug: There was a couple medications that I turned down because they told me I had to
sign a waiver.
Patients want mainstream medicine to honor their use of cannabis as medicine in
conjunction with standard treatments, but mainstream medicine often presents them with an
ultimatum. However, patients do not want to choose between one or the other because the
combination of allopathic and alternative medicine yields the best results. It is also interesting
how the popular imagination suspects many cannabis patients lie to get their medical cards, but
Jackie’s account suggests many patients might be forced to lie in order to get treatment from
regular healthcare providers. Perhaps this is why many of the patients surveyed by Kruger and
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Kruger (2019) do not discuss their use of medical cannabis with their regular physicians. They
know mainstream medicine considers prescriptions and cannabis to be incompatible, so
withholding information is necessary to receive the care one requires. Yet if forced to choose,
my data suggests patients prefer medical cannabis to standard pharmaceuticals for a number of
reasons.

Relief without Side Effects
The above discussion has shown that cannabis patients enjoy how their medicine is selfdirected, individualized, and versatile. However, they do not want cannabis to be completely
absorbed into society’s dominant model of medicine, and at the same time, they are alienated
from traditional medical providers. Since state-level medical cannabis policies have allowed this
alternative model of medicine to exist alongside mainstream medicine, patients want access to
both styles of care. This duality is preferred because medical cannabis may offer patients
something that prescription medicines, the primary tools of the modern allopath, do not. Whereas
the allopathic approach attempts to mitigate problems and restore normative functioning,
cannabis is seen as going a step further. The comments made by the members of Focus Group 1
touch on the strengths of the current medical cannabis system as well as the benefits of cannabis
itself:
Jimmy: I would say the best thing about medical cannabis is ease of access and that I can
develop a treatment plan that works best for me.
Avery: I would say the best thing about medical cannabis is that it gives people access to
things that would help them function where they wouldn't have been able to otherwise.
Becca: I said generally that the best thing about medical cannabis is that it saves lives.
Either literally or it gives people enough relief so they can function and have a life.
Sophia: Yeah, so they can live instead of just exist, and there’s a major difference.
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Indeed, patients described cannabis as promoting quality of life, as enhancing pleasure
while living with illness, and as something that restores vitality. Irene and Wanda from Focus
Group 2 each have incurable chronic conditions, and they also describe cannabis as something
that goes beyond restoring normal functioning:
Irene: You can call me Irene and I've been a patient for almost 30 years, so long before it
was legal by any means. For me cannabis is how I'm able to thrive in day-to-day life
instead of just surviving and making it through every day. I have two complicated genetic
disorders that result in several dislocations on a daily basis…
…
Wanda: My name is Wanda and to me cannabis is freedom. I'm stuck in my body in a
similar way to another participant, and it is a painful cage without cannabis. I was also in
a car accident a little over two years ago and I hadn't smoked or used cannabis in any
form before that. I'm a brand-new patient and I used to be vehemently against it. My
mother was a drug addict so I just lumped cannabis in with all the other thing she did. I
said I would never touch any of it until I did and it changed my life. I'm not pain free all
the time, but I am more than before, so it's a miracle, it really is.
The relief provided by cannabis is amplified when it is compared to traditional treatment
options. Many patients in the focus groups had devastating experiences stemming from
pharmaceutical drugs and surgical procedures. While cannabis did not completely solve their
health problems, it offered more effective relief without life-limiting side effects. Many
participants liked how cannabis kept their personality intact whereas pharmaceutical medications
disconnected their emotions. Deborah, from Focus Group 5, introduced herself in the following
way:
Deborah: My name is Deborah and I had my license for two years, but I was using
cannabis way before then. I'm sixty so I've been using it for a while for anxiety and then
after I had thyroid cancer, I got muscle cramps really bad. Cannabis helped that too. Of
course I tried pharmaceuticals first, for anxiety as well, but they make me not me. And so
I got sick of it. And then after you become tolerant to the level that they give you, they
jack it up and then you're less and less you. But on cannabis I can function, I can still be a
wife and a mother and work… And to me, cannabis is a possible natural solution to a
medical issue. I don't want to take pills.
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Likewise, this particularly illuminating response comes from Sophia in Focus Group 1
when asked to complete the sentence, To me, cannabis is…
Sophia: I said, to me cannabis is minimal pain. I was diagnosed with some type of
degenerative junk in my back a few years ago and I have like a curvature and some other
stuff going on. I really want to be active, but I've tried pain meds and they make me sleep
and feel weird to where I just can't function. So, I'm living like a functional life, where
I'm able to go places and do things and enjoy my family, rather than sleeping and feeling
weird all the time. And I feel like it's a gift from Mother Earth, so I am grateful for it. I
feel like it is here for us and we should appreciate it and it should be shared. Like, I can
live with this and the side effects are not going to kill me unlike a lot of other meds. And
I was on a lot of meds. I was on a high blood pressure medicine, I was on one for acid
reflux, and I was on antidepressants for a while. But I got to the point where I didn't even
cry anymore, and I was like this isn't me or how I want to be. So for the past five to seven
years I've been smoking strictly and enjoying life.
In fact, some patients stated that cannabis replaced multiple prescriptions, especially
those for psychiatric conditions, rather than just those for pain management. Indeed, others have
noted cannabis patients may use medical cannabis as an alternative to prescription drugs, as a
way to taper off prescription drugs, or as a compliment to prescription drugs (Bruce et al. 2018).
Like previous research, patients in my focus groups had horror stories about their experiences
with pharmaceuticals (Newhart & Dolphion 2019; Satterlund et al. 2015; Bottorff et al. 2011;
Chapkis & Webb 2008). Bailey’s story is particularly powerful in that cannabis saved her from a
toxic cycle of prescriptions which may have amplified her suicide ideation:
Bailey: My name is Bailey and my pronouns are they and them. And I said cannabis is a
civilization creator. Because without hemp I do not think we would be where we are, but
that's another topic. For me, personally, it is a lifesaver and what I talk about might be
triggering so I don't know if it's okay… [Group assures them it’s okay]… Well, I've been
a patient for six years and my qualifying condition is pain associated with PMDD. But
before that I had mental health issues and I was suicidal since I was a preteen. So I said
cannabis is a lifesaver because I truly believe that I would have succeeded in an attempt if
I didn't have it because I would have overdosed on pills. And that's what the doctor wants
to give you, so I found a non-lethal thing that helps.
Both Sophia and Bailey from Focus Group 1 had been diagnosed with premenstrual
dysphoric disorder (PMDD), a condition that causes severe depression, anxiety, or irritability
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leading up to menstruation. Each of them also found more relief with cannabis than any
prescription they have tried, perhaps because cannabis does not dull their sense of self or creative
capacities:
Sophia: I always ask my doctors if they rely on what they learned in school or if they
continue to learn. I remember seeing this one doctor and I think she was like ready to get
rid of me, and even after medical marijuana passed, I told her I felt like I was selfmedicating with cannabis. It was for PMDD and I was flipping out on my poor kids. She
was like, well, you're a phenomenal woman so we're going to prescribe this for you and
you won't even need marijuana anymore... [Bailey, who also has PMDD, laughs]… Yeah,
so I at least tried it but I realize that the medicine was not for me. I had gone to funerals
and I didn't cry, and that was not me. I didn't like it.
Bailey: So it shut off your emotions too much?
Sophia: Basically, yeah. Oh my goodness, it was so weird. I felt like I wasn't going to get
me back. My creativity was gone and it was not worth it to me.
Avery: Before I smoked marijuana that was one of my biggest fears. I had depression and
anxiety since as long as I can remember, and in 4th grade I can remember harming
myself because I didn't know how to cope. But I never wanted to get medication because
I had heard it shuts off your feelings. I am also a very creative person and since pills can
shut off your creativity, and I didn't want to do that. So marijuana helps me where other
meds cannot.
Other patients like Wade from Focus Group 3 commented on how cannabis relieved their
pain without numbing their physical sensation. This enabled them to perform normal tasks while
avoiding further injury caused by overexertion. But for the vast majority of the patients in the
focus groups, the best thing about medical cannabis was an escape from pills with undesirable
side effects. The following is from Focus Group 5:
Austin: The best thing about medical cannabis is that it is available.
Deborah: The best thing for me is no more pills.
Doug: That's basically what I said. I can take one medication instead of a million pills.
Deborah: A million pills with a million different side effects.
Damien: I said basically the same thing. It seems like it solves a lot more medical
problems and doesn't cause as many medical problems.
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Deborah: I'm looking forward to hearing the disclaimer on pot when they come up with
that, because you know they will. It'll be interesting to see what exactly they deem as a
downside.
Is being “high” a side effect? Only two of my participants expressed that the
psychological intoxication was occasionally undesirable. However, those participants also noted
there are other cannabis products available that provide pain relief without the high such as CBD
and THC-A. Most focus group participants appreciated how cannabis shifted their perception
with Greg from Focus Group 2 calling the high “an added benefit”. The two men in Focus Group
3 agree:
Moderator: What is the best thing about medical cannabis?
Wade: I would say the best thing is the relief and, like, the calming effect...
Gavin: No side effects.
Wade: Yeah, I haven't seen one side effect personally.
Gavin: And allegedly, there have been no deaths from it. But you can get killed from an
aspirin...
Moderator: What would you say to the people who would say that getting high is a side
effect?
Gavin: Well, is getting high a side effect or a benefit? That's a personal perspective
[Wade agrees]. But I would say that it is that core issue in you that that determines it.
Like, why are you drinking a beer after work? If you work heavy construction, you come
home and you drink a beer... and I'm not talking about get drunk... But you have a beer or
two and kick back. Is that a side effect? Or is that just enjoying life?
The high provided by cannabis may also lead to an added benefit not commonly
associated with prescription medications. Patients in the focus groups talked about cannabis’ prosocial properties, whether it be through reducing social anxiety or forging common bonds. It’s
availability as a recreational substance now facilitates the latter, potentially providing patients
with life-affirming social ties. Friendships were included with the “best parts” of medical
cannabis in Focus Group 1:
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Bailey: I think marijuana brings people together, all different types of people. And that's
my favorite part right there because I love different people.
Avery: It’s one of the best ways to meet people.
Sophia: Heck yeah! It's fun because you never know someone’s story and they're usually
pretty cool. I just feel a connection for some reason. When I know someone else smokes,
I'm like, dude we are there.
Avery: The barriers come down a little bit. And I know this is a different topic than what
we're on but with my anxiety and PTSD, in certain situations cannabis helps me calm
down too. So smoking is like the best way to get to know someone because I'm not super
anxious.
Sophia: Exactly.
Avery: And we can both kind of relax and chill.
To my knowledge, there are no support groups for medical cannabis patients in southwest
Michigan. There are no patient associations and outside of brief visits to dispensaries where
medicating on site is prohibited, no places to socialize and share experiences. Legalizing
cannabis for adult use may expand the social network of cannabis patients and the locations at
which patients feel at home. However, legalization is not without its drawbacks as cannabis
patients fear their medicine will become scarcer as the market adjusts to recreational consumers.
Yet this concern is minuscule when compared to another threat identified in all of the focus
groups—Big Pharma.

Big Pharma
Pharmaceutical companies have been tepidly researching cannabis medicines since the
late 1970s and so far, none of the resulting drugs have been more effective than whole plant
cannabis medicines. Nonetheless, some politicians, medical authorities, and pharmaceutical
companies have positioned themselves in opposition to state medical cannabis programs because
several cannabis-like pharmaceutical options exist for those living with chronic illness or
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managing terminal diseases like cancer or AIDS. Indeed, part of the reason the federal
government ceased using natural cannabis for the (now defunct) Investigational New Drug
Program program was that Marinol had become available on the prescription market (see
Appendix A). Not only are Marinol and other pharmaceutical cannabinoid drugs less effective
than natural cannabis, they are inaccessible for individuals without health insurance, significant
finances, or the ability to navigate the health care bureaucracy.
The overwhelming majority of patients in my focus groups and key informant interviews
were pessimistic about pharmaceutical companies becoming further involved with cannabis
medicines. In fact, the only positive comments about pharmaceutical developments were in terms
of research and increased understanding of cannabinoids. The ability of pharmaceutical
companies to conduct extensive studies came up in Focus Group 4:
Moderator: Since we think pharmaceutical companies are going to get involved, is that
going to be positive or negative?
Audrey: Negative.
Alexander: I think positive.
Audrey: I think it will just make it more corporate and prices go up higher, even though
it's medical, you know? And like insulin, they can set their own price, so...
Moderator: Good comparison. Alexander, how's it going to be positive?
Alexander: These companies have the money to put in for research where a caregiver,
such as myself, does not. These people have billions of dollars at their disposal. Why
wouldn't they research better quality, better potency? I mean, just over the last 10 years
we've come to a fuller understanding of marijuana.
Audrey: There's already people studying it though. Like people over in California, they
got lots of people studying it and have done lots of studies.
Alexander: Definitely. And that became possible after legalizing it. They can't begin to
study something that's illegal.
Several patients in my focus groups expressed their desire for retail pharmacies like
Walgreens to sell cannabis medicines, but they did so out of hope the medicines would be
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available over the counter (without a prescription). Only one participant noted that they desired
prescription cannabis medicines, but this was because they assumed medical insurance would
cover the cost. Yet every one was in agreement that “Big Pharma” would negatively impact
medical cannabis, and their fears centered around restricted access in the name of profit while
degrading the plant. Focus Group 1 raised the specter of pharmaceutical corruption before I had
chance to ask about it:
Bailey: Something I'm worried about is Big Pharma.
[everyone immediately agrees]
Jimmy: Yes, I was just about to say that too.
Sophia: Yeah me too because it's going to happen.
Moderator: What do you mean by Big Pharma?
Bailey: Like how it will be their brand, pre-rolled with additives in it maybe. And sure,
there could be like a Marlboro brand for recreational, but I'm just worried about them
taking over the industry so individual growers can't really participate in the medical
aspect, and then just changing things around.
Avery: Big Pharma will make it just another medication instead of this helpful herb that
we use.
Jimmy: What I'm assuming will happen is that there will be different strains that will be
patented. Like what we see with Monsanto with the different kinds of seeds.
Sophia: And they jacked those seeds up too, didn't they? I mean it started off sounding
good but now it's like killing the bees and all kinds of bad stuff is happening.
Since patients knew their use of cannabis allowed them to transition off or reduce
pharmaceutical medicines, they feared Big Pharma would attempt to reduce access to cannabis or
try to claim cannabis for themselves. Focus Group 5 was aware that the pharmaceutical
companies responsible for the opioid crises have histories of opposing medical and recreational
legalization:
Damien: With the big controversy about opioids, Big Pharma has got to make up that
money someplace, right? They have to, and what's the logical way for them to do it?
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Cannabis. You're already seeing studies where cannabis is taking the place of opioids for
a lot of people.
Deborah: Yeah, it's a natural alternative.
Damien: Right, so what's big pharma thinking? You know, they're putting a big bust on
us for doing opioids. We really need to claim this new industry for ourselves, like really
fast and make it big.
Austin: Right, before they can get a chance to privatize it.
The discussions above show that while cannabis patients recognize the benefits from
pharmaceutical innovation, they are concerned over big businesses restricting access to natural
cannabis medicines. Key informants had similar concerns but two of them, each of whom
worked on drafting Michigan’s adult-use legislation, believed the right to grow was well
established in Michigan. Nonetheless, state regulators recently changed the rules so caregivers
could no longer sell directly to licensed medical or adult-use dispensaries. Caregiver-grown
medicine had sustained Michigan’s medical cannabis system for over a decade with little
complaint on behalf of patients. The recent changes to the caregiver rules overwhelmingly
benefit corporations who invest significant sums in up-scale retail dispensaries and grow sites
capable of mass production. While everyone in Michigan has the right to grow 12 plants, it may
only be a matter of time until big businesses like pharmaceutical companies seek to curtail this
home-grown competition. If this happens, the diversity of cannabis strains and products may be
lost to the flattening effect of mass production. This would hamper the connoisseurship (see
Chapter 3) that has enabled patients to experiment with the wide array of cannabis medicines.

Conclusion
Will medical cannabis systems survive in the post-prohibition world? Patients in my
focus groups believe they will and even desire a distinct medical cannabis system to be
maintained. They also acknowledge the power of corporate-sponsored research into the efficacy
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of cannabis medicines, and while they hope mainstream medicines become more accommodating
of medical cannabis, patient sentiments appear to be against the total institutionalization of
cannabis within biomedicine. This fact has implications for how we theorize the medicalization
of cannabis. The most recent research into this area calls cannabis “incompletely medicalized”,
presuming that it is headed into the realm of biomedicine where medical authorities will become
the gatekeepers of cannabis medicines (Newhart & Dolphin 2019). Though the medical
profession is slowly warming up to the idea of treating cannabis as a medicine, the patients who
actually rely on the plant do not wish to see it totally medicalized.
Instead of “incompletely medicalized”, it may be more fruitful to consider cannabis as
“alternatively medicalized”. Overall, cannabis patients favor the current system of cannabis
being medicalized by the state (and society) where their status as a patient is legitimated outside
of medical institutions. This allows them to claim a patient label without placing themselves
under intrusive medical control, a status made more appealing by the current authoritative nature
of mainstream medicine. Nonetheless, patients in my study wanted their regular health care
providers to respect their use of medical cannabis, perhaps envisioning a system where
mainstream medicine and cannabis medicine cooperatively coexist to best address patient needs.
After all, medical cannabis has been theorized to be part of complementary and alternative
medicine or CAM (Newhart & Dolphin 2019; Subritzky 2018; Chapkis & Webb 2008) where it
is used to enhance wellbeing in the context of chronic illness. Chronic illness differs from
disease in that it refers to the subjective experience of the suffering individual rather than an
objective, visible entity (Mizrachi et al. 2005). Likewise, wellbeing transcends physiological
health and is often used as “an implicit critique of the ways in which biomedical knowledge has
traditionally constructed the passive patient” (Sointu 2006:346). While health is conceptualized
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as the absence of disease, wellbeing describes feeling good, satisfaction with life, and positive
functioning. Indeed, those who pursue CAM are often active, empowered, and knowledgeable
agents in their quest for a subjective sense of wellbeing (Brenton & Elliott 2014; Penn 2014;
Sointu 2006).
One problem with the alternative medicalization of cannabis will be its acceptance within
the biomedical community. Historically, biomedicine earned its prestige and dominance by
actively suppressing folk medicines, natural remedies, and traditional health care services
typically offered by women (midwifery, for example) (Ehrenreich & English 1978/2005). While
biomedicine created a firm boundary between their scientific approach to medicine and every
other approach to healing, the coexistence of biomedicine with CAM has been documented
before.
Mizrachi and colleagues (2005) conceptualize three stages of how biomedicine operates
alongside alternative medicines. Medical cannabis is perhaps best placed in the cautious
approval stage where it is perceived as valuable for its placebo effect since the “hard-core logic
of bioscience” (26) has yet to extract the precise mechanism the treatment has on the body.
While this is better than the negation stage where alternative medicine is excluded from
biomedical discourse, medical cannabis has yet to reach the reconciliation stage where it is
integrated into biomedicine. Yet even if this were to happen, reconciled alternative medicines are
restricted to the area of illness rather than disease (Mizrachi et al. 2005). As such, reconciling
medical cannabis with our dominant biomedical system may be beneficial to those suffering
from chronic illness. Cannabis patients would be able to access biomedical services when needed
while continuing their use of a natural remedy which helps them cope with persistent pain and
discomfort.
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Complementary and alternative medicines generally emphasize holism and
empowerment, and people often turn to CAM “because they distrust biomedicine or are unhappy
with their lack of control in traditional medical settings” (Brenton & Elliott 2014:91). Cannabis
has allowed them to claim some self-control over their conditions and treatment plans, and the
relative freedom from healthcare supervision allows them to use their medicine without
judgment or bureaucratic consequences like those found in pain contracts. Though some medical
researchers have called for greater physician oversight of medical cannabis (Choo et al. 2016;
Zolotov et al. 2016; Nussbaum, Boyer & Kondrad 2011), cannabis patients see such supervision
as undesirable and unnecessary. We must also keep in mind that there is a difference between
supervision and guidance. Victorson and colleagues (2019) discovered cannabis patients desire
more professional information regarding product options and effective medication regiments, but
like patients in my focus groups, they did not state they wanted medical cannabis available by
prescription. Perhaps Michigan should consider following other states which mandate a health
care professional be available for consultations in medical cannabis dispensaries.
This study also adds to Conrad’s (2005) argument that the engines of medicalization are
shifting to interests outside of the medical profession, namely expert patients (see also Conrad &
Barker 2010 and Conrad & Leiter 2004). However, these expert patients are not the product of
pharmaceutical advertising or other corporate interests. Instead, they are the product of a system
that had shunned them and their choice of medicine for the past several decades. When we
theorize cannabis as incompletely medicalized, we neglect the fact the many patients appear to
disdain the complete medicalization of cannabis. Since cannabis was medicalized by patients
rather than medical authorities, it might be wise to place patient interests first and foremost in
how we conceptualize this topic. If we do that, the word “incomplete” carries a grave
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consequence when considering medicalization. Instead of a linear continuum where cannabis is
moving towards total medicalization, patients desire an alternative medicalization of the plant.
They appreciate the current way the plant is medicalized, and while the current state-sponsored
system of medical cannabis is far from perfect, it appears more desirable than the familiar system
of routine doctors’ appointments and medicine by prescription.
Others have noted the benefits of switching non-toxic and non-addictive medicines from
prescription (RX) to over-the-counter (OTC). Chang et al. (2016) say such RX-to-OTC switches
save a consumer time, money, and the discomfort of having to discuss their personal lives with
relative strangers. While not without the potential of misuse, when smoking-cessation aids like
nicotine gum and patches became available OTC, their use among smokers more than doubled
within a year (Shiffman & Sweeney 2008). Perhaps a similar phenomenon may occur if medical
cannabis becomes more widely available. As has been noted throughout this study, many
medical cannabis patients eventually reduce the number of prescription drugs they consume,
most notably opioid pain killers. The Consumer Healthcare Products Association (n.d.) claims
OTC nicotine cessation products have a $2 billion public health benefit each year. Meanwhile,
the health care costs of the opioid crisis alone were estimated at $60.4 billion in 2018 with a total
cost to the economy of $179.4 billion (Davenport, Weaver & Caverly 2019). If medical cannabis
helps just a fraction of prescription opioid users to reduce, cease, or abstain from those highly
addictive medications, the economic savings would be enough to justify increased access to
medical cannabis. Yet while economics may prove to be a powerful argument for medical
cannabis, we should avoid placing this imperative above patient needs and their desire to
“thrive,” in the words of one of my participants, while living with chronic illness.
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CHAPTER VIII

GENDER IN THE MEDICAL CANNABIS COMMUNITY
This final chapter of my analysis will describe some of the ways gender manifests in the
medical cannabis community. As little research has been done in this area, my investigation of
the issue is broad and should serve as a useful starting point for future inquiries. The research
questions that guided my questioning of participants and analysis are: How does gender shape
the experiences of medical cannabis patients? And, how might hegemonic gender roles be
adhered to or challenged by cannabis patients? I begin by discussing some of the difficulties
with asking about gender while illuminating how parental status typically brought about a
nuanced conversation on the topic. I then detail how gender dynamics, primarily the gender
division of labor, manifests among cannabis entrepreneurs and business practices. Following
this, I describe how gender roles operate within the cannabis community. The next section
concerns how cannabis stigmas and stereotypes are mediated by gender, an interesting area
where both women and men report gender-specific devaluations over their use of cannabis
medicine. Finally, I reveal how cannabis may facilitate or attract non-hegemonic enactments of
masculinity.

Probing about Gender
The first task I gave focus group participants was to complete the following sentence: “To
me, cannabis is…”. The responses between men and women were more similar than different,
but men’s responses were more diverse. Women tended to describe cannabis in exclusively
medical frames such as “minimal pain,” “relief,” and a natural alternative to synthetic medicines.
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Men used these descriptors as well, but they also described cannabis as “an old friend”, “a way
of life”, and as a plant created by God. Unlike findings by Bottorff et al. (2011), two men and
one non-binary participant in my focus groups called cannabis a “lifesaver” whereas no women
used such a term. Interestingly, the three non-binary participants in my focus groups also
described cannabis in terms not used by men or women, as “freedom,” “a civilization creator,”
and “a potentially useful substance.” Finally, as my previous chapter demonstrates, participants
often framed medical cannabis as enabling self-reliance or restoring personal control over their
medical regiments. This was a theme common among participants of all gender identities in my
study whereas prior research found men were more likely to frame cannabis in such a way
(Bottorff et al. 2011).
Differences between what is expressed by participants in a study may be useful to
analyze gender, but asking them directly about the topic was my preferred approach.
Nevertheless, probing about gender in the focus groups was more difficult than I anticipated.
Like the youth focus groups conducted by Haines and colleagues (2009) and Warner and
colleagues (1999), the adult participants in my focus groups appeared hesitant to discuss gender
in relation to cannabis. I suspect this is because gender is something many people take for
granted, and cisgender privilege may function to make gender appear natural. After all, a
hallmark of social privilege is relative freedom from thought on the privileged category, so
gender may not be something my participants thought about often. When I asked about gender,
many participants interpreted my questions in biological terms as seen in this exchange from
Focus Group 2:
Moderator: Is there a difference between men and women who use cannabis?
Andrew: There are suppositories that women can use that men can’t.
Wanda: You can use them too. Just not in the same hole.
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Andrew: That's what I mean. As a man who does not have a vagina, I cannot use a
cannabis suppository that way.
Wanda: You can use it anally and it works similarly.
Andrew: Right and I have used them.
Sean: I didn't know they have suppositories. No kidding...
Andrew: Yep they do. But for me that's the only difference.
I often had to use numerous probes to get focus group participants and key informants to
think about gender differences. Restating the question in various ways sometimes helped spark a
discussion on gender, but after some time mulling over their thoughts, most participants began to
mention subtle differences until something significant got the conversation going. As seen in a
continuation of the discussion from Focus Group 2, this was sometimes parental status:
Wanda: I just don't know if this can be put in terms of gender…
Andrew: Yeah I'm having a tough time with the gender questions.
Irene: Yeah it's hard.
Moderator: That's okay, it's fine...
Wanda: I just don't see it being a gender issue.
Andrew: Unless it has to do with having a child. Under those circumstances, I think,
100%, women get screwed more.
Wanda: Oh yeah, you shouldn't smoke around your kids and things like that.
Irene: That's actually why I got my card.
Moderator: Is that different for fathers though?
Wanda: Yeah, they can smoke wherever they want.
[group in agreement]
Andrew: Right. If the kids not with you, it's like, let's step out in the garage and smoke
since the kid is with the wife. As long as he is not supposed to have the kid in his
possession, then technically he is allowed to smoke. Not that I agree with that, but…
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Wanda: Since the women are supposed to take care of the children, you're not allowed to
be inebriated. But the dads can go do whatever they want.
Irene: My old mother-in-law said that her daughter was never coming over my house
again because I was a drug addict...
Wanda: Yeah, like it's unsafe [sarcasm], and you hear that from families…
Participants were more aware of gender when thinking about parents who use medical
cannabis, and they primarily constructed mothers as the primary caretakers of children. Irene’s
comment above illustrates this as mothers who used medical cannabis may be seen as neglecting
to care for children in the home. This concern has also been documented elsewhere (Newhart &
Dolphin 2019; Dahl & Sveinung 2015; Haines-Saah et al. 2014; Reinarman et al. 2011), but
unique here is the relative tolerance given to fathers who medicate in the garage. This specific
space for men to escape the judgment of poor parenting was mentioned in three of the focus
groups. After all, the garage is constructed as a masculine space and one typically free from
meddling children. Perhaps this should cause us to question why women are not afforded a
similar private retreat in the traditional American home.
Despite patients being aware that mothers may face harsh judgment for using cannabis,
three women in my focus groups expressed they thought cannabis made them a better mother.
Irene from Focus Group 2 and Sophia from Focus Group 1 claimed their use of medical cannabis
allowed them to exercise more patience when it came to raising children. Similarly, Deborah
from Focus Group 5 described abstaining from alcohol when she began self-medicating with
cannabis decades ago, an important feat given that alcoholism runs in her family. Nonetheless,
the fear of being seen as a negligent mother was a concern for many of the women in my focus
groups, and these gender-based stigmas are explored more later in this chapter. Before I detail
how gender mediates stigma, it is worthy to examine how the changing legal status of cannabis
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has impacted gender representations in cannabis culture. The best place to begin is by analysis of
gender in the cannabis industry.

Organizing Gender in the Cannabis Industry
For the most part, when participants in my study described gender in relation to medical
cannabis, they tended to do so in traditional ways. There are many exceptions that are discussed
later in this chapter, but the hegemony of gender roles has certainly seeped into the medical
cannabis community. These traditional gender roles manifest in a variety of ways and sometimes
mirror the gender dynamics found in other areas of our society. Doug and Briana from Focus
Group 5, for example, described a traditional division of labor when it comes to growers and
processors:
Doug: I find more women doing more of the baking, the edibles, and things like that...
Briana: The cannabis butters...
Doug: Yeah I was gonna say the creams and stuff like that, women do those more. And I
think it has to do with... um... how things are looked at in life.
Briana: Gender roles in society, yeah.
Doug: Typically, women are made more or the kitchen and you know, certain things, and
men are made for certain things. And that's how I think it does follow through with a lot
of things. I've noticed with my caregivers, even though I talk to a female, she does all the
edibles and the oils and all that stuff while he strictly does the growing.
Briana: Yeah. I think some of it too is that I think guys might just be more interested in
that kind of work, like the farming aspect of it.
A similar division of labor was found by Alisha Adelman (2013) in her master’s thesis on
gender dynamics among marijuana cultivators in California’s Golden Triangle. Men primarily
took responsibility for the growing the family’s crops while women prepared the marijuana
market. Likewise, Cadigan (2018) found employees working in cannabis dispensaries are often
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arranged in ways where men are positioned as experts while women are placed in supporting
roles. Focus Group 1 also thought employees in dispensaries are often arranged in gendered
ways where men drive the hard business while women provide support:
Avery: [The dispensary] is still like a bro’s club.
Jimmy: Agreed. Whenever I walk into a dispensary, I feel like there is this bro mentality.
Sophia: In the front and the back?
Moderator: What do you mean by bro mentality?
Avery: They have like the women in the front and the bros in the back.
Jimmy: Yeah, there's usually a woman there as the front desk receptionist and she checks
you in and stuff… And it's hard because I'm a queer man and I always feel uncomfortable
talking to straight men and it's hard to explain. But I'm uncomfortable about it because
there might be some sort of homophobia thing going on or something, but it's also
because I can see straight through this mask they put on…
Sophia: Ya…
Jimmy: Am I right? [group expresses their agreement] … there's like these tough
straight hetero cis-gendered men who are like, [in deep voice] yeah let me go get this,
blah blah blah. And I’m like, yeah, man, whatever…
Bailey: It's like they're always after the sale and they don't want to connect with you if
that makes sense
Jimmy: Yeah, and then with the women helping people at the dispensary, I feel like… I
don't know, like they either try to fit in with the boys, with the mentality that the men are
carrying on, or it defaults back to that front desk, how may I help you…
The gendered organization of cannabis businesses was also mentioned by several of my
key informants. Hegemonic masculinity is partly characterized by risk tolerance, and when it
comes to establishing a dispensary, there are a lot of risks. Yet as the industry becomes more
established, some of the risks, especially the legal risks, disappear. This was the thinking of one
of my key informants who established her dispensary shortly after the MMFLA passed in 2016.
This regulatory passage provided cannabis businesses with licenses and legitimacy in the eyes of
the state:
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Kayla: A lot of times the female perspective is a little bit more calculated and thought
through, which ends up taking more time. So I think in the cannabis industry we are
going to see a decent female representation, and there already is in a lot of aspects, but it
will continue to develop as time goes on. I think that women are probably going to take
more of a strategic approach, to wait and see if this makes sense… a more sensible
approach than I took [laughs].
While Kayla still sees much risk in operating a licensed dispensary, her statement is
significant when contrasted to how a male dispensary owner describes his decision making.
Justin and his friends lost their insurance business in the wake of the 2008 financial crisis,
around the same time Michigan voters approved medical cannabis in the state. There was no
licensing system available at the time, so businesses operated in a gray area and were often
tacitly allowed to operate by local authorities:
Justin: So we're sitting in a situation, we're looking for something to do, we have a
building and this law passes in the city with over 80% of the vote. So we look at it, and
we say fuck, well in California they started doing it. I do a little bit of legal research and I
see [the medical cannabis law is only an] affirmative defense28 in Michigan. And that's all
they did it off of. But the California law not only had affirmative defense but also a
licensing component to it. So we're like, fuck, we can do this, let's do it! We didn't bother
consulting any lawyers or anything like that, or if we did it was by specific questions, and
we got going. If we hadn't done that, other people would have done it in their own way.
But I think it was good how we did it. We worked transparently with the local
government and we got going.”
Justin’s account of his business venture appears to be anything but “calculated and
thought through”. He continued to describe how he eventually learned the ins and outs of
running an unlicensed dispensary through responding to challenges rather than planning for
challenges. Fortunately, his business was successful and was eventually able to secure a license
when that option became available after 2016. His experience may be the exception as many
unlicensed dispensaries in pre-MMFLA Michigan failed due to raids, political issues, and/or not

“Affirmative Defense” was a common way to make medical uses of cannabis legal for patients registered in a
state medical cannabis program. These policies did not amend state laws on marijuana use and they did not make it
legal to sell medical cannabis. They simply provided patients a legally valid defense for use in court should the
patient be arrested and charged with a marijuana-related offense.
28
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being able to secure a license after one was needed. As such, this masculine embracement of
risks associated with running a dispensary may have helped Justin and others start their
dispensary at a time where both success and legality were far from certain.
This is not to say the initial masculinization of medical cannabis retail dispensaries was
entirely positive. Some of the drawbacks to the “fuck, we can do this, let’s do it” approach
include becoming entangled with an unregulated supply chain, exposing oneself and one’s
associates to legal risk, and the omnipresent possibility that the dispensary could be shut down at
any time. This might result in patients not being able to access medicine until they find a new
source, a relative rarity in southwest Michigan for the first decade of the state’s medical cannabis
program.
The above reasons and more are why Kayla, the dispensary owner previously quoted,
speculated that the quasi-legal status of the industry affects gender dynamics. However, she is
optimistic about the future and believes the growing focus on quality business practices will
weed out some of the problematic aspects associated with masculinized competition. For
example, she thinks the future will be more patient-centered instead of product-centered:
Kayla: There is this huge gender disparity between what was happening in what we call
the gray market and what is happening now in the legal market. I think that over time we
will see a phase-out of a lot of the grey market mentality. But I think the grey market
piece was very male-dominated, very macho, and kind of... harsh? I would say harsh, at
least more so than what we will see in the legal market. I don't think we will see a lot of
people post about how they are great growers and how they grow the best product so
much as we will see people talk about how they are good business people. And this is a
business. It is a business where I can help people, or maybe they are waiting for the rec
market, but it is a business where I can make good financial decisions where previously
in the grey market it was a little bit more about “let me show you how good I am”... “let
me show you how good of a product I can grow, how good of an extract I can make”. I
think it is more of a “let me show you how good I am” type of thing, not so much of a
business perspective. Hence the cannabis cups and how much they want to show you all
of the awards they won, and how they have the best strain. Well, in business, yeah, that
can play a part, but it is not the focus.
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The illegal nature of the industry has undoubtedly facilitated a gender gap in business
owners. Nonetheless, while women are gaining a strong foothold in this new multi-billion dollar
sector, we need to wary of at least two things.
The first is that as big money interests come into the picture, they may facilitate a
masculinized corporate culture endemic throughout society. This was a fear expressed by the
women “canna-preneurs” interviewed by Borchardt (2017), and unfortunately, this already
appears to be happening. In 2015, Marijuana Business Daily found 36% of industry leadership
roles were held by women, perhaps because the burgeoning legitimate sector had no glass ceiling
to break29. By 2017, that figure had reduced to 27%, possibly indicating a glass ceiling is being
established as male-dominated investment firms enter the scene. Amy Margolis runs a business
accelerator program for female cannabis entrepreneurs, and she is quoted as saying: “I don’t
think there’s any doubt that as traditional capital starts to come into this space, starts to
overwhelm the space, we are seeing women either pushed out or unable to get funding… Men
seem to control funding overall, and they would prefer to fund men” (Harris 2019, paragraph 3).
This need for significant sums of investment capital is partly a product of onerous state
regulations. In Michigan, for example, applicants for a cannabis business license must have
capitalization of at least $150,000 for a small grow operation (100 plants), $500,000 for a large
grow operation (2000 plants), and $300,000 for a provisioning center or a processor license. This
disadvantages women and minorities who are more likely than (white) men to lack the required
bankroll or borrowing ability.
The once-illegal nature of the cannabis industry may have worked to privilege men who
developed businesses, as their embracement of risk might have resulted in financial rewards as

29

Compared to 22% to 25% across every other industry (see Olson 2015, paragraph 9)
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well as a head start in the licensed industry. Steep capitalization requirements also privilege this
group, and now that the state has a social equity program that can reduce those requirements by
half (or more) for certain populations, this leveling of the playing field may provoke hostility in
those who do not want more fair competition.

Gender Roles in Cannabis Culture
The above section and more hint that the hegemonic gender structure has found its way
into the new world of legal cannabis. Perhaps it is too early to tell if legalization will help or
hinder gender equity in the new industry, but what about the larger cannabis community? The
certifying physician I interviewed thought much of the masculinization of the community was a
result of prohibition. These comments came up in the context of strain names which impart
masculine associations like “AK47” and “Alaska Thunder Fuck”:
Dr. Steven: There is that “hey dude” flavor in the community that kind of carried over
from when it was illegal. The naming also kind of carried over from when it was illegal,
and they used to name heroin batches too. I think it's kind of progressed. It's kind of
cutesy for something that is supposed to be a medicine, to give it a name like green crack.
I do hate that name. But people don't seem to get too hung up on that.
Overall, patients in my focus groups did not seem to get hung up on masculinized or
feminized products. Most patients appear to be able to see through marketing tactics, both in
terms of gender and beyond. They knew which products they preferred regardless of branding or
target audience, likely because the effects are more important than the image the product
conveyed, a finding also noted by Bottorff and colleagues (2013) in their comparison of tobacco
and marijuana smokers. Some men talked about buying topical creams, some women discussed
their preference for blunts, but most commonly, my participants mentioned using products not
widely associated with a gender category. One group had an interesting observation regarding
CBD products that are now widely available throughout the country:
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Greg: When it comes to the marketing and the packaging of the CBD products, that's not
aimed towards me…
Moderator: What do you mean?
Wanda: [laughs] Ya, this is girl bait [raises her colorful, slim can of CBD infused soda].
Greg: Exactly. That’s right.
Wanda: It's cute, it's in simple packaging…
Greg: Yep, and you were in marketing.
Darlene: It doesn't scream CBD...
Greg: It's subtle.
Irene: It's subtler and marketed towards women for sure.
Greg: Design, artwork, colors… all those things determine marketability.
[Darlene takes out a Mary’s edible product in a white packaging]
Darlene: Would you buy that?
[G signals Yes]
Andrew: Well, that's not marketed towards either women or men.
Darlene: No, but it's called Mary's.
Andrew: But that's because the company is called Mary's Medicinals. But it's still a very
gender-neutral packaging. They are historically a company that has been doing well
because they rely on the quality of their product.
[Group agrees]
While “gender-appropriate” products seemed of little importance, an area where
hegemonic gender roles were visible concerned the growing of cannabis, something largely
constructed to be a masculine endeavor. Not only does growing carry the risks of financial loss
and hostile neighbors, but it also involves hard work and science skills, each of which are
culturally coded as masculine. The following is from Focus Group 5:
Moderator: Why do we think it's gendered with the growing?
[Several say I don't know]
Briana: I know for me, personally, I am not a science person...
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Jackie: It's hard work, I know that...
Briana: ...Like, I don't know if I would be able to because it's sciencey. I mean, I can
grow a flower, but it dies a couple times and it needs water.
Jackie: ...There's a lot of physical labor involved too.
Briana: That too. And there are steps to the process. At one point I had a caregiver,
though I don't anymore, but I saw his grow set up and I mean, it's time-consuming. It is
basically a full-time job for yourself on top of... I mean, it really does increase your
electricity and your water bills. And the smell is really strong. So, you know, it just
depends on how you live, and if you have the opportunity to grow that.
Deborah: That's what made us stop growing because it didn't make any sense to spend
more. The electricity was just ridiculous and then you to get the smell thing. We had a
tenant in our basement, you know. Everything was closed up tight, but still...
Briana: And then all the materials that it takes. It can be costly.
Deborah: And that's what we found. It just wasn't worth it when it's available elsewhere.
Austin: You can do it outdoors and you can get a good crop without getting stuck with a
high priced bill. But most people don't think that's what they're paying for. I mean, you're
paying a lot more than you think. You're losing time, you're losing money...
Deborah: Yeah. And you have to worry about what happens when the electricity goes
out...
Austin: ...Right. And the other worry is that if somebody smells it outside of your house,
what's gonna happen? Especially having a family...
I also interviewed two caregivers, and each said that they have seen more men than
women becoming involved with growing. There are no statistics available on gender in this area,
but my observations support the existence of this gender gap. For example, the many grow
shops30 around Michigan are typically staffed by men, and the grower-focused Facebook groups
have a majority male membership. Yet while men may be over-represented among cannabis
growers in Michigan, it does not necessarily mean they are better at cultivation. Michael has

“Grow shops” are hydroponic supply shops. They sell everything one needs to grow cannabis indoors except the
seeds or plants. This includes lights, nutrients, soil mixes, grow tents, and much more. While the grow shops are set
up for general plant growing supplies, it’s obvious they structure their business around growing cannabis.
30
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been involved in growing since the MMMP launched in 2008, and he has held multiple roles as a
grow shop employee, caregiver, commercial grower, and business owner:
Michael: Women are better growers than men. I might be better at carrying water and
doing manual shit, but women are way better at growing cannabis than men. There’s not
many of them, and they’re like fucking unicorns when you see one. If a woman walked
into a grow shop, people’s heads would explode, and I bet she would get proposed to on
the spot… It’s a white male dominated industry, but what I have found is that women do
not have egos, and they seem to be a little more in tune, caring, patient, detail-oriented…
everything stereotypically associated with femininity. But the biggest thing is that they
don’t have the egos that men do. Women will listen to your suggestions on growing.
They may disagree, and they may have an argument or a debate, but that’s good and
shows sound reasoning. Men, on the other hand, will go, “You don’t know what you’re
talking about, bro”.
There may also be good news here as I estimated the gender ratio of all attendees around
60/40 at a recent Harvest Cup in southwest Michigan. There were also no “hot girls”
representing products at this post-prohibition cannabis event (Lidz 2015), and I hope this is from
changes in culture rather than differences in venue. Three years ago when I attended a larger
cannabis cup competition hosted by a major magazine, scantily-clad women were abound to
hand out information and samples from all sorts of cannabis businesses. This was also noted by
Duke in Focus Group 5 who has worked as a grower for the last five years:
Moderator: Do we think cannabis culture does a better job of appealing to one gender or
the other?
Duke: I've seen more men in the growing industry though it's been growing for women.
But like, for the longest time, women were only allowed in High Times if they had
bikinis on. But I think they're stopping that...
Briana: I would agree with you on that. If you're talking about the grow aspect, it is
probably more gendered towards men. But I think users in general, I think it's pretty
even.
Dissatisfaction with the subordination and objectification of women was brought up in
several focus groups. For example, Focus Group 1 had already talked about unequal gender roles
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in dispensaries where women are largely confined to the front desk. They were also concerned
about the sexualization of women:
Bailey: On the subject of women stereotypes, I don't know if I can think of any right now,
but what comes to mind is in the cannabis industry there is the problem of the
sexualization of women…
[everyone empathetically agrees]
Jimmy: O my god, yes…
Sophia: I've noticed. What are they doing now, like beer commercial type stuff?
Bailey: Oh yeah pretty much, girls in the bikinis and stuff…
Focus Group 2 also expressed their dissatisfaction with the sexual objectification of
women working in the industry. I had noticed one participant in this group wanted to express
something about gender before the conversation shifted to families and stigma:
Moderator: Andrew, you were going to say something a minute ago....
Andrew: Just that I still think there is this exploitation of women’s sexuality in the
cannabis business, and I don't see the same for men.
Wanda: Oh I have noticed that! The women in dispensaries wear very low-cut shirts...
Andrew: Well, even in advertising... And I would be the first one to not go to a
dispensary because… I don't want to say that there shouldn’t be women bud tending, but
when women are bud tending, or when anybody who is bud tending is put out to display
themselves…
Irene: Almost like Hooters mentality?
Andrew: Yes. And I disagree with that style. Even when it comes to the 420 thing... I
don't think that is conducive to the movement. I know a lot of doctors offices that
advertise in the back of magazines… I could just be remembering mostly Los Angeles,
but… It is definitely sexualizing this industry.
Irene: Well, it's the same for like anything. Automotive, beer, construction, you know…
no woman that actually works on their car is doing it in their bikini. You're just not going
to.
Wanda: But this is almost the first time that we can have advertisements for cannabis, so
where do you go with that? You go to what works.
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Sean: And that's certainly an eye-catcher.
Greg: Like a topless car wash.
Overall, patients in my focus groups were conscious of how the cannabis community is
perceived by outsiders. Andrew did not like the “420 thing” which is associated with the stoner
stereotype. In the cannabis subculture, April 20th and/or 4:20pm are times to get high, though the
“420” descriptor can also encapsulate the range of symbols and actions associated with excessive
marijuana use. He also raised the issue of businesses sexualizing their female employees to gain
a competitive edge, something that may happen in dispensaries though I believe it is more
common with “brand ambassadors” at cannabis events. Other studies have documented this
problem of sexualizing women in cannabis retail. When Michele Cadigan (2018) interviewed
employees at recreational dispensaries, she found women quit at significantly higher rates due to
sexism from their bosses, coworkers, and even customers. Once again, increasing the
representation of women in the industry may help in this regard. As more women become
dispensary owners, growers, and managers in the industry, sexualized female sales tactics may
not only become less effective, but empowered women in the community may also become more
of a go-to image for female cannabis users in general. Hopefully, the cannabis industry will
move beyond these sexist practices as it becomes more solidified in mainstream culture. After
all, stereotypes and stigmas related to the gender of cannabis users are still popular in our
collective conscience (Mortensen et al. 2019; Haines-Saah et al. 2014).

Gender, Stigma, and Stereotypes
As I have already demonstrated in Chapter 7, patients still navigate a range of cannabis
stigmas in their daily lives. Though things have been improving, the fact that stigmas remain a
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powerful force trouble claims that cannabis is normalized. But how might stigmas interact with
gender to differentially shape the experiences of men and women who use cannabis?
Overall, my key informants and focus group participants agreed that women face more
judgment for anything they’re doing. Ramona, who specializes in medical cannabis public
relations, told me she thought “women are more sensitive to the stigma”, and the four other
women I interviewed as key informants agreed. In fact, two of these key informants remarked
they knew other women who hid their use of cannabis from their husbands. No such statements
were expressed by the men I interviewed, and all of my focus group participants expressed their
families knew of their use of medical cannabis (even if their family was disapproving). Perhaps
this is why several of my interviewees and focus group participants thought women favored
more discrete cannabis products. For example, Madison, who helps promote cannabis business
opportunities in communities of color, thought women were more tactful in their consumption:
Madison: At the recent High Times Cannabis Cup, one woman took first, second, and
third place. So women definitely have the ability to do this. I think male consumption is
much more public, though. I don't think men consume at a much greater rate than
women; I just think that they can do it more freely. And I think that women's
consumption is much more disguised through things like edibles or things that look
dainty, things that are still consumption but things that are not necessarily perceived as
consuming cannabis. It's consumption if I roll a cone, and it's also consumption if I eat
some infused mints, but you didn't know that I ate infused mints. So I think that's where
there are some differences.
These observations of gendered consumption practices were noted by others in my study
and resemble findings where extreme consumption methods (dabbing, blunts, etc.) were
primarily practiced by men (Mostaghim 2019; Newhart & Dolphin 2019; Dahl & Sandberg
2015). Just like downing copious amounts of alcohol to prove one’s masculine toughness and
competency (Arnull & Ryder 2019; Peralta 2007; Measham 2002), the conspicuous public
consumption of cannabis may be interpreted as an enactment of masculinity. Typically, the more
smoke one inhales or the larger the smoking device, the more potent the effect.
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Another possible explanation for the relative ease at which men consume cannabis in
public may be due to the media. Most of our cultural images of stoners are men (Mostaghim
2019; Bacca 2015; Looby & Earleywine 2010), a fact noted by many participants in my study.
Even though stoners are commonly conceptualized as masculine, male privilege may facilitate
men’s identification with these playful stereotypes. After all, men are granted social authority on
account of their gender alone, while women consciously try to achieve empowered statuses.
Perhaps this why Madison and two other key informants had issues with “stoner chicks” in the
media:
Madison: I think that the only images of consumption that people saw were kind of like
stoner chicks. And that stoner chicks have this kind of air-headed mentality, and I don't
think that most empowered women align with that. It also could potentially be because
women are mothers, and there is a different set of expectations and responsibilities that
comes with that. And also marketing too, because they provide a lot of the images we
see.
These three key informants mentioned they thought media representations of women
cannabis users were unrelatable, a sentiment also shared in two of my focus groups. Women in
these groups discussed how female characters who used cannabis were traditionally depicted as
engaging in other criminal activity, particularly prostitution. This is not necessarily a new theme
either as Susan Boyd (2009) found anti-marijuana propaganda films often portrayed women who
use marijuana as more criminal and more interested in drugs than their male peers. Things may
be improving here, though, as Audrey from Focus Group 4 likes how modern representations are
more diverse:
Moderator: Do you think [the media] shows cannabis as more of a normative thing?
Alexander: I think so…
Audrey: I like seeing more ladies that smoke. Cause you didn't use to see that before, you
know? I mean, if they were, they were always the ones snorting coke and giving head in
the movies [laughs]. Not the ones that were funny and otherwise normal.
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As cannabis becomes more accepted in polite society, perhaps gender-based cannabis
representations will continue to evolve in the media. Alternatively, two women in my focus
groups remarked that they appreciated how cannabis challenges traditional constructions of
femininity. Sophia from Focus Group 1 did not care about the discreetness of her consumption,
and even mentioned how cannabis facilitated her break with emphasized femininity:
Sophia: I don't wear dresses very often, and I don't paint my toenails, and I don't wear
makeup, you know what I'm saying? I'm hairy in places that I probably shouldn't be
[laughs]. But I'm okay with it. I realize that I'm a female, but I don't feel like I need to
play a certain role. So maybe me drinking Hennessy straight out of the bottle or smoking
blunts makes me look a little more manly, but I'm okay with it. Like men act that way
and not women, but again, I'm okay with it and comfortable with it.
One may be tempted to say women are more stigmatized than men for using cannabis,
and while this may be true, men also experience gender-related stigmas surrounding cannabis
use. This is surprising because cannabis culture, like most other drug cultures, is coded as
masculine (Arnull & Ryder 2019; Mostaghim 2019; Dahl & Sandberg 2015; Haines-Saah et al.
2014; Haines et al. 2009). Yet there is something about cannabis stereotypes that trouble
hegemonic notions of masculinity such as competency, power, and the provider role. For
example, Focus Group 2 linked hegemonic ideals such as breadwinning to social disapproval
over men using cannabis:
Moderator: Do we think that women use medical cannabis differently than men?
Irene: I don't think so.
Wanda: I think it's more of a personal thing.
Sean: I think women use it more discreetly than men do, or in a more discreet way than
men do.
Darlene: I think men are stigmatized more than women are.
Sean: I can see that.
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Darlene: Because with women, it’s seen as a casual recreational thing. But if men are
doing it, then they are just potheads. I have seen women that have gotten that label too,
but in my family...
Sean: Women can get by with it more nonchalantly than a guy can, I think. You know
what I mean?
Darlene: My whole family was extremely gender oriented... Like, you need to cook, you
clean, but you can have a job…
Greg: So for females, it’s more acceptable because they're viewed as less important to the
family structure is what you mean?
Darlene: Pretty much, yeah.
Andrew: Yeah. Like, historically, they don't have to go out and be the breadwinner.
Sean: The same is true in my family, and they were a bunch of bible thumpers, but you
hit it right on the head…
Darlene: The man was the head of the household, the breadwinner…
Sean: Exactly. There were different expectations.
Greg: Yeah, more is expected from the breadwinner. And if you're smoking pot, then
you're not doing your best to provide for your family.
Sean: But you can go out and drink all you want to...
Greg: Yeah, yeah…
Since hegemonic masculinity encompasses attributes like career attainment, providing for
the family, and hard work (Schwalbe 2014; Peralta 2007; Connell 1995), cultural stereotypes
surrounding cannabis may be incompatible with the hegemonic ideal. If we believe cannabis
makes one lazy and unmotivated, then men who use cannabis are seen as failing to strive for the
hegemonic form of masculinity. Other research has suggested men can internalize these
stereotypes, possibly resulting in less personal confidence (Looby & Earleywine 2010). I believe
this is what happened to Alexander from Focus Group 4 who was unhappy with his “dead end”
job in construction (see Chapter 7). He connected his use of medical cannabis to lower career
attainment despite the existence of other factors like occupational discrimination through drug

231

testing, stagnating wages among the working classes, and more. Nonetheless, Alexander’s
account suggests the stereotype of being a cannabis user is counter to masculine ideals.
A final interesting example of the intersection between masculinity, medical cannabis,
and stigma concerns illness itself. Focus Group 2 continued their conversation from above:
Irene: I also think that medically speaking, men will face more stigma because they're not
supposed to have pain. They are supposed to be stronger and not complain about those
types of things.
Sean: Yep, and that goes back to what Greg said about men being the breadwinners.
Wanda: Right! Whereas with women, it all hurts and all the time, but men think it’s just
because we are super sensitive.
Irene: I think we should hook men up to that labor simulator, and then we can have this
conversation again.
Being a cannabis patient, in particular, requires admitting that something about one’s
health is bothersome. Patients must be certified by a physician where they discuss their pain or
discomfort, and in order to access medicine through a dispensary, a patient must show their
registry cards at every visit. These acts alone may be seen as unbecoming for a cultural definition
of masculinity based on toughness (Schwalbe 2014; Connell 1995). Fortunately, some evidence
exists that cannabis facilitates a reconsideration of hegemonic masculine attributes.

Cannabis Challenges Masculinity
Rather than saying that one gender experiences more stigma concerning cannabis use
(though this may indeed be true), my research illuminates how gender mediates cannabis-related
stigmas. Both men and women face stigma for using cannabis, whether it be medical or
recreational, perhaps indicating that cannabis is incompatible with traditional constructions of
gender. Yet this was perceived as somewhat positive to both the men and women in my sample.
For women, defying feminine ideals of sobriety can be empowering. For men, cannabis may
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facilitate alternative constructions of masculinity where aggression and indifference fade from
the picture. The men in Focus Group 3 acknowledge this:
Gavin: As I was growing up, I was on Ritalin as well as for most of my adult life until I
just like, enough is enough. With cannabis, they always told me it'll make you depressed.
Bullshit. It doesn't focus me like Ritalin as far as that part, but I find that I'm more than
willing to listen and therefore have a lot better chance of being reasonable, especially in
adverse situations. Like, if I was just on Ritalin alone, if I got into a car accident, chances
are tempers would flare... There would be some aggression or hostility. Whereas when
I'm on cannabis, I'm like, damn, are you okay?... You know, I would worry about the
other person because I have a whole different mindset.
Wade: I had an uncle and I'm sure he was smoking way before it was legal. He was
bright, like a hippie and stuff. You could tell when he wasn't smoking because when he
was smoking, he would become the nicest person. But when he wasn't smoking, you
would think he had some tequila or something, and he would be this angry, violent
person. But then when he was smoking, he was smiley, a lot calmer...
Gavin: In my opinion, when you're smoking, you have a tendency to do more inner
reflection. Like, you're laid back, and everything you kind of bottled up... You sit there
and you think about it, or last month’s events or, you know, instead of just popping on the
TV or reading the newspaper. I mean, there's a focus, and it's more inwards than
outwards.
These comments are similar to those made by men who use medical cannabis in
interviews done by Joan Bottorff and colleagues (2011). In that study as well as my own, men
credited cannabis with tempering the propensity towards anger that is culturally associated with
masculinity. Similar findings were uncovered by Eeva Sointu (2011) in her interviews of
individuals using CAM therapies. She found CAM challenges aspects of hegemonic masculinity
through focusing on emotional awareness, vulnerability, and intimacy. Indeed, alternative
medicines often provide a sense of tranquility and serenity achieved through an exploration of
one’s weaknesses.
Likewise, while my review of the literature in Chapter 4 cautions against inferring results
from drug studies on youth populations, these expressions are highly reminiscent of research on
boys who smoke cannabis (Haines et al. 2009; Warner et al. 1999). This tendency towards
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relaxation or tranquility was observed in some way within all five of my focus groups. Jimmy
from Focus Group 1, who identifies as a queer man, had an insightful perspective on this effect
where he likened hegemonic masculinity to a mask:
Jimmy: I do feel that role or that narrative that men put on to be masculine, like to be a
man and be aggressive and etc, I feel like those gender roles stem from previous trauma
or upbringing around masculine identity in the binary. So marijuana as a medical thing
kind of helps relax people so they don't have to stand with that mask in front of them.
The metaphor of a mask was even used by Wade from Focus Group 3:
Wade: I think the biggest misconception about medical marijuana is that it doesn't
actually help you. People still actually believe that, and it's bullshit, and they think we
just want to get high. If that's the case, then what's so bad that I would want to get high?
What you have to do is figure out what in your life is so bad where you think you have to
go out and do drugs to get through it. So therefore, you have to peel away... we have
mask, upon mask, upon mask in our persona. And you have to peel away all the layers to
get down to the core issue and deal with that core issue. And then you won't have a need
for all the things to make you forget that. Even though you might not think of it
consciously, it's still there nonetheless.
As the certifying physician I interviewed mentioned in the previous chapter, cannabis as
medicine facilitates a form of mindful reflection. Whether our attention is dominated by illness
or conforming to socially prescribed gender expectations, cannabis may allow us to deeply
examine the roots of our frustration, perhaps easing our break with social pressures to be manly
or act as if our lives are perfect.
Though cannabis is often described as calming, another explanation for the alternative
gendered expression with the cannabis community could be due to the type of people who are
attracted to the culture. Perhaps the kind of people who use cannabis are less invested in
mainstream cultural norms, including hegemonic gender norms. After all, cannabis has long been
position as a countercultural substance (Chasteen 2016; Becker 1973/1963), so maybe it appeals
to those who are less interested in adhering to dominant cultural codes. Yet the reality is likely
that it is a mix of drug, set, and setting (Lau et al. 2015a; Zinberg & Harding 1979), where the
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substance, individual’s motives for use, and cultural environment all impact the resulting effect.
While participants in my study did not have a consensus on the issue, we can see that
tridimensional construct being discussed in Focus Group 2:
Darlene: I think [cannabis] allows men to be different. Not just because they smoked, but
in that atmosphere…
Wanda: The social construct changes. Cannabis changes everything. It's a whole different
community, and the expectations of the way you should act are entirely different.
Darlene: Yes.
Greg: You were talking about socializing earlier… Cannabis has always determined who
is in my social circle. I have no friends that don't smoke. Period. It's a determining factor.
You're either in my life or you're not, and if you are in my life, then you smoke pot.
Darlene: I think it allows men to be more gentle and more calm… it lets them drop away
some of that social toughness they put on.
Wanda: Without feeling bad too, because everybody is calm and chill.
Greg: As I was saying, smoking together it's like a completely different social
construct… more akin to a Japanese tea ceremony than a bar.
Irene: I think it is more of the mindset in general, or the type of people that gravitate
towards cannabis more so than the actual cannabis use itself. I think it's more of the
people that are geared towards using it.
Sean: Right, it's the attitude of the person that determines how they behave on cannabis.
Andrew: Right, that's a huge factor.
While others have also found that men who use cannabis more readily break with
hegemonic masculine ideals (Taggart, Brown & Kershaw 2018; Dahl & Sandberg 2015; Haines
et al. 2009), it is unclear if cannabis causes this reformation of masculinity or if non-hegemonic
men are more drawn to consume cannabis. My research is unable to settle that debate, though I
did uncover structural factors that distance cannabis from hegemonic masculinity.
Firearms are strongly associated with masculinity, but existing laws forbid medical
cannabis patients and even cannabis users from owning or using firearms. The subject of gun
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rights was brought up in two focus groups, each time by men. However, there was a good deal of
confusion regarding the specifics of the law. Nonetheless, participants knew that guns and
marijuana were mutually exclusive in the eyes of the law, which was concerning to men in a
hunting state like Michigan. The exchange below from Focus Group 4 arose near the end of the
group after I asked if anyone had any final thoughts. Alexander brought up the subject of guns,
and he thought the law was about the proximity of a firearm to marijuana itself:
Alexander: There's a couple of things that we didn't discuss that I feel are a problem.
Moderator: Oh, sure. Go ahead...
Alexander: One is guns and medical marijuana... They're not allowed to be within a
certain amount of feet or whatever of marijuana. So now people don't have a way to
protect their homes or their marijuana.
Moderator: Really? It's by feet?
Alexander: Yep. And why is it okay for somebody who is drunk to have an open carry
license and wander around wherever? Whereas somebody who's growing marijuana
can't... or if you have your medical marijuana license, you can't carry a weapon.
Moderator: Can you still purchase a weapon, though, if your patient?
Audrey: I think you can purchase it as long as they don't know you have your card.
Alexander: Patient laws I don't know, because I only have looked into caregiver laws
because those pertain to me. Caregivers are not allowed to own any guns at all. But yes,
technically, yes. You can go purchase a gun, and they will give you the gun, but it is not
legal for you to own it. And I mean, they classify a lot of things as guns, you know, air
rifles, bows and arrows, and such. So, we're taking away somebody's amendment right
because they smoke or because they have medical marijuana. But now if I were to not tell
the state and I was just growing marijuana illegally, they could come in and bust me, and
if they found guns, I would not be charged for those guns.
The actual law related to firearms and marijuana is very confusing, but you still have to
pick one. The confusion stems from the fact that the federal government is responsible for
regulating the permissible use of firearms. Since the federal government defines cannabis as a
Schedule I prohibited drug, it is a violation of federal law to purchase, own, or operate a firearm
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(or ammunition) in conjunction with using cannabis31. This applies to both medical patients and
recreational users, the latter of which does not have to worry about having their information
available in a state database of registered patients. Technically, an individual must forfeit all of
the firearms upon becoming a patient, but states do not seem to consider it their duty to enforce
this provision. Nonetheless, when combined with the possibility of employment penalties, the
inability to lawfully own a firearm as a cannabis user may erect barriers to conforming to
hegemonic masculine ideals.

Conclusion
This chapter provides some of the first empirical evidence on how gender manifests in
the medical cannabis community. Overall, gender norms were adhered to in mostly traditional
ways, though cannabis patients appeared comfortable in eschewing some ingrained cultural
expectations about masculinity and femininity. Like research by Mullen and colleagues (2007), it
is likely these cannabis patients were more influenced by a complex combination of social
context and personal history over socially prescribed gender roles. Even when it comes to roles
within the community (growers especially), these appear to be more influenced by our societal
gendered division of labor than anything intrinsic to cannabis.
Nonetheless, something about cannabis appears to be associated with alternative
formations of masculinity. It could be an effect of the plant or how the subculture attracts a
particular type of man (or both), but cannabis facilitated a breaking with the hegemonic standard
of toughness and aggression. When we consider the structural stipulations that firearms are
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The United States Department of Justice, Bureau of Alcohol, Tobacco, Firearms and Explosives (BATFE) made
this clear in an open letter to all Federal Firearms Licensees on September 21, 2011:
https://www.atf.gov/file/60211/download
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incompatible with cannabis use, hegemonic masculinity within the cannabis community becomes
further unlikely. Does this mean that men who use medical cannabis feel subordinated among
other men? Absolutely not. While they were aware of cannabis stigmas and stereotypes related to
lower achievement, these were ultimately minor considerations when contrasted with the benefits
that cannabis bestows.
The women in my study appeared to reach similar conclusions about their use of cannabis
as medicine. They knew women were judged more than men for engaging in any deviant
behavior, but the judgments of others pale in comparison to the relief received through cannabis.
Instead of worrying over whether they were failing at feminine ideals of modesty, more
consequential sources of disapproval were those by their families or employers. The possible
exception to this concerns mothers who fear intrusion by CPS. While Haines and colleagues
(2009) found femininity impedes marijuana use among girls, my study suggests that being a
parent may impede medical cannabis use among women. This does not mean mothers are less
likely to use cannabis medicines, but rather that they recognize they face heightened social
disapproval. Remarkably, the mothers in my focus groups resisted the internalization of this
social attitude, even going as far as to credit medical cannabis with making them a better parent.
After all, untreated chronic illness or pharmaceutical side effects detract more from the parental
role than the opinions of others.
Perhaps the most conventional organization of gendered practices occurs among business
owners and business practices. The cut-throat culture of masculinized corporations is steadily
extending its reach over the newly legitimized industry, and this poses problems for more
cooperative models of dispensaries and cultivation facilities. In the “winner take all” world of
investment capital, those who already have vast sums of money have a better chance of gaining a
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foothold and squeezing out the competition. Unfortunately, men as a social group are the ones
who control most of this capital in our society, and the boy's clubs of the board room may soon
own a sizeable portion of cannabis businesses throughout the country. While the gray market
favored the (legal and financial) risk-taking propensity of masculinity, the legal market also
favors men in a society where men own and control most of the wealth and political power.
Regulations at the state level could be made more accommodating to women, racial/ethnic
minorities, and others who lack privilege in the economic realm, but when we look at the people
making such regulations, they tend to come from the more privileged groups in our society.
Ideally, social equity programs should be crafted and administered by the people such
programs are designed to help, but in lieu of such structural adjustments, resistance to the white
patriarchy of cannabis will have to come from elsewhere. The women I interviewed as key
informants were all involved in women-centered organizations like Women Grow, a national
association centered on empowering women in the cannabis industry. The resources and
community offered through such groups may be instrumental in combating male dominance in
the emerging industry. After all, most cannabis companies will fail as an overabundance of bigmoney interests are lured into investing through news reporting which makes consumer demand
appear more pronounced than it actually is. Likewise, all of the growers and business owners I
interviewed mentioned how growing top-tier cannabis is an astronomically tricky art. The same
individuals also expressed they were aware of many who tried to do so but ultimately failed due
to the naive rush to make a profit. When the investment bubble in the cannabis market inevitably
breaks, the mutual networking offered through organizations like Women Grow may allow
women to fare better than their individualistic male competition.
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CHAPTER IX

CONCLUSION
This study sought to illuminate the experiences of cannabis patients at a time where
adult-use (aka recreational) marijuana was becoming legalized throughout the nation.
Specifically, this study is the first to qualitatively investigate cannabis patients in the state of
Michigan, as well as the first to examine cannabis patients following the full-scale legalization of
marijuana. The use of focus groups as a primary method of inquiry is also novel among studies
on cannabis patients, as is the fact that the researcher is a complete member of the medical
cannabis community. While the broad scope of this research has been concerned with an array of
topics of interest to cannabis patients and users alike, these are both under-studied groups united
through their use of a historically maligned plant. Let’s consider what we learned by revisiting
the research questions.

Normalization Revisited
(RQ1) How does the medical cannabis community feel about the normative
status of medical cannabis in this moment of emerging recreational legalization?
And, what challenges do patients face in their social and professional lives?
Despite cannabis use increasing in American society, focus groups of cannabis patients
reveal that the plant still carries a deviant label and associated stigmas. This is not to say that
things have not improved following medical and recreational legalization—Indeed, criminal
penalties have decreased, media representations have diversified, and more people are using
cannabis than ever before. As such, it is no longer a substance exclusively confined to
criminogenic subcultures, rebellious youth, or other cultural outsiders. “Normal people” use
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cannabis, as do high-achievers like executives, athletes, and scientists. Nonetheless, the
acceptance of cannabis in society is uneven, and it appears we have a way to go before we can
safely say that cannabis is normalized.
The cannabis patients in this study report exercising discretion and experiencing anxiety
over their use of medicine. They are aware that even though their use is legal, social disapproval
is still found in family members, employers, school districts, neighbors, health care providers,
and the media. In particular, senior members in society have deeply internalized the anticannabis propaganda that pervaded public discourse for so long. While even the younger
generations can harbor negative sentiments towards cannabis, their views appear malleable when
confronted with compelling evidence on the plant’s benefits. The same may not be true with
older generations. When patients in my focus groups spoke of judgment from their families, it
was almost always on the part of their parents or grandparents. It is not surprising then that when
my focus groups and key informants spoke of generational cohort replacement, they often did so
with a sense of gleeful optimism. In the meantime, however, these disapproving individuals are
with us and cast their judgments through scorn, shunning, and civic engagement aimed at
preventing cannabis reforms.
Even though the media has improved in how cannabis is represented, they still perpetuate
stoner stereotypes in film and television. Some of my focus group participants found these
characterizations to be playfully humorous, while others found them distasteful or offensive.
Another source of ire was how news coverage of cannabis was often biased. Law enforcement
still appears to be a go-to source for commentary on cannabis-related events, and patients in my
focus groups were disheartened when airtime was given to opponents of legalization who cited
factually incorrect claims. Likewise, censorship still appears to be the default concerning

241

cannabis or related material. Subcultural literature is placed alongside pornography magazines,
while regulations on businesses and advertising marginalize the presence of the cannabis
community.
Perhaps the most significant evidence that cannabis has yet to be normalized is that of
employment discrimination. Card-carrying patients fear repercussions should their bosses or
coworkers discover they use cannabis since zero-tolerance, drug-free workplaces still appear to
be the norm. Even when patients find work that accepts their medicine, they feel trapped in their
current job for fear they will not be hired by others. This limits the occupational mobility of
cannabis patients and may even tarnish their sense of self. Likewise, the added psychic stress
associated with the mere possibility of drug testing may detract from productivity or satisfaction
with one’s work.
Finally, cannabis may be more or less acceptable based on group membership. If we
make the claim that cannabis is normalized, we may be doing so from a privileged position that
neglects the experiences of mothers and people of color. Generational membership also factors in
here since cannabis may be more normalization among youth, at least for the time being. Overall,
while cannabis may become normalized at some point in the future, this study cautions against
making such a sweeping claim at this moment in our society.

Medicalization Revisited
(RQ2) How do medical cannabis patients view the legalization of recreational
marijuana? And, do patients think medical cannabis will survive once marijuana
is fully legalized?
Cannabis patients in my focus groups welcome the post-prohibition world. They mostly
believe the plant should have never been criminalized to begin with, and that it should be
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accessible to all who seek it. Their primary concern about the legalization of recreational
marijuana was around how the state handles the situation. Overall, patients found existing
regulations too onerous and nonsensical, and they feared bureaucratic actions will somehow
reduce access to their medicine. For example, in December 2019, Michigan allowed the transfer
of medical cannabis into the state’s new adult-use system. This would not have been problematic
should it not have been for the banishment of caregiver-grown product from the medical system
earlier that summer. By requiring licensed provisioning centers to purchase only from licensed
growers (as opposed to hobbyists registered in the MMMP), regulators made medicine scare
leading up the rollout of recreational stores. It was a move that overwhelmingly favored the
interests of big businesses and corporate investors, and even though patients dreaded the arrival
of these players in the community, they favored legalization nonetheless.
Popular discourse frames medical cannabis as a hoax or intermediary phase on the path to
legalization, but that is not a sentiment shared by medical cannabis patients. The vast majority of
patients in this study plan to continue their participation in the MMMP even though adult-use
stores are emerging. Patients and key informants even commented that they have seen a growing
interest in medical cannabis following legalization in November 2018. This is likely due to the
reduction (not elimination) of stigma in the post-prohibition world as curious individuals no
longer feel in the wrong for experimenting with cannabis medicines. While the same substances
are available without a medical card, there is value in the legitimation a state-sponsored patient
registry provides.
Since the larger medical profession appears hostile to cannabis as a medicine, patients
benefit from having an alternative system that provides them with relief (and this relief may also
be greater than that received through allopathic medicine). Moreover, the relief cannabis
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provides also comes without toxicity, side effects, intrusive contracts, judgmental clinicians, and
dictatorial supervision. Patients favor the alternative medicalization of cannabis in that it restores
their control over their medical regiment, is more accessible than prescription-only medications,
allows them to reduce their reliance on pharmaceuticals, and drives patients to learn more about
their health, conditions, and medications. All in all, patients in this study desire this alternative
medicalization of cannabis to continue in the future. Although institutionalized medicine has yet
to incorporate cannabis into biomedicine, patients fear it is only a matter of time until Big
Pharma attempts to control the plant. Aside from increased understanding gained through clinical
trials, the patient community sees this as wholly negative.

Gender Revisited
(RQ3) How does gender shape the experiences of medical cannabis patients?
And, how might hegemonic gender roles be adhered to or challenged by cannabis
patients?
Hegemonic gender roles influence how gender is experienced in the cannabis community,
but patients also report a willingness to eschew some of the constraints placed on traditional
notions of femininity and masculinity. The consensus seemed to be that women face more stigma
than men for using cannabis, either medically or recreationally. This is likely because women are
judged more for engaging in any deviant behavior as cultural constructions of femininity demand
modesty and subservience on the part of women. Using cannabis may signal that one is
challenging cultural codes, and perhaps men even feel more empowered to call out the women
they find doing so. Women in this study reported using more discreet cannabis products than
men, but at the same time, they placed little consideration on the gendered messages their use
conveyed. Some women even expressed that using cannabis was empowering to their sense of
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self. Additionally, nearly all participants in this study denounced the sexualization of women by
cannabis businesses, advertisers, and the media. Nonetheless, a traditional gendered division of
labor was evident in how growers and budtenders were primarily male.
Cannabis may also facilitate a break with hegemonic constructions of masculinity.
Women in the focus groups commented on how cannabis appears to mellow men, and the men
agreed. Instead of the dispassionate toughness favored in our culture’s male archetype, men who
used cannabis were said to be more willing to examine their emotions while quelling anger or
aggression. This may be an effect of cannabis or related to the type of men who are drawn into
cannabis culture, but something about the plant appears to encourage an alternative construction
of masculinity. Similarly, structural limitations on gun rights and employment protections may
impede male cannabis users who strive for the hegemonic ideal. Finally, while this
reconstruction of masculinity is not total, it seems to be a healthier and more positive version of
manhood than that which is celebrated throughout our society.

Sociological Contributions
My dissertation expands sustentative knowledge related to medical cannabis and gender.
Sustentative theories are those which address problems in a discipline’s subareas, such as
theories applied to medicalization and masculinities (Charmaz 2006). Despite sustentative
knowledge having a good degree of utility, it is important to remember all theories are rhetorical
in that they do not exist independently of the data on which they are based. Formal theory, on the
other hand, is concerned with discipline-wide theories, especially those that link together
substantive areas. These theories speak about causal relationships between subareas by using
general theoretical models that can be applied to any given topic. The formalist approach is more
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related to the positivist paradigm which concerns itself with explanations and predictions.
Despite the generalizing tendency of this approach, qualitative explorations of substantive areas
can help refine formal theory (Charmaz 2006).
Generalizability has also not been a concern of my study, though some degree of
transferability can be established wherein results can illuminate similar groups, situations, or
contexts (Marshall & Rossman 2011). My research is descriptive with the goal of broadening
understanding of how medical cannabis patients perceive their situation in a unique moment of
recreational legalization. Nonetheless, my findings may be of use of others interested in
researching cannabis, medicalization, normalization, and gender. The important thing to keep in
mind here is to generalize or transfer with extreme care (Marshall & Rossman 2011).
My research also has a goal of empowerment. Medical cannabis patients exist in a social
environment which discredits their use of medicine and doubts their identity can continue when
recreational marijuana is fully legalized. According to Denzin (2013), qualitative research can
also be evaluated by its moral, ethical, and political commitments. From this perspective, which
borrows heavily from feminism, claims to knowledge are judged relative to their ability to
empower. Feminist researchers, for example, have a shared goal of empowering women and
dismantling patriarchal oppression (Fonow & Cook 2005). They make no apologies for their
political commitments and do not attempt to hide their position by using convoluted language.
Essentially, this way of doing sociology uses passion as motivation and produces practical
research that can be utilized in the pursuit of social change (Denzin 2013; Denzin & Lincoln
2013; Fonow & Cook 2005). Furthermore, Altheide and Johnson (2013) say the validity of a
study can be established by its utility and potential for empowerment, something they term
validity-as-relevance/advocacy.
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Many scholars now believe sociological research should be useful for those who
participate in the study and oriented towards social justice. While some researchers may feel that
this would compromise sociology’s supposed value-neutrality, this idea of neutrality is
illusionary, as sociology as a discipline is firmly embedded in webs of power, values, and
ideology (Denzin & Lincoln 2013). Moreover, there is a good reason for doing sociological
research based on its potential for social justice. Aldon Morris (2017) argues that some of the
greatest insights made in the discipline have come from scholars who saw sociology as a science
of human emancipation. The pedantic and oppressive push towards value-neutrality has neutered
the transformative potential of sociology and has led to theories that are unengaging and abstract
(Morris 2017). The way to change this is by rewarding research that serves a purpose other than
standard contributions to a discipline’s knowledge base.
My research may not be liberating, per se, but I hope it is affirming for patients in my
focus groups and all those who use cannabis as a medicine. I also hope my work can be used to
sustain the viability of medical cannabis in a time of emerging recreational legalization. This
research is highly value-laden for a good reason. Most commentators on medical cannabis have
no affinity to the issue, and they write as if medical cannabis will be nothing more than a
footnote in the history of marijuana legalization. My results here should not be interpreted as
conclusively disproving such theorizing. Rather, findings from this study should be used to
maintain a dynamic dialogue between scholars, policymakers, health care providers, and
entrepreneurs as laws change and new issues arise.
Medical cannabis patients and non-patient aficionados are a heterogeneous group, but
researchers tend to adopt singular frameworks that nullify diverse perspectives and experiences
(Newhart & Dolphin 2019; Temple et al. 2010). I hope I have problematized the single story of
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cannabis as framed through normalization, much like feminists successfully problematized the
single story of gender as framed through sex roles. Feminists have taught us all that much can be
learned by embracing and exploring ambiguity and uncertainty (Flax 1987). After all, “feminist
objectivity makes room for surprises and ironies at the heart of all knowledge production; we are
not in charge of the world” (Haraway 1988:594). I think it would be a wonderful thing if
cannabis scholars and commentators adopted a similar stance of infinite possibility rather than
absolute certainty. The social history of cannabis in American society is still evolving, and we
should resist the urge to impose totalizing frameworks during this transformational time.
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APPENDIX A
CANNABIS IN THE UNITED STATES
Cannabis Enters the Western World (prehistory to 1800)
Like all earth medicines, therapeutic uses of cannabis stretch back thousands of years,
and though the plant is believed to have originated in Asia and the Middle East, localized
varieties of cannabis are now found on nearly every continent (Preston 2002). Yet applications of
the plant extend far beyond medicine. Archeological evidence suggests cannabis is one of
humanity’s oldest cultivated crops with uses of hemp fiber appearing around the same time as
pottery making, approximately 10,000 years ago (Herer 1985). Likewise, for most of recorded
history, cannabis was primarily used as an entheogen (Ferrara 2016; Chasteen 2016).
Cannabis was an important crop throughout Europe for around 2000 years dating back to
at least the fifth century BCE. It was used for fiber, food, and medicine, and texts of the time
speak to slight effects “on the head.” Early Christians even considered the plant to be magical
and they would sow seeds on the days of saints who were known to be tall (Lawrence 2019).
Yet cannabis became heretical following a mandate by Pope Innocent VIII in 1484. His papal
fiat was part of the Church’s war on pre-Christian traditions which included witches’ unguents
and potions containing hemp extracts (Lee 2012). In this papal condemnation of witchcraft,
cannabis was explicitly cited as an anti-sacrament since pagan masses of the era commonly
featured cannabis in place of wine. As Michael Pollan postulates, “The fact that witches and
sorcerers were the first Europeans to exploit the psychoactive properties of cannabis probably
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sealed its fate in the West as a drug identified with feared outsiders and cultures conceived in
opposition: pagans, Africans, hippies” (2001:174).32
As for the Americas, historian John Charles Chasteen (2016) says there is a dearth of
information about cannabis prior to 1900, but it is likely that hemp was introduced on the
continent in the 1500s by the Spanish. Perhaps the first cultivation came when one of the
Spaniards led by Cortez forced his indigenous laborers to plant hemp around Mexico City in the
1530s. However, Lee (2012) says the first documented instance of cannabis in the Western
Hemisphere occurs in the early 1500s in Brazil where slaves working on sugar plantations
miraculously managed to bring seeds with them from Africa. Yet these plants were for
commercial purposes as there are no accounts of cannabis being used as a recreational intoxicant.
The first recorded instance of intoxication came in the 1760s when a Catholic priest learned
indigenous people around Mexico City were eating something known as pipiltzintzintlis. The
cannabis-containing concoction was used to access the spirit world, and as such, the Catholic
church condemned it once again as pagan (Chasteen 2016). Indeed, indigenous peoples in the
early Americas primarily utilized the plant’s psychoactive properties for spiritual pursuits:
“Psychoactive plants are bridges between the worlds of matter and spirit or, to update the
vocabulary, chemistry and consciousness” (Pollan 2001:144).
As a historical commodity, cannabis was primarily used as hemp where it had a vast
range of applications including ropes, textiles, and sails. Hemp was so versatile and valuable that
Jamestown Colony ordered all farmers to grow hemp starting in 1619 (though it was introduced

“Christianity and capitalism are both probably right to detest a plant like cannabis. Both faiths bid us to set our
sights on the future; both reject the pleasures of the moment and the senses in favor of the expectation of a
fulfillment yet to come—whether by earning salvation or by getting and spending. More even than most plant drugs,
cannabis, by immersing us in the present and offering something like a fulfillment here and now, short-circuits the
metaphysics of desire on which Christianity and capitalism depend” (Pollan 2001:175).
32
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in North America in 1606). Other colonial settlements adopted similar laws, and it is even true
that hemp was accepted as tax payment for over 200 years (Herer 1985). The importance of
hemp in Colonial America is evidenced by the numerous variations of town names like
Hempstead, Hemp Hill, and Hemp Field. An English-language guidebook for raising hemp was
first published in 1765, popularizing and refining hemp production throughout the young country
(Lee 2012).

Medicine, Marijuana, and Hashish (1800 to 1910)
While cannabis was used for thousands of years in different ways, it is Dr. William
O’Shaughnessy who is credited with popularizing its medicinal uses in the Americas in the
nineteenth century. In 1839, O’Shaughnessy reported Ayurvedic medical practitioners in India
were using hemp extracts to treat all sorts of illnesses his Western colleagues thought
untreatable. His work directly influenced the listing of cannabis in the U.S. Pharmacopoeia from
1854 to 1937 where it was used for over 100 separate conditions. Many patent medicines like the
famous Tilden’s Hemp Extract would go on to use cannabis as their primary ingredient (Herer
1985). However, while O’Shaughnessy’s reports predominantly frame cannabis as a harmless
and useful medical tool, he also acknowledged rare instances of delirium. These exceptions
helped fan the flames of preexisting rumors that cannabis induced violence and sexual
aggression, and the later was particularly terrifying in the prudish Victorian era (Lawrence
2019). This re-discovery of cannabis as medicine was also happening around the same time that
industrial hemp fiber production was beginning to decline, thanks to the inventions of the cotton
gin and steamship (Herer 1985).
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Yet cannabis is not only an industrial commodity or a medicine. It can also become an
intoxicating euphoriant when the female buds are heated. Martin Lee claims plantation owners in
Brazil permitted slaves to cultivate and smoke cannabis since it appeared to make them better
handle their work in the brutal tropical heat. He also says linguistic evidence suggests that the
word marijuana came from the Portuguese word for “intoxicant,” mariguango (Lee 2012). When
the Mexican Academy of Pharmacy published the nation’s first pharmacopeia in 1846, it noted
Cannabis sativa was used for medicinal hempseed oil while a sperate entry for “Rosa María”
was used for “narcotic leaves.” The pharmacopeia also listed another name for Rosa María as
mariguana, and in the 1850s, a pharmacist noted for the first time that it was smoked in
cigarettes (Chasteen 2016:54).
As for north of the Equator, unconfirmed accounts suggest Native Americans used
cannabis for many purposes, though likely primarily as an entheogen, following its introduction
to the continent in the sixteenth century (Ferrara 2016). Since it is unclear if they smoked it for
insight or pleasure, the first reliable reports of recreational marijuana smoking come from
Jamaica in the 1870s. “Ganja” was introduced to Jamaica by Indian indentured servants
following the abolition of slavery on the island in 1834 (Lawrence 2019; Chasteen 2016).
Smoking ganja was later adopted by sailors, many of whom were Black or Latino, who spread
the practice to Mexico and the southern United States. Cannabis was thought of as the “opium of
the poor” and “those of a more affluent standing tended to blame the problems of the less
fortunate on the consumption of cannabis. Its initial association with the dregs of society… made
marijuana a convenient scapegoat for deep-rooted social inequalities” (Lee 2012:39). The first
recorded instance of cannabis being smoked in the United States was by Mexicans in
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Brownsville, Texas in 1903. That same year the region passed the nation’s first marijuana
prohibition law though it applied only to Mexicans, not white people (Herer 1985).
Interestingly, white people were already accustomed to the idea that cannabis contained
intoxicating properties, but they were more familiar with cannabis as hashish as opposed to
marijuana. Hashish appeared in the Middle East around the year 1100, but it did not become
well-known in Europe until Napoleon’s army returned from their failed conquest of Egypt in
1798. At first confined to a few bohemians who chronicled exotic experiences in art and
literature, hashish eating became vogue by the 1840s when it was consumed by luminaries like
Honoré de Balzac, Victor Hugo, Charles Baudelaire, and Alexandre Dumas who featured
hashish in his adventure tale, The Count of Monte Cristo (Chasteen 2016). Around the same
time, an American travel writer named Bayard Taylor published a book recounting his trip to
Egypt where he consumed a large dose of “hasheesh.” Taylor’s vivid description of the high
inspired fellow American writer Fitz Hugh Ludlow to down an entire bottle of Tilden’s Cannabis
Indica, a common hash-based elixir of the era. Ludlow published his experience in his 1857 bestselling book, The Hashish Eater: Being Passages from the Life of a Pythagorean. This is perhaps
the first time cannabis and hashish enter into popular discourse within the middle and upper
stratas of American society (Lawrence 2019; Chasteen 2016).
Just like the current popularization of candies and other edibles containing cannabis
extracts, Americans in the nineteenth century were perhaps most familiar with a hashish
confection. In the 1860s, the Gunjah Wallah Company began selling a maple sugar candy with
hashish throughout the United States. It was immensely popular and easy or order through
catalogs like Sears & Roebuck. Both general Ulysses S. Grant and general Robert E. Lee would
endorse the candy as a medicine and stimulant for tired, wounded soldiers. Physicians, however,
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were quick to condemn the candy as quack medicine, though it would remain available until the
turn of the twentieth century (Lawrence 2019).
The fad of hashish eater’s clubs eventually reaches the United States where there was a
Turkish Hashish Pavilion at the Philadelphia Centennial Expedition in 1876. Afterwards, several
hashish parlors popped up in New York City, Chicago, and San Francisco. These establishments
were typically patronized by middle- and upper-class citizens while patent medicines containing
cannabis were available to all, though few knew hashish and medicinal cannabis extracts
contained the same psychoactive substance (Lawrence 2019; Chasteen 2016). There were also
sensationalized press accounts of the era decrying the phenomenon in publications like Harper’s
and The New York Times.
Perhaps since hashish was eaten and cannabis extracts were primarily a medicinal
ingredient, few Americans understood these came from the same plant as the marijuana smoked
by cultural outsiders. Throughout the 1910s and 1920s, recreational uses of marijuana were on
the rise throughout the country, and many states responded by passing laws banning the plant.
California and Utah were the first to enact state-wide marijuana prohibition in 1915 (Torgoff
2016) though El Paso, Texas, did so a year earlier (Lee 2012). While smoking marijuana was a
relatively recent introduction in the United States, scholars have also identified at least three
overlapping social currents that help explain these early efforts to prohibit marijuana.
The first and most often cited is that of xenophobia spurred further by economic
uncertainty. Mexican immigrants (and to some extent those immigrants from India) brought with
them the cultural practice of smoking marijuana, and it was soon adopted by other cultural
outsiders including black jazz musicians (Chasteen 2016; Torgoff 2016; Chapkis & Webb 2008;
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Gahlinger 2004; Marez 2004)33. Secondly, Conrad and Schrieder (1980) identify the growing
social awareness of addiction to (relatively new) intoxicating medicines like heroin and cocaine.
Widely used by doctors without thought given to their addictive qualities, these were ultimately
tightly regulated by the Harrison Narcotics Act of 1914 which asserted the first legal distinction
between recreational and medical drug use on the federal level (Fyre 2018; Lee 2012). Finally,
this was an era marked by a prohibitionist reform movement towards all intoxicants but most
notably that of alcohol. Federal prohibition of alcohol would be established after the ratification
of the Eighteenth Amendment in 1920 and would continue until 1933. With these three factors in
mind, it is hardly surprising that by the time the federal government passed the Marihuana Tax
Act of 1937, 38 of the 48 states had already enacted laws prohibiting marijuana (Torgoff 2016).
34

Jazz and Marijuana (1910s to 1930s)
An under-cited segment of marijuana’s history in the United States is that of jazz culture.
Scholars tend to begin their narratives in the counterculture of the 1960s though developments in
the roaring 1920s were equally impactful. Marijuana first appeared on the streets of New Orleans
sometime around 1910 when jazz culture was sprouting in vice-heavy neighborhoods like
Storyville. Realizing there was too much fun to be had for innocent young servicemen, in 1917
the U.S. Navy closed Storyville by banishing prostitution and drug use from the neighborhood
(Torgoff 2016). This occurred during the same time the Great Migration where African

33

Sociologist Curtis Marez (2004) notes that arrests of Mexicans for smoking marijuana were most common in
places and in times of labor organization efforts, particularly those led by Mexican anarchists and revolutionaries.
Arresting workers for smoking marijuana was a particularly convenient way for the nativist Texas Rangers to quell
collectivizing before it began.
34
Xenophobia was also a key factor in Canada’s decision to ban cannabis in 1923. The targeted group in this
instance were Chinese immigrants who occasionally consumed hashish. Among other sensationalized claims,
Canadian propaganda warned that hashish would lead white women to have mixed-race babies (Lawrence 2019).
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Americans were leaving the South for more industrious urban centers in the North. Many New
Orleans jazz musicians would join this migration, including Louis Armstrong, who would only
become enamored with marijuana after moving to Chicago in 1921.
Cultural historian Martin Torgoff says, “[Armstrong] became the first in a line of
powerful musical innovators and improvisers who are renowned for the use a particular
substance, and who also changed the face of music after them” (2016:44). He was even the first
celebrity in American history to be busted for pot when he was arrested in Los Angeles in 1930.
Though Armstrong was forced to apologize and publicly denounce marijuana, he continued to
smoke it regularly (probably daily) throughout his life (Torgoff 2016). Yet this was not purely a
recreationally-oriented style of use, for jazz musicians like Louis Armstrong also saw cannabis
as a way to self-medicate in the face of an exclusionary white society: “Armstrong said he used
reefer to unwind, to relieve stress, to ease the chronic pain of racism. Smoking marijuana helped
him deal with the daily humiliation meted out by Jim Crow- white society’s relentless, sickening
assault on his self-respect” (Lee 2012:12). It is likely cannabis found its way into numerous
African and Southern folk medicines of the era, and these remedies were more familiar to
impoverished musicians than anything the medical establishment had to offer.
The “New Orleans golden leaf” also moved from Chicago to New York and beyond:
Marijuana was hitting Harlem at a crucial moment in its history. Along with jazz,
it became a part of the experience of the first generation of African Americans to
come of age in New York after the Great Dispersal had transformed Harlem from
a small middle-class neighborhood with housing designed for sixty thousand into
a black city-within-a city of three hundred thousand. It arrived right at the time
when the promise and cultural fermentation of what had become known as the
Harlem Renaissance of the 1920s was fading, dissolving away to the despair of
the Great Depression, which would hit African Americans so hard (Torgoff
2016:32).
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Above all other places, Harlem cemented marijuana’s association with jazz music and an
underground culture. While Chasteen (2016) says only Mexico, Jamaica, and Brazil had local
traditions of intoxicating cannabis use prior to the 1960s, by the early 1930s, marijuana had
become a central part of the night club experience in most major American cities. At first it was
smoked openly on the dance floor, but mounting disapproval eventually forced smokers into
more discreet areas such as the bathrooms, cloakrooms, or telephone booths. There were even
entire establishments called tea pads dedicated to the after-hours crowd who wanted to relax,
smoke marijuana, and listen to music on a Victrola. These jazz-centered establishments lacked
the sophistication of fancy night clubs frequented by white people, and this helped solidify
marijuana’s status as something outside of the mainstream culture. It was also a cheap, easy, and
fun way to let loose as evidenced in the scores of jazz songs where marijuana is presented as a
mild and safe euphoriant rather than the demonic drug narrative pushed by the Federal Bureau of
Narcotics (Torgoff 2016).

The Marihuana Tax Act (1930s to 1960s)
The way the federal government would go about banning marijuana was through a
prohibitive tax. Yet in 1937 there were 28 pharmaceutical products containing cannabis on the
market (Torgoff 2016). For the most part, politicians, police, and the media had virtually no idea
that the marijuana used by Jazz musicians was just a weaker version of the potent cannabis
medicines they'd been taking since childhood (Herer 1985). So, when hearings for the Marihuana
Tax Act (MTA) began, the little-understood plant was easily distorted by fear-mongering
bureaucrats like Harry Anslinger.
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Harry Anslinger had worked in various enforcement agencies focused on thwarting
narcotics trafficking throughout his early career. Yet he was relatively silent on marijuana issues
until he was appointed to the new Federal Bureau of Narcotics (FBN) in 1930. What made
Anslinger despise cannabis so fervently? One could argue it was a paternalistic sense of morality
(McWilliams 1990), but sociologist Howard Becker believes Anslinger’s war on weed was
primarily undertaken to justify the existence of the new FBN. Manufacturing a marijuana
epidemic provided the bureau with a clear and urgent task for the floundering bureau, thus
making Anslinger a moral entrepreneur in exploiting deviance to advance his own interests
(Becker 1963). He also tactfully exploited pre-existing societal fears based in racism and
xenophobia, but perhaps most notably, he cited an Islamic legend as proof of marijuana’s ability
to provoke violence.
In the 1100s, an Islamic sect based in Syria was rumored to recruit innocent young men
to become assassins with the aid of a vision-producing potion thought to contain cannabis.
Specifically, these were religious dissenters known as the Nizari Ismailis but called “hashish
eaters” as a slur by other Muslims. Their leader was Hassan-ibn-Sabbah, also known as the Old
Man of the Mountain, who is widely seen as an Islamic heretic. This sect resorted to radical acts
including assassination, and while the legend diverges much from true events of the era, it has
been extensively cited as proof of cannabis’ evil properties. In fact, the Islamic word for hashish
(hashishin) is derived from their word for assassins (ashishin) (Lawrence 2019; Chasteen 2016).
Anslinger’s narrative portrayed marijuana as the assassin of youth, something that could trigger
aggression in non-white people, and a gateway to interracial romance. Author Martin Lee also
adds:
In addition to hexing blacks and Mexicans, Anslinger’s antimarijuana diatribes
served as a not-so-subtle reminder to white women, who had only recently won
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the right to vote, that they still needed strong men to protect them from the
“degenerate races”. He never tired of telling new versions of the same morality
tale, which featured a vulnerable young white woman whose tragic downfall is
triggered by smoking marijuana with dark-skinned rogues (Lee 2012:52).
As a moral crusader, Ansliger fabricated sensational stories, ignored facts which did not
match his worldview, and deliberately excluded non-sympathetic authorities from public
hearings regarding cannabis. In fact, during congressional deliberation on the MTA, only one
expert witness was ever called from the American Medical Association. This witness was
quickly dismissed for challenging Anslinger’s views by testifying cannabis had been a safe,
respected medicine and that addicts needed treatment and education, not punishment. More time
was spent hearing from representatives from companies that utilized parts of cannabis plants for
industrial purposes, most notably that of the birdseed industry and the Sherwin Williams Paint
Company (Torgoff 2016; McWilliams 1990; Becker 1973/1963).35 This was an issue where
“[y]ellow journalism, racial bias, and political opportunism had triumphed over medical science
and common sense” (Lee 2012:54).
Like the Harrison Narcotics Act of 1914, the MTA of 1937 permitted use of the drug for
medicinal purposes but required prescribing doctors to register with the federal government and
pay an exorbitant tax of $100 per ounce (Lawrence 2019). After these new bureaucratic
requirements, many doctors stopped prescribing marijuana, and the plant gradually fell out of
medical texts and the standard pharmacopeia (Pacula et al. 2001). Even before the MTA,
cannabis medicines were on the decline thanks to the popularization of pharmaceutical tablets
during the early twentieth century. Patent medicines with cannabis were commonly in the form
of alcohol or oil-based tinctures, and since production methods and the type of cannabis used

35

Howard Becker (1973/1963) also notes that during the hearings associated with the Marihuana Tax Act of 1937,
marijuana smokers did not have their view entered into the public record. They were unorganized and thus
powerless to protect the plant during the brief debate on prohibition.
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varied, the effects of these tinctures were unpredictable. Pills provided physicians and patients
with a means to dose medication in a consistent manner (Fyre 2018). As such, the MTA was
likely the final nail in the coffin for cannabis medicines in the United States.
Perhaps the most authoritative challenge to the MTA came from a 1944 report
commissioned by New York City Mayor Fiorello La Guardia. The report was both sociological
and clinical, and found marijuana did none of the things purported by the Federal Bureau of
Narcotics: it did not make users commit crime, it was not addictive, it did not lead to other types
of substance use, and it was not associated with juvenile delinquency. The FBN quickly
condemned the La Guardia report and quietly worked to have it removed from American
libraries (Torgoff 2016; McWilliams 1990; Herer 1985).
Censorship, denial, and refutation became the line of march for the government
concerning anything to do with cannabis. The only exception was made during World War II
when the USDA encouraged farmers to plant hemp by subsidizing mass cultivation, even making
make a 15-minute promotional film called Hemp for Victory (1942). Following such victory, law
enforcement spent countless hours trying to eradicate the non-psychoactive hemp plants which
had escaped farmer’s fields while the government set out to destroy all copies of the film and
strived to eliminate all knowledge of the wartime hemp program from public record (Lee 2012;
Herer 1985). They were successful at first, and the government denied the film ever existed until
1989 when hemp activists donated two exhaustingly-recovered copies to the National Archives.
This is just one of the many examples of how the government would attempt to monopolize
information on marijuana, thus creating a legacy that would long outlive the law itself36:

36

Another telling example of government censorship concerns something said on television by poet Alan Ginsberg.
Appearing on the John Crosby show in 1961 along with Ashley Montagu and Norman Mailer, Ginsberg said in their
discussion on modern sensibility that marijuana should be legalized or decriminalized. Montagu agreed and Mailer
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The moral panic and press sensationalism of [Anslinger’s] antimarijuana
campaign, along with his penchant for playing fast and loose with the facts about
drugs in America, established the template for all of the drug hysterias that
followed. It was Anslinger who first institutionalized the entire ideology of drug
prohibitionism that launched our drug war (Torgoff 2016:345).
Marijuana would be a relatively unknown drug throughout the 1950s where it was largely
consigned to underground cultural circles such as the Beat poets and novelists. Celebrated
literary works like Jack Kerouac’s On The Road (1957) helped construct marijuana as a hip
substance and are partly responsible for the resurgence of interest in marijuana as a
countercultural drug and therapeutic substance in the 1960s. The Beats get their name from their
bucking of a culture where “the good life” was characterized by holding a steady nine-to-five job
to fuel one’s addiction to consumerism. Straight society, as they called it, left them feeling
beaten down and exhausted to the point where they disconnected from the national mood. The
Cold War had also begun, and defeating communism meant working as hard as one possibly
could with unflinching patriotism. Perhaps this is why Harry Anslinger shifted his rhetoric to
depict marijuana as the drop-out drug, something that would pacify Americans and facilitate the
Red’s takeover of our hardworking country (Torgoff 2016; Lee 2012). This, of course, was the
total opposite of the crazed, aggressive marijuana fiend sensationalized in previous decades. But
then again, facts were never a priority to Anslinger.
Facts do matter, though. “As the use of marijuana soared among middle-class youth,
officialdom started to get anxious, especially when the sons and daughters of prominent
politicians were caught smoking it” (Lee 2012:80). In the early 1960s, marijuana-related arrests

along with Crosby even admitted to trying it before without negative effect. After the broadcast, the Federal
Communications Commission forced CBS to run a 7-minute PSA made by the Narcotics Bureau that denounced
Ginsberg, Montagu, and Mailer. Enraged by this official, mandated rebuke of a citizen’s freedom of speech,
Ginsberg began to compile an archive of government lies regarding marijuana. The information Ginsberg collected
would become valuable in the ensuing fight for marijuana reform (see Torgoff 2016 and Lee 2012)
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for whites were on the rise, and President Kennedy, dissatisfied with the FBN’s assault on his
people, sacked Anslinger in 1962. Though still fervently anti-marijuana, the National Institutes
of Health (NIH) was able to convince the FBN to permit the funding of research exploring the
plant. Partly funded by the NIH, a breakthrough came in 1964 when Dr. Raphael Mechoulam at
the University of Tel Aviv discovered THC, and for the first time, scientists understood exactly
what produced the sensation of being high (Lee 2012; Herer 1985)37. The United States
government even began sponsoring some research into the therapeutic uses of natural cannabis in
1966. Most important of all, The MTA would be overturned by the Supreme Court in their 1969
decision on Leary v. United States. Psychedelic activist Dr. Timothy Leary (the ex-Harvard
professor who told the world to “turn on, tune in, drop out”) had been arrested in 1965 for
possession of marijuana at the U.S./Mexico border. He successfully appealed his case on the
basis the MTA violated the Fifth Amendment since you had to incriminate yourself in order to
pay your marijuana taxes. However, this would prove to be little more than a personal victory for
Leary since Congress was already working on a new drug law (Torgoff 2001).

Sociology and the Marijuana Tax Act.
The MTA’s legacy is one of lasting disgrace and embarrassment on the part of the
government. Official statements on cannabis made by Harry Anslinger and the FBN have about
the same degree of integrity as Donald Trump’s Twitter account. As I hope this dissertation has
made clear, prohibition not only limits a drug’s availability, it also limits social and scientific
understanding of the drug. Federally mandated prohibition effectively creates a monopoly on

37

Mechoulam would later discover a non-psychoactive THC metabolite in urine, the compound leftover after the
body breaks down psychoactive THC. He regrettably did not patent his discovery which would serve as the
foundation for drug testing urine (Lee 2012).
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information about a substance because it is unavailable to others, including researchers. In the
early twentieth century, almost all commentary on prohibited drugs came from the very
government officials and organizations that established the laws. In situations like this, lies
readily replace facts to further support a political agenda. Yet throughout the twentieth century,
the discipline of sociology provided valuable critiques of these policies based on myths, fears,
and exaggerations.
Sociologist Bingham Dai was one of the first to actually ask drug users about their lives
rather than rely on information from authorities. His book, Opium Addiction in Chicago (1937),
is cited as the first drug ethnography in American history (Torgoff 2004). Alfred E. Lindesmith,
a sociologist and student of Dai’s, furthered this line of work with a series of books refuting
claims made by the Federal Bureau of Narcotics. In fact, Lindesmith would become an avowed
enemy of Harry Anslinger as the nation’s first drug czar repeatedly attempted to have Lindesmith
fired from his tenured position at the University of Indiana (Torgoff 2004; McWilliams 1990).
The poet Alan Ginsberg spent an entire summer in Lindesmith’s basement pouring over the
sociologist’s curated archive of marijuana-related documents (Torgoff 2016). He would use this
information to fight marijuana prohibition in addition to writing a piece in The Atlantic Monthly
called “The Great Marijuana Hoax: First Manifesto to End the Bringdown”:
Not only do I propose the end of prohibition of marijuana but I propose a
total dismantling of the whole cancerous bureaucracy that has perpetrated this
historic screw-up on the United States. And not only is it necessary that the
Bureau of Narcotics be dismantled & consigned to the wax museum of history,
where it belongs, but it is also about time that a full-scale congressional
investigation with all the resources of the embattled medical, legal & sociological
authorities, who for years have been complaining in vain, should be undertaken to
fix the precise responsibility for this vast swindle on the administrative & massmedia shoulders where it belongs (Ginsberg 1966).38
Ginsberg’s sociologically-inspired essay on the intellectual uses of marijuana may have influenced Carl Sagan to
experiment with the plant. Sagan eventually wrote an anonymous essay on marijuana in 1971 under the pseudonym
38
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Other sociological research helped to dispel the myths that drug addiction was permanent
and required forced abstinence in order the save the addict. Work by sociologists like Everett
Hughes and Charles Winick brought about our understanding of often-temporary deviant careers
and drug lifestyles, and these revelations directly influenced Howard Becker. One of the most
prominent sociologists in the United States, Howard Becker is well known for his works
“Becoming a Marijuana User” (1953) and “Marijuana and Social Control” (1955). These each
directly challenged the anti-cannabis narratives concocted by Harry Anslinger and the FBN, the
precursor to the DEA. Above all else, Becker found marijuana use did not lead to violence and
insanity, but rather users learned to perceive marijuana as pleasurable and calming.
These classic studies have since informed much social scientific research about drugs, but
they were written in a context where medical cannabis had faded from academic discourse. As
such, while Becker’s studies are immensely valuable in combating anti-drug hegemony, his work
has little direct influence on my study. My point in raising it here to show that sociologists have
long been on the front lines of the war drugs, though often in opposition to the lies spewed by the
government. It fills my heart with joy to know that in retirement, Anslinger complained about
“permissive parents, college administrators, pusillanimous judiciary officials, do-gooder
bleeding hearts and new-breed sociologists with their fluid notions of morality” (Harry Anslinger
as quoted in McWilliams 1990:186).

Mr. X. where he praises being high as a means of attaining profound insight while lamenting the difficulty of
believing such insights (which he swears are real) when sober. Like the mystics who consume entheogens to
experience something beyond the confines of normative human perception, “[w]e simply don’t have the words to
convey the force of these perceptions to our straight selves” (Pollan 2001:167).
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A Schedule I Controlled, Dangerous Substance (1970s to 1980s)
Despite the MTA being overturned, the federal government had already been working on
a replacement that would make cannabis a flat-out prohibited substance in all forms. The 1970
Comprehensive Drug Abuse Prevention and Control Act (now called the Federal Controlled
Substance Act of 1970) created five categories or “schedules” of drug regulation based on a
drug’s potential for abuse and the drug’s accepted medical value. Schedule 1 is reserved for
drugs that have a high potential for abuse and no currently accepted medical value, and here
cannabis was placed along with heroin, LSD, and peyote. Moreover, all Schedule 1 drugs are
totally prohibited in the United States; doctors may not prescribe them and research on the
substance is effectively killed. Yet there were many government-funded studies into the
therapeutic uses of natural cannabis from 1966-1976. Jack Herer (1985) claims that by 1983,
there were nearly 10,000 studies published on cannabis with 4,000 being from the United States.
Of the dozen which found some negative results, none has ever been replicated.
Marijuana’s designation as a Schedule 1 dangerous drug was supposed to be temporary
pending the findings of a presidential commission chaired by the former Republican Governor of
Pennsylvania, Raymond P. Shafer. The 480-page Shafer Report was released in March of 1972
and came to a remarkably similar conclusion as the La Guardia Report nearly 30 years earlier:
marijuana was not harmful, and problems associated with the drug were more the product of its
criminalization. Comparing marijuana to alcohol, the commission recommended it should be
regulated by means other than the Controlled Substance Act. Instead of rescheduling or
descheduling marijuana, the Nixon Administration ignored the Schafer Report and organized a
congressional subcommittee to oppose the original committee’s findings.
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Known as the Eastland Hearings, the subcommittee brought in a parade of witnesses who
made factually incorrect claims such as marijuana makes men grow breasts, causes people to
become homosexuals, leads to all sorts of birth defects and genetic anomalies, and results in
“amotivational syndrome.” Many of these conclusions would eventually become textbook
examples of scientific fraud,39 but the steady stream of misinformation was designed to leave the
impression that something about cannabis must be dangerous. This spurred the government to
continue investigating harms associated with the plant and marijuana remains a Schedule 1
substance at the federal level today (Lee 2012; Torgoff 2004).
In contrast to the artistic and playful protests staged by countercultural activists like the
Yippies, NORML (National Organization for the Reform of Marijuana Laws) was created in
1970 by attorney Keith Stroup. Based in Washington D.C., the group retained a panoply of
academics, doctors, lawyers, and politicians to lobby against the government’s unyielding
prohibitionist agenda. Unlike other pro-legalization activists, NORML embraced professionalism
and adopted a politics of respectability. Representatives dawned business suits, worked within
the bureaucracy, and attempted to impart the impression that pot smokers were as normal as beer
drinkers. Throughout the 1970s, 12 states either decriminalized marijuana possession or reduced
it to a misdemeanor thanks to NORML’s efforts. Victory on the federal level appeared to be in
reach when President Jimmy Carter, citing the Shafer Report, expressed support for marijuana
decriminalization. This support would be short-lived because NORML founder Keith Stroup
leaked information regarding alleged cocaine use by Carter’s pot-friendly drug czar. Stroup was
infuriated at the administration’s persistent spraying of the toxic herbicide paraquat on Mexican

39

One study frequently cited in the Eastland hearings involved brain damage in monkeys who put in air-tight gas
chambers which were then clouded with marijuana smoke for 5 minutes. The researcher claimed it was marijuana
causing brain damage rather than suffocation from a lack of oxygen.
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marijuana fields (Lee 2012). Nonetheless, NORML still campaigns for marijuana reform though
they heavily focus on recreational legalization rather than expanding access to medical use.
The 1970s was also the time when people suffering from illness began challenging the
government’s total prohibition of cannabis. One of the first was Robert Randall who successfully
argued before a court that his cultivation of marijuana was a medical necessity since he suffered
from glaucoma. With the urging of several organizations, the federal government began an
Individual Patient Investigational New Drug (IND) program in 1975 to explore the use of
marijuana as a medicine through carefully controlled clinical trials (Pacula et al. 2001). Not
much research resulted from the IND because the government never collected data, but patients
enrolled in the program received their marijuana directly from the federal government in the
form of pre-rolled marijuana cigarettes (joints). However, “[t]he onerous qualification process
was designed to deter applicants and their physicians, who had to wade through mountains of
paperwork and endure various indignities, including a background check and a visit from DEA
agents” (Lee 2012:167).
Since the gatekeeping to enroll was so strict, only 15 patients were ever accepted before
the IND program was closed to new applicants in 1992.40 Three of these individuals continue to
receive a giant tin of joints each month from the federal government as of 2019, but the quality
of the medicine is very poor. Described as resembling “green talcum powder”, the marijuana is
grown outdoors by the University of Mississippi, the only federally approved cultivation
established by NIDA in 1968. They also supply all of the cannabis used in clinical trials. This is
The IND program was unilaterally terminated in 1991 by James O’Mason, chief of the US Public Health Service
and notorious homophobe (Werner 2001). A compromise was reached in 1992 to allow the program to continue but
only for existing patients and applicants. Lee (2012) says the program was flooded with applications after Robert
Randall distributed information packets walking patients through the application process. If the federal government
began a mass distribution of medical cannabis, then they would be forced to acknowledge the medical value of
cannabis. Chapkis and Webb (2008) believe the Bush administration supported the termination of the program
because many of the new applicants were suffering from AIDS rather than glaucoma or cancer.
40
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concerning because their product does not have a consistent level of THC, being off by 5%
according to one independent test. More appalling is the marijuana these patients receive can
sometimes be 14 years old, is occasionally infected with mold or yeast, and is always very dry
with loads of seeds and stems (Patients Out of Time 2019; Hellerman 2017).
Shortly after the creation of the IND program, publicly accessible research into cannabis
ended in 1976 when pharmaceutical companies lobbied the government for exclusive control
over cannabis research to find patentable synthetic preparations. The Ford administration agreed
to their requests and allowed private pharmaceutical corporations to do "no high" research on
THC only, not any of the hundreds of other compounds in the plant. This action took cannabis
research away from the public sector—out of the universities and government-sponsored
studies—and placed it into the sole hands of the for-profit sector (Herer 1985). They would
eventually develop one drug known as Marinol which is 100% pure THC, and as such, does not
produce benefits anywhere near those achieved by the “entourage effect” where the multitudes of
cannabinoids work in synergy.
Because the federal government refused to reschedule cannabis to recognize its medicinal
value, activists pressured states to permit medical marijuana consumption or research in some
form. Robert Randall, the first IND patient and former college professor, teamed up with Alice
O’Leary to form the Alliance for Cannabis Therapeutics in 1981, a nonprofit with an agenda to
advance medical cannabis access. By 1983, 34 states (including Michigan) had passed some sort
of legislation that theoretically allowed for medical marijuana under clinical trials, but nothing
practical resulted since the federal government supervises licenses for prescription medicines and
controlled the supply of cannabis for medical research (Pacula et al. 2001; Werner 2001). It was
also the reign of Ronald Reagan and his administration showed zero sympathy for loosening

293

marijuana laws. Under his administration, the rhetoric around legal and medical cannabis began
to shift with advocates for prohibition stressing the “message” such policies would send to youth
as well as a religious desire to protect the country from the demons of communist sympathizers
(Lee 2012; Chapkis & Webb 2008). Since many of the early medical marijuana state laws were
passed in hopes that cannabis would be rescheduled on the federal level, most of these laws were
eventually allowed to expire or would be repealed amidst the anti-drug zeitgeist of the 1980s.
Like the La Guardia Report and the Schafer Report, in 1982 the National Academy of
Sciences published findings from a six-year investigation that concluded marijuana was not
physically or socially harmful and that a better approach of regulating the drug would be
decriminalization at the federal level. And just like Presidents Roosevelt and Nixon, President
Reagan totally ignored the report. In fact, he did just the opposite of the report’s
recommendations by ramping up a drug war to where a person could be arrested for selling pot
paraphernalia (Lee 2012). The Reagan Administration even floated the idea in 1983 of forcing
American universities to destroy all copies of the cannabis research sponsored by the federal
government between 1966 to 1976 (Herer 1985). The plans were dropped after fierce backlash,
but information still disappeared and many important historical documents vanished from public
archives. NIDA, for example, blacklisted 64 of its previous publications which included
favorable comments regarding marijuana use. They purportedly did this by eliminating all
documents that included the word “social” in conjunction with variations of the word
“marijuana” (Lee 2012).
One hallmark of Reagan’s War on Drugs was the escalation of the civil asset forfeiture
provisions for marijuana and other drugs. In 1984, law enforcement was permitted to sell all
confiscated property involved or purchased with drug possession, cultivation, and sales. This was
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designed to prevent drug dealers from continuing their vice while awaiting trial, but the policy
has since morphed into a lucrative way to strip citizens of their earthly possessions upon being
suspected of selling an illicit substance. In 2014, Michigan couple Annette and Dale Shattuck
had their home raided and property confiscated after they tried to open a medical cannabis
dispensary. Law enforcement trashed their house and took their children’s’ Christmas presents,
important documents like health insurance cards and driver licenses, and nude photos the couple
shared between themselves. In a similar case, Michigan resident Ginnifer Hency had property
like her vibrator confiscated after a task force raided her home following information that she
was a caregiver in the state’s medical marijuana program (Komorn 2015). The vast majority of
sized assets belong to individuals who are never charged with a crime or have their charges
dismissed, like each of the examples raised here. Nonetheless, these innocent individuals must
fight the government in court for the return of their property which totaled more than $80,000 for
the Shattucks (Andavolu 2016).41
Some progress was still made in terms of medicalizing cannabis though it had its
drawbacks. The mono-cannabinoid drug Marinol was approved by the FDA in 1985 and
classified as a Schedule II controlled substance (alongside cocaine and morphine) and was later
placed within Schedule III. Made by infusing THC into sesame oil, Marinol pills were large,
expensive, and mostly inaccessible (Werner 2001). With something similar to marijuana now
prescriptible, some advocates no longer felt the need to push for marijuana reform.
Unfortunately, those whose bodies were deteriorating from cancer or AIDS (and had the money

Michigan’s government took steps to amend the state’s civil asset forfeiture laws following the bad publicity
generated by these two cases. The laws were also amended in 2019 to require a criminal conviction before property
can be confiscated.
41
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to afford a pharmaceutical drug) found little relief from Marinol. They wanted accessible whole
plant medicine.

Gay People Make Marijuana a Medicine Again (1990s)
The next part of the story occurs in California with Dennis Peron, a gay Vietnam veteran
who became an advocate for marijuana legalization in 1970s. Even though he would be busted
for selling cannabis more than a dozen times, Peron was politically active in San Francisco
where he was good friends with Harvey Milk. As Milk was making his fourth run for city
council, Peron was trying to decriminalize marijuana in San Francisco with Proposition W. His
dream was to make San Francisco the Amsterdam of America, and he boldly operated an openair marijuana marketplace called the Big Top until it was raided by city police in 1977 (Gardner
2007). During the bust, Peron was shot in the leg by a homophobic officer, and this would
actually prove beneficial to Peron’s defense:
We knew the cops hated gay people so we teased them a lot… One day outside in
the hallway, I said to [the officer] ‘We love your shoes today. Where’d you get
those Guccis?’ And he said, ‘You motherfucking faggot, I should have killed you
so there’d be one less faggot in San Francisco!’ He didn’t know that there was a
whole string of lawyers behind him who heard him say it. They got him back on
the stand and then they just wore him down (Dennis Peron quoted in Torgoff
2004:299).
Even though the raid on Peron’s marketplace yielded 200lbs of cannabis along with loads
of other drugs, Peron received a mere six months in jail due to police misconduct. By this time,
Proposition W had received enough signatures and it was placed on San Francisco’s city ballot.
It passed with 56% of the vote in November 1978 along with the reelection of Harvey Milk and
the city’s pot-friendly mayor. Regrettably, several weeks later, Milk and the mayor were
murdered by an ex-council member with a record of homophobic and anti-marijuana remarks.
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Peron was in jail at the time and the city’s new mayor, Diane Feinstein, refused to implement
any of Proposition W’s decriminalization measures (Torgoff 2004).
Dennis Peron’s emphasis on medical cannabis would come in 1990 as his partner,
Jonathan West, was dying of AIDS. The couple’s home was raided by police who made AIDSrelated and homophobic jokes after seeing a photograph of Peron with Harvey Milk. Only Peron
was charged when the cops found four ounces of cannabis, and while spending the night in jail,
Denis Peron had a vivid dream:
He saw sick people, people in wheelchairs, men and women, young and old, black
and white, all sitting in a large room, laughing, hugging, and sharing cannabis.
That’s how Peron got the idea for a public medical marijuana dispensary, a place
where people like Jonathan could gather and smoke pot with friends, unashamed
of their skin abrasions and their obvious infirmities (Lee 2012:231).
Frail from wasting syndrome, Jonathan West would eventually testify at the trial that the
confiscated marijuana was his own, and this got Peron off the hook. The judge even scolded the
officers for their harassment of a dying man and his caretaker. Jonathan West would die in
September of 1990 as the AIDS virus reached epidemic proportions in queer communities
throughout the nation.
There was widespread apathy towards individuals with AIDS at this time in our history.
First documented in 1981, the disease was commonly called Gay-Related Immune Deficiency
(GRID) or even “gay cancer.” Moreover, since its victims were largely gay men or drug addicts,
popular sentiment for these so-called “guilty victims” anything but empathetic. Chapkis & Webb
(2008) even say that AIDS victims replaced immigrants as the despised group connected to
marijuana, becoming the new “dangerous class” (Reinarman 1994) upon which the government
justified continued marijuana prohibition. This created a sense that if anything were to be done
about AIDS, it would have to come from within the affected community. Pharmaceutical
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companies felt developing a treatment would be unprofitable while the Reagan administration
allocated a mere $8,991 per AIDS death to the National Institute of Health42 (Werner 2001).
Those who used marijuana as medicine quickly found an effective message to garner
popular support. They emphasized that the federal prohibition of marijuana resulted in
unnecessary suffering most often for those nearing the end of the lives. Chapkis and Webb
(2008) say the momentum for medical cannabis was akin to a “social movement spillover” since
the community was already steeped in activism from the gay liberation movement. Many early
AIDS victims were pioneers in the gay rights movement and had already established an
infrastructure of activism (Werner 2001). Yet sexuality was not the only identity pertinent to
their struggle. These individuals were also marginalized due to their social class and race, both of
which affect the quality of professional care individuals receive at medical institutions.
Furthermore, the only legal option at the time was Marinol, and this was not only less effective
than whole-plant cannabis, but it also was not accessible to those without health insurance or the
means to navigate the health care bureaucracy.
Part of the appeal of cannabis as a medicine was its cost, availability, and familiarity.
Networks of cultivators, dealers, and users were already well established when the AIDS crisis
hit, and the relatively inexpensive street drug was quickly found to be more effective in dulling
pain and stimulating appetite than anything available through a physician. Cannabis also
eliminated the need to visit judgmental health care providers and it was undeniably pleasurable.
While the low cost of cannabis certainly made it more accessible for many, the major challenge
was in distribution. Patients needed a reliable and trustworthy source, and many were too ill to
scour an underworld of vice for a reputable supply.

42

Compare to $36,100 per death from Toxic Shock Syndrome and $34,841 for Legionaire’s disease in 1982.
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Buyer’s clubs for non-FDA-approved AIDS medicines were already in existence when
Dennis Peron decided to apply the business model to cannabis. These facilities would enroll club
members who would then have access to the club’s supply of medicine, usually with nominal
cost. Beginning in San Francisco and New York City in 1987, buyers’ clubs placed all the risk
onto the owner(s) since members could pick up from a secure location rather than pushing their
luck on the streets (Chapkis & Webb 2008; Werner 2001). At the time, there were limited
conventional treatment options for those with AIDS since the disease was not well understood by
medical institutions. The preferred way of managing the disease was with AZT, an antiretroviral
medication, but this suppressed appetite to an extreme degree and resulted in many deaths due to
wasting syndrome. Early buyers’ clubs for AIDS patients focused on vitamin infusions and drugs
with anecdotal reports of relieving AIDS symptoms, among them an AL-721 (an Israeli egg-yolk
extract) that was commercially unavailable in the U.S. (Gardner 2007).
In 1991, Peron teamed up with psychiatrist Tod Mikuriya to open the nation’s first
cannabis buyers club in San Francisco43. Dr. Mikuriya was an early proponent of harm reduction
strategies and headed the National Institute of Mental Health’s marijuana research program in
the late 1960s. After becoming frustrated with the government’s mandate to exclusively study
harms associated with marijuana, he quit the organization after several months and later released
a compendium called Marijuana: Medical Papers 1839-1972. The anthology contained 25
previously published studies and served as a call for medicine for rediscovering marijuana’s
therapeutic properties. Released in 1973, the book is cited by some as the beginning of the
modern medical cannabis movement (Lee 2012). Mikuriya’s medical expertise combined with
Dennis Peron’s political capital resulted in two significant initiatives, the first of which was a

Peron’s buyers’ club opened at the site of a short-lived medicinal marijuana retail location. It had been organized
by Thomas O’Malley to help patients with AIDS before O’Malley succumbed to the disease himself.
43
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city ordinance known as Proposition P. Permitting the use and sale of cannabis medicines to
anyone who could benefit, Proposition P passed with 80% of the votes in 1991, effectively
making San Francisco the nation’s first medical marijuana oasis. The city of Santa Cruz passed a
similar ordinance in 1992 (Chapkis & Webb 2008) and others would follow in the future as well.
Dr. Mikuriya refers to Peron’s buyer’s club as a “medical speakeasy” (1995:10) where
individuals carrying a doctor’s note enter through a nondescript door with a peephole lens.
Senior citizens were granted automatic admission and free cannabis was regularly given to poor
patients (Lee 2012). Yet unlike many medical cannabis facilities of today, patients could
consume cannabis on-site through smoking or vaping. Like other buyers’ clubs, this one offered
support services, opportunities to connect with other patients, and encouraged its members to
become politically active. Denis Peron is quoted as saying, “[M]arijuana is part of it, but the
biggest part of healing is not being alone. They always find that people who are alone die faster”
(Gardner 1997).
Dennis Peron and his associates would ultimately mobilize their political capital to
endorse two bills introduced in California’s state legislature. Each was focused on permitting
medical uses of cannabis, each passed both houses of the legislature, and each was vetoed by the
state’s Republican governor. The activists eventually turned their sights to a ballot initiative
(Proposition 215), which rather than legalizing cannabis, would create a doctor-recommended
exception at the state level as to not conflict with federal law (Lee 2012). The most controversial
component of the ballot measure was the inclusion of a catch-all category allowing medical
cannabis to anyone who could benefit. Being very attentive to how the language would be
perceived, many feared the open-ended nature of qualifying conditions would cost the initiative
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support. However, Dennis Peron and Dr. Mikuriya insisted medical cannabis should not be
limited to a handful of major diseases:
The final draft [language] filed with the Secretary of State reflects Dennis’s view
of himself as a “caregiver” and of his club as an extension of his living room and
personality. Its open-ended nature is asserted in the first sentence, which allows
doctors to approve “the use of marijuana in the treatment of cancer, anorexia,
AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness
for which marijuana provides relief” (Gardner 2007:18).
Initially, Peron and the buyers’ club wanted to keep the signature drive a grassroots
affair. However, they were slow to collect enough signatures until a now-renowned drug policy
expert named Ethan Nadelmann offered help. Nadelmann was able to bring in big money
backers, including billionaire George Soros44 and George Zimmer, the owner of Men’s
Wearhouse suit stores. They would form a group called Californians for Medical Rights (CMR)
and would eventually submit over 800,000 signatures, nearly double the number required. The
initiative was opposed by the governor, most of California’s politicians (both Republican and
Democrat), the state police, and even President Bill Clinton. In fact, after the initiative was
officially placed on the ballot, the first moves by the opposition were to shut down Peron’s
buyers’ club and conduct raids on the homes of his staff and patients. Undeterred, Peron was
such an advocate for medical cannabis that the CMA struggled to convince him to stop providing
cannabis until after the election was over (Gardner 2007)
Dennis Peron is also famous for saying “all use is medical” to reporters during their
coverage of the AIDS epidemic45. He received intense criticisms for this statement, with many
medical advocates saying it trivializes individuals with severe health issues and provides

“Soros became interested in drug policy after he met Allen Ginsberg. The intellectually engaging poet told Soros
about how he had spent an entire summer researching the files of Indiana University sociologist Alfred Lindesmith,
the first prominent U.S. academic to challenge America’s heavy-handed war on drugs” (Lee 2012:241).
45
Dennis Peron told author Martin Lee that he actually said: “In a society where kids are prescribed Prozac for
shyness, all marijuana use is medical” (2012:247).
44
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ammunition to those opposed to medical cannabis laws (Preston 2002). True to his word, Peron
would spend the latter part of his life growing cannabis in rural California, an act he interpreted
as making a public statement about a patient’s right to grow their medicine. He would also sell
his crop to patients at $200 a pound compared to the going price of $4,000 a pound. It’s no
wonder, then, that Peron barely hung onto a dime during his lifetime despite dealing mountains
of cannabis (Preston 2002). He saw the plant as curative or therapeutic regardless of how it was
used, and he fervently dedicated his life to making it more available to those who could benefit.
He was not alone.
Mary Rathburn is known as San Francisco’s Mother Teresa and was twice awarded
“Volunteer of the Year” at San Francisco General Hospital prior to becoming a media sensation.
A pro-union, pro-choice activist turned IHOP waitress, Rathburn first met Dennis Peron in 1972
when she asked for a hit of his joint while waitressing. She supplemented her income by selling
brownies made with cannabis butter, and following her second arrest, her mandated community
service included driving AIDS patients to the hospital. Realizing her brownies could be of help
to these patients, “Brownie Mary” would eventually give away 1,600 cannabis-infused brownies
per month to what she called “her kids” (Lawrence 2019; Ewbank 2018). In 1992, she would be
arrested for the third time after a raid on her home uncovered 20lbs of cannabis along with
massive piles of ingredients for brownies46. In the police car she is reported to have said: "If the
narcs think I'm gonna stop baking brownies for my kids with AIDS, they can go fuck themselves
in Macy's window” (Margolin 2019). The image of a 69-year old lady being arrested for giving
The “pot brownie” made its debut in the original 1954 edition of The Alice B. Toklas Cook Book, though it was
not included in the U.S. edition until 1961. A life-long partner of poet Gertrude Stein, Toklas was an epicurean who
collected recipes during the couple’s years hosting luminaries and bohemians at their home in Paris. She would
publish these at the age of 74 along with exotic contributions from fellow bohemians like Brion Gysin, a Canadian
poet who submitted a recipe for “Hashish Fudge”. In 1968 the fudge was transformed into a brownie for the film I
Love You, Alice B. Toklas!, the first major motion picture which featured cannabis-laced foods (Lawrence 2019). It
is unknown if Toklas ever actually ate an infused brownie.
46
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away medicinal brownies made international headlines, and the charges against Rathburn were
soon dropped. She would work side-by-side with Dennis Peron on legalizing cannabis and they
both served as grand marshals for San Francisco’s gay pride parade in 1997 (Ewbank 2018).
News stories of Rathburn’s 1992 arrest reached two significant individuals. Rick Doblin
was the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) which
facilitated clinical research on Schedule I drugs. Seeing Rathburn volunteered at a renowned
AIDS facility, Doblin wrote to the hospital about the possibility of establishing a clinical trial on
cannabis’ efficacy. The letter eventually reached Dr. Donald Abrams, the Assistant Director of
San Francisco General’s AIDS Program where he specialized in community-based clinical trials.
Luckily, Dr. Abrams had also seen Brownie Mary’s arrest on the news and was motivated to
begin working with Doblin in designing a community-based clinical trial on smoked cannabis
(Werner 2001). They would need the approval of eight different agencies to proceed (Lee 2012).
The main challenge for such a study was in acquiring cannabis, which even today is only
available to researchers through the National Institute of Drug Abuse (NIDA). Dr. Abrams
submitted their rigorous and vetted design to the NIDA in 1994, the organization purposefully
stalled on issuing a decision. Nine months later, NIDA rejected the study without explanation,
and Dr. Abrams went on a media blitz. Controversy ensued and NIDA was forced to restructure
their application process so any study passing the organization’s peer review would be granted
cannabis. The resubmitted application would also be rejected with Dr. Abrams explaining:
Two of the three reviewers mentioned in their comments that they were unclear as
to why the Consortium investigators would choose to conduct a trial with a
“toxic” substance. The final reviewer was concerned that if patients with AIDS
wasting developed increased appetite following marijuana ingestion… that they
may subsequently develop hypertension (high cholesterol and triglycerides) and
atherosclerosis (Werner 2001:30).
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While this second rejection was disappointing, it also came three months before the
citizens of California voted on Proposition 215. Medical activists would use the rejection as
proof of the government’s dishonesty on the issue, and another national debate ensued where
former general and drug czar Barry McCaffrey repeatedly came off as ignorant on the issue
(Werner 2001). Pro-cannabis activists emphasized that the federal prohibition of marijuana and
blockade on cannabis research resulted in unnecessary suffering (Chapkis & Webb 2008). In
November of 1996, Proposition 215 would pass with the support of 55.6% of California’s voters.
In fact, more people voted for Proposition 215 than they did for Bill Clinton (Herer 1985).
With victory in hand, Dennis Peron would go on to open another buyers club and
continue to advocate for marijuana reform. He would be joined by countless others, some of
whom pioneered different models of delivering medicine and support to those who need it.
Among them were Valerie and Michael Corral who founded the Wo/Men’s Alliance for Medical
Marijuana (WAMM), an experimental communal support group where members were asked (not
required) to volunteer in exchange for free medicine. Their mission was informed by the recent
women’s health care movements which saw “health care as a right rather than a commercial
commodity and patients as active participants in (not passive recipients of) medical care”
(Chapkis & Webb 2008:51). The WAMM would ask members to help cultivate and prepare
cannabis-infused muffins and soymilk beverages which would be dispensed at no cost to
members at weekly meetings. In turn, the organization provides a sense of family and a type of
long-term care policy. For example, members routinely provide informal hospice care to others,
and for those suffering from a stigmatized disease like AIDS, this provided the invaluable
possibility of “dying in the embrace of friends” (Chapkis & Webb 2008:104).
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Yet the federal government did not acquiesce on their anti-cannabis position. In response
to California and Arizona47, the DEA and Attorney General Janet Reno (with support from
NIDA) threatened to crack down on any physician who recommended a prohibited substance.
Fortunately, other models of care outside of mainstream medicine like buyers’ clubs and the
WAMM had already been established. Unfortunately, in the years to come these clubs would be
frequently raided by DEA agents, and many of their owners would be imprisoned for long
periods of time. The federal government would also eventually adopt a new strategy following
the rise of medical cannabis programs. As juries could be persuaded someone’s use was
medically justified, the federal government began suing distributors in civil court where a judge
can be the sole decider of the case (Preston 2002).
Likewise, state medical cannabis programs did little to ease bureaucratic barriers in
studying cannabis. At a time when nearly anyone with a few dollars could acquire cannabis
being sold on the streets, Dr. Abrams still struggled to get cannabis for his clinical trial. Yet after
more public outrage following the government’s announced crackdown, the NIDA director
informed Dr. Abrams:
[T]hat the Institute was “the National Institute on Drug Abuse, not for Drug
Abuse”. Consequently, Dr. Abrams and the marijuana team devised a study to
assess the potential harm that marijuana or [Marinol] might cause by interfering
with the new AIDS drugs, protease inhibitors. The study also included an
examination of weight gain and other measures that could indicate if there was a
therapeutic benefit of cannabis for the subjects (Werner 2001:31).
With the target of the proposed study now seeking to measure harm associated with
cannabis use, the NIDA agreed to supply the medicine, and the research team began enrolling

47

Also in November of 1996, Arizona voters also passed a sweeping measure allowing for the medical use of all
Schedule I substances. Afterwards, and for the first time in 90 years, the state’s governor and legislature exercised
their ability to veto a ballot initiative. The angry citizens of Arizona began working once again to collect signatures
for a 1998 ballot initiative for medical cannabis use which would go on to become law (Herer 1985).
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patients in May of 1998. Results of the trial would be among the first to support the anecdotal
claims of tens of thousands of AIDS patients that marijuana eased their suffering, particularly for
a condition called peripheral neuropathy which also affects cancer patients and diabetics (Lee
2012; Werner 2001). Yet it took nearly four years for NIDA to approve the study, and this tactic
of bureaucratic delay would be adopted by other agencies.
In June of 2001, Dr. Lyle Cracker submitted an application to the DEA for the
development of an additional medical cannabis production facility at the University of
Massachusetts Amherst. After waiting six months for a reply, he was informed the application
had been lost and that a photocopy would not be accepted48. Over a year later, in July 2002,
while still working to reassemble the original application documents, Dr. Cracker received the
original application back in the mail. It was stamped as received by the DEA over a year earlier
(Chapkis & Webb 2008). Undeterred, he sent the application back, and in March of 2003, 20
months after the original submission, his request was denied. The DEA wanted credible evidence
that NIDA cannabis was not adequately made available to researchers. Once again, Dr. Cracker
sent the revised application back and received no word from the DEA for an entire year. In July
2004, three years after the original submission, the DEA was sued by Dr. Cracker, Rick Doblin,
and Valerie Corral for unreasonable delay. It would take the courts until 2013 to ultimately rule
in favor of the DEA. Yet in August of 2016, the DEA announced it intended to end NIDA’s 48year monopoly on cannabis cultivation for science by licensing other production facilities

48

The tactic of losing applications for cannabis research stretches back many decades. McWilliams (1990) describes
attempts by the National Institute of Mental Health (NIMH) to conduct research on marijuana back in the 1960s. It
took months for the NIMH to obtain permission from the Federal Bureau of Narcotics because the bureau claimed
they had lost the application multiple times. The bureau also repeatedly questioned why NIMH would want to study
marijuana since the organization’s director, Dr. Tod Mikuriya, was known to have views opposed to cannabis
prohibition.
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(MAPS 2019). As of early 2020, no other cultivation facilities have been granted licenses,
perhaps indicating the tactic of bureaucratic delay is still in the gamebook.
The way the government approaches cannabis still defies all logic. They say it has no
medical value by classifying it as a Schedule I substance, but they also ship canisters of joints to
patients in the IND program. They declare more evidence is needed to change this scheduling
though no evidence was consulted in placing cannabis there, and they deny almost all attempts to
study cannabis further. Even when citizens practice their democratic rights by voting for changes
in cannabis law, elected officials attempt to neutralize such changes in complex bureaucratic
maneuvering. In this environment of entrenched political resistance, it is remarkable that
patients—many of whom are severely ill or dying – were able to make some progress in
expanding access to the plant. Much work still needs to be done, though, as access varies widely
by state and municipality.
This appendix was designed to educate readers on how we got to where we are now
regarding cannabis’ status in the United States. It is not exhaustive and omits more detail than it
contains, but an over-arching trend appears to be twilight for prohibition as we know it. Several
significant developments occurred at the federal level under the Obama administration. In 2009,
the United States Department of Justice sent a letter to U.S. Attorneys saying it will “not focus
federal resources in your States on individuals whose actions are in clear and unambiguous
compliance with existing state laws providing for the medical use of marijuana” (Ogden 2009).
In 2013, the Department of Justice also extended this hands-off approach to state recreational
marijuana laws, saying it will not intervene in “jurisdictions that have enacted laws legalizing
marijuana in some form and that have also implemented strong and effective regulatory and
enforcement systems to control the cultivation, distribution, sale and possession of marijuana"
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(Cole 2013). While each of these memorandums did not change federal law, they each gave state
lawmakers reassurance that the federal government would not crack down on state marijuana
reform.49 Fortunately, Congress passed the Rohrabacher-Blumenauer Amendment in 2014 which
also forbids the Justice Department from using federal funds to interfere with a state cannabis
program so long as it follows state law, though the amendment needs to be renewed each fiscal
year as part of the omnibus spending bill. Following these memos, many states revised their
medical and/or recreational cannabis laws to permit licensed growers and dispensaries, and we
shall see this with Michigan in the next appendix.

49

Attorney General Jeff Sessions rescinded the Cole memo on January 4, 2018. This caused anxiety in states with
recreational marijuana laws, but the Department of Justice had no actual plans for a crackdown or change in federal
enforcement. Following the termination of Jeff Sessions by President Trump in November 2018, the administration
verbally reassured states that it would continue to tolerate state-level marijuana reform.
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APPENDIX B
THE HISTORY OF CANNABIS IN MICHIGAN
Earlier Activism (1960s-2000s)
John Sinclair is a jazz poet as well as an early figurehead in Michigan’s marijuana
legalization movement. After his first marijuana bust in 1964, Sinclair started the Michigan
chapter of LEMAR, an organization short for "legalize marijuana” championed by fellow poets
Ed Sanders and Allen Ginsberg50. While LEMAR would fizzle out in the years to come, John
Sinclair became a legend after he was convicted for the possession of two joints in 1969.
Michigan had some of the most stringent marijuana laws at the time, and since it was Sinclair’s
third marijuana-related arrest, the judge handed down a sentence of 10 years. His wife, Leni
Sinclair, worked relentlessly on his freedom with her efforts cumulating on December 10, 1971,
at the John Sinclair Freedom Rally in Ann Arbor. The rally drew an estimated crowd of 10,000
people thanks to a lineup of artistic talent that included Stevie Wonder, Bob Seger, and John
Lennon. Three days later, Sinclair was released on appeal bond and would begin to adjudicate
his original sentence (Gabriel 2019b).
On March 9, 1972, Michigan’s Supreme Court decided Sinclair’s original sentence was
cruel and unusual, and even more surprisingly, deemed the state’s marijuana law as
unconstitutional. This left Michigan without an enforceable marijuana law for 22 days until the
legislature passed a new law on April 1, 1972. To protest this new law and to “re-legalize”
marijuana, Sinclair and his supporters organized the first Hash Bash at the University of

50

LEMAR was the first organization dedicated to challenging cannabis prohibition. It was started by liberatarian
attorney James R. White III as part of a defense strategy for his client, Lowell Eggemeier. As an act of civil
disobedience, Eggemeier smoked marijuana in front of the San Francisco police station on August 16, 1964. He was
ultimately convicted of possession and served a short sentence.
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Michigan campus in Ann Arbor. This pro-legalization rally has been held each April for the past
48 years (Gabriel 2019b; Glenn 2009). The original Hash Bash of 1972 also saw the beginning
of the Michigan Marijuana Initiative, the first serious attempt at putting marijuana legalization on
Michigan’s ballot. This effort failed to collect anywhere near the required number of signatures
to make the ballot, and even if it did, Huey (2018) cites that over 80% of Americans disapproved
of legalization at this time.
Michigan’s marijuana movement continued through the 1970s with a predominantly local
focus. John Sinclair became a part of the Human Rights Party which won seats on town councils
in cities like Ann Arbor, Ypsilanti, and East Lansing. These political activists used their newly
found authority to amend local marijuana laws, often making simple possession a civil offense
punishable by a mere $5 fine. There was an unsuccessful push to enact something similar in the
state’s legislature in 1977, and while attempts at legalization dwindled afterward, a symbolic
push for medical cannabis research was successful in 1979.
Known as “Grandma Marijuana”, Mae Nutt became an advocate for therapeutic use after
her son Keith developed cancer. Marijuana was the only thing that reduced the nausea associated
with her son’s chemotherapy, and she began her crusade in Michigan in the late 1970s. Keith
would die on October 10, 1979, the same day The Michigan Controlled Substances Therapeutic
Research Program was signed into law. Unfortunately, the state-level research programs of this
era were largely symbolic in that no research or therapies were implemented. Nonetheless, Mae
began operating the “Green Cross” from her home in Beaverton, Michigan, where she gave
marijuana, edibles, and suppositories to those who could benefit (Clarke Historical Library). She
would eventually join Robert Randall as a co-founder for the Alliance for Cannabis
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Therapeutics, and later served as the director for Patients Out of Time, an educational charity
dedicated to teaching the efficacy of therapeutic cannabis.
The 1980s were an era marked by conservative anti-drug crusades like Reagan’s war on
drugs, and Michigan’s marijuana community was largely driven underground. Their political
activism may have stalled, but they secretly adopted indoor and underground grow operations
which were the precursors to today’s legal production infrastructure (Gabriel 2019b). As the war
on drugs ramped into full gear, another legendary figure in the struggle for cannabis reform
would arise in the mid-1990s. “Highway Howie” Wooldridge was a detective from Bath
Township, Michigan, who was known for his tough stance on drunk drivers. In his retirement,
officer Wooldridge became critical of the war on drugs and founded LEAP (Law Enforcement
Against Prohibition) in 2002, and within a decade the organization had over 40,000 members. He
would go on to ride his horse Misty across the country while on a publicity campaign, calling
marijuana prohibition “the most dysfunctional, immoral domestic policy since slavery and Jim
Crow” (Lee 2012:2). Yet right before Highway Howie’s activism came another pivotal moment
in Michigan’s cannabis movement.
Rainbow Farm was Michigan’s center for cannabis activism from 1996 through 2001.
Located about an hour south of Kalamazoo, the property was the site of biannual marijuanacentered festivals aptly named Hemp Aid and Roach Roast. These festivals were organized and
funded by the farm’s owner, Tom Crosslin, along with his boyfriend Rollie Rohm and a team of
blue-collar activists. Tom Crosslin was surely a larger-than-life character. He was a Vietnam
veteran and is further epitomized by author Dean Kuipers (2006) as a gay libertarian pot-smoker
who cultivated a troubling relationship with authorities over his beliefs in absolute freedom of
property rights. Crosslin’s staunch ideology is credited as the source of the pot festivals, several
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early attempts to legalize marijuana in Michigan, and the tragic reason why Rainbow Farm is
legendary in Michigan’s cannabis community.
Following a 2001 tax raid on the farm which also revealed a basement garden with some
200 immature plants (Gabriel 2019b), Crosslin decided to set fire to the structures on the farm
rather than surrender the property peacefully in an upcoming civil asset forfeiture case. The
Michigan State Police came to the farm as did the FBI, and both Crosslin and Rohm were killed
after an ensuing three-day standoff. The disaster garnered national media attention for several
days until the morning of September 11, 2001. Much controversy remains regarding the arson,
deaths, and validity of the prosecutor’s civil asset forfeiture case. Rainbow Farm was always
careful to stay out of activities that could lead to civil asset forfeiture, and many believe the
authorities were more motivated by Crosslin’s politics, particularly his role in the proposed
Personal Responsibility Amendment (PRA).
Ballot initiatives work well when popular issues are too hot for politicians to handle
themselves. By 1999, five states and the District of Columbia had passed ballot measures
legalizing medical cannabis, and activists in Michigan thought they could accomplish something
similar but more profound. A lawyer named Greg Schmid hoped Michigan’s libertarian-leaning
conservatives would enthusiastically support a constitutional amendment legalizing hemp
production, establishing cannabis as a medicine, and decriminalizing small-scale possession and
growth of marijuana51. The PRA was much more radical than the medical cannabis initiatives in
other states, and for this reason, mainstream pro-legalization organizations like NORML

51

Information on the Personal Responsibility Amendment (as well as other initiatives that never made it to the
ballot) is surprisingly difficult to find. The exact wording of the PRA can only be found in this guest blog post from
the year 2000: https://www.420magazine.com/community/threads/the-personal-responsibility-amendmentmichigan.4133/
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withheld their support. Rainbow Farm, however, enthusiastically sponsored the amendment and
began collecting the near 400,000 signatures needed to get it on the ballot (Kuipers 2006).
The PRA campaign had no official office, lacked fulltime staff, and only spent around
$24,000. While they were short roughly 150,000 signatures by the July 10, 2000 deadline, the
momentum was strong enough for authorities to view the PRA as a legitimate threat. This was
one of the first times the state’s marijuana movement organized around a single initiative and
they would try again in 2001, only to fall short by another 112,000 signatures. That same year, a
George Soros-backed organization called American for Medical Rights (AMR) launch a similar
campaign in Michigan with ballot language modeled after states who successfully passed
medical cannabis initiatives. This campaign would spend over $1 million, and while they
achieved the required number of signatures, Michigan’s Supreme Court invalidated the measure
on the technicality that the MRA had misnumbered some paperwork (Kuipers 2006).
Rainbow Farm became a clarion call for Michigan’s marijuana movement and is cited as
evidence of law enforcement overreach a la the war on drugs. Cops had harassed festival
attendees and organizers for years leading up to the tragedy, but their investigations rendered
nothing aside from small-scale illicit drug dealing by attendees (not the festival organizers).
Dean Kuipers thoroughly documented the story in his book Burning Rainbow Farm: How a
Stoner Utopia Went Up in Smoke (2006), and his detailed account advocates that Crosslin
wanted little more than the right to enjoy cannabis on his private property. Many believe Crosslin
may have never become a marijuana activist if authorities had simply left him and his property
alone. While his farm and festivals were far from a utopia, often being plagued by fighting,
mismanaged finances, and numerous other problems, the farm was far from the public threat
authorities claim. In the wake of September 11, authorities tried to paint Crosslin and his crew as
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domestic terrorists in a politicized attempt to justify police actions. Their distortions of the facts
were met with backlash from supporters and festival attendees, arguably adding more fuel on the
political fire. In the end, law enforcement has since been cleared of any wrongdoing, but the civil
asset forfeiture lawsuit was also dropped (Kuipers 2006). Debates surrounding the incident
continue through this day and Rainbow Farm will forever remain a landmark in Michigan’s
history of cannabis reform.
On the heels of the Rainbow Farm incident and the series of unsuccessful state ballot
initiatives, cannabis activism began to focus more on the local level. In August of 2004,
Detroiters passed a ballot initiative permitting medical marijuana use within the city. Following
this example, similar measures received a majority vote in the cities of Ann Arbor, Ferndale,
Traverse City, and Flint. Additionally, decriminalization and deprioritization52 measures would
pass in 14 Michigan municipalities, including Kalamazoo, Berkley, and Grand Rapids (Gabriel
2019b). These local successes would give activists in the state valuable political experience
necessary to launch another state-wide effort which came in 2008.

Michigan’s Medical Marihuana Act
The Michigan Coalition for Compassionate Care (MCCC) headed by former state
representative Dianne Byrum launched a successful signature drive for the November 2008 state
ballot. Their proposal was called the Michigan Compassionate Care Initiative which would
create a state registry of patients and establish the right to cultivate cannabis for medical use by
registered patients or their caregivers. It also gave patients an affirmative defense to use in court

52

Despite it still being illegal on the national and state levels, municipalities can direct their police departments to
lower the priority of marijuana-related issues. Since most small-scale drug enforcement is done at the local level,
deprioritizing marijuana enforcement effectively permits responsible individual use within the municipality.
Marijuana possession is still illegal in these places but the cops won’t bust you for it.
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should they be arrested and charged. The coalition partnered with the Marijuana Policy Project
(MPP), a national policy reform organization, and together they raised $1.5 million for their
campaign. Their opposition was a conservative collation called Citizens Protecting Michigan's
Kids chaired by future gubernatorial candidate Bill Schuette (it’s worth noting that medical and
recreational marijuana laws have no effect on youth use rates). The opposition raised a mere
$125,500 and funded a fear-mongering television commercial warning of California-style “pot
shops” in Michigan communities. Meanwhile, the MCCC and MPP had commercials featuring
patients suffering from cancer and multiple sclerosis (Associated Press 2008). Numerous polling
agencies found strong voter support for the measure (Ballotpedia 2019).
Michigan’s Compassionate Care Initiative was approved on November 6, 2008 with 63%
of voters supporting the ballot measure. The measure implemented the Michigan Medical
Marihuana Act (MMMA) which later established the state’s patient registry called the Michigan
Medical Marihuana Program (MMMP). Since going into effect, the law has continually been
challenged, revised, updated, and clarified by lawmakers, and issues pertaining to the law have
been heard by Michigan’s Supreme Court nine times (Ballotpedia 2019). Yet the basic law
pertaining to patients has not changed much since its 2008 inception. Patients may possess up to
2.5 ounces of herbal cannabis, grow up to 12 plants, and are immune from prosecution for
growing and using cannabis within legal limits. Patients may also designate a caregiver who is
responsible for growing or obtaining their medicine. The caregiver does not need to be a patient
themselves but must still register with the state. This caregiver provision was designed so
gravely-ill patients have access to medicine should they be unable to acquire it on their own. It
has also been used as a cooperative-like cultivation model where a patient transfers their right to
grow 12 plants onto their caregiver, who in turn, provides them with medicine (often for a small
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fee). Caregivers must be at least 21 years of age and cannot have any prior felonies. Each
caregiver can provide for up to five patients for a total of 60 plants. Furthermore, the state has
allowed the selling of excess medicine grown by caregivers to dispensaries and other registered
patients. This process enabled buyers’ clubs and provisioning centers in the state in the first eight
years of the MMMP before the 2016 licensing process. Unfortunately, these organizations were
frequently raided or forced to close through hostile town councils.
Unlike California, Michigan has a state registry of patients, caregivers, and businesses
participating in the MMMP. Most recent statistics find there are 297,515 card-carrying patients
in the state, with 93% approved for severe and chronic pain. Michigan also has the most patients
when considering the state's population, nearly 30 for every 1000 residents (Biolchini 2019a).
The registration process involves having a bona fide relationship with the recommending
physician which often means checking in at least once per year. Patients in Michigan must also
file for renewal through the state every two years, a process that costs somewhere in the region
of $200 when considering the physician certification. A list of qualifying conditions in Michigan
can found as FIGURE 1 in Appendix L.

Regulations, Licenses, and Headaches
The most significant changes to medical cannabis in Michigan came in 2016 when the
state implemented a licensing process for dispensaries (also called provisioning centers) and
other medical cannabis businesses. Known as the Medical Marihuana Facilities Licensing Act
(MMFLA), the legislation created a clear pathway for businesses to serve patients while
complying with state law. Prior to this, businesses operated in a grey area and were frequently
targeted by state and local authorities. This produced a landscape where many patients had
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inconsistent access to their medicine, particularly in southwest Michigan where medical
dispensaries are few and far between when compared with the east side of the state. A map of
currently licensed provisioning centers has been included as Figure 2 in Appendix M. The
scarcity of facilities in southwest Michigan is often attributed to the region’s conservative
political climate and anti-cannabis attitudes held by municipal leaders.
While registered but unlicensed caregivers provided most of the state’s medicine in the
first eight years of the MMMP, the MMFLA restricts cannabis production and sales to licensed
businesses only. This policy is designed to be “business-friendly” for the primary purposes of
shrinking the black market and collecting more tax revenue. As such, the MMFLA has been
criticized as being more interested in permitting corporate profit than serving the needs of
patients. However, the owners and investors in one type of business are limited in their abilities
to invest in other sectors. These sectors include (see LARA 2019):
(1) Growers: permitted to cultivate, dry, trim, cure, and package cannabis for sale to a
processor or provisioning center. There are three levels of growing licenses with Class A
permitting up to 500 plants, Class B up to 1,000 plants, and Class C up to 1,500 plants.
(2) Secure Transporters: permitted to store and transport cannabis between licensed
facilities. Only these entities can transport cannabis in the regulated system but they do not
transport cannabis to patients or caregivers.
(3) Processors: permitted to purchase cannabis from a grower for processing. This can
involve extracting resin or creating cannabis-infused products for sale and transfer in packaged
form to a licensed provisioning center.
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(4) Testing Facilities (referred to as Safety Compliance Centers): permitted to test
cannabis and products from licensed facilities for contaminants as well as to ascertain THC and
other cannabinoid levels.
(5) Dispensaries (referred to as Provisioning Centers): permitted to sell cannabis and
cannabis-infused products to patients and caregivers. These facilities must purchase cannabis
from a licensed grower or processor. They can only sell or provide cannabis or cannabis products
to registered patients or to the patient’s caregiver.
Most patients in Michigan will only ever interact with dispensaries or caregivers, as the
other four businesses are restricted to serving licensed facilities. Nonetheless, patient purchases
of medicine support the entire system, and some fear this will result in higher prices. For
example, one Ann Arbor edible company reports paying $500 for a one-mile delivery by a secure
transport van (Stanton 2019). Businesses are also wary of the stringent safety-compliance
standards for cannabis flowers and cannabis products, with the same Ann Arbor company saying
the cost to test products at a licensed testing facility has increased from $60 to $400. Yet the
most significant financial hurdle is getting through the licensing system. One family-operated
medical dispensary in Detroit reports spending more than $120,000 on their state license and
another $6,000 for their local license, and these figures do not include overhead or other routine
operations while the business awaits state and local approval (Gabriel 2019a). Other medical
cannabis businesses face similar regulatory and financial hurdles, including growers, processors,
secure transportation operators, and testing facilities. Many business experts believe these costs
are the primary factor hindering the development of minority-owned cannabis businesses,
especially since asset requirements range from $150,000 to $500,000 depending on the type of
license (Gray 2019).
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Even though the licensing system provided hope for some businesses, 2018 was a
difficult year for Michigan’s medical cannabis industry. As new operational licenses were now
required for businesses working in the industry, a regulatory backlog forced many businesses to
close and created an atmosphere of uncertainty for others. In the start of 2019, only a quarter of
the 900 prospective medical cannabis businesses were reviewed by Michigan’s Department of
Licensing and Regulatory Affairs (LARA), and only 99 of these were approved (Biolchini
2019a). Many of these businesses, from growers to dispensaries, were in operation prior to the
licensing mandate, but LARA created a deadline wherein unlicensed businesses would be forced
to close. Operating without a license jeopardizes the chances of being approved for a license,
even if the application was already submitted and pending review. As such, the beginning of
2019 saw the closure of at least 72 dispensaries and many other unlicensed businesses, though
most of these had submitted licensing applications nearly one year prior (Biolchini 2019a). This
shut-down deadline was extended by courts multiple times in 2019, with May 31 being the final
date to terminate unlicensed commerce. Thankfully, it appears enough facilities had been
licensed to where a scarcity of medicine was avoided. Though in the State of Michigan, getting
state approval is just one part of a prolonged process. Local approval can be just as difficult,
especially since municipalities can ban or impose a moratorium on medical and/or recreational
cannabis businesses.
A survey of municipal officials by the University of Michigan found only 17% favored
medical cannabis businesses operating in their communities, and just 21% expressed their
support for legalizing recreational marijuana use (Fitzpatrick et al. 2018). These figures show a
significant disjunction between the attitudes of voters and the attitudes of their elected officials,
as 63% of Michiganders voted for medical cannabis in 2008, and 56% percent voted in favor of
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recreational marijuana in 2018. Michigan’s law makes it possible for municipalities to pass their
own regulations as well as opt-out of cannabis commerce altogether. Nearly 75% of Michigan’s
local jurisdictions have barred any cannabis businesses from operating, leaving little more than
100 municipalities where state-approved medical facilities can operate (Fitzpatrick, Horner &
Ivacko 2018). Communities opting-in to medical cannabis can expect increases in their tax
revenue, more employment opportunities, and the goodwill of providing accessible medication
for patients living in the area.
The present situation is one where Michigan’s medical cannabis businesses are feeling a
squeeze from tough regulatory mandates, hostile municipal leaders, and fierce competition. Yet
their incentive to keep operating is obvious from an economic perspective. As more states
legalize medical and recreational cannabis, a “green rush” has ensued as entrepreneurs race to
claim turf in the budding industry. Over $10 billion was invested in North America’s cannabis
market in 2018, and sales are projected to exceed $16 billion in 2019 (Associated Press 2018a).
Figures like these may get hopeful entrepreneurs excited, but as I have already shown,
establishing a medical cannabis business is enormously expensive in Michigan. However, there
is talk of an added benefit for licensed medical cannabis facilities: preferred approval for
recreational marijuana licenses.

Recreational Marijuana and The Uncertain Future
Before marijuana legalization was successfully placed on Michigan’s ballot in 2018,
there were two other attempts that both failed to collect enough valid signatures. In 2012 The
Committee for a Safer Michigan launched its drive for the Michigan Marijuana Legalization
Amendment but only collected around 50,000 of the 322,609 signatures needed (Sands 2012).
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They pledged to try again in 2014 but turned their efforts towards local initiatives instead. In the
meanwhile, MI NORML began urging supporters to participate in the annual Labor Day
Mackinac Bridge Walk, a tradition led by the state’s governor stretching back to 1958 in
commemoration of the bridge’s completion. Starting in 2013, hundreds of activists wearing
conspicuous green shirts joined the crowds to express their solidarity and make a visible public
statement.
In the wake of the failed 2012 initiative, a coalition known as MI Legalize launched a
well-funded effort at a ballot measure for the state’s 2016 November election. They collected
more signatures than needed for their statute, but election officials declared many were collected
outside of the mandated 180-day period for signature gathering. MI Legalize was a grassroots
effort and prone to misinterpreting Michigan’s complex election code, and while they may have
had a chance to excuse their oversight in court, the Republican-controlled state legislature
removed that provision shortly after signatures were filed. It was a bitter blow to the movement
which took the issue to the state’s Supreme Court only to be defeated (Laitner 2016).
Yet since popular support for legalization was evident in the state, it would only be a
matter of time until something was put to the voters. Shortly after the 2016 defeat, MI Legalize
partnered with the Marijuana Policy Project, the same national policy reform organization which
helped get medical cannabis on the ballot in 2008, and the two organizations created the
Coalition to Regulate Marijuana Like Alcohol (Gabriel 2019b). They surpassed the number of
signatures needed within the 180-day window and had their initiative placed on the November
2018 ballot. The law would legalize possession of up to 2.5 ounces of dried marijuana, permit
consumption in private residences, authorize individuals to grow up to 12 plants, and establish a
regulated production and sales system for adults over age 21 (often called a “seed to sale”
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system). The initiative would pass with 56% of voters approving. It did not, however, institute a
process of expungement for an activity that is now legal. Of the 11 states where marijuana has
been legalized, Michigan and Alaska are the only states where there has been no action to clear
marijuana-related criminal records. More than 10,000 Michiganders have been convicted of
minor pot-related offenses in the past decades, and an additional 3,500 residents are still behind
bars or on probation for felony marijuana offense (Neavling, Jayyousi & Emrich 2019).
Governor Gretchen Whitmer ran on a pro-legalization platform and promised swift action to
clear marijuana-related crimes, but as of January 2020, nothing has been discussed by her or the
state’s legislature.
Although Michigan voters legalized recreational marijuana in November 2018,
commercial sales only began in a limited fashion in December 2019.53 While the state legislature
was negotiating regulatory guidelines, a gray market has arose where marijuana was “gifted” to
customers who purchased select items. Some of these business schemes sell over-priced books,
chocolate, or t-shirts which all conveniently come with “free” marijuana (Biolchini 2019b).
Other schemes include cannabis membership clubs which often meet at bars once a month with
the promise of being able to consume (but not purchase) cannabis on-site. Regulators have so far
tolerated such operations and expect them to disappear once licensed recreational dispensaries
begin to flourish. In the meanwhile, hopeful businesses are preparing themselves for the
forthcoming recreational market which promises to quickly eclipse the scale of the current
medical market. Even if medical cannabis in Michigan is dwarfed by recreational marijuana,
having two separate systems and regulatory processes is probably a better solution than what
Washington state decided to do.

53

On the morning on December 1, 2019, John Sinclair was the first person to legally purchase non-medical
marijuana at a dispensary in Ann Arbor.
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Lessons from Other States
Like most marijuana reform, the citizens of Washington voted in favor of initiatives for
medical cannabis in 1998 and recreational marijuana in 2012. Under the medical cannabis
initiative, patients could grow their own medicine or purchase it through unregulated and
untaxed dispensaries throughout the state. Yet the 2012 initiative established a strict regulatory
and taxation system for recreational marijuana, and shortly afterward, regulators decided upon a
maximum of 334 retail licenses. Washington medical cannabis dispensaries did not pursue these
because they were operating under a different legal provision, but in 2015 the state legislature
decided it would be best to merge or “align” the two systems under the state Liquor and
Cannabis Board (Young 2016). As the original 334 retail licenses had already been granted to
recreational facilities, they created another 222 retail licenses to replace the state’s estimated
1,500 unlicensed medical cannabis storefronts. The new licenses were also supposed to be
competitive, but unscrupulous applicants found a loophole54 , and most newly issued retail
licenses went to business owners with little to no intention of opening a medically focused
facility. When the new licensing requirements went into effect on July 1, 2016, the vast majority
of existing medical cannabis retailers were forced to closed while more recreational stores
opened (Coughlin-Bogue 2016a).
Washington “folded” their medical cannabis into their recreational system, but mishaps in
the licensing system marginalized medical facilities. The state did institute a certification process

Washington’s licensing processes favored applicants with prior experience operating or working in medical
cannabis dispensaries. To prove this experience, applicants were apparently asked to submit pay stubs.
Unscrupulous applicants turned to online forums where they sought to purchase old pay stubs, sometimes offering
upwards of $100,000. The other approach was to an individual with experience sign on the license application,
though this individual had no real role or stake in the business (see Coughlin-Bogue 2016a for more information).
54
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for “medical marijuana consultants” to work at recreational dispensaries, but this does not
necessarily mean the dispensary carries specialized medicines favored by many patients. Patients
can also buy more cannabis than non-patients as well as products with higher levels of THC. In
terms of taxes, medical patients still must pay the state’s 37% marijuana excise tax but are
exempt from local sales taxes (Young 2016). Interestingly, though, Washington also established
a voluntary patient registry in 2016, and it has grown each month despite accessible recreational
marijuana55. However, it is unknown how many patients were in the state prior to this registry or
how many current patients have decided not to register.
In Michigan, medical cannabis businesses know they will be given preference in the
impending recreational licensing process. The first year of adult-use licensing will only consider
applications that already hold medical business licenses. This has caused some concern among
patients in the state. One woman in Grand Rapids told news reporters: "What happened in
Colorado, 90 percent of their medicinal switched to recreational. It's like going into a liquor
store” (WoodTV8 2018). This sentiment was also expressed by another woman in the same
broadcast: “I hope that it doesn't just bring more pot shops, where its strings away from medicine
and into just more of how we have breweries everywhere and things like that… I'd like it to stay
where medicine is an option" (WoodTV8 2018). It will be interesting to see what becomes of the
cannabis landscape in Michigan over the next year or so. Unlike states on the west coast,
Michigan will be the only midwestern state with a legal recreational marijuana industry and there
are currently no plans to restrict sales to Michigan residents only. The potential for profit is
enormous, but there are also cautionary tales from other states who have experienced similar
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Patients certified by a physician who do not want to be entered into Washington’s state database are allowed six
ounces of dried cannabis and may grow up to four plants in their homes. Patients who enter themselves into the
database can have eight ounces and six plants. Patients not in the state database may only purchase the same amount
as nonpatients in stores.
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transformations in their cannabis economies. With California leading the way on this issue, it is
worthwhile to examine what happened in the wake of their shift to a legal recreational market.
Murder Mountain is a six-part documentary series released on Netflix in late 2018.
Despite the sensationalized title, the plot centers on cannabis cultivation in Northern California’s
fabled “Emerald Triangle”, the legendary epicenter of marijuana production in the United States
for the past 50 years. Both licensed and law-breaking farmers there are estimated to produce
most of the nation’s domestic supply of cannabis. Since the region is remote and culturally
inhospitable to law enforcement, crimes related to cannabis cultivation tend to be severely
underreported. The series traces the unsolved murders of several individuals who all arrived in
the region with hopes of working in the famous marijuana industry. Many of them sought to start
their own grow operations and compete in the market. Though violent crime in the marijuana
industry is exceedingly rare, the series illuminates anomie (normlessness) among the long-time
growers of California.
Oddly enough, legalization has made things harder for California’s marijuana businesses.
Crop prices have plummeted as legal product has flooded the market. Newly licensed businesses
may have invested hundreds of thousands of dollars to established legal grow sites, and now they
are losing money due to oversupply problems. Since cannabis cannot be legally shipped over
state lines, all legally-grown cannabis must remain in its state of origin. Indeed, prices have
declined exponentially. The price per pound of marijuana in California peaked at around $5000
in 1994 and fell to around $1200 in 2011 (Rendon 2012). In 2018, that price fell further to less
than $500 per pound (Andersen 2018). A similar situation has occurred in Oregon where
approximately 1 million pounds of extra marijuana now sits in the state’s tracking system,
enough to meet residents’ current demand for approximately 6.5 years. When Oregon began to
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permit recreational dispensaries in October 2015, the median price per gram of marijuana was
around $14. As of early 2019, the median price per gram of marijuana at retail dispensaries had
dropped to below $5 (Danko 2019). In both California and Oregon, businesses typically blame
the state’s liberal licensing system for granting too many operational and production permits56.
While this is good news for individual consumers and patients in these states, it is
devastating news for entrepreneurs looking to make a return on their investment. It is also bad
news for small-scale “mom and pop” businesses as the trend has been towards consolidation
(Danko 2019). Larger businesses can bleed money longer, attract additional investors when
needed, and they often buy up struggling independent businesses as a convenient means to
damper competition. There are also environmental concerns over legalized marijuana production
as growers fail to comply with costly regulations and engage in more intensive farming practices.
The problem here, however, is not inherent in cannabis as a crop but rather the capitalistic
propensity to turn a profit while ignoring sustainability (Polson 2019). It is also likely that as
cannabis cultivation continues to scale, we will see the same exploitative labor practices endemic
in the American agriculture system. Instead of paying competitive wages to individuals from the
local community, large growers may find it economically advantageous to bring in underpaid
immigrant workers.
With commercialized cultivation becoming the norm, many believe more money can be
made selling cannabis on the black market which has reportedly grown since California legalized
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Declining prices of marijuana are also a result of the burgeoning demand of oils, concentrates, edibles, and other
processed products. It takes a significant amount of raw cannabis to refine down to a concentrate, but this raw
cannabis does not need to be immaculate like the cannabis buds sold in dispensaries. When you buy smokable
cannabis buds from a dispensary, you are essentially purchasing the highest-quality crop available. Most of the
cannabis grown (especially outdoor crops) may have imperfections, discoloration, and other defects which make it
less desirable to sell in raw form. It commands a lower price and is most often processed into oils or tinctures with
concentrated amounts of THC. This is analogous to most other agricultural products. The best-looking apples can be
sold as produce in stores while blemished apples are mainly transformed into processed products such as apple
sauce.
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recreational cannabis in 2016. Even customers have begun to illegally profit from cheap legal
marijuana. In a practice known as “looping”, a customer makes numerous trips to one or more
dispensaries where they buy the maximum amount of bud allowed under state law (hence the
loop). They then take their purchases to a neighboring state without recreational marijuana
facilities and make a profit from selling a legally purchased product where it is unavailable or
prohibited (Schaneman 2016). The incentive of higher returns also has the potential to entangle
licensed cultivators with an illicit supply chain, effectively mirroring how cannabis was sold in a
pre-legalized era. Anecdotally, I know many patients fear a similar situation could happen in
Michigan, and just as Rendon (2012) interviewed California growers against legalization,
something leads me to believe similar sentiments can be uncovered here. Rumor has it that
Michigan regulators are turning to Colorado as a model for the forthcoming recreational system,
and while far from perfect, Colorado’s marijuana system has faired better than others discussed
in this chapter.
Voters in Colorado passed a ballot measure legalizing medical cannabis in 2000 but a
2010 bill in the state’s legislature finally paved the way for a formalized dispensary system.
Following this bill, the number of registered patients in Colorado grew exponentially, reaching a
peak of 128,698 in June 2011. In the years to follow, the number of registered patients would
hold steady around the 110,000 mark before declining in 2015 (CDPHE 2019; Warner 2010).
What happened in this time period was that voters passed a ballot measure legalizing recreational
marijuana in 2012, and the state legislature formalized a public sales system in 2014. Many
believed it would be the end of the medical cannabis in Colorado, and while sales dropped and
the number of registered patients bottomed out to near 86,000 in 2018, it is far from the collapse
of a system as many anticipated. In fact, the latest available data indicates the number of
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registered patients has been growing slightly, reaching 89,492 in April 2019 (CDPHE 2019).
This growth could be partly due to some parts of the state banning recreational marijuana stores
while permitting medical ones (Markus 2018).
Regardless, patients in Colorado did not vacate the medical system in favor of the
recreational system, but lawmakers have been attempting to funnel patients towards the
recreational system. As with many states, medical cannabis has some tax exemptions while
recreational marijuana does not. This means the state and municipalities receive greater revenue
from recreational sales than they do medical. While patients must pay for a physician
certification and a registration fee, this source of revenue largely funds the regulatory system.
Recreational marijuana taxes, however, can be a significant source of revenue for the state and
municipalities. This has led some cities like Aurora to ban medical cannabis facilities while
welcoming recreational facilities (Roberts 2018). Colorado also imposed a strict 12 plant limit in
2017 for both recreational and medical cannabis, and many patients feel this was an effort to
push them towards taxable retail outlets (Simmons 2017).
Colorado was also able to strike a balance between supply and demand, avoiding market
collapses like those in California, Oregon, and Washington. While the price of cannabis in
Colorado has declined since recreational production began, the state had at least two wise
policies to avoid a rampant black market. The first was giving existing medical marijuana
growers priority for new recreational grower applications. The second was requiring recreational
growers to sell at least 85% of their crop before permitting them to expand their growing
operations. These measures have helped protect against overproduction through deterring
accumulation and giving scarce licenses to individuals with a stake in the community
(Associated Press 2018b).
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Many medical growers and dispensaries did switch to the recreational market, but the
major reason appears to be in the hurdles of becoming a patient and operating a medical store.
Like Michigan, Colorado patients must pay for a physician's recommendation, file paperwork
with the state, and pay an additional application fee on top of the physician’s fee. Unlike
Michigan, however, patients in Colorado must also find a store to designate as their official
caregiver. This allows the store to grow more medicine but some dispensary owners have
expressed concern about not having enough patients on their rolls. Growing fewer plants not
only means less product for sale, but also less diversity. Different strains of cannabis produce
different bodily effects, and patients like to have a wide variety of choices as some work better
for different ailments and different medication regiments. One Colorado dispensary owner says
of the medical system's regulations: “It becomes a ridiculous business model that the State of
Colorado put together that makes absolutely no sense from a business standpoint or from a
patient standpoint. And that’s why medical marijuana is not working” (Markus 2018). She and
other dispensary owners also remark that many of their customers at recreational stores are there
for explicitly medical purposes, and while they pay a higher tax rate, they are free from the
arduous registration process and restrictive supply policies.
Colorado’s model may have deterred the expansion of a black market and transforming
such illegal sales into taxable, legal sales have been the primary focus of many regulators. Yet
among patients and their caregivers, a related controversy may have serious implications for the
future of safe access to medicine. It may be stretch to say the cannabis community was united
under blanket prohibition, but a divisive war of perception may well be occurring as we shift to a
regulated market. Both medical and recreational businesses with the privilege of a license enjoy
throwing around words like “black market,” “illegal,” “unregulated,” and “untested” to disparage
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their unlicensed competition. These labels are technically correct, but the reality is far less shady
or dangerous than such terms imply. Take the case of Maria, a medical dispensary owner in
Washington state, as reported by Tobias Coughlin-Bogue of Seattle Weekly:
After her attempts to get a license failed, Maria gave up on pot, at least
publicly. However, I recently attended an “Ice Cream Social” at her former
storefront, now converted to something of a hangout for her patients… As a
bunch of friendly suburbanites—some of whom brought their kids—passed
around infused brownies a la mode, Maria stepped frequently into her office for
what she called “the other party”: providing the rest of her inventory to patients
desperately seeking cheap medicine. Though the scene was aggressively tame,
this was technically a black-market deal. One patient picked up what in a retail
store would have been $380 worth of flowers, kief, and edibles. Maria hooked
him up for $180. Trent [a patient] said he bought all his weed on the black market
since the new law passed. “What are we to do?” he asked. “It’s inhumane for
anyone to deny us anything that medically benefits us.” He’d tried the
[recreational] store, he said, but they didn’t have the right strains and the prices
were way too high. Maria, however, still had some of the particular high-THC
indica that worked to calm his PTSD without putting him to sleep. And that, more
than money, was what drove Maria to host her polite little party (Coughlin-Bogue
2016).
It seems unfair to lump Maria into the same category as a stereotypical smuggler or street
dealer with suspicious product. All are technically illegal, but Maria’s crime is qualitatively
different. If anything, she and her clients are more the victims of an inadequate regulatory
system, legally proving medicine for years but being forced to close through an unfair licensing
process. While money certainly plays a role in this illicit commerce, it is undoubtedly not the
only factor of importance to Maria or her customers. The recreational marijuana industry does
not prioritize the needs of patients and licensed medical cannabis facilities may be few and far
between. Something akin to the case above is currently occurring in Michigan.
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Caregivers and Controversy
As discussed previously in this chapter, state regulators have allowed medical cannabis
grown by unlicensed caregivers to be sold to provisioning centers and patients. This medicine
has supported Michigan’s medical cannabis community for over a decade and is still necessary
because newly licensed growers have thus far been unable to produce enough to meet patient
demand. In the six months preceding April 2019, caregiver grown medicine accounted for 92.8%
of the cannabis in the state’s tracking system (Biolchini 2019e). However, caregiver-grown
medicine is not required to be tested for contamination like the medicine grown by licensed
cultivators. This has so far resulted in a series of seven recalls in 2019 after independent analysis
found contaminants like mold, E. coli, Salmonella, and heavy metals (Biolchini 2019c). While
no illnesses have been reported57, and while this contaminated medicine represents a mere
fraction of the total medicine produced by caregivers in the state, the recalls have provided fuel
for intense politicking on the part of corporatized cultivators.
Green Peak Innovations (aka SkyMint) reportedly spent $13 million to open its licensed
cultivation facility near Lansing in early 2019. As of early 2020, the corporation holds over half
of all cannabis licenses granted in Michigan. With 27 different grow rooms, they are permitted to
grow up to 15,000 plants for Michigan’s medical market and have the capacity to produce
roughly 30,000 pounds of marijuana per year. While this facility and others like it may
eventually push small growers out of the market, they are currently competing with unregulated
and less-expensive caregiver-grown medicine. To end this competition, Green Peak Innovations
launched a massive public relations blitz in April 2019 with the goal of getting Governor
Gretchen Whitmer to stop the sale of all caregiver-grown cannabis to dispensaries. They

To paraphrase a common expression about lab testing controversies: “I’ve been smoking untested marijuana for
decades and never had a problem”.
57
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purchased full-page ads in several Michigan newspapers, bought eight billboards around
Lansing, and started a website called micleancannabis.org:
When the voters of Michigan made marijuana legal, they did it believing
that it would move from being a dirty, illegal business into one that was clean. It
would be an industry that was a force for health and healing, as well as force in
driving the Michigan economy. Right now, that’s not happening. Currently, the
laws as they are written, are not being followed, and that’s putting people’s lives
in danger. For years, anyone who used marijuana for medical purposes had to
accept what they could get their hands. Once they found a trusted caregiver,
they’d be highly loyal to the person and products that helped keep them well. It
was an imperfect system, but one that had to be maintained for the health and
well-being of the patients. Today, it is possible to cultivate and harvest marijuana
that’s free from harmful pesticides, toxins and poisons. Grown with the best seeds
and soil, as well as the utmost dedication, it’s free of harmful organisms that can
make you worse, and not better. Why is the State of Michigan allowing untested,
unsafe and illegal medical marijuana to continue to be sold? (MI Clean Cannabis
2019).
It is clear Green Peak Innovations stands to profit from a system that prohibits the sale of
caregiver-grown medicine in retail dispensaries. It’s also clear their ambitions have less to do
with the medical market and more to do with the recreational market. In late-April 2019, a small
protest occurred outside of the Lansing capitol building involving around 100 employees from
Green Peak and other corporate growers with hopes of moving the governor towards action.
They were met by around 20 counter-protestors who were angry at the corporate take over of
medical cannabis in Michigan (Biolchini 2019d). Patient discontent at Green Peak is best
captured in a news article from earlier in April where they loathed how corporate growers were
not producing specialty medicinal products commonly used by patients (Biolchini 2019c).
Instead of THC/CBD tinctures and Rick Simpson Oil, large-scale cultivators are primarily
producing edibles and other recreationally-focused products. Without an ample supply of
affordable caregiver-grown medicine, patients fear they will run out of the specialty products
they have relied upon for so long. Neither side received the exact outcome they had hoped for, as
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the courts ruled caregiver sales to dispensaries must stop after April 30, 2019. However,
regulators will allow caregivers to sell their medicine to licensed growers and processors, who
are then obligated to have it tested before it can be sold to dispensaries. Unfortunately, the black
market offers a higher price for caregiver-grown cannabis than licensed growers or processors
are willing to pay (Biolchini 2019f).
While not total, this decision was more of a victory for corporate interests than patients.
Competition from unlicensed growers may have slightly decreased but so too did the availability
of specialty medical products. This is what led Sherry Hoover, a 57-year-old cancer patient, to
file suit against Michigan’s Department of Licensing and Regulatory Affairs in early June 2019.
Hoover’s lawsuit says the new state restrictions against caregiver-grown cannabis violate her due
process rights as her specialty medicine is no longer available at her local dispensary. She was
seeking a temporary reintroduction of direct-to-dispensary caregiver cannabis back into the
regulated market, but her case was eventually dismissed (Biolchini 2019f). Corporate mega
growers have said they will eventually focus on replicating these medicines but are more
concerned now with producing products with mass appeal. Jeff Radway, the CEO of Green Peak
Innovations, is even quoted as saying:
We have started with flower, we have started with distillate; we’re
launching edibles next month, we’re launching vape carts -- we’re starting with
the medicines the patients need most… We’re one of many dozens licensed
suppliers. GPI has never claimed we’re going to make every product. GM doesn’t
make every car: there’s room in the market for Alfa, and Chrysler, and Ford. We
are one of many suppliers, but we make 98 percent of the products that patients
want (Biolchini 2019d).
While Radway’s comparison to the auto industry contains a kernel of truth, it is unlikely
that GM is trying to shut down their competition by claiming their competitors’ vehicles are
unsafe and should thus be barred from sale. The statement also reveals that Radway’s top
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priorities are in producing products that sell at the highest volumes. In other words, patient needs
are an after-thought even though his business is a licensed medical cannabis facility. His
priorities make more sense for a recreational market which he will surely pursue once regulators
start a licensing system for recreational facilities. In the meantime, Radway and Green Peak
obtained over half of the scarce medical licenses issued by the state, licenses which could have
gone to one of the many medically-focused growers who are patiently waiting.

Looking Up
This chapter has so far explored cannabis activism in Michigan and the inevitable
problems arising from new regulatory systems across the United States. It is also worthwhile to
look beyond our borders, especially since our neighbor to the north has also recently reformed its
cannabis laws. On October 17, 2018, Canada became the first North American country to
legalize marijuana for adult use. They also established a regulated sales system that exists
alongside of the country’s medical cannabis program. While legalization in areas of the United
States has seen prices plummet and declines in the number of enrolled medical patients, the exact
opposite has occurred in Canada. The number of patients has increased and so has the average
price of both medical and recreational cannabis. However, Canada’s situation may not be exactly
comparable to the United States as their national system is structured very differently. Perhaps
the most important difference is the regulated legal market in Canada was established through
bureaucratic action rather than grassroots mobilization like the ballot initiatives in the United
States.
In contrast to many state models, Canada’s system operates on a clear public health
mandate, which gives the government monopolistic control over cannabis commerce. They not
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only banned all branding, advertising, and marketing, but they also gave health professionals
oversight on where and how cannabis could be manufactured and sold (Rolles 2018). This
resulted in a system much more restrictive than any in the United States. Unsurprisingly, when
recreational marijuana was legalized in Canada, licensed stores quickly ran out of available
products. Several months later, stores are still facing product shortfalls with one survey finding
over half of the listed products were out of stock (Alpert 2019).
Statistics Canada also found prices of dried cannabis flower increased 17.6% following
legalization, though these figures are based on a small sample size (NCS 2019). This is partly
due to increased consumer demand, a lack of licensed growers, and grower anticipation of
lucrative edibles market opening in October 2019. Infused foods are not currently permitted in
Canada’s recreational marijuana industry58, but that is about to change later this year. In the
meanwhile, producers have been stockpiling cannabis and cannabis oils in preparation for what
they perceive as the “second wave” of legalization (Armstrong 2019). Edibles are essentially
cannabis oil baked into food or added to a beverage, and while anyone can easily do this
themselves, the convenience of pre-packed “magic” food is arguably more appealing.
With shortages of recreational marijuana and inflated retail prices, it is no surprise that a
recent study found 60% of Canadians are still buying from illicit sources, top reasons being
price, quality, and convenience (Charlebois et al. 2019). The same study also found popular
support for marijuana legalization decreased from 68.6% in 2017 to 50.1% when survey data was
collected in April 2019. Not many changed their opinion to against legalization, but frustrations
with how legalization unfolded caused many respondents to become “uncertain” of legalization.
Canada’s media has also aired many stories about children being hospitalized and pets becoming

Canada did not initially legalize edibles because of “the gummy bear problem”, the fear that children will
accidentally ingest cannabis by consuming candies and cookies infused with THC (Lawrence 2019).
58
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ill after ingesting cannabis. Despite these concerns, 18% of Canadian adults report using
cannabis within the last three months. This is up from 14% pre-legalization, the largest increases
occurring among males and people ages 45 to 64 (NCS 2019). With shortages and frustrations
with Canada’s legal marijuana system, it is no surprise that their medical cannabis system has
remained strong, perhaps even flourishing.
Canada’s medical cannabis program was created in 2001 and expanded in 2013 to
include large-scale production and distribution. This increased accessibility caused the number of
registered patients to quickly grow from less than 30,000 in 2015 to 345,520 in October 2018,
the same month as recreational legalization (Health Canada 2019). The Canadian system is
structured where patients must choose one of three suppliers after getting a physician’s
recommendation. The patient can either grow their own medicine or designate a personal grower,
they can purchase dried cannabis directly through Health Canada, or they can submit their
patient certificate to a dispensary where they will be allowed to purchase products for sale.
Patients can only purchase in dispensaries where they have submitted a certificate, but additional
certificates are available through Health Canada (Health Canada 2016).
Despite the availability of recreational marijuana, Canada’s medical cannabis program
continues to expand under legalization. As already stated, there were 345,520 registered patients
in October 2018, but as of March 2019, that figure increased to 354,538 (Health Canada 2019).
Moreover, monthly calls answered by Health Canada about questions about becoming a patient
have tripled since legalization, growing to nearly 1900 in June 2019 alone. Dr. Sana-Ara Ahmed,
a Calgary physician who prescribes medical cannabis to her patients, says the increase is due to
lessened drug stigma from legalization. She also estimates the total number of patients to be
around 400,000 as of June 2019 (data from Health Canada not yet available) and believes it will
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reach one million by 2025. Many health care professionals say legalization has facilitated
discussions between medical providers and their patients, and patients are more willing to try
medicines made from the once-prohibited plant (Kaufmann 2019). This paints an encouraging
picture for the future of medical cannabis, but it will be interesting to see how the medical
cannabis program fares once recreational suppliers manage to stock a steady stream of products.
Nonetheless, medical cannabis systems appear to fare well even after the plant is fully legalized.
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APPENDIX C
ANNOTATED DICTIONARY
o Cannabinoids = Chemical compounds produced by the cannabis plant that bond the
cellular receptors in the human body (called the endocannabinoid system). There are at
least 85 unique cannabinoids, each with differing effects, though more may be discovered
as scientific interest in this area expands. Some prominent cannabinoids include
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and cannabigerol
(CBG). Each of these is also activated at different temperatures. If the cannabinoid is not
activated before being ingested, it will not be efficiently absorbed in the body. This also
means it is impossible to get high just by touching raw cannabis.
o Cannabis = a term used in this study to refer to marijuana used for medical purposes.
Cannabis is the scientific term for the plant’s genus and is commonly described as having
three unique subspecies: Cannabis sativa has uplifting mental effects and is widely used
as day medicine among patients. Cannabis indica has sedating bodily effects and is
widely used as night medicine among patients. In reality, the vast majority of cannabis
has been hybridized between these two subspecies with nearly all commercially available
strains being various degrees of cross-breeds between sativa and indica. There is also
Cannabis ruderalis but this rarely used for commercial purposes since it is small and has
scant amounts of THC. Nonetheless, ruderalis has been incredibly valuable to cannabis
cultivation since it is flowers as it ages rather than being dependent on changing light
levels like the other two varieties. Most cannabis plants require diminishing levels of
light in order to bloom while “auto-flowering” plants bloom after a certain number of
days regardless of light exposure.
o CBD = Cannabidiol, a non-psychoactive component found in cannabis plants with many
medical benefits. CBD is commonly described as relieving physical pain and muscle
spasms without the effects of feeling high. It is also an anti-inflammatory and can be used
as a mild sedative. Many believe CBD helps “balance” the high resulting from
psychoactive THC. The compound can be extracted from marijuana or hemp plants, as
well as synthesized in a lab. The State of Michigan does not consider CBD to be
marijuana if the plant or extract contains less than 0.3% THC. This makes it quasi-legal
to buy and sell CBD without being registered in Michigan’s Medical Marihuana
Program, but the state is waiting for the 2020 federal farm bill to solidify their CBD
regulations (CBD is currently regulated like hemp and hemp is classified as an
agricultural commodity). Since CBD does not get one high, it has historically been bred
out of cannabis plants as growers opted for varieties with increasingly concentrated
amounts of THC. This has made CBD-rich strains rarer though they are becoming more
popular. The genes that moderate THC and CBD are located on the same chromosome,
making it currently impossible to have a single plant produce high levels of each
cannabinoid.
o Edibles = Foods infused with cannabis and/or cannabinoids. Since cannabinoids are
soluble in fat as opposed to water, many edibles are made with infused butter or oils.
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Alcohol can also be used to extract cannabinoids making non-fatty foods like gummy
bears possible. The range of edibles on store shelves today is truly impressive. I have
seen brownies, cookies, cakes, sugary candies, chocolates, ice cream, soda, juice,
pretzels, granola, peanut butter, honey sticks, and more. None of these are healthy but
they do not need to be since you typically only consume a small amount per dose. Edibles
range in their concentrations of THC and other cannabinoids, and the effects can take one
to two hours to be felt. This has resulted in many people over-medicating since they eat
more than they should.
o The Entourage Effect = How multiple compounds in cannabis plants work in synergy to
produce an effect greater than the sum of isolated compounds. THC, CBD, other
cannabinoids, and terpenes work together to make “whole plant medicine” the most
potent form of cannabis medicine. This is why patients prefer natural cannabis compared
to existing pharmaceuticals that contain only one or two cannabinoids. This is also why
different cannabis products produce different effects. Edibles, oil extracts, and other
processed products often contain THC-only as the other cannabinoids and terpenes are
destroyed in the extraction process or the extracts are made from near-exclusive THC
plants. Mono-cannabinoid products have a much different “psychological texture” than
smoking cannabis flowers.
o Hemp = Cannabis plants or parts of cannabis plants little to no psychoactive THC and
often used for industrial purposes. The federal government defines hemp as cannabis
plant matter with less than 0.3% THC by dry weight. Hemp fibers can be made into cloth,
rope, paper, and more. Hemp seeds are widely available as a health food boasting high
levels of fatty acids and protein. One of the more recent and interesting developments is
“Hempcrete”, an eco-friendly concrete fortified with hemp for use in construction and
insulation. In 2018 hemp was removed from the controlled substances act, effectively
legalizing CBD on a national level.
o Kief = Sometimes spelled keef, this is the potent crystalline resin produced by female
cannabis plants. The flowers of female cannabis plants are covered in sticky trichomes
which contain THC and other cannabinoids. When some of these trichomes fall off the
bud during processing (e.g, grinding), they become a brownish powder known as kief.
There are many different uses for kief and it is very high in THC since it lacks green
plant matter. Kief is often slightly heated and pressed into hash or hashish, a form of
cannabis more popular in Europe. In the United States, “moonrocks” are fresh cannabis
buds rolled in kief to boost THC levels. Kief can also be dissolved in oil or alcohol
extracts.
o Marijuana = a term used in this study to refer to cannabis used for recreational purposes.
Many laws and official programs spell marihuana with an “H” including Michigan’s
Medical Marihuana Act of 2008. The state defines marijuana as cannabis plant matter
containing more than 0.3% THC. Only registered patients and licensed businesses can
buy and sell marijuana in Michigan. The penal code changed when voters legalized
recreational marijuana in November 2018, but state regulators are still working out
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details on how it will be commercially regulated. The initial projection for marijuana
retail shops for those over age 21 is in early 2020.
o Terpenes = organic chemical compounds produced by plants with distinct odors and
tastes. Interest in terpenes by cannabis researchers and consumers is relatively new, and
much is still to be discovered. Simply put, each strain of cannabis has a different odor and
sometimes the same strain of cannabis can smell different based on how it is cultivated.
Terpenes are not unique to cannabis plants, but they interact with cannabinoids to
moderate bodily effects. For example, Alpha-Pinene smells like pine trees and is said to
boost alertness, Linalool smells like lavender and is said to promote relaxation, and
Limonene smells like citrus and is said to elevate mood. These different terpenes are why
visitors to dispensaries are encouraged to use their nose when selecting cannabis to buy.
Many labs now offer tests for common terpene levels and over 350 different terpenes
have been discovered in cannabis plants. While research is still developing in this area,
some experts have even claimed terpenes are better indicators of a strain’s effects than
the traditional sativa/indica divide. Terpenes have certainly added another level of
connoisseurship to cannabis as smell increasingly becomes an important quality to
consumers.
o THC = Tetrahydrocannabinol, the main psychoactive component in cannabis plants. THC
is produced by female cannabis plants through their flowers, commonly called buds. The
compound is most concentrated in the crystalline resin found on flowering parts of the
plant. While consuming THC produces the high associated with marijuana, it has also
been shown to help with pain, nausea, and glaucoma. Since THC has well-known
psychoactive effects, cannabis breeders have focused on increasing THC levels in their
plants over the past several decades. Overtime, this has resulted in marijuana becoming
significantly more potent. There are also different types of THC each of which is
activated at a different temperature. THC and other cannabinoids must be heated in order
to be felt.
o Vaping = Heating cannabis or cannabis resins without combustion. There are two basic
types of vaporizers available today. First are flower vaporizers that heat ground cannabis
flowers, essentially baking rather than smoking the “bud”. This method allows one to
inhale cannabis vapors without the risks associated with smoking. Since cannabinoids are
activated at different temperatures, adjustable-temperature vaporizers allow one to
precisely control which cannabinoids are consumed. These flower vaporizers are often
large or bulky since they require large batteries or electrical cords. The second type of
vaporizer involves heating oil placed inside a cartridge. The oil contains varying levels of
cannabinoids like THC, CBD, and others, but there are health concerns over some of the
chemical solvents used in extracting these cannabinoids. The advantage, though, is that
oil vaporizers are efficient and very small. Some are the size of pens or smaller (hence
the term “vape pen”). However, something unique to whole-plant cannabis is lost in the
oil extraction process. Some cannabinoids may be destroyed upon extraction and others
may be left behind, limiting the “entourage effect” received from consuming the 85+
known cannabinoids. This difference was perhaps best expressed on the Howard Stern
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Show by comedian Jonah Hill in 2015, who said: “[Vaping] gives me a high I don’t
understand”.
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APPENDIX D
TABLE 1: KEY INFORMANT INTERVIEWS

KEY
INFORMANT
INTERVIEWS

Description

Date

Duration

Method

Randy

Board member for MI NORML and
cannabis activist.

June 25

43 Minutes

Phone

Justin

Cannabis activist, dispensary coowner, and radio host.

June 25

65 Minutes

Phone

Ramona

Owner of a cannabis marketing firm
and public relations professional.

June 27

30 Minutes

Phone

Madison

Executive in the Michigan Cannabis
Industry Association and cannabis
lobbyist.

June 28

70 Minutes

Phone

Dispensary owner in southwest
Michigan

June 28

50 Minutes

In Person

July 2

44 Minutes

Phone

July 5

78 Minutes

In Person

Kayla
Jackie
Dr. Steven

Founder of a cannabis networking
association and a leader in
Michigan’s chapter of Women Grow.
A certifying physician in the MMMP
and the owner of a holistic health
center.

May

A long-time caregiver in the MMMP.

August 15

39 Minutes

Phone

Michael

A long-time caregiver in the MMMP
and former commercial grower.

August 23

120 Minutes

In Person
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APPENDIX E
INTERVIEW GUIDE
-

What is cannabis?
Describe your typical customer (age, race, gender, social class, etc.)
What questions are you asked the most?
Why did you enter this business?
Aside from your customers, how does the public view your business?
What is the most frustrating part of being a ----------?
What does the media get right or wrong about your role?
What will medical cannabis look like 20 years from now?
If you could change one thing about medical cannabis in MI, what would it be and why?
How do you think your business will change over the next few years with the emerging
recreational market?
Is recreational cannabis a friend or foe to medical cannabis?
What is different about medical cannabis in SW Michigan compared to other places?
If the cannabis community had a gender, what would it be and why?
Is there a difference in how society looks at a man or woman who uses cannabis?

Certifying Physician:
- If you had the power to change the state’s list of qualifying conditions, what would you
add and what would you remove?
- What role does the pharmaceutical industry play in medicalizing cannabis?
- Would you like to see cannabis absorbed more into mainstream medicine, or something
else?
Marketing Professionals:
- What are the legal parameters of how cannabis can be marketed here in Michigan?
- Is there a difference in marketing medical cannabis?
- Have you seen people take cannabis advertising too far?
NORML Board Member:
- Could you briefly describe how cannabis came to be medicalized in Michigan?
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APPENDIX F
TABLE 2: OBSERVATIONS

OBSERVATIONS

Description

Nature’s Healing

A provisioning center only accessible
to those in the MMMP. Access limited
to the waiting room as patients are
taken into private rooms for sales.

Alternative
Midwestern
Medicine
MMMP
Conference

Boutique Herb
(pop in)

Kosmic Buds
(pop in)

MI Harvest Fest

Observation 1

Office of a physician who certifies
patients for the MMMP in addition to
offering a range of classes and hemp
products. Not able to observe doctorpatient consultations.
An event for patients and caregivers in
a large hotel’s conference area. There
were two main rooms with one devoted
to presentations and another for vender
booths.
An upscale dispensary chain new to the
West Michigan area. I visited as a firsttime patient.
A new dispensary in the West
Michigan area with plans of vertical
integration. I visited as a first-time
patient.
The first public cannabis event in the
area following legalization. Akin to a
smaller “cannabis cup” competition.
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Observation 2

July 5

July 13

6:00pm to 7:05pm

2:00pm to 3:00pm

July 10

July 15

10:20am to 11:30am

10:00am to 11:00am

July 28
1:00pm to 4:00pm

July 6
4:00pm to 4:15pm

July 24
5:20pm to 5:35pm

October 27
3:00pm to 5:30pm

na

na

na

na

APPENDIX G
OBSERVATION GUIDE
Notes on Physical Setting:
- Journeying to the place (general location, nearby points of interest, etc.)
- Outside of the place (parking, pavement, physical building, neighboring sites, vibe, etc.)
- Décor (non-functional items)
o Particularly, how much is cannabis-related? How much is related to medicine
and/or health?
- Signage
o Bulletin boards, announcements, notifications, instructions, business information,
etc.
- Lighting and texture
o Is the place well-lit? Natural or artificial light? Is the place organized? How does
it feel?
- Smells and atmosphere (Does it smell like cannabis? Something else? Is the air clear or
cloudy?)
- Security (Cameras, locks, ID checks, signs, windows, etc… Are security devices
conspicuous or no?)
- Sounds:
o Non-verbal noises
o Music / entertainment
Notes on People:
- Number of visitors (distinguishing between those who come to purchase medicine and
those who do not)
- Characteristics of people (general age, perceived race and gender, overall physical health,
clothing and style, energy/enthusiasm, etc.)
Notes on Talk:
- Who is speaking? What are they saying? Who is actively listening? Is it routine language
for the business? Or is it personalized communication? Is it hushed or loud? Is it said
with emotion? How long does it last? How do others respond?
Notes on Action:
- What are people doing? Are they avoidant or open? Are they engaged in something or are
they idle?
- What is purchased? How long does someone spend at the counter or in the office?
Notes on Products or Services:
- What is for sale? How many brands/types/flavors/styles? Are shelves stocked full or
empty?
- What services are offered here? What services or products are suggested (through ads
such as fliers, pamphlets, etc.)?
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APPENDIX H
TABLE 3: FOCUS GROUPS

FOCUS
GROUPS

Participants
(n=21)

Group 1

n=4

July 16

(6 confirmed)

Group 2

n=6

July 23

(7 confirmed)

Group 3

n=2

July 25

(6 confirmed)

Group 4

n=2

August 4

(6 confirmed)

Group 5

n=7

August 11

(8 confirmed)

Race

Age Range

Duration

Average
Years in
MMMP

3 White
1 Biracial

18 to 43

1 Hour, 45
Minutes

2.75
(1 to 6)

6 White

34 to 66

2 Hours

3.33
(1 to 6)

2 Men

1 White
1 Biracial

39 to 53

1 Hour, 15
Minutes

7
(4 to 10)

1 Man
1 Woman

2 White

32 to 41

1 Hour, 30
Minutes

5.5
(2 to 9)

4 Men
3 Women

6 White
1 Native
American

28 to 64

2 Hours

3.42
(1 to 8)

Gender
1 Man
1 Woman
2 Non-binary
3 Men
2 Women
1 Non-binary
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APPENDIX I
FOCUS GROUP QUESTIONS
Opening Questions:
-

[Write down answer and share] To me, cannabis is…
Tell us who you are, how long you’ve been a patient, and your favorite way to medicate.
Imagination Question (Krueger & Casey 2009):
o Suppose you’ve been frozen, asleep, or in a coma for 20 years. You wake up.
What do you think “medical cannabis” will look like?

Medical v. Recreational:
-

By a show of hands, who plans to renew their medical card after it expires? (Does this
change a year from now when recreational stores will be open)?
In your opinion, what separates “medical marijuana” from “recreational marijuana”?
Do you think medical marijuana will exist if or when marijuana is fully legalized?
If you could change the law surrounding medical marijuana in Michigan, what would you
change and why?
Do you think some people exploit the system by claiming to need medical marijuana
when they want to recreate with it?
Thinking of how marijuana is commonly portrayed in media… Is it presented as amore of
a medical or recreational thing?

Stigma:
-

-

By a show of hands, whose family members know about your medical marijuana use?
By a show of hands, whose co-workers know about your medical marijuana use?
By a show of hands, who is open to their family about their cannabis use? To most of
their friends?
o Why do we remain secretive about our medicine around these individuals?
o What factors made you feel comfortable about disclosing your use of medicine to
others at your job, around your friends, or with your family?
o Do you think your professional image would suffer if others found out? (Or has it
suffered when others found out?)
Have there been cases where someone raised concern about your cannabis consumption?
How do people generally react when you tell them that you are a cannabis patient?
Do you ever feel as though you have been alienated in some way as a result of your
cannabis use?
Have you ever experienced direct discrimination due to your identification as a cannabis
patient? (or cannabis use)?
Some people say marijuana is no longer a deviant thing. Do you agree with this sort of
claim?
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Gender:
-

If cannabis culture had a gender, what would it be and why?
Have you ever purchased medicine geared towards one gender or another?
Do you think medical marijuana does a better job appealing to men or women?
What image is projected by someone who uses a lot of cannabis? Is this image different
in the person is male or female?
Is there a difference in how society looks at a man or woman who uses cannabis?
Do you think more men or more women are cannabis users, or do you think its about the
same? Why?
FOR OPPOSITE GENDERS: Do ---- use medical marijuana differently than ----?

Closing Questions:
-

What is the best thing about medical cannabis? (write and share these with the group).
What is the biggest misconception about medical cannabis? (write down and then share
these with the group).
What advice would you have for someone who has just received their medical marijuana
card? (Hathaway 2004)

PROBES (from Krueger & Casey 2009):
-

Would you explain further?
Can you give us an example?
Would you say more?
What experiences have you had that make you feel that way?
Tell us more.
Say more.
Is there anything else?
Please describe what you mean.
I don’t understand.
Does anyone see it differently?
Has anyone had a different experience?
Are there other points of view?
Thank you -----, are there others who wish to comment on the question/topic?
[NAME], I don’t want to leave you out of the conversation. What do you think?
[NAME], you haven’t had a chance. How do you feel about this?
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APPENDIX J
SCREENING SURVEY
This brief survey is designed to evaluate your eligibility in the study as well as to gather some
personal information of interest to the researcher. The survey is 17 questions and should take
approximately 15 minutes of your time. Some of these questions will determine whether you are
eligible to participate in the focus group, so leaving items blank may result in you being removed
from the study.
1. INFORMED CONSENT [see Appendix 9] (selection required to proceed)
a. I agree to participate in this study.
b. I do not agree to participate in this study.
i. Ends survey if selected and submitted.
2. Do you possess an active, valid card for Michigan’s Medical Marihuana Program
(MMMP)?
a. Yes
b. No
3. Approximately how many years have you been a registered MMMP patient in the State
of Michigan?
a. [OPEN ENDED]
4. For what condition(s) do you use cannabis?
a. [OPEN ENDED]
5. Do any of the following apply to you? Please select all that apply.
a. I use medical cannabis for a terminal illness.
b. I have an appointed legal guardian.
c. I cannot read questionnaires in English.
d. I cannot speak or understand spoken English.
e. None of these apply to me.
6. What is your current employment status?
a. I work full time
b. I work part time
c. I am currently unemployed
7. What is your current job title or occupation? Please be as specific as you are comfortable
with. If you are unemployed, please say so.
a. [OPEN ENDED]
8. Which best describes your gender identity?
a. Man
b. Woman
c. Trans / Non-binary
9. What is your age?
a. [OPEN ENDED]
10. How would you describe your race? (check all that apply)
a. White
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b. Black or African American
c. Latino or Hispanic
d. Asian
e. Middle Eastern
f. Native American
g. Other (please describe)
h. None of these
11. What is the highest level of education you have completed?
a. High School
b. Vocational / Trade School
c. Associates Degree
d. Bachelors Degree
e. Masters or Professional Degree
f. Doctoral Degree
g. Other (specify)
12. What is your individual annual income?
a. Less than $20,000
b. $21,000 - $40,000
c. $41,000 - $60,000
d. $61,000 - $80,000
e. $81,000 - $100,000
f. Over $100,000 per year
g. Prefer not to answer
13. Thinking back to November 2018, did you vote in favor of Proposal 1 which legalized
recreational marijuana in Michigan?
a. Yes, I voted in favor of this proposal.
b. No, I voted against this proposal.
c. I did not vote in the election OR I did not vote on the proposal.
d. No answer / Do not recall.
14. Do you agree to participate in a focus group discussion regarding your experiences as a
medical cannabis patient? Focus groups will consist of 4 to 7 individuals and last no less
than 60 minutes and no more than 120 minutes.
a. Yes
b. No
15. In which county do you currently live? Focus groups will be held in Kalamazoo county.
a. [OPEN ENDED]
16. In order to help the researcher schedule focus groups, please indicate your typical
availability for each day of the week. Select all where you are typically available.
a. [Matrix of days of the week by Mornings/Afternoons/Evenings]
17. What is the best email address to send you an invitation to the focus group?
a. [OPEN ENDED]
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APPENDIX K
HSIRB APPROVAL
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APPENDIX L
FIGURE 1: QUALIFYING CONDITIONS FOR THE MMMP
List of qualifying medical conditions for Michigan’s Medical Marihuana Program as of March
2019. Persons over the age of 18 need a physician to certify their eligibility for the program
while those under age 18 need two certifying physicians. This list of conditions was taken
directly from Michigan’s Department of Licensing and Regulatory Affairs (LARA) but has been
listed in alphabetical order.
1. A chronic or debilitating disease or medical condition or its treatment that produces one
or more of the following: Cachexia or Wasting Syndrome, Severe and Chronic Pain,
Severe Nausea, Seizures (including but not limited to those characteristic of epilepsy),
and/or Severe and Persistent Muscle Spasms (including but not limited to those
characteristic of multiple sclerosis).
2. Agitation of Alzheimer’s Disease
3. AIDS
4. Amyotrophic Lateral Sclerosis (ALS)
5. Arthritis
6. Autism
7. Cancer
8. Cerebral Palsy
9. Chronic Pain
10. Colitis
11. Crohn’s Disease
12. Glaucoma
13. Hepatitis C
14. HIV Positive
15. Inflammatory Bowel Disease
16. Nail Patella
17. Obsessive Compulsive Disorder (OCD)
18. Parkinson’s Disease
19. Post-Traumatic Stress Disorder (PTSD)
20. Rheumatoid Arthritis
21. Spinal Cord Injury
22. Tourette’s Disease
23. Ulcerative Colitis
Most prevalent conditions among patients in Michigan (LARA 2019):
• Severe and Chronic Pain (36.75%)
• Chronic Pain (24.84%)
• Arthritis (10.38%)
• Muscle Spasms (10.33%)
• Severe Nausea (4.82%)
• Cancer (3.27%)
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•
•

PTSD (2.98%)
Seizures (1.14%)
o [All other conditions occur at less than 1.00% each]
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APPENDIX M
FIGURE 2: MAP OF LICENSED PROVISIONING CENTERS

Provisioning Centers (Green Dots) and Home Delivery Services (Red Dots)
Map Current as of May 31, 2019
SOURCE: Michigan Department of Liscensing a Regulatory Affairs
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NOTES: (1) There is one licensed provisioning center in the Upper Penninsula (not shown). (2)
Some of these facilities are not open to customers yet. They have received a state license but
have not yet opened up shop, which will presumably happen in the near future. (3) My primary
purpose for including this map is to show the disparity between facilities on the west side and the
east side of the state. Some cities on the east side have facilities so close to one another that it is
hard to see exactly how many there are on this map.
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